US20090253166A1 - Conjugation of Peptides - Google Patents
Conjugation of Peptides Download PDFInfo
- Publication number
- US20090253166A1 US20090253166A1 US12/406,267 US40626709A US2009253166A1 US 20090253166 A1 US20090253166 A1 US 20090253166A1 US 40626709 A US40626709 A US 40626709A US 2009253166 A1 US2009253166 A1 US 2009253166A1
- Authority
- US
- United States
- Prior art keywords
- glp
- amino
- peptide
- human insulin
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 213
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 71
- 230000021615 conjugation Effects 0.000 title abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 143
- 238000000034 method Methods 0.000 claims abstract description 132
- 125000000524 functional group Chemical group 0.000 claims abstract description 59
- 238000006243 chemical reaction Methods 0.000 claims abstract description 49
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 18
- 238000010348 incorporation Methods 0.000 claims abstract description 9
- -1 keto- Chemical class 0.000 claims description 239
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 96
- 229920001427 mPEG Polymers 0.000 claims description 86
- 235000001014 amino acid Nutrition 0.000 claims description 69
- 150000001413 amino acids Chemical group 0.000 claims description 64
- 229940012413 factor vii Drugs 0.000 claims description 56
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 53
- 102100023804 Coagulation factor VII Human genes 0.000 claims description 52
- 108010023321 Factor VII Proteins 0.000 claims description 52
- 125000000539 amino acid group Chemical group 0.000 claims description 51
- 125000001424 substituent group Chemical group 0.000 claims description 42
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 41
- 102000004877 Insulin Human genes 0.000 claims description 40
- 108090001061 Insulin Proteins 0.000 claims description 40
- 229940125396 insulin Drugs 0.000 claims description 39
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims description 33
- 150000001408 amides Chemical class 0.000 claims description 29
- 102000004190 Enzymes Human genes 0.000 claims description 28
- 108090000790 Enzymes Proteins 0.000 claims description 28
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 25
- 150000003254 radicals Chemical group 0.000 claims description 25
- 125000003118 aryl group Chemical group 0.000 claims description 24
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 claims description 24
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 23
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 claims description 22
- 229910052736 halogen Inorganic materials 0.000 claims description 21
- ZDPHROOEEOARMN-UHFFFAOYSA-N n-hendecanoic acid Natural products CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 claims description 21
- 102000005367 Carboxypeptidases Human genes 0.000 claims description 19
- 108010006303 Carboxypeptidases Proteins 0.000 claims description 19
- 150000002367 halogens Chemical class 0.000 claims description 19
- 229920001223 polyethylene glycol Polymers 0.000 claims description 19
- 102000018997 Growth Hormone Human genes 0.000 claims description 18
- 108010051696 Growth Hormone Proteins 0.000 claims description 18
- 239000000122 growth hormone Substances 0.000 claims description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 17
- 229940080818 propionamide Drugs 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 15
- 230000001268 conjugating effect Effects 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 150000001345 alkine derivatives Chemical class 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 14
- 102000005572 Cathepsin A Human genes 0.000 claims description 13
- 108010059081 Cathepsin A Proteins 0.000 claims description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 13
- XNDRSFBGEJIIHJ-NSHDSACASA-N (2s)-2-amino-3-(4-prop-2-ynoxyphenyl)propanamide Chemical compound NC(=O)[C@@H](N)CC1=CC=C(OCC#C)C=C1 XNDRSFBGEJIIHJ-NSHDSACASA-N 0.000 claims description 12
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 12
- 125000000732 arylene group Chemical group 0.000 claims description 12
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 12
- 150000001540 azides Chemical class 0.000 claims description 10
- 125000005647 linker group Chemical group 0.000 claims description 10
- 150000001412 amines Chemical class 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 8
- 102000009027 Albumins Human genes 0.000 claims description 8
- 108010088751 Albumins Proteins 0.000 claims description 8
- 235000008206 alpha-amino acids Nutrition 0.000 claims description 8
- 230000007423 decrease Effects 0.000 claims description 8
- 150000002391 heterocyclic compounds Chemical class 0.000 claims description 8
- 150000007857 hydrazones Chemical group 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
- 108010091867 peptide P Proteins 0.000 claims description 8
- VATZVGRLQJZFOK-NSHDSACASA-N (2s)-2-amino-3-[4-(2-oxopropoxy)phenyl]propanamide Chemical compound CC(=O)COC1=CC=C(C[C@H](N)C(N)=O)C=C1 VATZVGRLQJZFOK-NSHDSACASA-N 0.000 claims description 7
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims description 7
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims description 7
- YKDOPNDFFQQFAW-ZDUSSCGKSA-N 4-acetyl-n-[(5s)-5,6-diamino-6-oxohexyl]benzamide Chemical compound CC(=O)C1=CC=C(C(=O)NCCCC[C@H](N)C(N)=O)C=C1 YKDOPNDFFQQFAW-ZDUSSCGKSA-N 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 150000001491 aromatic compounds Chemical class 0.000 claims description 7
- 150000002923 oximes Chemical group 0.000 claims description 7
- DZIIHGWVCBOLHF-ZDUSSCGKSA-N (2s)-2-amino-6-[(4-oxo-4-phenylbutanoyl)amino]hexanamide Chemical compound NC(=O)[C@@H](N)CCCCNC(=O)CCC(=O)C1=CC=CC=C1 DZIIHGWVCBOLHF-ZDUSSCGKSA-N 0.000 claims description 6
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 6
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 claims description 6
- KHUXNRRPPZOJPT-UHFFFAOYSA-N phenoxy radical Chemical group O=C1C=C[CH]C=C1 KHUXNRRPPZOJPT-UHFFFAOYSA-N 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- 235000019260 propionic acid Nutrition 0.000 claims description 6
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 6
- HTEIULCKLVWXAB-BYPYZUCNSA-N (2s)-2-aminopent-4-ynamide Chemical compound NC(=O)[C@@H](N)CC#C HTEIULCKLVWXAB-BYPYZUCNSA-N 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 5
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- IUACJEXJTANCBV-LBPRGKRZSA-N (2s)-2-amino-3-[4-(2-oxobutoxy)phenyl]propanamide Chemical compound CCC(=O)COC1=CC=C(C[C@H](N)C(N)=O)C=C1 IUACJEXJTANCBV-LBPRGKRZSA-N 0.000 claims description 4
- GAKQFAWKMLSMEO-ZDUSSCGKSA-N (2s)-2-amino-3-[4-(2-oxopentoxy)phenyl]propanamide Chemical compound CCCC(=O)COC1=CC=C(C[C@H](N)C(N)=O)C=C1 GAKQFAWKMLSMEO-ZDUSSCGKSA-N 0.000 claims description 4
- MTTYGOZNOQQPPL-ZDUSSCGKSA-N (2s)-2-amino-3-[4-(4-oxopentoxy)phenyl]propanamide Chemical compound CC(=O)CCCOC1=CC=C(C[C@H](N)C(N)=O)C=C1 MTTYGOZNOQQPPL-ZDUSSCGKSA-N 0.000 claims description 4
- RVPJPBOXUPPNMZ-ZDUSSCGKSA-N 2-acetyl-n-[(5s)-5,6-diamino-6-oxohexyl]benzamide Chemical compound CC(=O)C1=CC=CC=C1C(=O)NCCCC[C@H](N)C(N)=O RVPJPBOXUPPNMZ-ZDUSSCGKSA-N 0.000 claims description 4
- XGHIBMZOHPEVMK-UHFFFAOYSA-N 2-amino-3-oxopropanamide Chemical compound O=CC(N)C(N)=O XGHIBMZOHPEVMK-UHFFFAOYSA-N 0.000 claims description 4
- BNCPRODQXDWFJW-ZDUSSCGKSA-N 3-acetyl-n-[(5s)-5,6-diamino-6-oxohexyl]benzamide Chemical compound CC(=O)C1=CC=CC(C(=O)NCCCC[C@H](N)C(N)=O)=C1 BNCPRODQXDWFJW-ZDUSSCGKSA-N 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 4
- ALBYIUDWACNRRB-UHFFFAOYSA-N hexanamide Chemical compound CCCCCC(N)=O ALBYIUDWACNRRB-UHFFFAOYSA-N 0.000 claims description 4
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 102000004378 Melanocortin Receptors Human genes 0.000 claims description 3
- 108090000950 Melanocortin Receptors Proteins 0.000 claims description 3
- 239000004952 Polyamide Substances 0.000 claims description 3
- 239000003607 modifier Substances 0.000 claims description 3
- 229920002647 polyamide Polymers 0.000 claims description 3
- 125000001425 triazolyl group Chemical group 0.000 claims description 3
- ISTGRUKCYILABE-UHFFFAOYSA-N 2-amino-3-oxobutanamide Chemical compound CC(=O)C(N)C(N)=O ISTGRUKCYILABE-UHFFFAOYSA-N 0.000 claims description 2
- TZSMOAXVHLDDJG-UHFFFAOYSA-N 2-amino-3-phenacylsulfanylpropanamide Chemical compound NC(=O)C(N)CSCC(=O)C1=CC=CC=C1 TZSMOAXVHLDDJG-UHFFFAOYSA-N 0.000 claims description 2
- AULUINXDLCVMOX-UHFFFAOYSA-N 2-amino-5-oxohexanamide Chemical compound CC(=O)CCC(N)C(N)=O AULUINXDLCVMOX-UHFFFAOYSA-N 0.000 claims description 2
- DWRNVMSNEYEZOA-UHFFFAOYSA-N 2-amino-6-(4-oxopentanoylamino)hexanamide Chemical compound CC(=O)CCC(=O)NCCCCC(N)C(N)=O DWRNVMSNEYEZOA-UHFFFAOYSA-N 0.000 claims description 2
- YKDOPNDFFQQFAW-UHFFFAOYSA-N 4-acetyl-n-(5,6-diamino-6-oxohexyl)benzamide Chemical compound CC(=O)C1=CC=C(C(=O)NCCCCC(N)C(N)=O)C=C1 YKDOPNDFFQQFAW-UHFFFAOYSA-N 0.000 claims description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- YYXLGGIKSIZHSF-UHFFFAOYSA-N ethene;furan-2,5-dione Chemical compound C=C.O=C1OC(=O)C=C1 YYXLGGIKSIZHSF-UHFFFAOYSA-N 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 2
- 150000007659 semicarbazones Chemical class 0.000 claims description 2
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 claims 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 2
- 125000003971 isoxazolinyl group Chemical group 0.000 claims 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims 1
- 125000002355 alkine group Chemical group 0.000 claims 1
- YKCWQPZFAFZLBI-UHFFFAOYSA-N cibacron blue Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=C1S(O)(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC=C1S(O)(=O)=O YKCWQPZFAFZLBI-UHFFFAOYSA-N 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 abstract description 2
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 346
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 343
- 102220554117 Cyclic GMP-AMP synthase_L17T_mutation Human genes 0.000 description 119
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 98
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 92
- 102200068713 rs281865218 Human genes 0.000 description 90
- 239000000203 mixture Substances 0.000 description 83
- 239000000243 solution Substances 0.000 description 79
- 229940024606 amino acid Drugs 0.000 description 68
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 67
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 55
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 50
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 48
- 239000002904 solvent Substances 0.000 description 48
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 44
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 42
- 239000011541 reaction mixture Substances 0.000 description 42
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 41
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- 125000006239 protecting group Chemical group 0.000 description 38
- 239000007864 aqueous solution Substances 0.000 description 37
- 238000011282 treatment Methods 0.000 description 37
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 36
- 102100040918 Pro-glucagon Human genes 0.000 description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 35
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 34
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 31
- 201000010099 disease Diseases 0.000 description 31
- 235000018102 proteins Nutrition 0.000 description 30
- 102000004169 proteins and genes Human genes 0.000 description 30
- 108090000623 proteins and genes Proteins 0.000 description 30
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 28
- 238000005160 1H NMR spectroscopy Methods 0.000 description 27
- 108010054265 Factor VIIa Proteins 0.000 description 27
- 229940012414 factor viia Drugs 0.000 description 27
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 26
- 229940088598 enzyme Drugs 0.000 description 26
- 238000007429 general method Methods 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 239000000562 conjugate Substances 0.000 description 25
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 24
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 23
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 22
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 20
- 150000003839 salts Chemical class 0.000 description 20
- 239000003153 chemical reaction reagent Substances 0.000 description 19
- 230000002473 insulinotropic effect Effects 0.000 description 19
- PMZURENOXWZQFD-UHFFFAOYSA-L sodium sulphate Substances [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 19
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 18
- 230000004071 biological effect Effects 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 18
- 108010000521 Human Growth Hormone Proteins 0.000 description 17
- 102000002265 Human Growth Hormone Human genes 0.000 description 17
- 239000000854 Human Growth Hormone Substances 0.000 description 17
- 239000012043 crude product Substances 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 17
- 229920001184 polypeptide Polymers 0.000 description 17
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 16
- 150000002148 esters Chemical class 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- 235000019341 magnesium sulphate Nutrition 0.000 description 16
- 125000003275 alpha amino acid group Chemical group 0.000 description 15
- 239000000872 buffer Substances 0.000 description 15
- 238000004128 high performance liquid chromatography Methods 0.000 description 15
- 239000012044 organic layer Substances 0.000 description 15
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 description 14
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 14
- 239000002585 base Substances 0.000 description 14
- 238000006467 substitution reaction Methods 0.000 description 14
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 13
- 238000007792 addition Methods 0.000 description 13
- 229960001519 exenatide Drugs 0.000 description 13
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 13
- 239000000758 substrate Substances 0.000 description 13
- CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 125000000217 alkyl group Chemical group 0.000 description 12
- 125000003277 amino group Chemical group 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 125000001072 heteroaryl group Chemical group 0.000 description 12
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 12
- 239000004475 Arginine Substances 0.000 description 11
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 11
- 108010011459 Exenatide Proteins 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 235000004279 alanine Nutrition 0.000 description 11
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 11
- 235000009697 arginine Nutrition 0.000 description 11
- 229960003121 arginine Drugs 0.000 description 11
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 11
- 239000003480 eluent Substances 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 229930182817 methionine Natural products 0.000 description 11
- 235000006109 methionine Nutrition 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- 239000000377 silicon dioxide Substances 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- 235000017557 sodium bicarbonate Nutrition 0.000 description 11
- QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 10
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 10
- 102400000324 Glucagon-like peptide 1(7-37) Human genes 0.000 description 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 10
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 10
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 10
- 229910021529 ammonia Inorganic materials 0.000 description 10
- 238000003818 flash chromatography Methods 0.000 description 10
- FODJWPHPWBKDON-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 FODJWPHPWBKDON-IBGZPJMESA-N 0.000 description 9
- QXVFEIPAZSXRGM-DJJJIMSYSA-N (2s,3s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@@H](C)CC)C(O)=O)C3=CC=CC=C3C2=C1 QXVFEIPAZSXRGM-DJJJIMSYSA-N 0.000 description 9
- 108010000499 Thromboplastin Proteins 0.000 description 9
- 102000002262 Thromboplastin Human genes 0.000 description 9
- 239000002738 chelating agent Substances 0.000 description 9
- 230000008878 coupling Effects 0.000 description 9
- 238000010168 coupling process Methods 0.000 description 9
- 238000005859 coupling reaction Methods 0.000 description 9
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 235000018977 lysine Nutrition 0.000 description 9
- 239000012038 nucleophile Substances 0.000 description 9
- 230000000269 nucleophilic effect Effects 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 239000003755 preservative agent Substances 0.000 description 9
- LZOLWEQBVPVDPR-VLIAUNLRSA-N (2s,3r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@H](OC(C)(C)C)C)C(O)=O)C3=CC=CC=C3C2=C1 LZOLWEQBVPVDPR-VLIAUNLRSA-N 0.000 description 8
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 8
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 8
- HJBLUNHMOKFZQX-UHFFFAOYSA-N 3-hydroxy-1,2,3-benzotriazin-4-one Chemical compound C1=CC=C2C(=O)N(O)N=NC2=C1 HJBLUNHMOKFZQX-UHFFFAOYSA-N 0.000 description 8
- 150000003862 amino acid derivatives Chemical class 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- 235000003704 aspartic acid Nutrition 0.000 description 8
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 8
- 230000001747 exhibiting effect Effects 0.000 description 8
- 239000007951 isotonicity adjuster Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 230000002335 preservative effect Effects 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- REITVGIIZHFVGU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-IBGZPJMESA-N 0.000 description 7
- OTKXCALUHMPIGM-FQEVSTJZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 OTKXCALUHMPIGM-FQEVSTJZSA-N 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 239000007995 HEPES buffer Substances 0.000 description 7
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 7
- 239000004472 Lysine Substances 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Chemical group OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 229960001375 lactose Drugs 0.000 description 7
- 229960003646 lysine Drugs 0.000 description 7
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 7
- 229910052700 potassium Inorganic materials 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 102220237748 rs281865531 Human genes 0.000 description 7
- 102220084989 rs771075821 Human genes 0.000 description 7
- 102220069125 rs77384282 Human genes 0.000 description 7
- 102220217525 rs794726912 Human genes 0.000 description 7
- 125000006850 spacer group Chemical group 0.000 description 7
- 239000003381 stabilizer Substances 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- 150000005846 sugar alcohols Chemical class 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 6
- KJYAFJQCGPUXJY-UMSFTDKQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-oxo-4-(tritylamino)butanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KJYAFJQCGPUXJY-UMSFTDKQSA-N 0.000 description 6
- 102220466237 Acyl-coenzyme A thioesterase MBLAC2_K168A_mutation Human genes 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229960005261 aspartic acid Drugs 0.000 description 6
- 150000001718 carbodiimides Chemical class 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 229910052731 fluorine Inorganic materials 0.000 description 6
- 229960002885 histidine Drugs 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- NUKZAGXMHTUAFE-UHFFFAOYSA-N methyl hexanoate Chemical compound CCCCCC(=O)OC NUKZAGXMHTUAFE-UHFFFAOYSA-N 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 6
- 102220179712 rs369544006 Human genes 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- IOLIFIOLILZQQH-NSHDSACASA-N tert-butyl n-[(2s)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H](C(N)=O)CC1=CC=C(O)C=C1 IOLIFIOLILZQQH-NSHDSACASA-N 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 150000003852 triazoles Chemical class 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 5
- 108010016626 Dipeptides Proteins 0.000 description 5
- 108010014173 Factor X Proteins 0.000 description 5
- 208000002705 Glucose Intolerance Diseases 0.000 description 5
- 101500028771 Homo sapiens Glucagon-like peptide 2 Proteins 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 5
- 102100033320 Lysosomal Pro-X carboxypeptidase Human genes 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 230000029936 alkylation Effects 0.000 description 5
- 238000005804 alkylation reaction Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
- 235000014304 histidine Nutrition 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- 108010057284 lysosomal Pro-X carboxypeptidase Proteins 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 201000009104 prediabetes syndrome Diseases 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 229940044601 receptor agonist Drugs 0.000 description 5
- 239000000018 receptor agonist Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000005924 transacylation reaction Methods 0.000 description 5
- 230000008733 trauma Effects 0.000 description 5
- 229910052727 yttrium Inorganic materials 0.000 description 5
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 4
- PEGODJOFVRYPMO-WEVVVXLNSA-N (ne)-n-[(3-chlorophenyl)methylidene]hydroxylamine Chemical compound O\N=C\C1=CC=CC(Cl)=C1 PEGODJOFVRYPMO-WEVVVXLNSA-N 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 208000005968 HIV-Associated Lipodystrophy Syndrome Diseases 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 102000008316 Type 4 Melanocortin Receptor Human genes 0.000 description 4
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 description 4
- 102220636130 Zinc finger and BTB domain-containing protein 34_F10A_mutation Human genes 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 150000001335 aliphatic alkanes Chemical class 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 229960002449 glycine Drugs 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 4
- 235000008521 threonine Nutrition 0.000 description 4
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- XXMYDXUIZKNHDT-QNGWXLTQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(1-tritylimidazol-4-yl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(N=C1)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 XXMYDXUIZKNHDT-QNGWXLTQSA-N 0.000 description 3
- ADOHASQZJSJZBT-SANMLTNESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]propanoic acid Chemical compound C12=CC=CC=C2N(C(=O)OC(C)(C)C)C=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ADOHASQZJSJZBT-SANMLTNESA-N 0.000 description 3
- WDGICUODAOGOMO-DHUJRADRSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxo-5-(tritylamino)pentanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CC(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WDGICUODAOGOMO-DHUJRADRSA-N 0.000 description 3
- QTWZCODKTSUZJN-LJAQVGFWSA-N (2s)-5-[[amino-[(2,2,5,7,8-pentamethyl-3,4-dihydrochromen-6-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C(C(C)=C1C)=C(C)C2=C1OC(C)(C)CC2 QTWZCODKTSUZJN-LJAQVGFWSA-N 0.000 description 3
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 3
- LXAVFOAOGZWQKT-UHFFFAOYSA-N 11-azidoundecanoic acid Chemical compound OC(=O)CCCCCCCCCCN=[N+]=[N-] LXAVFOAOGZWQKT-UHFFFAOYSA-N 0.000 description 3
- SBAAPANEVTVRSF-UHFFFAOYSA-N 2-(2-piperidin-4-ylethoxy)isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1OCCC1CCNCC1 SBAAPANEVTVRSF-UHFFFAOYSA-N 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 3
- BOJCKNCGRSBWCH-UHFFFAOYSA-N 2-[2-(1-hexadecanoylpiperidin-4-yl)ethoxy]isoindole-1,3-dione Chemical compound C1CN(C(=O)CCCCCCCCCCCCCCC)CCC1CCON1C(=O)C2=CC=CC=C2C1=O BOJCKNCGRSBWCH-UHFFFAOYSA-N 0.000 description 3
- VQNDBXJTIJKJPV-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyridine Chemical compound C1=CC=NC2=NNN=C21 VQNDBXJTIJKJPV-UHFFFAOYSA-N 0.000 description 3
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 description 3
- LXMUZFSBKZIWHQ-UHFFFAOYSA-N 4-[[3-(hydroxyiminomethyl)phenyl]methylamino]-4-oxobutanoic acid Chemical compound ON=CC1=CC=CC(CNC(=O)CCC(O)=O)=C1 LXMUZFSBKZIWHQ-UHFFFAOYSA-N 0.000 description 3
- LJGFXAKKZLFEDR-LBPRGKRZSA-N 9h-fluoren-9-ylmethyl n-[(2s)-1-oxopropan-2-yl]carbamate Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C=O)C3=CC=CC=C3C2=C1 LJGFXAKKZLFEDR-LBPRGKRZSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 102100026657 Cathepsin Z Human genes 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 description 3
- 102000003951 Erythropoietin Human genes 0.000 description 3
- 108090000394 Erythropoietin Proteins 0.000 description 3
- 108010074860 Factor Xa Proteins 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 239000001828 Gelatine Substances 0.000 description 3
- 206010056438 Growth hormone deficiency Diseases 0.000 description 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 3
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 3
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 3
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical group C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 108010004832 Serine-Type D-Ala-D-Ala Carboxypeptidase Proteins 0.000 description 3
- 102000030899 Serine-Type D-Ala-D-Ala Carboxypeptidase Human genes 0.000 description 3
- 239000005708 Sodium hypochlorite Substances 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 102000007641 Trefoil Factors Human genes 0.000 description 3
- 108010007389 Trefoil Factors Proteins 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Chemical group C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- KCTYUINIEPILPS-UHFFFAOYSA-N [3-(aminomethyl)phenyl]methanol Chemical compound NCC1=CC=CC(CO)=C1 KCTYUINIEPILPS-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 230000010933 acylation Effects 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- 238000010640 amide synthesis reaction Methods 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 206010009887 colitis Diseases 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 150000001944 cysteine derivatives Chemical class 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 229940088679 drug related substance Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229940105423 erythropoietin Drugs 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 108010063245 glucagon-like peptide 1 (7-36)amide Proteins 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 3
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- YGCWMLUTPRODGD-UHFFFAOYSA-N methyl 11-azidoundecanoate Chemical compound COC(=O)CCCCCCCCCCN=[N+]=[N-] YGCWMLUTPRODGD-UHFFFAOYSA-N 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- WHQSYGRFZMUQGQ-UHFFFAOYSA-N n,n-dimethylformamide;hydrate Chemical compound O.CN(C)C=O WHQSYGRFZMUQGQ-UHFFFAOYSA-N 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 102200076281 rs199474716 Human genes 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 235000004400 serine Nutrition 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- MKMGFACVSDUQTM-UHFFFAOYSA-N tert-butyl 4-[(3-formylphenyl)methylamino]-4-oxobutanoate Chemical compound CC(C)(C)OC(=O)CCC(=O)NCC1=CC=CC(C=O)=C1 MKMGFACVSDUQTM-UHFFFAOYSA-N 0.000 description 3
- VXMZDKZVIPFRLR-UHFFFAOYSA-N tert-butyl 4-[2-(1,3-dioxoisoindol-2-yl)oxyethyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CCON1C(=O)C2=CC=CC=C2C1=O VXMZDKZVIPFRLR-UHFFFAOYSA-N 0.000 description 3
- HHUVXSXDFBEVET-UHFFFAOYSA-N tert-butyl 4-[2-(4-methylphenyl)sulfonyloxyethyl]piperidine-1-carboxylate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCC1CCN(C(=O)OC(C)(C)C)CC1 HHUVXSXDFBEVET-UHFFFAOYSA-N 0.000 description 3
- LQVLCMVCHQCFTO-UHFFFAOYSA-N tert-butyl 4-[[3-(hydroxyiminomethyl)phenyl]methylamino]-4-oxobutanoate Chemical compound CC(C)(C)OC(=O)CCC(=O)NCC1=CC=CC(C=NO)=C1 LQVLCMVCHQCFTO-UHFFFAOYSA-N 0.000 description 3
- FJDTXSBQDMZUDC-UHFFFAOYSA-N tert-butyl 4-[[3-(hydroxymethyl)phenyl]methylamino]-4-oxobutanoate Chemical compound CC(C)(C)OC(=O)CCC(=O)NCC1=CC=CC(CO)=C1 FJDTXSBQDMZUDC-UHFFFAOYSA-N 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- LPSVEAPODLQHER-AWEZNQCLSA-N tert-butyl n-[(2s)-1-amino-1-oxo-3-(4-prop-2-ynoxyphenyl)propan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H](C(N)=O)CC1=CC=C(OCC#C)C=C1 LPSVEAPODLQHER-AWEZNQCLSA-N 0.000 description 3
- ITRWXUSNOIEGRZ-AWEZNQCLSA-N tert-butyl n-[(2s)-1-amino-1-oxo-3-[4-(2-oxopropoxy)phenyl]propan-2-yl]carbamate Chemical compound CC(=O)COC1=CC=C(C[C@H](NC(=O)OC(C)(C)C)C(N)=O)C=C1 ITRWXUSNOIEGRZ-AWEZNQCLSA-N 0.000 description 3
- SLCNMQUCTCAXMF-INIZCTEOSA-N tert-butyl n-[(2s)-1-amino-1-oxo-6-[(4-oxo-4-phenylbutanoyl)amino]hexan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H](C(N)=O)CCCCNC(=O)CCC(=O)C1=CC=CC=C1 SLCNMQUCTCAXMF-INIZCTEOSA-N 0.000 description 3
- WCPCDCUVVOEEHU-ZETCQYMHSA-N tert-butyl n-[(2s)-1-amino-1-oxopent-4-yn-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H](C(N)=O)CC#C WCPCDCUVVOEEHU-ZETCQYMHSA-N 0.000 description 3
- QNDFFICIIGQGDV-UHFFFAOYSA-N tert-butyl n-[[3-(hydroxymethyl)phenyl]methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=CC(CO)=C1 QNDFFICIIGQGDV-UHFFFAOYSA-N 0.000 description 3
- 229960002898 threonine Drugs 0.000 description 3
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 229960004799 tryptophan Drugs 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- KREIQPRHHRVPJD-FVGYRXGTSA-N (2r)-2-amino-3-phenacylsulfanylpropanamide;hydrochloride Chemical compound Cl.NC(=O)[C@@H](N)CSCC(=O)C1=CC=CC=C1 KREIQPRHHRVPJD-FVGYRXGTSA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- UGNIYGNGCNXHTR-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UGNIYGNGCNXHTR-SFHVURJKSA-N 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- YKWHUGFAZWACFU-UHFFFAOYSA-N 1-[4-(2-aminooxyethyl)piperidin-1-yl]hexadecan-1-one Chemical compound CCCCCCCCCCCCCCCC(=O)N1CCC(CCON)CC1 YKWHUGFAZWACFU-UHFFFAOYSA-N 0.000 description 2
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- FZTIWOBQQYPTCJ-UHFFFAOYSA-N 4-[4-(4-carboxyphenyl)phenyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(O)=O)C=C1 FZTIWOBQQYPTCJ-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- QBHDSQZASIBAAI-UHFFFAOYSA-N 4-acetylbenzoic acid Chemical compound CC(=O)C1=CC=C(C(O)=O)C=C1 QBHDSQZASIBAAI-UHFFFAOYSA-N 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- KMQLIDDEQAJAGJ-UHFFFAOYSA-N 4-oxo-4-phenylbutyric acid Chemical compound OC(=O)CCC(=O)C1=CC=CC=C1 KMQLIDDEQAJAGJ-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- 102220554240 APC membrane recruitment protein 1_E65A_mutation Human genes 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 208000004300 Atrophic Gastritis Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 108090000087 Carboxypeptidase B Proteins 0.000 description 2
- 102000003670 Carboxypeptidase B Human genes 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102100022641 Coagulation factor IX Human genes 0.000 description 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- NZNMSOFKMUBTKW-UHFFFAOYSA-N Cyclohexanecarboxylic acid Natural products OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 108010076282 Factor IX Proteins 0.000 description 2
- 108010048049 Factor IXa Proteins 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000036495 Gastritis atrophic Diseases 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 206010053759 Growth retardation Diseases 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 241000270453 Heloderma horridum Species 0.000 description 2
- 241000270431 Heloderma suspectum Species 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 101000910979 Homo sapiens Cathepsin Z Proteins 0.000 description 2
- 101000788682 Homo sapiens GATA-type zinc finger protein 1 Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 102220494366 Methylmalonyl-CoA mutase, mitochondrial_H18A_mutation Human genes 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 102220482069 Nuclear cap-binding protein subunit 2_F25A_mutation Human genes 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Chemical class 0.000 description 2
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 2
- 108010058003 Proglucagon Proteins 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 102220567290 Rab3 GTPase-activating protein non-catalytic subunit_Q29A_mutation Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241001072909 Salvia Species 0.000 description 2
- 235000017276 Salvia Nutrition 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 108030000574 Serine-type carboxypeptidases Proteins 0.000 description 2
- 102000034328 Serine-type carboxypeptidases Human genes 0.000 description 2
- 208000020221 Short stature Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 102220499387 Transcriptional protein SWT1_Q22A_mutation Human genes 0.000 description 2
- 208000026928 Turner syndrome Diseases 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000012382 advanced drug delivery Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 125000003172 aldehyde group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 150000001371 alpha-amino acids Chemical class 0.000 description 2
- AFVLVVWMAFSXCK-VMPITWQZSA-N alpha-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(\C#N)=C\C1=CC=C(O)C=C1 AFVLVVWMAFSXCK-VMPITWQZSA-N 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 229940000635 beta-alanine Drugs 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- DWKPZOZZBLWFJX-UHFFFAOYSA-L calcium;1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate Chemical compound [Ca+2].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC.CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC DWKPZOZZBLWFJX-UHFFFAOYSA-L 0.000 description 2
- XEVRDFDBXJMZFG-UHFFFAOYSA-N carbonyl dihydrazine Chemical class NNC(=O)NN XEVRDFDBXJMZFG-UHFFFAOYSA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960004222 factor ix Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 210000001624 hip Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 235000014705 isoleucine Nutrition 0.000 description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000004973 liquid crystal related substance Substances 0.000 description 2
- 208000018773 low birth weight Diseases 0.000 description 2
- 231100000533 low birth weight Toxicity 0.000 description 2
- 150000002669 lysines Chemical class 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- MHWBZSIJPFOLCO-ZDUSSCGKSA-N methyl (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenacylsulfanylpropanoate Chemical compound CC(C)(C)OC(=O)N[C@H](C(=O)OC)CSCC(=O)C1=CC=CC=C1 MHWBZSIJPFOLCO-ZDUSSCGKSA-N 0.000 description 2
- 108091005601 modified peptides Proteins 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- LQRJAEQXMSMEDP-XCHBZYMASA-N peptide a Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)NCCCC[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C/C=1C=CC=CC=1)C(N)=O)C(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C\C1=CC=CC=C1 LQRJAEQXMSMEDP-XCHBZYMASA-N 0.000 description 2
- 239000000863 peptide conjugate Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical group OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- CACRHRQTJDKAPJ-UHFFFAOYSA-M potassium;1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate Chemical compound [K+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC CACRHRQTJDKAPJ-UHFFFAOYSA-M 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 102200037713 rs34068461 Human genes 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- 210000002832 shoulder Anatomy 0.000 description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- QOWBXWFYRXSBAS-UHFFFAOYSA-N (2,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C(OC)=C1 QOWBXWFYRXSBAS-UHFFFAOYSA-N 0.000 description 1
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- YEDNBEGNKOANMB-REOHCLBHSA-N (2r)-2-amino-3-sulfanylpropanamide Chemical compound SC[C@H](N)C(N)=O YEDNBEGNKOANMB-REOHCLBHSA-N 0.000 description 1
- JAUKCFULLJFBFN-VWLOTQADSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JAUKCFULLJFBFN-VWLOTQADSA-N 0.000 description 1
- BUBGAUHBELNDEW-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylsulfanylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCSC)C(O)=O)C3=CC=CC=C3C2=C1 BUBGAUHBELNDEW-SFHVURJKSA-N 0.000 description 1
- LAXXPOJCFVMVAX-ZETCQYMHSA-N (2s)-2-amino-4-butylsulfanylbutanoic acid Chemical compound CCCCSCC[C@H](N)C(O)=O LAXXPOJCFVMVAX-ZETCQYMHSA-N 0.000 description 1
- BUVCJVSDXCCEOY-LURJTMIESA-N (2s)-5-(diaminomethylideneamino)-2-(ethylamino)pentanoic acid Chemical compound CCN[C@H](C(O)=O)CCCNC(N)=N BUVCJVSDXCCEOY-LURJTMIESA-N 0.000 description 1
- JYEVQYFWINBXJU-QFIPXVFZSA-N (2s)-6-(9h-fluoren-9-ylmethoxycarbonylamino)-2-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)NCCCC[C@H](NC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 JYEVQYFWINBXJU-QFIPXVFZSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical class CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical group C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ZPDQFUYPBVXUKS-YADHBBJMSA-N 1-stearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OC[C@H](N)C(O)=O ZPDQFUYPBVXUKS-YADHBBJMSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 1
- WBBPRCNXBQTYLF-UHFFFAOYSA-N 2-methylthioethanol Chemical compound CSCCO WBBPRCNXBQTYLF-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
- MQNHKLMHRZYTBZ-UHFFFAOYSA-N 3-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]benzoic acid Chemical compound CC(C)(C)OC(=O)NCC1=CC=CC(C(O)=O)=C1 MQNHKLMHRZYTBZ-UHFFFAOYSA-N 0.000 description 1
- TUBRCQBRKJXJEA-UHFFFAOYSA-N 3-[hexadecyl(dimethyl)azaniumyl]propane-1-sulfonate Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O TUBRCQBRKJXJEA-UHFFFAOYSA-N 0.000 description 1
- SRWILAKSARHZPR-UHFFFAOYSA-N 3-chlorobenzaldehyde Chemical compound ClC1=CC=CC(C=O)=C1 SRWILAKSARHZPR-UHFFFAOYSA-N 0.000 description 1
- PCOCFIOYWNCGBM-UHFFFAOYSA-N 4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound CC(C)(C)OC(=O)CCC(O)=O PCOCFIOYWNCGBM-UHFFFAOYSA-N 0.000 description 1
- DUVVGYBLYHSFMV-YGEZULPYSA-N 4-methyl-n-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]carbamoyl]benzamide Chemical compound C1=CC(C)=CC=C1C(=O)NC(=O)N[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DUVVGYBLYHSFMV-YGEZULPYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- 108700040115 Adenosine deaminases Proteins 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 101000910993 Arabidopsis thaliana Cathepsin B-like protease 2 Proteins 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000212384 Bifora Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108090000018 Carboxypeptidase D Proteins 0.000 description 1
- 102100032407 Carboxypeptidase D Human genes 0.000 description 1
- 101710093141 Carboxypeptidase S Proteins 0.000 description 1
- 101710095175 Carboxypeptidase S1 Proteins 0.000 description 1
- 108010080937 Carboxypeptidases A Proteins 0.000 description 1
- 102000000496 Carboxypeptidases A Human genes 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 102000005575 Cellulases Human genes 0.000 description 1
- 108010084185 Cellulases Proteins 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 206010008723 Chondrodystrophy Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 1
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 1
- 108030001451 Cysteine-type carboxypeptidases Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 244000258539 Epigaea repens Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 206010017085 Fracture malunion Diseases 0.000 description 1
- 206010017088 Fracture nonunion Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Chemical class C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102000015626 Glucagon-Like Peptide-2 Receptor Human genes 0.000 description 1
- 108010024044 Glucagon-Like Peptide-2 Receptor Proteins 0.000 description 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 1
- 102400000325 Glucagon-like peptide 1(7-36) Human genes 0.000 description 1
- 101800004295 Glucagon-like peptide 1(7-36) Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 108010008488 Glycylglycine Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 229920003114 HPC-L Polymers 0.000 description 1
- 229920003115 HPC-SL Polymers 0.000 description 1
- 206010054272 Helicobacter gastritis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019670 Hepatic function abnormal Diseases 0.000 description 1
- 241001622557 Hesperia Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102100039897 Interleukin-5 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 208000037112 Intestinal Failure Diseases 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- GGLZPLKKBSSKCX-YFKPBYRVSA-N L-ethionine Chemical compound CCSCC[C@H](N)C(O)=O GGLZPLKKBSSKCX-YFKPBYRVSA-N 0.000 description 1
- XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 1
- PQFMNVGMJJMLAE-QMMMGPOBSA-N L-tyrosinamide Chemical compound NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PQFMNVGMJJMLAE-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010029541 Laccase Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 206010052315 Lymphatic obstruction Diseases 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010085169 Lysine carboxypeptidase Proteins 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 108030000089 Metallocarboxypeptidases Proteins 0.000 description 1
- 102000006166 Metallocarboxypeptidases Human genes 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-O Methylammonium ion Chemical compound [NH3+]C BAVYZALUXZFZLV-UHFFFAOYSA-O 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010029748 Noonan syndrome Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101710202686 Penicillin-sensitive transpeptidase Proteins 0.000 description 1
- 108010079943 Pentagastrin Proteins 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 108010005991 Pork Regular Insulin Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102220539290 Programmed cell death 1 ligand 2_E62S_mutation Human genes 0.000 description 1
- 102100024819 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- IDIDJDIHTAOVLG-UHFFFAOYSA-N S-methyl-L-cysteine Natural products CSCC(N)C(O)=O IDIDJDIHTAOVLG-UHFFFAOYSA-N 0.000 description 1
- IDIDJDIHTAOVLG-VKHMYHEASA-N S-methylcysteine Chemical compound CSC[C@H](N)C(O)=O IDIDJDIHTAOVLG-VKHMYHEASA-N 0.000 description 1
- 101000715359 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Carboxypeptidase S Proteins 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010049416 Short-bowel syndrome Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 206010072610 Skeletal dysplasia Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical group [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 102100022831 Somatoliberin Human genes 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical class O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 241000950638 Symphysodon discus Species 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108010012944 Tetragastrin Proteins 0.000 description 1
- 229920002359 Tetronic® Polymers 0.000 description 1
- LJTFFORYSFGNCT-UHFFFAOYSA-N Thiocarbohydrazide Chemical class NNC(=S)NN LJTFFORYSFGNCT-UHFFFAOYSA-N 0.000 description 1
- 206010043647 Thrombotic Stroke Diseases 0.000 description 1
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 1
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 1
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 102000008816 Trefoil Factor-2 Human genes 0.000 description 1
- 108010088411 Trefoil Factor-2 Proteins 0.000 description 1
- 102000014456 Trefoil Factor-3 Human genes 0.000 description 1
- 108010078184 Trefoil Factor-3 Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 239000006035 Tryptophane Chemical group 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027276 Von Willebrand disease Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 208000008919 achondroplasia Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940059260 amidate Drugs 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 208000014759 blood platelet disease Diseases 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 229960003168 bronopol Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-O butylazanium Chemical compound CCCC[NH3+] HQABUPZFAYXKJW-UHFFFAOYSA-O 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- OWIUPIRUAQMTTK-UHFFFAOYSA-N carbazic acid Chemical class NNC(O)=O OWIUPIRUAQMTTK-UHFFFAOYSA-N 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- MXOAEAUPQDYUQM-UHFFFAOYSA-N chlorphenesin Chemical compound OCC(O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-UHFFFAOYSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000019069 chronic childhood arthritis Diseases 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000002288 cocrystallisation Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000037411 cognitive enhancing Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- UVJHQYIOXKWHFD-UHFFFAOYSA-N cyclohexa-1,4-diene Chemical compound C1C=CCC=C1 UVJHQYIOXKWHFD-UHFFFAOYSA-N 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 101150113541 desA1 gene Proteins 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229940099371 diacetylated monoglycerides Drugs 0.000 description 1
- GDGUATCKWWKTLM-UHFFFAOYSA-N dicyclopropylmethanamine Chemical compound C1CC1C(N)C1CC1 GDGUATCKWWKTLM-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Chemical compound CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-O diethylammonium Chemical compound CC[NH2+]CC HPNMFZURTQLUMO-UHFFFAOYSA-O 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- FRKBLBQTSTUKOV-UHFFFAOYSA-N diphosphatidyl glycerol Natural products OP(O)(=O)OCC(OP(O)(O)=O)COP(O)(O)=O FRKBLBQTSTUKOV-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940018614 docusate calcium Drugs 0.000 description 1
- 229940018600 docusate potassium Drugs 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- QBHFVMDLPTZDOI-UHFFFAOYSA-N dodecylphosphocholine Chemical compound CCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C QBHFVMDLPTZDOI-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000003717 douglas' pouch Anatomy 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 238000002283 elective surgery Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-O ethylaminium Chemical compound CC[NH3+] QUSNBJAOOMFDIB-UHFFFAOYSA-O 0.000 description 1
- HXQVQGWHFRNKMS-UHFFFAOYSA-M ethylmercurithiosalicylic acid Chemical compound CC[Hg]SC1=CC=CC=C1C(O)=O HXQVQGWHFRNKMS-UHFFFAOYSA-M 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 108010015174 exendin 3 Proteins 0.000 description 1
- LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002082 fibula Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 150000002307 glutamic acids Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229940043257 glycylglycine Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229940099816 human factor vii Drugs 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 210000002758 humerus Anatomy 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- XPXMKIXDFWLRAA-UHFFFAOYSA-N hydrazinide Chemical compound [NH-]N XPXMKIXDFWLRAA-UHFFFAOYSA-N 0.000 description 1
- 125000005597 hydrazone group Chemical group 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 201000010072 hypochondroplasia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000002303 hypothalamus releasing factor Substances 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 150000002462 imidazolines Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 229940113174 imidurea Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- HOQADATXFBOEGG-UHFFFAOYSA-N isofenphos Chemical compound CCOP(=S)(NC(C)C)OC1=CC=CC=C1C(=O)OC(C)C HOQADATXFBOEGG-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000001847 jaw Anatomy 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 101150107787 kex1 gene Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- NJGIAKIPSDCYAC-LURJTMIESA-N methyl (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-sulfanylpropanoate Chemical compound COC(=O)[C@H](CS)NC(=O)OC(C)(C)C NJGIAKIPSDCYAC-LURJTMIESA-N 0.000 description 1
- HFNPVFKUZYCDIB-UHFFFAOYSA-N methyl 11-bromoundecanoate Chemical compound COC(=O)CCCCCCCCCCBr HFNPVFKUZYCDIB-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000012434 nucleophilic reagent Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 125000005489 p-toluenesulfonic acid group Chemical class 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 229940055076 parasympathomimetics choline ester Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 1
- 229960000444 pentagastrin Drugs 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 229940066734 peptide hydrolases Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229940083254 peripheral vasodilators imidazoline derivative Drugs 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- KTNLYTNKBOKXRW-UHFFFAOYSA-N phenyliodanium Chemical compound [IH+]C1=CC=CC=C1 KTNLYTNKBOKXRW-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 229920001987 poloxamine Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000573 polyethylene Chemical class 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000003161 proteinsynthetic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 210000002320 radius Anatomy 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 102220005352 rs281864814 Human genes 0.000 description 1
- 102220026812 rs63750850 Human genes 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 150000003349 semicarbazides Chemical class 0.000 description 1
- 150000003355 serines Chemical class 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 229960005480 sodium caprylate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940001593 sodium carbonate Drugs 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 1
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- IWQPOPSAISBUAH-VOVMJQHHSA-M sodium;2-[[(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyl-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylheptanoyl]amino]ethanesulfonate Chemical compound [Na+].C1C[C@@H](O)[C@@H](C)[C@@H]2CC[C@]3(C)[C@@]4(C)C[C@H](C(C)=O)/C(=C(C(=O)NCCS([O-])(=O)=O)/CCCC(C)C)[C@@H]4C[C@@H](O)[C@H]3[C@]21C IWQPOPSAISBUAH-VOVMJQHHSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 108700031632 somatrem Proteins 0.000 description 1
- 229960003259 somatrem Drugs 0.000 description 1
- 229960004532 somatropin Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000006076 specific stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical class S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 1
- 235000010269 sulphur dioxide Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- RGYLYUZOGHTBRF-BIHRQFPBSA-N tetragastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)CCSC)C(N)=O)C1=CC=CC=C1 RGYLYUZOGHTBRF-BIHRQFPBSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 150000003583 thiosemicarbazides Chemical class 0.000 description 1
- 150000003588 threonines Chemical class 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- KIRKGWILHWJIMS-UHFFFAOYSA-K trisodium;1-amino-4-[4-[[4-chloro-6-(2-sulfonatoanilino)-1,3,5-triazin-2-yl]amino]-3-sulfonatoanilino]-9,10-dioxoanthracene-2-sulfonate Chemical group [Na+].[Na+].[Na+].C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S([O-])(=O)=O)C=C1NC(C=C1S([O-])(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC=C1S([O-])(=O)=O KIRKGWILHWJIMS-UHFFFAOYSA-K 0.000 description 1
- 206010044697 tropical sprue Diseases 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000000623 ulna Anatomy 0.000 description 1
- SCXZATZIVUFOFT-UHFFFAOYSA-N undec-5-ene Chemical compound [CH2]CCCC=CCCCCC SCXZATZIVUFOFT-UHFFFAOYSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000006213 vaginal ring Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000008979 vitamin B4 Nutrition 0.000 description 1
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
- AFVLVVWMAFSXCK-UHFFFAOYSA-N α-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(C#N)=CC1=CC=C(O)C=C1 AFVLVVWMAFSXCK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a novel method for post-translational conjugation of peptides.
- Said conjugated peptides have altered characteristics and may thus be of use in therapeutic applications or they may ease the analysis or isolation and purification of said peptides.
- the method exploits an enzyme capable of incorporating a compound comprising a suitable functional group into the C-terminal end of a peptide, where said functional group is subsequently used as a point where to conjugate.
- carboxypeptidases to modify the C-terminal of peptides has been described earlier.
- WO 92/05271 discloses the use of carboxypeptidases and nucleophilic compounds to amidate the C-terminal carboxy group
- WO 98/38285 discloses variants of carboxypeptidase Y particular apt for this purpose.
- EP 605 963 discloses the grafting of aqueous polymers which form an oxime linkage with an aldehyde group on a protein. None of the natural amino acid comprises an aldehyde, so a hydroxyl group thus has to be oxidized as a first step in the conjugating process.
- EP 243 929 discloses the use of carboxypeptidase to incorporate polypeptides, reporter groups or cytotoxic agents into the C-terminal of proteins or polypeptides.
- enzymes e.g. carboxypeptidases may be used to incorporate into the C-terminal of peptides a first compound comprising one or more functional groups, which are not accessible in the peptide, to form a transacylated compound, and that this transacylated compound may subsequently be reacted with another compound comprising one or more functional groups which react with the functional group of the first compound but not with other functional groups accessible in the peptide.
- Such method provides a high degree of specificity in that the enzyme is chosen so that it only catalyses the incorporation at the C-terminal, and the two functional groups are selected so that they only react with each other, not with other functional groups accesible in the peptide. In this way, the conjugating group is only attached at one locus, and by selecting the functional groups, the number of conjugated groups can be controlled.
- the present invention provides a method for conjugating peptides, said method comprising the steps of
- the present invention provides the use of peptides conjugated by methods of the present invention in therapy.
- compositions e.g. pharmaceutical compositions comprising peptides conjugated by methods of the present invention.
- transacylation is intended to indicate a reaction in which a leaving group is exchanged for a nucleophile, wherein a nucleophile is understood to be an electron-rich reagent that tends to attack the nucleus of carbons.
- Transpeptidation is one example of a transacylation.
- not accessible is intended to indicate that something is absent or de facto absent in the sense that it cannot be reached.
- functional groups are not accessible in a peptide to be conjugated it is intended to indicate that said functional group is absent from the peptide or, if present, in some way prevented from taking part in reactions.
- said functional group could be buried deep in the structure of the peptide so that it is shielded from participating in the reaction. It is recognised that whether or not a functional group is accessible depends on the reaction conditions. It may be envisaged that in the presence of denaturing agents or at elevated temperatures the peptide may unfold to expose otherwise not accessible functional groups. It is to be understood that “not accessible” means “not accessible at the reaction condition chosen for the particular reaction of interest”.
- oxime bond is intended to indicate a moiety of the formula —C ⁇ N—O—.
- hydrazone bond is intended to indicate a moiety of the formula —C ⁇ N—N—.
- phenylhydrazone bond is intended to indicate a moiety of the formula
- semiconductor bond is intended to indicate a moiety of the formula —C ⁇ N—N—C(O)—N—.
- alkane is intended to indicate a saturated, linear, branched and/or cyclic hydrocarbon. Unless specified with another number of carbon atoms, the term is intended to indicate hydrocarbons with from 1 to 30 (both included) carbon atoms, such as 1 to 20 (both included), such as from 1 to 10 (both included), e.g. from 1 to 5 (both included).
- alkyl and alkylene refer to the corresponding radical and bi-radical, respectively.
- alkene is intended to indicate linear, branched and/or cyclic hydrocarbons comprising at least one carbon-carbon double bond. Unless specified with another number of carbon atoms, the term is intended to indicate hydrocarbons with from 2 to 30 (both included) carbon atoms, such as 2 to 20 (both included), such as from 2 to 10 (both included), e.g. from 2 to 5 (both included).
- alkenyl and alkenylene refer to the corresponding radical and biradical, respectively.
- alkyne is intended to indicate linear, branched and/or cyclic hydrocarbons comprising at least one carbon-carbon triple bond, and it may optionally comprise one or more carbon-carbon double bonds. Unless specified with another number of carbon atoms, the term is intended to indicate hydrocarbons with from 2 to 30 (both included) carbon atoms, such as from 2 to 20 (both included), such as from 2 to 10 (both included), e.g. from 2 to 5 (both included).
- alkynyl and alkynylene refer to the corresponding radical and bi-radical, respectively.
- homocyclic aromatic compound is intended to indicate aromatic hydrocarbons, such as benzene and naphthalene.
- heterocyclic compound is intended to indicate a cyclic compound comprising 5, 6 or 7 ring atoms from which 1, 2, 3 or 4 are hetero atoms selected from N, O and/or S.
- heterocyclic aromatic compounds such as thiophene, furan, pyran, pyrrole, imidazole, pyrazole, isothiazole, isooxazole, pyridine, pyrazine, pyrimidine, pyridazine, as well as their partly or fully hydrogenated equivalents, such as piperidine, pirazolidine, pyrrolidine, pyroline, imidazolidine, imidazoline, piperazine and morpholine.
- hetero alkane is intended to indicate alkanes, alkenes and alkynes as defined above, in which one or more hetero atom or group have been inserted into the structure of said moieties.
- hetero groups and atoms include —O—, —S—, —S(O)—, —S(O) 2 —, —C(O)— —C(S)— and —N(R*)—, wherein R* represents hydrogen or C 1 -C 6 -alkyl.
- heteroalkanes include.
- radical or “biradical” is intended to indicate a compound from which one or two, respectively, hydrogen atoms have been removed.
- a radical may also indicate the moiety formed by the formal removal of a larger group of atoms, e.g. hydroxyl, from a compound.
- halogen is intended to indicate members of the seventh main group of the periodic table, i.e. F, Cl, Br and I.
- PEG polyethylene glycol of a molecular weight between 500 and 150,000 Da, including analogues thereof, wherein for instance the terminal OH-group has been replaced by a methoxy group (referred to as mPEG).
- peptide and “protein” are used interchangeably and are intended to indicate the same.
- peptide is intended to indicate a compound with two or more amino acid residues linked by a peptide bond.
- the amino acids may be natural or unnatural.
- the term is also intended to include said compounds substituted with other peptides, saccharides, lipids, or other organic compound, as well as compounds wherein one or more amino acid residue have been chemically modified and peptides comprising a prosthetic group.
- aryl is intended to indicate a carbocyclic aromatic ring radical or a fused aromatic ring system radical wherein at least one of the rings are aromatic.
- Typical aryl groups include phenyl, biphenylyl, naphthyl, and the like.
- heteroaryl refers to an aromatic ring radical with for instance 5 to 7 member atoms, or to a fused aromatic ring system radical with for instance from 7 to 18 member atoms, wherein at least one ring is aromatic, containing one or more heteroatoms as ring atoms selected from nitrogen, oxygen, or sulfur heteroatoms, wherein N-oxides and sulfur monoxides and sulfur dioxides are permissible heteroaromatic substitutions.
- Examples include furanyl, thienyl, thiophenyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrazinyl, pyrimidinyl, quinolinyl, isoquinolinyl, benzofuranyl, benzothiophenyl, indolyl, and indazolyl, and the like.
- conjugate as a noun is intended to indicate a modified peptide, i.e. a peptide with a moiety bonded to it to modify the properties of said peptide.
- conjugate is intended to indicate the process of bonding a moiety to a peptide to modify the properties of said peptide.
- prodrug indicates biohydrolyzable amides and biohydrolyzable esters and also encompasses a) compounds in which the biohydrolyzable functionality in such a prodrug is encompassed in the compound according to the present invention, and b) compounds which may be oxidized or reduced biologically at a given functional group to yield drug substances according to the present invention.
- these functional groups include 1,4-dihydropyridine, N-alkylcarbonyl-1,4-dihydropyridine, 1,4-cyclohexadiene, tert-butyl, and the like.
- biohydrolyzable ester is an ester of a drug substance (in casu, a compound according to the invention) which either a) does not interfere with the biological activity of the parent substance but confers on that substance advantageous properties in vivo such as duration of action, onset of action, and the like, or b) is biologically inactive but is readily converted in vivo by the subject to the biologically active principle.
- the advantage is, for example increased solubility or that the biohydrolyzable ester is orally absorbed from the gut and is transformed to a compound according to the present invention in plasma.
- lower alkyl esters e.g., C 1 -C 4
- lower acyloxyalkyl esters lower alkoxyacyloxyalkyl esters
- alkoxyacyloxy esters alkyl acylamino alkyl esters
- choline esters e.g., choline esters
- biohydrolyzable amide is an amide of a drug substance (in casu, a compound according to the present invention) which either a) does not interfere with the biological activity of the parent substance but confers on that substance advantageous properties in vivo such as duration of action, onset of action, and the like, or b) is biologically inactive but is readily converted in vivo by the subject to the biologically active principle.
- the advantage is, for example increased solubility or that the biohydrolyzable amide is orally absorbed from the gut and is transformed to a compound according to the present invention in plasma.
- Many examples of such are known in the art and include by way of example lower alkyl amides, ⁇ -amino acid amides, alkoxyacyl amides, and alkylaminoalkylcarbonyl amides.
- salts are intended to indicate salts which are not harmful to the patient.
- Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable metal salts, ammonium and alkylated ammonium salts.
- Acid addition salts include salts of inorganic acids as well as organic acids. Representative examples of suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, nitric acids and the like.
- suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methanesulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids and the like.
- compositions include the pharmaceutically acceptable salts listed in J. Pharm. Sci. 1977, 66, 2, which is incorporated herein by reference.
- metal salts include lithium, sodium, potassium, magnesium salts and the like.
- ammonium and alkylated ammonium salts include ammonium, methylammonium, dimethylammonium, trimethylammonium, ethylammonium, hydroxyethylammonium, diethylammonium, butylammonium, tetramethylammonium salts and the like.
- a “therapeutically effective amount” of a compound as used herein means an amount sufficient to cure, alleviate or partially arrest the clinical manifestations of a given disease and its complications. An amount adequate to accomplish this is defined as “therapeutically effective amount”. Effective amounts for each purpose will depend on the severity of the disease or injury as well as the weight and general state of the subject. It will be understood that determining an appropriate dosage may be achieved using routine experimentation, by constructing a matrix of values and testing different points in the matrix, which is all within the ordinary skills of a trained physician or veterinary.
- treatment means the management and care of a patient for the purpose of combating a condition, such as a disease or a disorder.
- the term is intended to include the full spectrum of treatments for a given condition from which the patient is suffering, such as administration of the active compound to alleviate the symptoms or complications, to delay the progression of the disease, disorder or condition, to alleviate or relief the symptoms and complications, and/or to cure or eliminate the disease, disorder or condition as well as to prevent the condition, wherein prevention is to be understood as the management and care of a patient for the purpose of combating the disease, condition, or disorder and includes the administration of the active compounds to prevent the onset of the symptoms or complications.
- the patient to be treated is preferably a mammal, in particular a human being, but it may also include animals, such as dogs, cats, cows, sheep and pigs.
- any enzyme capable of catalysing the incorporation of a compound into a peptide is useful in the methods of the present invention.
- useful enzymes include carboxypeptidases, which constitute a group of peptide hydrolases belonging to the classification groups E.C. 3.4.16, 3.4.17 and 3.4.18.
- the in vivo reaction catalysed by said enzymes is the hydrolysis of the C-terminal amino acid residue.
- carboxypeptidases are known and they differ in what terminal amino acid residue they are capable of cleaving off.
- an enzyme-substrate complex is formed which under normal in vivo conditions is subjected to a nucleophilic attack by a water molecule, which eventually leads to the hydrolysis of the peptide bond.
- a nucleophilic reagent is added, which can out compete water as a nucleophile.
- the water activity may be reduced by running the reaction in solvents or in aqueous solvents.
- said nucleophile attacks the enzyme-substrate complex eventually forming a transacylated compound.
- said reagent also has to comprise one or more functional groups, which are not accessible in the peptide to be conjugated.
- enzymes which could be applied in the methods of the present invention include trypsin.
- the reaction of the peptide and the nucleophile affords a transacylated peptide wherein the C-terminal amino acid residue has been exchanged with the nucleophilic compound, which comprises one or more functional groups which are not accessible in the peptide to be conjugated.
- the overall result of this reaction is an incorporation of one or more functional groups into the peptide which are present at only one locus in the peptide.
- a subsequent reaction (or series of reactions) of this transacylated peptide with a compound comprising the moiety to be conjugated to the peptide and one or more functional groups, which only react with the functional groups added to the peptide in the transacylation reaction effects a selective conjugation of the peptide to be conjugated.
- the method of the present invention offers the advantage of improved selectivity.
- the incorporation of one or more functional groups not accessible in the peptide ensures that the conjugation takes place at only specified loci.
- any enzyme capable of catalysing the incorporation of a compound into a peptide may be used in the methods of the present invention, and in particular carboxypeptidases are useful.
- carboxypeptidases are serine-type carboxypeptidases, such as lysosomalPro-X carboxypeptidase (also known as proline carboxypeptidase, angiotensinase C, lysosomal carboxypeptidase C and prolylcarboxypeptidase), serine-type D-Ala-D-Ala carboxypeptidase (also known as D-alanyl-D-alanine carboxypeptidase, DD-peptidase and DD-transpeptidase), carboxypeptidase C (also known as Serine-type carboxypeptidase I, cathepsin A, carboxypeptidase Y and lysosomal protective protein) and carboxypeptidase D (also known as carboxypeptidase D (also
- carboxypeptidases may be changed, added or deleted in the sequence of carboxypeptidases to modify the catalytic properties of the enzyme.
- modified carboxypeptidases are disclosed in, e.g. WO 98/38285, which is incorporated herein by reference. Particular mentioning is made of carboxypeptidase Y as a useful enzyme.
- nucleophilic compounds which could be incorporated into peptides according to the methods of the present invention, and ⁇ -amino acids is one such type of nucleophilic compounds.
- One example of such compounds is amides of ⁇ -amino acids as carboxy amidated peptides are not substrates for carboxypeptidases.
- a compound is a substrate for a given enzyme in principle depends on the conditions, e.g. the time frame, under which the reaction takes place. Given sufficient time, many compounds are, in fact, substrates for an enzyme although they are not under normal conditions regarded as such.
- the transacylated compound itself should not be a substrate of the enzyme it is intended to indicate that the tranacylated compound itself is not a substrate for the enzyme to an extent where the following reactions in the method of the present invention are disturbed. If the transacylated compound is, in fact, a substrate for the enzyme, the enzyme may be removed or inactivated, e.g. by enzyme inhibitors, following the transacylation reaction.
- the invention relates to a method of conjugating peptides, wherein a peptide P is reacted in one or more steps with a first compound, which is an ⁇ -amino acid amide represented by the formula
- transacylated peptide being further reacted in one or more steps with a second compound of the formula
- R represents a linker or a bond
- P′ represents the peptide obtained when the C-terminal amino acid is removed from the peptide P
- X represents a radical comprising a functional group not accessible in the amino acid residues constituting the peptide P′
- Y represents a radical comprising one or more functional groups which groups react with functional groups present in X, and which functional groups do not react with functional groups accessible in the peptide P′
- E represents a linker or a bond
- A represents the moiety formed by the reaction between the functional groups comprised in X and Y
- Z is the moiety to be conjugated to the peptide, wherein said moiety decreases the clearance of the compound of formula [a] in comparison with the clearance of P.
- the invention relates to methods of conjugating peptides as disclosed above, which further comprises the step of formulating the resulting conjugated peptide in a pharmaceutical composition.
- the conjugated peptide may be isolated and purified by techniques well-known in the art.
- the conjugated peptide may also be converted into a pharmaceutically acceptable salt or prodrug, if relevant.
- the moiety, A, formed in the reaction between the functional groups of X and Y may in principle be of any kind depending on what properties of the final conjugated peptide is desired. In some situation it may be desirable to have a labile bond which can be cleaved at some later stage, e.g. by some enzymatic action or by photolysis. In other situations, it may be desirable to have a stable bond, so that a stable conjugated peptide is obtained. Particular mentioning is made of the type of moieties formed by reactions between amine derivatives and carbonyl groups, such as oxime, hydrazone, phenylhydrazone and semicarbazone moieties.
- the functional groups of X and Y are selected from amongst carbonyl groups, such as keto and aldehyde groups, and amino derivatives, such as
- hydrazine derivatives —NH—NH 2 , hydrazine carboxylate derivatives —O—C(O)—NH—NH 2 , semicarbazide derivatives —NH—C(O)—NH—NH 2 , thiosemicarbazide derivatives —NH—C(S)—NH—NH 2 , carbonic acid dihydrazide derivatives —NHC(O)—NH—NH—C(O)—NH—NH 2 , carbazide derivatives —NH—NH—C(O)—NH—NH 2 , thiocarbazide derivatives —NH—NH—C(S)—NH—NH 2 , aryl hydrazine derivatives —NH—C(O)—C 6 H 4 —NH—NH 2 , and hydrazide derivatives —C(O)—NH—NH 2 ; oxylamine derivatives, such as —O—NH 2 , —C(O)—O—NH 2 , —
- the functional group comprised in X is a carbonyl group
- the functional group comprised in Y is an amine derivative, and vice versa. Due to the presence of —NH 2 groups in most peptides, a better selectivity is believed to be obtained if X comprises a keto- or an aldehyde-functionality.
- X and Y are azide derivatives (—N 3 ) and alkynes which react to form a triazole moiety.
- Another example of a suitable pair of X and Y is alkyne and nitril-oxide, which reacts to form a isooxazolidine moiety.
- 2-amino-3-oxo-butyramide 2-amino-6-(4-oxo-pentanoylamino)-hexanoic acid amide
- 2-amino-3-(2-oxo-2-phenyl-ethylsulfanyl)-propionamide 2-amino-5-oxo-hexanoic acid amide
- 2-amino-3-oxo-propionamide 2-amino-6-(4-acetylbenzoylamino)hexanoic acid amide
- 2-amino-3-oxopropionic acid amide 2-S)-Amino-3-[4-(2-oxopropoxy)phenyl]propionamide
- (2S)-Amino-3-[4-(2-oxopentoxy)phenyl]propionamide (2S)-Amino
- Both the compound to be transacylated and the compound to be reacted with the transacylated peptide comprises a linker, R and E, respectively.
- These linkers which are independent of each other, may be absent or selected from amongst alkane, alkene or alkyne diradicals and hetero alkane, hetero alkene and hetero alkyne diradicals, wherein one or more optionally substituted aromatic homocyclic biradical or biradical of a heterocyclic compound, e.g. phenylene or piperidine biradical may be inserted into the aforementioned biradicals.
- said linkers may also comprise substitutions by groups selected from amongst hydroxyl, halogen, nitro, cyano, carboxyl, aryl, alkyl and heteroaryl.
- linkers E and R represent bonds or linkers, and in the present context the term “linker” is intended to indicate a moiety functioning as a means to separate Y from Z and X from NH 2 —C(O)—C(NH 2 )—, respectively.
- One function of the linkers E and R may be to provide adequate flexibility in the linkage between the peptide and the conjugated moiety Z.
- E and R include bi-radicals of straight, branched and/or cyclic C 1-10 alkane, C 2-10 alkene, C 2-10 alkyne, C 1-10 heteroalkane, C 2-10 heteroalkene, C 2-10 heteroalkyne, wherein one or more homocyclic aromatic compound biradical or heterocyclic compound biradical may be inserted.
- Particular examples of E and R include
- a need for modifying peptides may arise for any number of reasons, and this is also reflected in the kind of compounds that may be conjugated to peptides according to the methods of the present invention. It may be desirable to conjugate peptides to alter the physicochemical properties of the peptide, such as e.g. to increase (or to decrease) solubility to modify the bioavailability of therapeutic peptides. In another embodiment, it may be desirable to modify the clearance rate in the body, e.g. by conjugating compounds to the peptide which binds to plasma proteins, such as e.g. albumin, or which increase the size of the peptide to prevent or delay discharge through the kidneys.
- a label may be desirable to conjugate a label to facilitate analysis of the peptide.
- label include radioactive isotopes, fluorescent markers and enzyme substrates.
- a compound is conjugated to a peptide to facilitate isolation of the peptide.
- a compound with a specific affinity to a particular column material may be conjugated to the peptide.
- It may also be desirable to modify the immunogenecity of a peptide, e.g. by conjugating a peptide so as to hide, mask or eclipse one or more immunogenic epitopes at the peptide.
- the methods of the present invention may be used to decrease the clearance in order to increase the plasma half-life of the modified peptide compared to the corresponding un-modified peptide.
- plasma half-life is used in its ordinary meaning, i.e. the time at which 50% of the biological activity of the peptide is present in the plasma prior to being cleared.
- Alternative terms include serum half-life, circulating half-life, circulatory half-life, serum clearance, plasma clearance, and clearance half-life.
- the term “increased” used in connection with plasma half-life is used to indicate that the half-life of the conjugated peptide is significantly increased relative to the half-life of the corresponding un-modified peptide.
- the half-life may be increased by at least 25%, at least 50%, at least 100%, at least 150%, at least 200% or even at least 500%.
- the present invention relates to methods of conjugating peptides as disclosed above, which further comprises the step of measuring whether an increase in the plasma half-life has been effected.
- dextrans dextrans
- polyamide radicals e.g. polyamino acid radicals; PVP radicals; PVA radicals; poly(1-3-dioxalane); poly(1,3,6-trioxane); ethylene/maleic anhydride polymer; Cibacron dye stuffs, such as Cibacron Blue 3GA, and polyamide chains of specified length, as disclosed in WO 00/12587, which is incorporated herein by reference.
- C 10-20 alkyl such as C 15 and C 17
- the PEG conjugated to a peptide according to the present invention may be of any molecular weight.
- the molecular weight may be between 500 and 100,000 Da, such as between 500 and 60,000 Da, such as between 1000 and 40,000 Da, such as between 5000 and 40,000 Da.
- PEG with molecular weights of 10000 Da, 20000 Da, 30000 Da or 40000 Da may be used in the present invention.
- Z comprises one or more moieties that are known to bind to plasma proteins, such as e.g. albumin.
- the ability of a compound to bind to albumin may be determined as described in J. Med. Chem., 43, 2000, 1986-1992, which is incorporated herein by reference.
- a compound is defined as binding to albumin if Ru/Da is above 0.05, such as above 0.10, such as above 0.12 or even above 0.15.
- the albumin binding moiety is a peptide, such as a peptide comprising less than 40 amino acid residues.
- a number of small peptides which are albumin binding moieties are disclosed in J. Biol. Chem. 277, 38 (2002) 35035-35043, which is incorporated herein by reference.
- Z may be branched so that Z comprises more than one of the above mentioned labels or radicals.
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 10 kDa
- mPEG has a molecular weight of 10 kDa
- mPEG has a molecular weight of 10 kDa
- mPEG has a molecular weight of 10 kDa
- mPEG has a molecular weight of 10 kDa
- mPEG has a molecular weight of 10 kDa
- mPEG has a molecular weight of 10 kDa
- mPEG has a molecular weight of 10 kDa
- mPEG has a molecular weight of 10 kDa
- mPEG has a molecular weight of 10 kDa
- mPEG has a molecular weight of 10 kDa
- mPEG has a molecular weight of 10 kDa
- mPEG has a molecular weight of 10 kDa
- mPEG has a molecular weight of 10 kDa
- mPEG has a molecular weight of 10 kDa
- mPEG has a molecular weight of 10 kDa
- mPEG has a molecular weight of 10 kDa
- mPEG has a molecular weight of 10 kDa
- mPEG has a molecular weight of 10 kDa
- mPEG has a molecular weight of 10 kDa
- mPEG has a molecular weight of 10 kDa
- mPEG has a molecular weight of 10 kDa
- mPEG has a molecular weight of 10 kDa
- mPEG has a molecular weight of 10 kDa
- mPEG has a molecular weight of 10 kDa
- mPEG has a molecular weight of 10 kDa
- mPEG has a molecular weight of 10 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 30 kDa
- mPEG has a molecular weight of 30 kDa
- mPEG has a molecular weight of 30 kDa
- mPEG has a molecular weight of 30 kDa
- mPEG has a molecular weight of 30 kDa
- mPEG has a molecular weight of 30 kDa
- mPEG has a molecular weight of 30 kDa
- mPEG has a molecular weight of 30 kDa
- mPEG has a molecular weight of 30 kDa
- mPEG has a molecular weight of 30 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa
- mPEG has a molecular weight of 20 kDa.
- some peptides e.g. insulin and Factor VII, comprise more than one chain, which in turn means that they have more than one C-terminal.
- it might be necessary to introduce a difference between the C-terminals e.g. by adding or deleting one or more amino acid residues from one of the C-terminals to effect a conjugation at only a limited number of the C-terminals present.
- Any peptide can be conjugated by the methods of the present invention, such as e.g. enzymes, peptide hormones, growth factors, antibodies, cytokines, receptors, lymphokines and vaccine antigenes, and particular mentioning is made of therapeutic peptides, such as insulin, glucagon like-peptide 1 (GLP-1), glucagon like-peptide 2 (GLP-2), growth hormone, cytokines, trefoil factor peptides (TFF), peptide melanocortin receptor modifiers and factor VII compounds.
- therapeutic peptides such as insulin, glucagon like-peptide 1 (GLP-1), glucagon like-peptide 2 (GLP-2), growth hormone, cytokines, trefoil factor peptides (TFF), peptide melanocortin receptor modifiers and factor VII compounds.
- human insulin refers to naturally produced insulin or recombinantly produced insulin.
- Recombinant human insulin may be produced in any suitable host cell, for example the host cells may be bacterial, fungal (including yeast), insect, animal or plant cells.
- many insulin compounds have been disclosed in the literature, and they too are particular useful in the methods of the present invention.
- insulin compound (and related expressions) is meant human insulin in which one or more amino acids have been deleted and/or replaced by other amino acids, including non-codeable amino acids, and/or human insulin comprising additional amino acids, i.e. more than 51 amino acids, and/or human insulin in which at least one organic substituent is bound to one or more of the amino acids.
- N ⁇ B29 —(CO—(CH 2 ) 14 —COOH) human insulin N ⁇ B29 —(CO—(CH 2 ) 16 —COOH) human insulin; N ⁇ B29 —(CO—(CH 2 ) 18 —COOH) human insulin; N ⁇ B29 —(CO—(CH 2 ) 2 O—COOH); N ⁇ B29 —(CO—(CH 2 ) 22 —COOH) human insulin; N ⁇ B29 —(CO—(CH 2 ) 14 —COOH) Asp B28 -human insulin; N ⁇ B29 —(CO—(CH 2 ) 16 —COOH) Asp B28 -human insulin; N ⁇ B29 —(CO—(CH 2 ) 18 —COOH) Asp B28 -human insulin; N ⁇ B29 —(CO—(CH 2 ) 20 —COOH) Asp B28 -human insulin; N ⁇ B29 —(CO—(CH 2 ) 20 —
- WO 96/29344 (Novo Nordisk), which is incorporated herein by reference, discloses insulin compounds with a protracted activity profile wherein either the amino group of the N-terminal amino acid of the B-chain has a lipophilic substituent comprising from 12 to 40 carbon atoms attached, or wherein the carboxylic acid group of the C-terminal amino acid of the B-chain has a lipophilic substituent comprising from 12 to 40 carbon atoms attached.
- WO 95/07931 discloses insulin compounds with a protracted activity profile, wherein the ⁇ -amino group of Lys B29 has a lipophilic substituent.
- WO 97/02043 (Novo Nordisk), which is incorporated herein by reference discloses hormonally inactive insulin compounds which are useful in insulin prophylaxis, and in particular such analogues of human insulin are selected from amongst desA1 human insulin; des(A1-A2) human insulin; des(A1-A3) human insulin; desA21 human insulin; des(B1-B5) human insulin; des(B1-B6) human insulin; des(B23-B30) human insulin; des(B24-B30) human insulin; des(B25-B30) human insulin; Gly A2 human insulin; Ala A2 human insulin; Nle A2 human insulin; Thr A2 human insulin; Pro A2 human insulin; D-allo Ile A2 human insulin; Nva A3 human insulin; Nle A3 human insulin; Leu A3 human insulin; Val A2 ,Ile A3 human insulin; Abu A2 ,Abu A3 human insulin; Gly A2 ,Gly A3 human insulin; D-Cys A6 human
- WO 92/15611 (Novo nordisk), which is incorporated herein by reference, discloses analogues of human insulin with a fast association rate constants in the insulin receptor binding process and characterised by comprising a tyrosine in position A13 and/or a phenylalanin, tryptophane or tyrosine in position B17.
- such analogues are selected from amongst Tyr A13 human insulin, Phe B17 human insulin, Trp B17 human insulin, Tyr B17 human insulin, Tyr A13 ,Phe B17 human insulin, Tyr A13 , Trp B17 human insulin, Tyr A13 , Tyr B17 human insulin, Phe 13 ,Phe B17 human insulin, Phe A13 ,Trp B17 human insulin, Phe A13 ,Tyr B17 human insulin, Trp A13 ,Phe B17 human insulin, Trp A13 ,Trp B17 human insulin and Trp A13 ,Tyr B17 human insulin.
- WO 92/00322 (Novo Nordisk), which is incorporated herein by reference, discloses analogues of human insulin which are capable of being targeted to specific tissues, and which are characterized by having in the A13 position and/or in the B17 position in the insulin molecule a naturally occurring amino acid residue different from leucine and/or by having in the B18 position in the insulin molecule a naturally occurring amino acid residue different from valine.
- such analogues are selected from amongst Ala B17 human insulin, Ala B18 human insulin, Asn A13 human insulin, Asn A13 ,Ala B17 human insulin, Asn A13 ,Asp B17 human insulin, Asn B13 ,Glu B17 human insulin, Asn B18 human insulin, Asp A13 human insulin, Asp A13 ,Ala B17 human insulin, Asp A13 ,Asp B17 human insulin, Asp A13 ,Glu B17 human insulin, Asp B18 human insulin, Gln A13 human insulin, Gln A13 ,Ala B17 human insulin, Gln A13 ,Asp B17 human insulin, Gln B18 human insulin, Glu A13 human insulin, Glu A13 ,Ala B17 human insulin, Glu A13 ,Ala B17 human insulin, Glu A13 ,Ala B17 human insulin, Glu A13 ,Ala B17 human insulin, Glu A13 ,Ala B17 human insulin, Glu A13 ,
- WO 90/01038 (Novo Nordisk), which is incorporated herein by reference, discloses analogues of human insulin with high biological activity and characterized by having Phe B25 substituted by His or Tyr, by having substitutions in one or more of positions A4, A8, A17, A21, B9, B10, B12, B13, B21, B26, B27, B28 and B30, and by having the amino acid residue at position B30 optionally absent.
- such analogues are selected from amongst Tyr B25 human insulin, Tyr B25 , Asp B28 human insulin, His B25 human insulin, His B25 , Asp B21 human insulin, Tyr B25 human insulin-B30-amide and His B25 human insulin-B30-amide.
- WO 86/05496 discloses analogues of human insulin with a protracted action and characterized by having a blocked B30 carboxylic group, and by having one to four blocked carboxylic groups in the amino acid residues at positions A4, A17, A21, B13 and B21.
- such analogues are selected from amongst insulin-B30-octyl ester, insulin-B30-dodecyl amide, insulin-B30-hexadecyl amide, insulin-(B21,B30)-dimethyl ester, insulin-(B17,B30)-dimethyl ester, insulin-(A4,B30) diamide, insulin-A17amide-B30-octyl ester, insulin-(A4,B13)-diamide-B30-hexylamide, insulin-(A4,A17,B21,B30)-tetraamide, insulin-(A17,B30)-diamide, A4-Ala-insulin-B30-amide and B30-Leu-insulin-(A4,B30)-diamide.
- WO 86/05497 discloses insulin compounds in which one or more of the four amino acid residues in positions A4, A17, B13 and B21 comprises an uncharged side chain. Particular mentioning is made of human insulin A17-Gln, human insulin A4-Gln, porcine insulin B21-Gln, human insulin B13-Gln, human insulin (A17,B21)-Gln, human insulin A4-Ala, human insulin B21-Thr, human insulin B13-Val, human insulin-Thr-A17-Gln, human insulin B21-methyl ester and human insulin A17-methyl ester.
- WO 92/00321 discloses insulin compounds with prolonged activity wherein a positive charge in the N-terminal end of the B-chain has been introduced. Particular mentioning is made of Arg B5 ,Ser A21 ,Thr B30 -NH 2 human insulin, Arg B5 ,Pro B6 ,Ser A21 ,Thr B30 -NH 2 human insulin, Arg B5 ,Gly A21 ,Thr B30 -NH 2 human insulin, Arg B5 ,Pro B6 ,Gly A21 ,Thr B30 -NH 2 human insulin, Arg B2 ,Ser A21 ,Thr B30 -NH 2 human insulin, Arg B2 ,Pro B3 ,Ser A21 ,Thr B30 -NH 2 human insulin, Arg B2 ,Gly A21 , Thr B30 -NH 2 human insulin, Arg B2 ,Pro B3 ,Gly A21 ,Thr B30 -NH 2 human insulin, Arg B2 ,Pro B3 ,Gly A
- WO 90/07522 (Novo Nordisk), which is incorporated herein by reference, discloses insulin compounds exhibiting a low ability to associate in solution wherein there is a positively charged amino acid residue, i.e. Lys or Arg in the position B28.
- WO 90/11290 (Novo Nordisk), which is incorporated herein by reference discloses insulin compounds with a prolonged activity. Particular mentioning is made of [Arg A0 ]-human insulin-(B30-amide), [Arg A0 ,Gln B13 ]-human insulin-(B30-amide), [Arg A0 ,Gln A4 ,Asp A21 ]-human insulin-(B30-amide), [Arg A0 ,Ser A21 ]-human insulin-(B30-amide) and [Arg A0 ,Arg B27 ]-des[Thr B30 ]-human insulin.
- WO 90/10645 (Novo Nordisk), which is incorporated herein by reference discloses glycosylated insulins. Particular mentioning is made of Phe(B1) glucose human insulin, Phe(B1) mannose human insulin, Gly(A1) mannose human insulin, Lys(B29) mannose human insulin, Phe(B1) galactose human insulin, Gly(A1) galactose human insulin, Lys(B29) galactose human insulin, Phe(B1) maltose human insulin, Phe(B1) lactose human insulin, Gly(A1) glucose human insulin, Gly(A1) maltose human insulin, Gly(A1) lactose human insulin, Lys(B29) glucose human insulin, Lys(B29) maltose human insulin, Lys(B29) lactose human insulin, Gly(A1), Phe(B1) diglucose human insulin, Gly(A1), Lys(B29) diglucose human insulin, Phe(B1),
- WO 88/065999 (Novo Nordisk), which is incorporated herein by reference, discloses stabilized insulin compounds, wherein Ans 21A has been substituted with other amino acid residues. Particular mentioning is made of Gly A21 human insulin, Ala A21 human insulin, Ser A21 human insulin, Thr A21 human insulin and hSer A21 human insulin.
- EP 254516 (Novo Nordisk), which is incorporated herein by reference, discloses insulin compounds with a prolonged action, wherein basic amino acid residues have been substituted by neutral amino acid residues. Particular mentioning is made of Gly A21 ,Lys B27 ,Thr B30 -NH 2 human insulin, Ser A21 , Lys B27 ,Thr B30 -NH 2 human insulin, Thr A21 ,Lys B27 ,Thr B30 -NH 2 human insulin, Ala B21 ,Lys B27 ,Thr B30 -NH 2 human insulin, His A21 ,Lys B27 ,Thr B30 -NH 2 human insulin, Asp B21 ,Lys B27 ,Thr B30 -NH 2 human Insulin, Gly A21 ,Arg B21 ,Thr B30 -NH 2 human insulin, Ser A21 ,Arg B27 ,Thr B30 -NH 2 human insulin, Thr A21 ,Arg B27 ,Thr B30 -NH 2 human insulin, Ala B
- EP 214826 (Novo Nordisk), which is incorporated herein by reference, discloses rapid onset insulin compounds.
- EP 194864 discloses insulin compounds with a prolonged action, wherein basic amino acid residues have been substituted by neutral amino acid residues. Particular mentioning is made of Gln A17 ,Arg B27 ,Thr B31 -NH 2 human insulin, Gln A17 ,Gln B13 ,Thr B30 -NH 2 human insulin, Gln A17 ,Lys B27 ,Thr B30 —NH 2 human insulin, Gln A17 ,Lys B27 -NH 2 human insulin, Gln A17 , Gln A17 ,Thr B30 -NH 2 human insulin, Gln B13 ,Arg B27 ,Thr B30 -NH 2 human insulin, Gln B13 ,Lys B27 ,Thr B30 -NH 2 human insulin, Gln B13 ,Lys B30 -NH 2 human insulin, Gln B13 ,Thr B30 -NH 2 human insulin, Arg B27 ,Arg B30 -NH 2 human insulin, Gln B13
- GB Patent No. 1.492.997 discloses insulin compounds with a carbamyl substitution at N ⁇ B29 with an improved profile of hypoglycaemic effect.
- JP laid-open patent application No. 1-254699 discloses insulin compounds, wherein an alkanoyl group is bound to the amino group of Phe B1 or to the ⁇ -amino group of Lys B29 or to both of these.
- JP laid-open patent application No. 57-067548 (Shionogi), which is incorporated herein by reference discloses insulin compounds, in which the B30 position have an amino acid having at least five carbon atoms which cannot necessarily be coded for by a triplet of nucleotides.
- WO 03/053339 (Eli Lilly), which is incorporated herein by reference, disclose insulin compounds, wherein the A-chain in the N-terminal has been extended with two amino acid residues, A-1 and A0, wherein the B-chain has been extended at the N-terminal with two amino acid residues, B-1 and B0, wherein the amino acid residues at positions B28, B29 and B39 may be substituted, and wherein the ⁇ -amino group of Lys at position B28 or B29 is covalently bound to the ⁇ -carboxyl group of a positively charged amino acid to form a Lys-N ⁇ -aminoacid derivative.
- A-1 and B-1 are both absent, and wherein A0 represent Arg and B0 represents Arg or is absent.
- Insulin compounds selected from the group consisting of
- des(B30) human insulin is also applicable in the methods of the present invention.
- Other applicable insulin compounds are selected from the group consisting of B29-N ⁇ -myristoyl-des(B30) human insulin, B29-N ⁇ -palmitoyl-des(B30) human insulin, B29-N ⁇ -myristoyl human insulin, B29-N ⁇ -palmitoyl human insulin, B28-N ⁇ -myristoyl Lys B28 Pro B29 human insulin, B28-N ⁇ -palmitoyl Lys B28 Pro B29 human insulin, B30-N ⁇ -myristoyl-Thr B29 Lys B30 human insulin, B30-N ⁇ -palmitoyl-Thr B29 Lys B30 human insulin, B29-N ⁇ -(N-palmitoyl- ⁇ -glutamyl)-des(B30) human insulin, B29-N ⁇ -(N-lithocholyl- ⁇ -glutamyl)-des(B30) human insulin, B29-N ⁇ -( ⁇
- GLP-1 examples include human GLP-1 and GLP-1 compounds.
- Human GLP-1 is a 37 amino acid residue peptide originating from preproglucagon which is synthesised i.a. in the L-cells in the distal ileum, in the pancreas and in the brain. GLP-1 is an important gut hormone with regulatory function in glucose metabolism and gastrointestinal secretion and metabolism. Processing of preproglucagon to give GLP-1(7-36)-amide, GLP-1(7-37) and GLP-2 occurs mainly in the L-cells. The fragments GLP-1(7-36)-amide and GLP-1(7-37) are both glucose-dependent insulinotropic agents.
- Exendin-4 is a 39 amino acid residue peptide isolated from the venom of Heloderma horridum , and this peptide shares 52% homology with GLP-1.
- Exendin-4 is a potent GLP-1 receptor agonist which has been shown to stimulate insulin release and ensuring lowering of the blood glucose level when injected into dogs.
- GLP-1(1-37) and exendin-4(1-39) and certain fragments, analogues and derivatives thereof are potent insulinotropic agents, and they are all applicable in the method of the present invention.
- Insulinotropic fragments of GLP-1(1-37) are insulinotropic peptides for which the entire sequence can be found in the sequence of GLP-1(1-37) and where at least one terminal amino acid has been deleted.
- Examples of insulinotropic fragments of GLP-1(1-37) are GLP-1(7-37) wherein the amino acid residues in positions 1-6 of GLP-1(1-37) have been deleted, and GLP-1(7-36) where the amino acid residues in position 1-6 and 37 of GLP-1(1-37) have been deleted.
- insulinotropic fragments of exendin-4(1-39) are exendin-4(1-38) and exendin-4(1-31).
- the insulinotropic property of a compound may be determined by in vivo or in vitro assays well known in the art. For instance, the compound may be administered to an animal and monitoring the insulin concentration over time.
- Insulinotropic analogs of GLP-1(1-37) and exendin-4(1-39) refer to the respective molecules wherein one or more of the amino acids residues have been exchanged with other amino acid residues and/or from which one or more amino acid residues have been deleted and/or from which one or more amino acid residues have been added with the proviso that said analogue either is insulinotropic or is a prodrug of an insulinotropic compound.
- insulinotropic analogs of GLP-1(1-37) is e.g. Met 8 -GLP-1(7-37) wherein the alanine in position 8 has been replaced by methionine and the amino acid residues in position 1 to 6 have been deleted, and Arg 34 -GLP-1(7-37) wherein the valine in position 34 has been replaced with arginine and the amino acid residues in position 1 to 6 have been deleted.
- An example of an insulinotropic analog of exendin-4(1-39) is Ser 2 Asp 3 -exendin-4(1-39) wherein the amino acid residues in position 2 and 3 have been replaced with serine and aspartic acid, respectively (this particular analog also being known in the art as exendin-3).
- Insulinotropic derivatives of GLP-1(1-37), exendin-4(1-39) and analogs thereof are what the person skilled in the art considers to be derivatives of these peptides, i.e. having at least one substituent which is not present in the parent peptide molecule with the proviso that said derivative either is insulinotropic or is a prodrug of an insulinotropic compound.
- substituents are amides, carbohydrates, alkyl groups and lipophilic substituents.
- insulinotropic derivatives of GLP-1(1-37), exendin-4(1-39) and analogs thereof are GLP-1(7-36)-amide, Arg 34 , Lys 26 (N ⁇ -( ⁇ -Glu(N-hexadecanoyl)))-GLP-1(7-37) and Tyr 31 -exendin-4(1-31)-amide.
- Further examples of GLP-1(1-37), exendin-4(1-39), insulinotropic fragments thereof, insulinotropic analogs thereof and insulinotropic derivatives thereof are described in WO 98/08871, WO 99/43706, U.S. Pat. No. 5,424,286 and WO 00/09666, which are all enclosed herein by reference.
- GLP-2 and GLP-2 compounds may also be modified by the methods provided by the present invention.
- a GLP-2 compound binds to a GLP-2 receptor, preferably with an affinity constant (K D ) or a potency (EC 50 ) of below 1 ⁇ M, e.g. below 100 nM.
- K D affinity constant
- EC 50 potency
- GLP-2 compound is intended to indicate human GLP-2 in which one or more amino acid residue has been deleted and/or replaced by another amino acid residue, natural or unnatural, and/or human GLP-2 comprising additional amino acid residues, and/or human GLP-2 in which at least one organic substituent is bound to one or more of the amino acid residues.
- those peptides are considered, which amino acid sequence exhibit at any sequence of 33 consecutive amino acids more than 60% of the amino acid sequence of human GLP-2. Also those peptides are considered, which amino acid sequence exhibit at any sequence of 37 consecutive amino acids more than 60% of the amino acid sequence of human GLP-2 when up to four amino acids are deleted from the amino acid sequence. Also those peptides are considered, which amino acid sequence exhibit at any sequence of 31 consecutive amino acids more than 60% of the amino acid sequence of GLP-2, when up to two amino acids are added to their amino acid sequence.
- GLP compounds also includes natural allelic variations that may exist and occur from one individual to another. Also, degree and location of glycosylation or other post-translation modifications may vary depending on the chosen host cells and the nature of the host cellular environment.
- GLP-2 compounds which may be used according to the present invention include the GLP-2 compounds described in WO 96/32414, WO 97/39031, WO 98/03547, WO 96/29342, WO 97/31943, WO 98/08872, which are all incorporated herein by reference.
- GLP-2 compounds are applicable in the methods of the present invention: A2G-GLP-2(1-33); K30R-GLP-2(1-33); S5K-GLP-2(1-33); S7K-GLP-2(1-33); D8K-GLP-2(1-33); E9K-GLP-2(1-33); M10K-GLP-2(1-33); N11K-GLP-2(1-33); T12K-GLP-2(1-33); 113K-GLP-2(1-33); L14K-GLP-2(1-33); D15K-GLP-2(1-33); N16K-GLP-2(1-33); L17K-GLP-2(1-33); A18K-GLP-2(1-33); D21K-GLP-2(1-33); N24K-GLP-2(1-33); Q28K-GLP-2(1-33); S5K/K30R-GLP-2(1-33); S7K/K30R-GLP-2(1-33); D8K/K30R-
- the GLP-2 compound is selected from GLP-2(1-33), 34R-GLP-2(1-34), A2G-GLP-2(1-33), A2G/34R-GLP-2(1-34), K30R-GLP-2(1-33); S5K-GLP-2(1-33); S7K-GLP-2(1-33); D8K-GLP-2(1-33); E9K-GLP-2(1-33); M10K-GLP-2(1-33); N11K-GLP-2(1-33); T12K-GLP-2(1-33); 113K-GLP-2(1-33); L14K-GLP-2(1-33); D15K-GLP-2(1-33); N16K-GLP-2(1-33); L17K-GLP-2(1-33); A18K-GLP-2(1-33); D21K-GLP-2(1-33); N24K-GLP-2(1-33); Q28K-GLP-2(1-33); S5K/K30R-GLP-2(1-33); S5
- GLP-2 derivatives with only one lipophilic substituent attached to the GLP-2 peptide are also applicable in the methods of the present invention, such as GLP-2 derivatives wherein the lipophilic substituent comprises from 4 to 40 carbon atoms, such as from 8 to 25 carbon atoms, e.g. from 12 to 20 carbon atoms.
- the lipophilic substituent may be attached to an amino acid residue in such a way that a carboxyl group of the lipophilic substituent forms an amide bond with an amino group of the amino acid residue.
- the lipophilic substituent is attached to a Lys residue.
- the lipophilic substituent may be attached to an amino acid residue in such a way that an amino group of the lipophilic substituent forms an amide bond with a carboxyl group of the amino acid residue.
- the lipophilic substituent may also be attached to the GLP-2 peptide by means of a spacer, and said spacer may be selected from amongst ⁇ -alanine, gamma-aminobutyric acid (GABA), ⁇ -glutamic acid, Lys, Asp, Glu, a dipeptide containing Asp, a dipeptide containing Glu, or a dipeptide containing Lys.
- the spacer is ⁇ -alanine.
- a carboxyl group of the parent GLP-2 peptide may also form an amide bond with an amino group of a spacer, and the carboxyl group of the amino acid or dipeptide spacer forms an amide bond with an amino group of the lipophilic substituent.
- An amino group of the parent GLP-2 peptide may also form an amide bond with a carboxylic group of a spacer, and an amino group of the spacer forms an amide bond with a carboxyl group of the lipophilic substituent.
- the lipophilic substituent is a straight-chain or branched alkyl group. In one embodiment of the invention the lipophilic substituent is the acyl group of a straight-chain or branched fatty acid.
- the lipophilic substituent is an acyl group of a straight-chain or branched alkane ⁇ , ⁇ -dicarboxylic acid.
- the GLP-2 derivative has one lipophilic substituent. In one embodiment of the invention the GLP-2 derivative has two lipophilic substituents. In one embodiment of the invention the GLP-2 derivative has three lipophilic substituents. In one embodiment of the invention the GLP-2 derivative has four lipophilic substituents.
- Factor VII compounds applicable in the methods of the present invention encompasses wild-type Factor VII (i.e., a polypeptide having the amino acid sequence disclosed in U.S. Pat. No. 4,784,950), as well as variants of Factor VII exhibiting substantially the same or improved biological activity relative to wild-type Factor VII, Factor VII-related polypeptides as well as Factor VII derivatives and Factor VII conjugates.
- the term “Factor VII compounds” is intended to encompass Factor VII polypeptides in their uncleaved (zymogen) form, as well as those that have been proteolytically processed to yield their respective bioactive forms, which may be designated Factor VIIa.
- Factor VII is cleaved between residues 152 and 153 to yield Factor VIIa.
- variants of Factor VII may exhibit different properties relative to human Factor VII, including stability, phospholipid binding, altered specific activity, and the like.
- Factor VII-related polypeptides encompasses polypeptides, including variants, in which the Factor VIIa biological activity has been substantially modified or reduced relative to the activity of wild-type Factor VIIa.
- These polypeptides include, without limitation, Factor VII or Factor VIIa into which specific amino acid sequence alterations have been introduced that modify or disrupt the bioactivity of the polypeptide.
- Factor VII derivative is intended to designate wild-type Factor VII, variants of Factor VII exhibiting substantially the same or improved biological activity relative to wild-type Factor VII and Factor VII-related polypeptides, in which one or more of the amino acids of the parent peptide have been chemically modified, e.g. by alkylation, PEGylation, acylation, ester formation or amide formation or the like. This includes but are not limited to PEGylated human Factor VIIa, cysteine-PEGylated human Factor VIIa and variants thereof.
- PEGylated human Factor VIIa means human Factor VIIa, having a PEG molecule conjugated to a human Factor VIIa polypeptide. It is to be understood, that the PEG molecule may be attached to any part of the Factor VIIa polypeptide including any amino acid residue or carbohydrate moiety of the Factor VIIa polypeptide.
- cyste-PEGylated human Factor VIIa means Factor VIIa having a PEG molecule conjugated to a sulfhydryl group of a cysteine introduced in human Factor VIIa.
- Factor VIIa The biological activity of Factor VIIa in blood clotting derives from its ability to (i) bind to tissue factor (TF) and (ii) catalyze the proteolytic cleavage of Factor IX or Factor X to produce activated Factor IX or X (Factor IXa or Xa, respectively).
- Factor VIIa biological activity may be quantified by measuring the ability of a preparation to promote blood clotting using Factor VII-deficient plasma and thromboplastin, as described, e.g., in U.S. Pat. No. 5,997,864.
- Factor VIIa biological activity is expressed as the reduction in clotting time relative to a control sample and is converted to “Factor VII units” by comparison with a pooled human serum standard containing 1 unit/ml Factor VII activity.
- Factor VIIa biological activity may be quantified by (i) measuring the ability of Factor VIIa to produce of Factor Xa in a system comprising TF embedded in a lipid membrane and Factor X. (Persson et al., J. Biol. Chem.
- Factor VII variants having substantially the same or improved biological activity relative to wild-type Factor VIIa encompass those that exhibit at least about 25%, preferably at least about 50%, more preferably at least about 75% and most preferably at least about 90% of the specific activity of Factor VIIa that has been produced in the same cell type, when tested in one or more of a clotting assay, proteolysis assay, or TF binding assay as described above.
- Factor VII variants having substantially reduced biological activity relative to wild-type Factor VIIa are those that exhibit less than about 25%, preferably less than about 10%, more preferably less than about 5% and most preferably less than about 1% of the specific activity of wild-type Factor VIIa that has been produced in the same cell type when tested in one or more of a clotting assay, proteolysis assay, or TF binding assay as described above.
- Factor VII variants having a substantially modified biological activity relative to wild-type Factor VII include, without limitation, Factor VII variants that exhibit TF-independent Factor X proteolytic activity and those that bind TF but do not cleave Factor X.
- Variants of Factor VII include, without limitation, polypeptides having an amino acid sequence that differs from the sequence of wild-type Factor VII by insertion, deletion, or substitution of one or more amino acids.
- variant or “variants”, as used herein, is intended to designate Factor VII having the sequence of wild-type factor VII, wherein one or more amino acids of the parent protein have been substituted by another amino acid and/or wherein one or more amino acids of the parent protein have been deleted and/or wherein one or more amino acids have been inserted in protein and/or wherein one or more amino acids have been added to the parent protein. Such addition can take place either at the N-terminal end or at the C-terminal end of the parent protein or both.
- the “variant” or “variants” within this definition still have FVII activity in its activated form.
- a variant is 70% identical with the sequence of wild-type Factor VII.
- a variant is 80% identical with the sequence of wild-type factor VII.
- a variant is 90% identical with the sequence of wild-type factor VII.
- a variant is 95% identical with the sequence of wild-type factor VII.
- Non-limiting examples of Factor VII variants having substantially the same biological activity as wild-type Factor VII include S52A-FVIIa, S60A-FVIIa (Lino et al., Arch. Biochem. Biophys. 352: 182-192, 1998); FVIIa variants exhibiting increased proteolytic stability as disclosed in U.S. Pat. No. 5,580,560; Factor VIIa that has been proteolytically cleaved between residues 290 and 291 or between residues 315 and 316 (Mollerup et al., Biotechnol. Bioeng. 48:501-505, 1995); oxidized forms of Factor VIIa (Kornfelt et al., Arch. Biochem. Biophys.
- FVII variants as disclosed in PCT/DK02/00189; and FVII variants exhibiting increased proteolytic stability as disclosed in WO 02/38162 (Scripps Research Institute); FVII variants having a modified Gla-domain and exhibiting an enhanced membrane binding as disclosed in WO 99/20767 (University of Minnesota) and WO 00/66753 (University of Minnesota); and FVII variants as disclosed in WO 01/58935 (Maxygen ApS), WO 03/93465 (Maxygen ApS) and WO 04/029091 (Maxygen ApS) all of which are incorporated herein by reference.
- FVII variants having increased biological activity compared to wild-type FVIIa include FVII variants as disclosed in WO 01/83725, WO 02/22776, WO 02/077218, PCT/DK02/00635, WO 2004/029090, WO 2003/037932; WO 02/38162 (Scripps Research Institute); and FVIIa variants with enhanced activity as disclosed in JP 2001061479 (Chemo-Sero-Therapeutic Res Inst.), all of which are incorporated herein by reference, all of which are incorporated herein by reference.
- Factor VII variants having substantially reduced or modified biological activity relative to wild-type Factor VII include R152E-FVIIa (Wildgoose et al., Biochem 29:3413-3420, 1990), S344A-FVIIa (Kazama et al., J. Biol. Chem. 270:66-72, 1995), FFR-FVIIa (Holst et al., Eur. J. Vasc. Endovasc. Surg. 15:515-520, 1998), and Factor VIIa lacking the Gla domain, (Nicolaisen et al., FEBS Letts. 317:245-249, 1993), all of which are incorporated herein by reference.
- variants of factor VII, factor VII or factor VII-related polypeptides include wild-type Factor VII, L305V-FVII, L305V/M306D/D309S-FVII, L3051-FVII, L305T-FVII, F374P-FVII, V158T/M298Q-FVII, V158D/E296V/M298Q-FVII, K337A-FVII, M298Q-FVII, V158D/M298Q-FVII, L305V/K337A-FVII, V158D/E296V/M298Q/L305V-FVII, V158D/E296V/M298Q/K337A-FVII, V158D/E296V/M298Q/L305V/K337A-FVII, V158D/E296V/M298Q/L305V/K337A-FVII, K157A-
- Growth hormone applicable in the methods of the present invention includes human growth hormone (hGH), which sequence and characteristics are set froth in, e.g. Hormone Drugs , Gueriguian, U.S.P. Covention, Rockvill, 1982 and growth hormone compounds.
- growth hormone compound is intended to indicate human growth hormone (hGH) in which one or more amino acid residues have been deleted and/or replaced by other amino acid residues, natural or unnatural, and/or hGH comprising addition amino acid residues, natural or unnatural, and/or hGH in which at least one organic substituent is bound to one or more organic substituent.
- hGH human growth hormone
- Particular mentioning is made of the 191 native amino acid sequence (somatropin) and the 192 amino acid N-terminal methionine species (somatrem).
- EPO erythropoietin
- INF- ⁇ interleukin-1 ⁇
- IFN- ⁇ interleukin-1 ⁇
- IL-1- ⁇ interleukin-1 ⁇
- IL-3 interleukin-1 ⁇
- IL-4 interleukin
- IL-20 particularly examples include those disclosed in WO 99/27103 (Zymo-genetics), which is incorporated herein by reference.
- IL-20 is intended to indicate IL-20 itself and fragments thereof as well as polypeptides being at least 90% identical to IL-20 or fragments thereof.
- Proteins particular applicable in the methods of the present invention includes those disclosed in WO 99/27103 as SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34 and S
- TTF are applicable in the methods of the present invention.
- TTF peptides are a family of peptides found mainly in association with the gastrointestinal tract. Particular mentioning is made of breast cancer associated pS2 peptide (TFF-1), which is known from human, mouse, and rat, spasmolytical polypeptide (TFF-2), which is known from human, pig, rat, and mouse and intestinal trefoil factor (TFF-3), known from human, rat and mouse.
- TTF-1 breast cancer associated pS2 peptide
- TTF-2 spasmolytical polypeptide
- TMF-3 intestinal trefoil factor
- TFF-2 peptide wherein a TFF2 peptide with an amino acid as disclosed in SEQ ID NO:1 of WO 02/46226 comprising disulphide bonds between Cys6-Cys104, Cys8-Cys35, Cys19-Cys34, Cys29-Cys46, Cys58-Cys84, Cys68-Cys83, and Cys78-Cys95 and wherein a moiety X independently selected from sugar residues and oligosaccharides is covalently attached to Asn15.
- TFF-1 and TFF-3 dimers as those disclosed in WO 96/06861 (Novo Nordisk), which is incorporated herein by reference.
- enzymes Other classes of peptides or proteins which are applicable in the methods of the present invention include enzymes. Many enzymes are used for various industrial purposes, and particular mentioning is made of hydrolases (proteases, lipases, cellulases, esterases), oxidoreductases (laccases, peroxidaxes, catalases, superoxide dismutases, lipoxygenases), transferases and isomerases.
- peptides or proteins applicable in the methods of the present invention include ACTH, corticotropin-releasing factor, angiotensin, calcitonin, insulin and fragments and analogues thereof, glucagon, IGF-1, IGF-2, enterogastrin, gastrin, tetragastrin, pentagastrin, urogastrin, epidermal growth factor, secretin, nerve growth factor, thyrotropin releasing hormone, somatostatin, growth hormone releasing hormone, somatomedin, parathyroid hormone, thrombopoietin, erythropoietin, hypothalamic releasing factors, prolactin, thyroid stimulating hormones, endorphins, enkephalins, vasopressin, oxytocin, opiods and analogues thereof, asparaginase, arginase, arginine deaminase, adenosine deaminase and ribonuclease.
- Peptides to be modified according to the methods of the present invention may either be isolated from natural sources (e.g. plants, animals or micro-organisms, such as yeast, bacteria, fungi or vira) or they may be synthesised.
- Peptides form natural sources also include peptides form transgenic sources, e.g. sources which have been genetically modified to express or to increase the expression of a peptide, wherein said peptide may be “natural” in the sense that it exists in nature or “unnatural” in the sense that it only exists due to human intervention.
- Peptides isolated form natural sources may also be subjected to synthetic modification prior to the conjugation of the present invention.
- the invention relates to conjugated peptides obtainable according to the methods of the present invention. If the conjugated peptide obtained by the methods of the present invention is a therapeutic peptide, the invention also provides the use of such compounds in therapy, and pharmaceutical compositions comprising such compounds.
- the invention provides conjugated peptides of the formula
- Insulin is used to treat or prevent diabetes, and in one embodiment, the present invention thus provides a method of treating type 1 or type 2 diabetes, the method comprising administering to a subject in need thereof a therapeutically effective amount of an insulin or insulin compound conjugate according to the present invention.
- the invention provides the use of an insulin or insulin compound conjugate according to the present invention in the manufacture of a medicament used in the treatment of type 1 or type 2 diabetes.
- GLP-1 may be used in the treatment of hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, obesity, hypertension, syndrome X, dyslipidemia, ⁇ -cell apoptosis, ⁇ -cell deficiency, inflammatory bowel syndrome, dyspepsia, cognitive disorders, e.g. cognitive enhancing, neuroprotection, atheroschlerosis, coronary heart disease and other cardiovascular disorders.
- the present invention thus provides a method of treating said diseases, the method comprising administering to a subject in need thereof a therapeutically effective amount of a GLP-1 or GLP-1 compound conjugate according to the present invention.
- the invention provides the use of a GLP-1 or GLP-1 compound conjugate according to the present invention in the manufacture of a medicament used in the treatment of the above mentioned diseases.
- GLP-2 may be used in the treatment of intestinal failure leading to malabsorption of nutrients in the intestines, and in particular GLP-2 may be used in the treatment of small bowel syndrome, Inflammatory bowel syndrome, Crohns disease, colitis including collagen colitis, radiation colitis, post radiation atrophy, non-tropical (gluten intolerance) and tropical sprue, damaged tissue after vascular obstruction or trauma, tourist diarrhea, dehydration, bacteremia, sepsis, anorexia nervosa, damaged tissue after chemotherapy, premature infants, schleroderma, gastritis including atrophic gastritis, postantrectomy atrophic gastritis and helicobacter pylori gastritis, ulcers, enteritis, cul-de-sac, lymphatic obstruction, vascular disease and graft-versus-host, healing after surgical procedures, post radiation atrophy and chemotherapy, and osteoporosis. It is therefore an intension of the present invention to provide methods of treating the above diseases, the method compris
- the present invention provides the use of a GLP-2 or GLP-2 compound conjugate according to this invention in the manufacture of a medicament used in the treatment of the above mentioned diseases.
- the invention provides a method for the treatment of growth hormone deficiency (GHD); Turner Syndrome; Prader-Willi syndrome (PWS); Noonan syndrome; Down syndrome; chronic renal disease, juvenile rheumatoid arthritis; cystic fibrosis, HIV-infection in children receiving HAART treatment (HIV/HALS children); short children born short for gestational age (SGA); short stature in children born with very low birth weight (VLBW) but SGA; skeletal dysplasia; hypochondroplasia; achondroplasia; idiopathic short stature (ISS); GHD in adults; fractures in or of long bones, such as tibia, fibula, femur, humerus, radius, ulna, clavicula, matacarpea, matatarsea, and digit; fractures in or of spongious bones, such as the scul
- APCD chronic dialysis
- malnutritional associated cardiovascular disease in APCD reversal of cachexia in APCD; cancer in APCD; chronic abstractive pulmonal disease in APCD; HIV in APCD; elderly with APCD; chronic liver disease in APCD, fatigue syndrome in APCD; Crohn's disease; impaired liver function; males with HIV infections; short bowel syndrome; central obesity; HIV-associated lipodystrophy syndrome (HALS); male infertility; patients after major elective surgery, alcohol/drug detoxification or neurological trauma; aging; frail elderly; osteo-arthritis; traumatically damaged cartilage; erectile dysfunction; fibromyalgia; memory disorders; depression; traumatic brain injury; subarachnoid haemorrhage; very low birth
- the invention provides a method for the acceleration of the healing of muscle tissue, nervous tissue or wounds; the acceleration or improvement of blood flow to damaged tissue; or the decrease of infection rate in damaged tissue, the method comprising administration to a patient in need thereof an effective amount of a growth hormone compound onjugayte according to the present invention.
- the invention provides the use of growth hormone compound conjugates according to the present invention in the manufacture of medicaments for the treatment of the above mentioned diseases.
- Cytokines are implicated in the etiology of a host of diseases involving the immune system.
- IL-20 could be involved in psoriasis and its treatment, and I-21 is believed to be involved in cancer and could constitute a treatment to this disease.
- the invention provides a method for the treatment of psoriasis comprising the administration of IL-20 conjugates according to the present invention.
- the invention relates to the use of an IL-20 conjugate of the present invention in the manufacture of a medicament used in the treatment of psoriasis.
- the present invention relates to a method of treating cancer, the method comprising administration of an IL-21 conjugate of the present invention to a subject in need thereof.
- the invention relates to the use of an IL-21 conjugate according to the present invention in the manufacture of a medicament used in the treatment of cancer.
- TTF peptides may be used to increase the viscosity of muscus layers in subject, to reduce secretion of salvia, e.g. where the increase salvia secretion is caused by irradiation therapy, treatment with anticholinergics or Sjogren's syndrome, to treat allergic rhinitis, stress induced gastric ulcers secondary to trauma, shock, large operations, renal or liver diseases, treatment with NSAID, e.g. aspirin, steroids or alcohol.
- TTF peptides may also be used to treat Chrohn's disease, ulcerative colitis, keratoconjunctivitis, chronic bladder infections, intestinal cystitis, papillomas and bladder cancer.
- the invention thus relates the a method of treating the above mention diseases or states, the method comprising administering to a subject patient in need thereof a therapeutically effective amount of a TTF conjugate according to the present invention.
- the invention relates the use of a TTF conjugate of the present invention in the manufacture of a medicament for the treatment of the above mentioned diseases or states.
- the present invention provides a method for preventing or delaying the progression of impaired glucose tolerance (IGT) to non-insulin requiring type 2 diabetes, for preventing or delaying the progression of non-insulin requiring type 2 diabetes to insulin requiring diabetes, for treating obesity and for regulating the appetite.
- ITT impaired glucose tolerance
- Melanocortin 4 receptor agonists have also been implicated in the treatment of diseases selected from atherosclerosis, hypertension, diabetes, type 2 diabetes, impaired glucose tolerance (IGT), dyslipidemia, coronary heart disease, gallbladder disease, gall stone, osteoarthritis, cancer, sexual dysfunction and the risk of premature death.
- the invention thus provides a method of treating the above diseases or states, the method comprising administering to a subject in need thereof a therapeutically effective amount of an melanocortin 4 receptor agonist conjugate of the present invention.
- the invention relates to the use of a melanocortin 4 receptor agonist conjugate of the present invention in the manufacture of a medicament for the treatment of the above mentioned diseases or states.
- Factor VII compounds have been implicated in the treatment of disease related to coagulation, and biological active Factor VII compounds in particular have been implicated in the treatment of hemophiliacs, hemophiliacs with inhibitors to Factor VIII and IX, patients with thrombocytopenia, patients with thrombocytopathies, such as Glanzmann's thrombastenia platelet release defect and strorage pool defects, patient with von Willebrand's disease, patients with liver disease and bleeding problems associated with traumas or surgery.
- Biologically inactive Factor VII compounds have been implicated in the treatment of patients being in hypercoagluable states, such as patients with sepsis, deep-vein thrombosis, patients in risk of myocardial infections or thrombotic stroke, pulmonary embolism, patients with acute coronary syndromes, patients undergoing coronary cardiac, prevention of cardiac events and restenosis for patient receiving angioplasty, patient with peripheral vascular diseases, and acute respiratory distress syndrome.
- the invention thus provides a method for the treatment of the above mentioned diseases or states, the method comprising administering to a subject in need thereof a therapeutically effective amount of a Factor VII compound conjugate according to the present invention.
- the invention provides the use of a Factor VII compound conjugate according to the present invention in the manufacture of a medicament used in the treatment of the above mentioned diseases or states.
- the present invention provides the use of conjugated peptides of the present invention in diagnostics.
- ⁇ -amino acid amides are, as mentioned previously, particular well-suited as a nucleophile in the methods of the present invention.
- the invention thus provides compounds according to formula (I)
- a and E independently represent C 1-6 alkylene, C 2-6 alkenylene, C 2-6 alkynylene or arylene, all of which may optionally be substituted with one or more substituents selected from halogen, amino, cyano and nitro;
- B and D represents —C(O)— or —NH— with the proviso that when B represents —C(O)— then D must represent —NH—, and when B represents —NH— then D must represent —C(O)—;
- G represents hydrogen or C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl or aryl, all of which may optionally be substituted with one or more substituents selected from halogen, amino, cyano and nitro.
- a and E independently represent C 1-6 alkylene, such as methylene, ethylene, propylene, butylenes, pentylene or hexylene, or arylene, such as phenylene.
- G represents hydrogen or methyl, ethyl, propyl or butyl.
- the invention provides compounds according to formula II
- J and L independently represent C 1-6 alkylene, C 2-6 alkenylene, C 2-6 alkynylene or arylene, all of which may optionally be substituted with one or more substituents selected from halogen, amino, cyano and nitro; and M represents hydrogen or C 1-6 alkyl.
- J and L independently represent C 1-6 alkylene, such as methylene, ethylene, propylene, butylenes, pentylene or hexylene, or arylene, such as phenylene.
- M represents hydrogen or methyl, ethyl, propyl or butyl.
- the compounds of formula II are selected from amongst
- the invention provides compounds according to formula III
- Q represents represent C 1-6 alkylene, C 2-6 alkenylene, C 2-6 alkynylene or arylene, all of which may optionally be substituted with one or more substituents selected from halogen, amino, cyano and nitro; and T represents hydrogen or C 1-6 alkyl.
- Q represents C 1-6 alkylene, such as methylene, ethylene, propylene, butylenes, pentylene or hexylene, or arylene, such as phenylene.
- T represents hydrogen or methyl, ethyl, propyl or butyl.
- the invention provides compounds according to formula IV
- J′′ and L′′ independently represent C 1-6 alkylene or arylene, all of which may optionally be substituted with one or more substituents selected from halogen amino, cyano and nitro.
- J and L independently represent methylene or ethylene.
- the compounds of formula IV are selected from amongst
- Another object of the present invention is to provide a pharmaceutical composition
- a pharmaceutical composition comprising a compound of formula [a]which is present in a concentration from 10 ⁇ 12 mg/ml to 200 mg/ml, such as e.g. 10 ⁇ 10 mg/ml to 5 mg/ml and wherein said composition has a pH from 2.0 to 10.0.
- the composition may further comprise a buffer system, preservative(s), tonicity agent(s), chelating agent(s), stabilizers and surfactants.
- the pharmaceutical composition is an aqueous composition, i.e. composition comprising water. Such composition is typically a solution or a suspension.
- the pharmaceutical composition is an aqueous solution.
- aqueous composition is defined as a composition comprising at least 50% w/w water.
- aqueous solution is defined as a solution comprising at least 50% w/w water, and the term “aqueous suspension” is defined as a suspension comprising at least 50% w/w water.
- the pharmaceutical composition is a freeze-dried composition, whereto the physician or the patient adds solvents and/or diluents prior to use.
- the pharmaceutical composition is a dried composition (e.g. freeze-dried or spray-dried) ready for use without any prior dissolution.
- the invention in a further aspect relates to a pharmaceutical composition
- a pharmaceutical composition comprising an aqueous solution of a compound of formula [a], and a buffer, wherein said compound of formula [a] is present in a concentration from 0.1-100 mg/ml or above, and wherein said composition has a pH from about 2.0 to about 10.0.
- the pH of the composition is selected from the list consisting of 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, and 10.0.
- the buffer is selected from the group consisting of sodium acetate, sodium carbonate, citrate, glycylglycine, histidine, glycine, lysine, arginine, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate, and tris(hydroxymethyl)-aminomethan, bicine, tricine, malic acid, succinate, maleic acid, fumaric acid, tartaric acid, aspartic acid or mixtures thereof.
- Each one of these specific buffers constitutes an alternative embodiment of the invention.
- the composition further comprises a pharmaceutically acceptable preservative.
- the preservative is selected from the group consisting of phenol, o-cresol, m-cresol, p-cresol, methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, 2-phenoxyethanol, butyl p-hydroxybenzoate, 2-phenylethanol, benzyl alcohol, chlorobutanol, and thiomerosal, bronopol, benzoic acid, imidurea, chlorohexidine, sodium dehydroacetate, chlorocresol, ethyl p-hydroxybenzoate, benzethonium chloride, chlorphenesine (3p-chlorphenoxypropane-1,2-diol) or mixtures thereof.
- the preservative is present in a concentration from 0.1 mg/ml to 20 mg/ml. In a further embodiment of the invention the preservative is present in a concentration from 0.1 mg/ml to 5 mg/ml. In a further embodiment of the invention the preservative is present in a concentration from 5 mg/ml to 10 mg/ml. In a further embodiment of the invention the preservative is present in a concentration from 10 mg/ml to 20 mg/ml. Each one of these specific preservatives constitutes an alternative embodiment of the invention.
- the use of a preservative in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: The Science and Practice of Pharmacy, 20 th edition, 2000.
- composition further comprises an isotonic agent.
- isotonic agent is selected from the group consisting of a salt (e.g. sodium chloride), a sugar or sugar alcohol, an amino acid (e.g. L-glycine, L-histidine, arginine, lysine, isoleucine, aspartic acid, tryptophan, threonine),
- alditol e.g. glycerol (glycerine), 1,2-propanediol (propyleneglycol), 1,3-propanediol, 1,3-butanediol
- polyethyleneglycol e.g. PEG400
- Any sugar such as mono-, di-, or polysaccharides, or water-soluble glucans, including for example fructose, glucose, mannose, sorbose, xylose, maltose, lactose, sucrose, trehalose, dextran, pullulan, dextrin, cyclodextrin, soluble starch, hydroxyethyl starch and carboxymethylcellulose-Na may be used.
- the sugar additive is sucrose.
- Sugar alcohol is defined as a C 4 -C 8 hydrocarbon having at least one —OH group and includes, for example, mannitol, sorbitol, inositol, galactitol, dulcitol, xylitol, and arabitol.
- the sugar alcohol additive is mannitol.
- the sugars or sugar alcohols mentioned above may be used individually or in combination. There is no fixed limit to the amount used, as long as the sugar or sugar alcohol is soluble in the liquid preparation and does not adversely effect the stabilizing effects obtained using the methods of the invention.
- the sugar or sugar alcohol concentration is between about 1 mg/ml and about 150 mg/ml.
- the isotonic agent is present in a concentration from 1 mg/ml to 50 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 1 mg/ml to 7 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 8 mg/ml to 24 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 25 mg/ml to 50 mg/ml. Each one of these specific isotonic agents constitutes an alternative embodiment of the invention.
- the use of an isotonic agent in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: The Science and Practice of Pharmacy, 20 th edition, 2000.
- the composition further comprises a chelating agent.
- the chelating agent is selected from salts of ethylenediaminetetraacetic acid (EDTA), citric acid, and aspartic acid, and mixtures thereof.
- the chelating agent is present in a concentration from 0.1 mg/ml to 5 mg/ml.
- the chelating agent is present in a concentration from 0.1 mg/ml to 2 mg/ml.
- the chelating agent is present in a concentration from 2 mg/ml to 5 mg/ml.
- Each one of these specific chelating agents constitutes an alternative embodiment of the invention.
- the use of a chelating agent in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: The Science and Practice of Pharmacy, 20 th edition, 2000.
- composition further comprises a stabilizer.
- a stabilizer in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: The Science and Practice of Pharmacy, 20 th edition, 2000.
- compositions of the invention are stabilized liquid pharmaceutical compositions whose therapeutically active components include a protein that possibly exhibits aggregate formation during storage in liquid pharmaceutical compositions.
- aggregate formation is intended a physical interaction between the protein molecules that results in formation of oligomers, which may remain soluble, or large visible aggregates that precipitate from the solution.
- during storage is intended a liquid pharmaceutical composition or composition once prepared, is not immediately administered to a subject. Rather, following preparation, it is packaged for storage, either in a liquid form, in a frozen state, or in a dried form for later reconstitution into a liquid form or other form suitable for administration to a subject.
- liquid pharmaceutical composition or composition is dried either by freeze drying (i.e., lyophilization; see, for example, Williams and Polli (1984) J. Parenteral Sci. Technol. 38:48-59), spray drying (see Masters (1991) in Spray-Drying Handbook (5th ed; Longman Scientific and Technical, Essez, U.K.), pp. 491-676; Broadhead et al. (1992) Drug Devel. Ind. Pharm. 18:1169-1206; and Mumenthaler et al. (1994) Pharm. Res. 11:12-20), or air drying (Carpenter and Crowe (1988) Cryobiology 25:459-470; and Roser (1991) Biopharm. 4:47-53).
- Aggregate formation by a protein during storage of a liquid pharmaceutical composition can adversely affect biological activity of that protein, resulting in loss of therapeutic efficacy of the pharmaceutical composition. Furthermore, aggregate formation may cause other problems such as blockage of tubing, membranes, or pumps when the protein-containing pharmaceutical composition is administered using an infusion system.
- compositions of the invention may further comprise an amount of an amino acid base sufficient to decrease aggregate formation by the protein during storage of the composition.
- amino acid base is intended an amino acid or a combination of amino acids, where any given amino acid is present either in its free base form or in its salt form. Where a combination of amino acids is used, all of the amino acids may be present in their free base forms, all may be present in their salt forms, or some may be present in their free base forms while others are present in their salt forms.
- amino acids to use in preparing the compositions of the invention are those carrying a charged side chain, such as arginine, lysine, aspartic acid, and glutamic acid.
- Any stereoisomer (i.e., L or D isomer, or mixtures thereof) of a particular amino acid (methionine, histidine, arginine, lysine, isoleucine, aspartic acid, tryptophan, threonine and mixtures thereof) or combinations of these stereoisomers or glycine or an organic base such as but not limited to imidazole, may be present in the pharmaceutical compositions of the invention so long as the particular amino acid or organic base is present either in its free base form or its salt form.
- the L-stereoisomer of an amino acid is used.
- the D-stereoisomer is used.
- Compositions of the invention may also be formulated with analogues of these amino acids.
- amino acid analogue is intended a derivative of the naturally occurring amino acid that brings about the desired effect of decreasing aggregate formation by the protein during storage of the liquid pharmaceutical compositions of the invention.
- Suitable arginine analogues include, for example, aminoguanidine, ornithine and N-monoethyl L-arginine
- suitable methionine analogues include ethionine and buthionine
- suitable cysteine analogues include S-methyl-L cysteine.
- the amino acid analogues are incorporated into the compositions in either their free base form or their salt form.
- the amino acids or amino acid analogues are used in a concentration, which is sufficient to prevent or delay aggregation of the protein.
- methionine (or other sulphuric amino acids or amino acid analogous) may be added to inhibit oxidation of methionine residues to methionine sulfoxide when the protein acting as the therapeutic agent is a protein comprising at least one methionine residue susceptible to such oxidation.
- inhibitor is intended minimal accumulation of methionine oxidized species over time. Inhibiting methionine oxidation results in greater retention of the protein in its proper molecular form. Any stereoisomer of methionine (L or D isomer) or any combinations thereof can be used.
- the amount to be added should be an amount sufficient to inhibit oxidation of the methionine residues such that the amount of methionine sulfoxide is acceptable to regulatory agencies. Typically, this means that the composition contains no more than about 10% to about 30% methionine sulfoxide. Generally, this can be obtained by adding methionine such that the ratio of methionine added to methionine residues ranges from about 1:1 to about 1000:1, such as 10:1 to about 100:1.
- the composition further comprises a stabilizer selected from the group of high molecular weight polymers or low molecular compounds.
- the stabilizer is selected from polyethylene glycol (e.g. PEG 3350), polyvinyl alcohol (PVA), polyvinylpyrrolidone, carboxy-/hydroxycellulose or derivates thereof (e.g. HPC, HPC-SL, HPC-L and HPMC), cyclodextrins, sulphur-containing substances as monothioglycerol, thioglycolic acid and 2-methylthioethanol, and different salts (e.g. sodium chloride).
- PEG 3350 polyethylene glycol
- PVA polyvinyl alcohol
- PVpyrrolidone polyvinylpyrrolidone
- carboxy-/hydroxycellulose or derivates thereof e.g. HPC, HPC-SL, HPC-L and HPMC
- cyclodextrins e.g. sulphur-containing substances as monothioglycerol,
- compositions may also comprise additional stabilizing agents, which further enhance stability of a therapeutically active protein therein.
- Stabilizing agents of particular interest to the present invention include, but are not limited to, methionine and EDTA, which protect the protein against methionine oxidation, and a nonionic surfactant, which protects the protein against aggregation associated with freeze-thawing or mechanical shearing.
- the composition further comprises a surfactant.
- the surfactant is selected from a detergent, ethoxylated castor oil, polyglycolized glycerides, acetylated monoglycerides, sorbitan fatty acid esters, polyoxypropylene-polyoxyethylene block polymers (e.g. poloxamers such as Pluronice F68, poloxamer 188 and 407, Triton X-100), polyoxyethylene sorbitan fatty acid esters, polyoxyethylene and polyethylene derivatives such as alkylated and alkoxylated derivatives (tweens, e.g.
- Tween-20, Tween-40, Tween-80 and Brij-35 monoglycerides or ethoxylated derivatives thereof, diglycerides or polyoxyethylene derivatives thereof, alcohols, glycerol, lectins and phospholipids (e.g. phosphatidyl serine, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, diphosphatidyl glycerol and sphingomyelin), derivates of phospholipids (e.g. dipalmitoyl phosphatidic acid) and lysophospholipids (e.g.
- ceramides e.g. sodium tauro-dihydrofusidate etc.
- long-chain fatty acids and salts thereof C 6 -C 12 e.g.
- acylcarnitines and derivatives N-acylated derivatives of lysine, arginine or histidine, or side-chain acylated derivatives of lysine or arginine, N-acylated derivatives of dipeptides comprising any combination of lysine, arginine or histidine and a neutral or acidic amino acid, N-acylated derivative of a tripeptide comprising any combination of a neutral amino acid and two charged amino acids, DSS (docusate sodium, CAS registry no [577-11-7]), docusate calcium, CAS registry no [128-49-4]), docusate potassium, CAS registry no [7491-09-0]), SDS (sodium dodecyl sulphate or sodium lauryl sulphate), sodium caprylate, cholic acid or derivatives thereof, bile acids and salts thereof and glycine or taurine conjugates, ursodeoxycholic acid
- N-alkyl-N,N-dimethylammonio-1-propanesulfonates 3-cholamido-1-propyldimethylammonio-1-propanesulfonate
- cationic surfactants quaternary ammonium bases
- cetyl-trimethylammonium bromide cetylpyridinium chloride
- non-ionic surfactants e.g. Dodecyl ⁇ -D-glucopyranoside
- poloxamines e.g.
- Tetronic's which are tetrafunctional block copolymers derived from sequential addition of propylene oxide and ethylene oxide to ethylenediamine, or the surfactant may be selected from the group of imidazoline derivatives, or mixtures thereof. Each one of these specific surfactants constitutes an alternative embodiment of the invention.
- Such additional ingredients may include wetting agents, emulsifiers, antioxidants, bulking agents, tonicity modifiers, chelating agents, metal ions, oleaginous vehicles, proteins (e.g., human serum albumin, gelatine or proteins) and a zwitterion (e.g., an amino acid such as betaine, taurine, arginine, glycine, lysine and histidine).
- additional ingredients should not adversely affect the overall stability of the pharmaceutical composition of the present invention.
- compositions containing a compound of formula [a]according to the present invention may be administered to a patient in need of such treatment at several sites, for example, at topical sites, for example, skin and mucosal sites, at sites which bypass absorption, for example, administration in an artery, in a vein, in the heart, and at sites which involve absorption, for example, administration in the skin, under the skin, in a muscle or in the abdomen.
- topical sites for example, skin and mucosal sites
- sites which bypass absorption for example, administration in an artery, in a vein, in the heart
- sites which involve absorption for example, administration in the skin, under the skin, in a muscle or in the abdomen.
- Administration of pharmaceutical compositions according to the invention may be through several routes of administration, for example, lingual, sublingual, buccal, in the mouth, oral, in the stomach and intestine, nasal, pulmonary, for example, through the bronchioles and alveoli or a combination thereof, epidermal, dermal, transdermal, vaginal, rectal, ocular, for examples through the conjunctiva, uretal, and parenteral to patients in need of such a treatment.
- routes of administration for example, lingual, sublingual, buccal, in the mouth, oral, in the stomach and intestine, nasal, pulmonary, for example, through the bronchioles and alveoli or a combination thereof, epidermal, dermal, transdermal, vaginal, rectal, ocular, for examples through the conjunctiva, uretal, and parenteral to patients in need of such a treatment.
- compositions of the present invention may be administered in several dosage forms, for example, as solutions, suspensions, emulsions, microemulsions, multiple emulsion, foams, salves, pastes, plasters, ointments, tablets, coated tablets, rinses, capsules, for example, hard gelatine capsules and soft gelatine capsules, suppositories, rectal capsules, drops, gels, sprays, powder, aerosols, inhalants, eye drops, ophthalmic ointments, ophthalmic rinses, vaginal pessaries, vaginal rings, vaginal ointments, injection solution, in situ transforming solutions, for example in situ gelling, in situ setting, in situ precipitating, in situ crystallization, infusion solution, and implants.
- solutions for example, suspensions, emulsions, microemulsions, multiple emulsion, foams, salves, pastes, plasters, ointments, tablets, coated tablets, rinses,
- compositions of the invention may further be compounded in, or attached to, for example through covalent, hydrophobic and electrostatic interactions, a drug carrier, drug delivery system and advanced drug delivery system in order to further enhance stability of the compound of formula [a], increase bioavailability, increase solubility, decrease adverse effects, achieve chronotherapy well known to those skilled in the art, and increase patient compliance or any combination thereof.
- carriers, drug delivery systems and advanced drug delivery systems include, but are not limited to, polymers, for example cellulose and derivatives, polysaccharides, for example dextran and derivatives, starch and derivatives, poly(vinyl alcohol), acrylate and methacrylate polymers, polylactic and polyglycolic acid and block co-polymers thereof, polyethylene glycols, carrier proteins, for example albumin, gels, for example, thermogelling systems, for example block co-polymeric systems well known to those skilled in the art, micelles, liposomes, microspheres, nanoparticulates, liquid crystals and dispersions thereof, L2 phase and dispersions there of, well known to those skilled in the art of phase behaviour in lipid-water systems, polymeric micelles, multiple emulsions, self-emulsifying, self-microemulsifying, cyclodextrins and derivatives thereof, and dendrimers.
- polymers for example cellulose and derivatives, polysaccharides, for example dextran and derivative
- compositions of the present invention are useful in the composition of solids, semisolids, powder and solutions for pulmonary administration of compound of formula [a], using, for example a metered dose inhaler, dry powder inhaler and a nebulizer, all being devices well known to those skilled in the art.
- compositions of the current invention are specifically useful in the composition of controlled, sustained, protracting, retarded, and slow release drug delivery systems. More specifically, but not limited to, compositions are useful in composition of parenteral controlled release and sustained release systems (both systems leading to a many-fold reduction in number of administrations), well known to those skilled in the art. Even more preferably, are controlled release and sustained release systems administered subcutaneous.
- examples of useful controlled release system and compositions are hydrogels, oleaginous gels, liquid crystals, polymeric micelles, microspheres, nanoparticles,
- Methods to produce controlled release systems useful for compositions of the current invention include, but are not limited to, crystallization, condensation, co-crystallization, precipitation, co-precipitation, emulsification, dispersion, high pressure homogenisation, encapsulation, spray drying, microencapsulating, coacervation, phase separation, solvent evaporation to produce microspheres, extrusion and supercritical fluid processes.
- General reference is made to Handbook of Pharmaceutical Controlled Release (Wise, D. L., ed. Marcel Dekker, New York, 2000) and Drug and the Pharmaceutical Sciences vol. 99: Protein Composition and Delivery (MacNally, E. J., ed. Marcel Dekker, New York, 2000).
- Parenteral administration may be performed by subcutaneous, intramuscular, intraperitoneal or intravenous injection by means of a syringe, optionally a pen-like syringe.
- parenteral administration can be performed by means of an infusion pump.
- a further option is a composition which may be a solution or suspension for the administration of the Compound of formula [a] in the form of a nasal or pulmonal spray.
- the pharmaceutical compositions containing the compound of formula [a]of the invention can also be adapted to transdermal administration, e.g. by needle-free injection or from a patch, optionally an iontophoretic patch, or transmucosal, e.g. buccal, administration.
- the RP-analyses was performed using an Alliance Waters 2695 system fitted with a Waters 2487 dualband detector. UV detections at 214 nm and 254 nm were collected using a Symmetry300 C18, 5 um, 3.9 mm ⁇ 150 mm column, 42° C. The compounds are eluted with a linear gradient of 5-95% acetonitrile in water which is buffered with 0.05% trifluoroacetic acid over 15 minutes at a flow-rate of 1.0 min/min.
- the RP-analysis was performed using a Waters 2690 systems fitted with a Waters 996 diode array detector. UV detections were collected at 214, 254, 276, and 301 nm on a 218TP54 4.6 mm ⁇ 250 mm 5 ⁇ C-18 silica column (The Seperations Group, Hesperia), which was eluted at 1 ml/min at 42° C. The column was equilibrated with 5% acetonitrile, which was buffered with 0.1% trifluoroacetic acid, in a 0.1% aqueous solution of trifluoroacetic acid in water.
- the sample was eluted by a gradient of 0% to 90% acetonitrile, which was buffered with 0.1% trifluoroacetic acid, in a 0.1% aqueous solution of trifluoroacetic acid in water during 50 min.
- transacylating compound e.g. the compound of the formula
- Y-E-Z may either be acquired commercially or synthesized according to the following guidelines in general methods below.
- R′ and R′′ independently represents C 1-15 alkylene, C 2-15 alkenylene, C 2-15 alkynylene, C 11-15 heteroalkylene, C 2-15 heteroalkenylene, C 2-15 heteroalkynylene, wherein one or more homocyclic aromatic compound biradical or heterocyclic compound biradical may be inserted, may be prepared from a suitable amino acid methyl ester which is protected at the alpha-amino group by a suitable protecting group PG as described in the literature (e.g. T. W. Greene, P. G. M. Wuts, Protective groups in organic synthesis, 2 nd ed., 1991 John Wiley & Sons, Inc. New York)
- acylation method e.g. using an suitable acid, in which X may or may not be protected by a suitable protective group, as described in the literature (e.g. T. W. Greene, P. G. M. Wuts, Protective groups in organic synthesis, 2 nd ed., 1991 John Wiley & Sons, Inc. New York)
- a coupling reagent such as e.g. 1-hydroxybenzotriazole, 3,4-dihydro-3-hydroxybenzotriazin-4-one or 7-azabenzotriazole in combination with e.g. a carbodiimide such as e.g. diisopropylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in the presence or absence of a suitable base such as e.g. triethylamine or ethyldiisopropylamine to form the ester of type
- a coupling reagent such as e.g. 1-hydroxybenzotriazole, 3,4-dihydro-3-hydroxybenzotriazin-4-one or 7-azabenzotriazole in combination with e.g. a carbodiimide such as e.g. diisopropylcarbodiimide or 1-(3-dimethylaminopropyl
- the ester may be transformed into the corresponding amide by reaction with e.g. ammonia in a suitable solvent or mixture of solvents such as e.g. water or N,N-dimethylformamide.
- a suitable solvent or mixture of solvents such as e.g. water or N,N-dimethylformamide.
- Amino acid methyl esters are generally commercially available, or they may be synthesized by well-known methods.
- R′ and R′′ are defined as above, may be prepared from a suitable amino acid methyl ester which is protected at the alpha-amino group by a suitable protecting group PG, as described in the literature (e.g. T. W. Greene, P. G. M. Wuts, Protective groups in organic synthesis, 2 nd ed., 1991 John Wiley & Sons, Inc. New York)
- PG protecting group
- the ester may be transformed into the corresponding amide by reaction with e.g. ammonia in a suitable solvent or mixture of solvents such as e.g. water or N,N-dimethylformamide.
- a suitable solvent or mixture of solvents such as e.g. water or N,N-dimethylformamide.
- R′ and R′′ are defined as above, may be prepared from a suitable amino acid methyl ester which is protected at the alpha-amino group by a suitable protecting group PG, as and described in the literature, e.g. in T. W. Greene, P. G. M. Wuts, Protective groups in organic synthesis, 2 nd ed., 1991 John Wiley & Sons, Inc. New York)
- the anion of LG′ is a suitable leaving group such as halogenide or sulfonate and X may or may not be protected by a suitable protective group as described in the literature, e.g. in T. W. Greene, P. G. M. Wuts, Protective groups in organic synthesis, 2 nd ed., 1991 John Wiley & Sons, Inc. New York.
- the reaction may take place under basic conditions, applying bases such as e.g. potassium carbonate, diazabicylo[5,4,0]undec-5-ene, or tert-butyltetramethyluanidine at a suitable temperature, typically between ⁇ 78° C. and 200° C.
- the ester may be transformed into the corresponding amide by reaction with e.g. ammonia in a suitable solvent or mixture of solvents such as e.g. water or N,N-dimethylformamide.
- a suitable solvent or mixture of solvents such as e.g. water or N,N-dimethylformamide.
- R′ and R′′ are defined as above, may be prepared from a suitable acid which is protected at the alpha-amino group by a suitable protecting group PG, as described in the literature, e.g. in T. W. Greene, P. G. M. Wuts, Protective groups in organic synthesis, 2 nd ed., 1991 John Wiley & Sons, Inc. New York
- acylation conditions known to a person skilled in the art e.g. a coupling reagent such as e.g. 1-hydroxybenzotriazole, 3,4-dihydro-3-hydroxybenzotriazin-4-one or 7-azabenzotriazole in combination with e.g. a carbodiimide such as e.g. diisopropylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in the presence or absence of a suitable base such as e.g. triethylamine or ethyldiisopropylamine to form an amide
- a coupling reagent such as e.g. 1-hydroxybenzotriazole, 3,4-dihydro-3-hydroxybenzotriazin-4-one or 7-azabenzotriazole in combination with e.g. a carbodiimide such as e.g. diisopropylcarbodi
- N-protected cysteine derivative for instance an ester, N-(2,4-dimethoxybenzyl)amide or N-bis(cyclopropyl)methyl amide
- R 51 represents C 1-6 alkyl, partially or completely fluorinated C 1-6 alkyl, or aryl, optionally substituted with alkyl, halogen, nitro, cyano, or acetamido
- R 50 represents hydrogen, alkyl, aryl, or heteroaryl, said aryl or heteroaryl being optionally substituted once or several times with C 1-6 alkoxy, hydroxy
- This derivative is converted into an amino acid amide by conversion of the acid derivative into an amide and deprotection of the alpha-amino group.
- Suitable N-protecting groups are for instance trityl, phthaloyl, or alkoxycarbonyl groups, such as tert-butyloxycarbonyl
- Aspartic or glutamic acids can be selectively protected by treatment of an N-alkoxycarbonyl derivative with formaldehyde, to yield cyclic esters as shown below:
- R 60 represents tert-butyl, benzyl, 2-chlorobenzyl, allyl, 2-(trimethylsilyl)ethyl, 2,2,2-trichloroethyl, or benzhydryl
- R 80 represents alkyl, aryl, or heteroaryl, said aryl or heteroaryl being optionally substituted once or several times with C 1-6 alkoxy, hydroxy, halogen, cyano, acyl, alkyl, or nitro
- M 1 represents an alkali metal, Mg, Zn, Ti, Zr, Mn, Cu, Ce, or Ca, optionally in the presence of a suitable catalyst. Reaction of the product with ammonia and deprotection will yield the
- reaction of N-alkoxycarbonyl pyroglutamic acid esters in which R 70 represents tert-butyl, benzyl, 2-chlorobenzyl, allyl, 2-(trimethylsilyl)ethyl, 2,2,2-trichloroethyl, or benzhydryl, and R 80 represents lower alkyl, with nucleophilic carbon reagents can yield protected, keto-group-containing amino acid derivatives. Reaction of the product with ammonia and deprotection will yield the desired amino acid amide:
- N-protected glutamic acid diesters as those shown below, in which R 90 represents lower alkyl, can be selectively acylated at carbon to yield, after hydrolysis and decarboxylation, protected derivatives of keto-group-containing amino acids, which can be converted into amino acid amides using standard procedures
- R′′′ represents C 1-15 alkylene, C 2-15 alkenylene, C 2-15 alkynylene, C 1-15 heteroalkylene, C 2-15 heteroalkenylene, C 2-15 heteroalkynylene, wherein one or more homocyclic aromatic compound biradical or heterocyclic compound biradical may be inserted, may be prepared from a suitable protected primary or secondary amine
- PG may be a suitable protection group, as described in the literature, e.g. in T. W. Greene, P. G. M. Wuts, Protective groups in organic synthesis, 2 nd ed., 1991 John Wiley & Sons, Inc. New York, and wherein the anion of LG′′′ is a leaving group, such as e.g. halogenide or sulfonate.
- PG′ is a protecting group, which is chosen in a way that PG can be removed from an amine without removal of PG′ from the hydroxylamine. Examples for that can be found in the literature, e.g. in T. W. Greene, P. G. M. Wuts, Protective groups in organic synthesis, 2 nd ed., 1991 John Wiley & Sons, Inc. New York.
- the two components are reacted under basic conditions such as e.g. sodium hydride at a suitable temperature such as e.g. ⁇ 78° C. to 200° C.
- the protecting group of the amine may be removed selectively with a method described in the literature
- the amine may be acylated with a suitable acid and a coupling reagent such as e.g. 1-hydroxybenzotriazole, 3,4-dihydro-3-hydroxybenzotriazin-4-one or 7-azabenzotriazole in combination with e.g. a carbodiimide such as e.g. diisopropylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in the presence or absence of a suitable base such as e.g. triethylamine or ethyldiisopropylamine to give an amide.
- a coupling reagent such as e.g. 1-hydroxybenzotriazole, 3,4-dihydro-3-hydroxybenzotriazin-4-one or 7-azabenzotriazole in combination with e.g. a carbodiimide such as e.g. diisopropylcarbodiimide
- the protecting group of the hydroxylamine may be removed by a method described in the literature, e.g. in T. W. Greene, P. G. M. Wuts, Protective groups in organic synthesis, 2 nd ed., 1991 John Wiley & Sons, Inc. New York
- R IV is C 1-10 alkyl in a suitable solvent such as ethanol by addition of hydrazine hydrate.
- a solution of the peptide in question (final concentration 1-10 mM) and the nucleophile in question (final concentration 10 mM-2M) is dissolved or suspended in water containing low concentrations of EDTA.
- Organic solvents may be added to improve the solubility of the reactants.
- the mixture may be buffered to a suitable pH-value such as e.g. between pH 1 and pH 14, between e.g. between pH 3.5 and pH 9, between pH 6 and pH 8.5, with a suitable buffer such as e.g. phosphate buffer or HEPES, or the pH can be maintained by addition of base or acid.
- a suitable enzyme e.g. carboxypeptidase Y is added to the said mixture of peptide and nucleophile.
- the reaction may be stopped after a suitable time e.g. between 5 min and 10 days, by changing temperature or pH-value, by adding organic solvents, or by dialysis or gel filtration.
- the pH of choice is determined e.g. by the solubility of the peptide to be conjugated and the activity of the enzyme to be used. Solubility of peptides is to a large extent determined by the pKa of the peptide. Normally, the solubility of a given peptide is at its minimum when pH equals pKa of the peptide. It lies within the skills of a skilled person to choose a pH at which to run the reaction taking due care to the above considerations.
- An oxime moiety may be formed by dissolving the transacylated peptide in question, in which R V may be a substituted or unsubstituted aromatic ring, a substituted or an unsubstituted heteroaromatic ring, hydrogen, or C 1-10 alkyl, in water.
- Organic solvents may be added to increase solubility.
- the solution is buffered to a suitable pH-value such as e.g. between pH 0 and pH 14, between pH 3 and pH 6, or pH 5 and kept at a suitable temperature such as e.g. 0-60° C.
- the hydroxylamine in question is added, and oxime moiety is formed according to the reaction scheme below
- the pH of choice is determined e.g. by the solubility of the peptide to be. Solubility of peptides is to a large extent determined by the pKa of the peptide. Normally, the solubility of a given peptide is at its minimum when pH equals pKa of the peptide. It lies within the skills of a skilled person to choose a pH at which to run the reaction taking due care to the above consideration.
- An hydrazone moiety is formed by dissolving the transacylated peptide in question, in which R VI may be a substituted or unsubstituted aromatic ring, a substituted or an unsubstituted heteroaromatic ring, hydrogen, or C 1-10 alkyl, in water.
- the solution is buffered to a suitable pH-value such as e.g. between pH 2 and pH 14 or between pH 0 and pH 4 and kept at a suitable temperature such as e.g. 0-60° C.
- the hydrazide in question is added, whereby the hydrazone is formed
- An hydrazone is formed by dissolving the transacylated peptide in question, in which R VII may be a substituted or unsubstituted aromatic ring, a substituted or an unsubstituted heteroaromatic ring, hydrogen, or C 1-10 alkyl, in water.
- the solution is buffered to a suitable pH-value such as e.g. between pH 2 and pH 14 or between pH 0 and pH 4 and kept at a suitable temperature such as e.g. 0-60° C.
- the hydrazine in question is added, whereby the hydrazone is formed
- An isoxazole can be formed by reaction between a nitril-oxide and an alkyne.
- the nitril-oxide is formed by addition of a suitable oxidation-reagent such as e.g. bleach to an excess of a suitable oxime.
- a suitable oxidation-reagent such as e.g. bleach
- a solution of an excess of the freshly formed nitrile-oxide may be added to the peptide in question.
- a triazole can be formed by reaction between an azide which is attached to the group Z and an alkyne, which is attached to the peptide in question, in the presence of Cu(I)-ions in a suitable solvent such as water or a mixture of water and an organic solvent such as e.g. acetonitrile.
- a suitable solvent such as water or a mixture of water and an organic solvent such as e.g. acetonitrile.
- the triazole may be formed in two possible regioisomers.
- a triazole can be formed by reaction between an alkyne which is attached to the group Z and an azide, which is attached to the peptide in question, in the presence of Cu(I)-ions in a suitable solvent such as water or a mixture of water and an organic solvent such as e.g. acetonitrile.
- a suitable solvent such as water or a mixture of water and an organic solvent such as e.g. acetonitrile.
- the triazole may be formed in two possible regioisomers.
- An amide can be regioselectively formed by reaction of an azide, which is covalently attached to a peptide with an ester, containing a triphenylphosphine-moiety as it is described in e.g. Tetrahedron Lett. 2003, 44, 4515-4518.
- An amide can be regioselectively formed by reaction of an azide, which is covalently attached to a peptide with a thioester, containing a diphenylphosphine-moiety as it is described in e.g. J. Org. Chem. 2002, 67, 4993-4996.
- An arylalkyne can be formed by reaction between an alkyne, which is covalently attached to a peptide and a haloaryl compound in the presence of a palladium catalyst, which is water-soluable, as described in e.g. Bioconjugate Chemistry, 2004, 15, 231-234.
- the haloaryl compound may be exchanged with the corresponding aryl trifluorosulfonate.
- An arylalkyne might be formed by reaction between a haloaryl-moiety, which is covalently attached to a peptide and an alkyne in the presence of a palladium catalyst, which is water-soluable, as described in e.g. Bioconjugate Chemistry, 2004, 15, 231-234.
- a palladium catalyst which is water-soluable, as described in e.g. Bioconjugate Chemistry, 2004, 15, 231-234.
- a trifluorosulfonyloxyaryl-moiety which is attached to a peptide can be used as well.
- R′ and R′′ are as defined above may be prepared from a suitable amino acid, which is protected at the alpha-amino group, with an acid-labile protecting group PG 1 such as e.g. BOC or trityl, and which is protected at the omega-amino group with a base-labile protecting group PG 2 such as e.g. Fmoc.
- the acid may be attached to a Rink-amide resin using standard coupling conditions known to a person skilled in the art, such as e.g. use of a carbodiimide e.g. diisopropylcarbodiimide in the presence or absence of a reagent such as e.g.
- 1-hydroxybenzotriazole 1-hydroxy-7-azabenzotriazole or 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazin and in the presence or absence of a base such as e.g. triethylamine or ethyldiisopropylamine.
- the protecting group at the omega-amine PG 2 may be removed under basic conditions described for the particular protecting group in the literature such as e.g. T. W. Greene, P. G. M. Wuts, Protective groups in organic synthesis, 2 nd ed., 1991 John Wiley & Sons, Inc. New York.
- An acid can be attached to the omega amino moiety using standard coupling conditions, such as e.g. use of a carbodiimide e.g. diisopropylcarbodiimide in the presence or absence of a reagent such as e.g. 1-hydroxybenzotriazole, 1-hydroxy-7-azabenzotriazole or 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazin and in the presence or absence of a base such as e.g. triethylamine or ethyldiisopropylamine.
- the intermediate may be cleaved from the solid support under acidic conditions such as e.g. trifluoroacetic acid or a 20-70% solution of trifluoroacetic acid in dichloromethane to give the desired aminamide.
- R′ and R′′ are defined as above, may be prepared from a suitable amino acid, which is protected with an acid labile protecting group PG 1 , such as e.g. Boc or trityl, which is reacted with an excess of ammonia in the presence of a coupling reagent, such as e.g. a carbodiimide e.g. diisopropylcarbodiimide in the presence or absence of a reagent such as e.g. 1-hydroxybenzotriazole, 1-hydroxy-7-azabenzotriazole or 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazin.
- PG 1 such as e.g. Boc or trityl
- a coupling reagent such as e.g. a carbodiimide e.g. diisopropylcarbodiimide in the presence or absence of a reagent such as e.g. 1-hydroxybenzotriazole, 1-hydroxy
- the phenolic hydroxyl group may be alkylated with a suitable halogenide or sulfonate, in which R a is any suitable substituted alkyl or aryl radical, in the presence of a suitable base such as e.g. potassium carbonate or tetramethylguanidine.
- the protecting group PG 1 may be removed from the alpha amino acid under acidic conditions and described in the literature for the particular protecting group chosen e.g. in T. W. Greene, P. G. M. Wuts, Protective groups in organic synthesis, 2 nd ed., 1991 John Wiley & Sons, Inc. New York, to give the desired amino amide.
- E may be prepared from a suitable acid, which may be activated by reaction with a suitable reagent or a combination of reagents, such as e.g. 2-succinimido-1,1,3,3,-tetramethyluronium tetrafluoroborate (TSTU) in a suitable solvent such as e.g. N,N-dimethylformamide.
- a suitable reagent such as 2-succinimido-1,1,3,3,-tetramethyluronium tetrafluoroborate (TSTU) in a suitable solvent such as e.g. N,N-dimethylformamide.
- the activated acid e.g. the obtained 2,5-dioxopyrrodin-1yl ester of said acid may be reacted with commercially available PEG-reagents, which are functionalized with a primary amine, optionally in the presence of a suitable base such as e.g. ethyldiisopropylamine or triethyl
- Trifluoroacetic acid 25 ml was added to a solution of [(1S)-1-carbamoyl-5-(4-oxo-4-phenylbutyrylamino)pentyl]carbamic acid tert-butyl ester (0.56 g, 1.38 mmol) in dichloromethane (25 ml). The reaction mixture was stirred for 1 h at room temperature. The solvent was removed. The crude product was purified by HPLC on a RP-18 column, using a gradient of 20-45% acetonitrile in water, containing 0.1% of trifluoracetic acid as buffer to give 92 mg of the title compound with a purity of approx. 85%, which was used for the further experiments.
- Step A S-Phenacyl-N-Boc-Cystein Methyl Ester
- Step B S-Phenacyl-N-Boc Cysteine Amide
- Rink-amide-resin (loading: 0.43 mmol/g, 6.66 g, 2.86 mmol) was swelled with dichloromethane (50 ml). The solvent was removed. A 20% solution of piperidine in N-methylpyrrolidinone was added (50 ml). The reactor was shaken for 20 min. The liquid was removed. The resin was washed with N-methylpyrrolidinone (3 ⁇ 50 ml) and dichloromethane (5 ⁇ 50 ml).
- Tosyl chloride (4.16 g, 21.8 mmol) was added to a solution of commercially available 4-(2-hydroxyethyl)piperidine-1-carbocylic ester tert-butyl ester (e.g. Aldrich 54, 724-7, 5.0 g, 21.8 mmol) and triethylamine (4.25 ml, 30.5 mmol) in dichloromethane (100 ml).
- the reaction mixture was stirred at room temperature for 16 h. It was diluted with ethyl acetate (300 ml) and washed with a 10% aqueous solution of sodium hydrogensulphate (200 ml).
- the aqueous phase was extracted with ethyl acetate (150 ml).
- the combined organic layers were washed with a saturated aqueous solution of sodium hydrogencarbonate (250 ml) and dried over magnesium sulphate.
- the solvent was removed in vacuo.
- the crude product was purified by flash chromatography on silica (80 g), using ethyl acetate/heptane first: 1:2 then 1:1 as eluent, to give 6.04 g of 4-[2-(toluene-4-sulfonyloxy)ethyl]piperidine-1-carboxylic acid tert-butyl ester.
- the reaction mixture was heated to 60° C. for 2 days and cooled to room temperature. Water (5 ml) was added carefully.
- the reaction mixture was diluted with ethyl acetate (250 ml) and washed with a 10% aqueous solution of sodium hydrogensulphate (200 ml).
- the aqueous phase was extracted with ethyl acetate (200 ml).
- the combined organic layers were washed with a saturated aqueous solution of sodium hydrogencarbonate (150 ml) and dried over magnesium sulphate. The solvent was removed in vacuo.
- Trifluoroacetic acid (20 ml) was added to a solution of 4-[2-(1,3-dioxo-1,3-dihydroisoindol-2-yloxy)ethyl]piperidine-1-carboxylic acid tert-butyl ester (4.26 g, 11.4 mmol) in dichloromethane (20 ml).
- the reaction mixture was stirred at room temperature for 50 min.
- the solvent was removed in vacuo.
- the residue was dissolved in dichloromethane (50 ml) and the solvent was removed in vacuo.
- the latter procedure was repeated twice to give 6.46 g of the crude trifluoroacetate salt of 2-(2-(piperidin-4-yl)ethoxy)isoindole-1,3-dione.
- the crude product was purified by flash chromatography on silica (30 g), using a mixture of dichloromethane/methanol/25% aqueous ammonia (100:10:1) as eluent, to give 800 mg of 1-[4-(2-(aminooxy)ethyl)piperidin-1-yl]hexadecan-1-one.
- Trifluoroacetic acid (3 ml) was added to a solution of ((S)-1-carbamoylbut-3-ynyl)carbamic acid tert-butyl ester (138 mg, 0.65 mmol) in dichloromethane (3 ml). The reaction mixture was stirred for 1.25 h at room temperature. The solvent was removed in vacuo. The residue was dissolved in dichloromethane (40 ml) and the solvent was removed in vacuo. The latter procedure was repeated twice to give crude trifluoroacetate salt of (S)-2-aminopent-4-ynoic acid amide, which was used for the following experiments.
- MALDI-TOF (CHCA): m/z 3508, 3485, 3604, 3413.
- Trifluoroacetic acid (10 ml) was added to a solution of [(S)-1-carbamoyl-2-(4-(prop-2-ynyloxy)phenyl)ethyl]carbamic acid tert-butyl ester (998 mg, 3.13 mmol) in dichloromethane (10 ml). The reaction mixture was stirred for 1.5 h at room temperature. The solvent was removed. The residue was dissolved in dichloromethane (30 ml). The solvent was removed. The latter procedure was repeated twice to give 1.53 g of the trifluoroacetate salt of (2S)-2-amino-3-(4-(prop-2-ynyloxy)phenyl)propionamide.
- Trifluoroacetic acid 50 ml was added to a solution of ⁇ (S)-1-carbamoyl-2-[4-(2-oxopropoxy)phenyl]ethyl ⁇ carbamic acid tert-butyl ester (2.65 g, 7.88 mmol) in dichloromethane (50 ml). The reaction mixture was stirred for 1 h at room temperature. The solvent was removed in vacuo. The residue was dissolved in dichloromethane (50 ml) and the solvent was removed in vacuo. The latter procedure was repeated once.
- the solution was diluted to a final volume of 0.127 ml with an aqueous buffer containing 250 mM HEPES and 5 mM EDTA, which had been adjusted to pH 8 with sodium hydroxide.
- a solution of CPY in water (0.005 ml, 1 U) was added.
- the reaction mixture was left at room temperature for 16 h.
- the MS analysis showed the formation of the product with the desired mass.
- MS (electrospray): m/z 1366 (M 3+ ), 1024 (M 4+ ), and 819 (M 5+ ).
- the crude product was purified on a reversed phase C 18 -HPLC, using a gradient of 40-80% acetonitrile in water in a 0.1% buffer of TFA. Using an absorption coefficient of 1500000 at 214 nm, a yield of 0.132 mg was determined.
- Trifluoroacetic acid (5 ml) was added to a solution of (3-hydroxymethylbenzyl)carbamic acid tert butylester (1.70 g, 7.17 mmol) in dichloromethane (5 ml). The reaction mixture was stirred for 40 min. The solvent was removed in vacuo. The residue was dissolved in dichloromethane (40 ml). The solvent was removed in vacuo. The latter procedure was repeated twice. The residue was dissolved in water (50 ml) and an 1 N aqueous solution of sodium hydroxide (100 ml). It was washed with tert-butyl methyl ether (3 ⁇ 100 ml). It was saturated with sodium chloride and extracted with dichloromethane (3 ⁇ 75 ml). The combined dichloromethane-phases were dried over magnesium sulphate. The solvent was removed in vacuo to give 328 mg of crude (3-(aminomethyl)phenyl)methanol, which was used for the further steps without purification.
- Trifluoroacetic acid (7 ml) was added to a solution of crude N-[3-((hydroxyimino)methyl)benzyl]succinamic acid tert-butyl ester (249 mg, 0.81 mmol) in dichloromethane (7 ml). The reaction mixture was stirred for 55 min at room temperature. The solvent was removed in vacuo. The residue was redissolved in dichloromethane (50 ml). The solvent was removed in vacuo. The latter procedure was repeated twice to give 294 mg of crude N-[3-(hydroxyiminomethyl)benzyl]succinamic acid, which was used in the next step without further purification.
- a 10% aqueous solution of sodium hypochlorite (0.0015 ml, 2600 pmol) was added to a solution of crude N-[3-(hydroxyiminomethyl)benzyl]succinamic acid (1.29 mg, 5150 pmol) in a mixture of water (0.11 ml) and a saturated aqueous solution of sodium hydrogencarbonate (0.01 ml). The reaction mixture was left for 10 min at room temperature.
- the reaction mixture was stirred at room temperature for 16 h. Water (50 ml) was added. The mixture was acidified to pH 2 by addition of a 10% aqueous solution of sodium hydrogensulphate and was extracted with ethyl acetate (3 ⁇ 50 ml). The combined organic layers were dried over sodium sulphate. The solvent was removed in vacuo to give 3.13 g of 11-azidoundecanoic acid.
- 2,6-Lutidine was added to a mixture of (2S)-2-([Glu 3 ]GLP-2ylleucinylamino)-3-(4-(prop-2-ynyloxy)phenyl)propionamide (1.0 mg, 244 pmol) in water (0.5 ml) to give a clear solution.
- a solution of 11-azidoundecanoic acid (0.554 mg, 0.0025 mmol) in acetonitrile (0.25 ml) and a solution of copper(I) iodide (0.467 mg, 0.0025 mmol) in acetonitrile (0.25 ml) were added successively. The reaction mixture was left for 16 h at room temperature.
- N,N,N′,N′-Tetramethyl-O-(N-succinimidyl)uranium tetrafluoroborate (1.32 g, 4.40 mmol) was added to a solution of 11-azidoundecanoic acid (1.00 g, 4.40 mmol) and triethylamine (0.61 ml, 4.40 mmol) in N,N-dimethylformamide (10 ml). The reaction mixture was stirred for 2 h at room temperature. It was diluted with ethyl acetate (50 ml) and washed with water (3 ⁇ 50 ml). The organic phase was dried over sodium sulphate. The solvent was removed in vacuo to give 1.40 g of crude 11-azidoundecanoic acid 2,5-dioxopyrroldin-1-yl ester, which was used in the next steps without further purification.
- reaction mixture content was about 22% of the remaining starting compound [Leu 37 ]GLP-1(7-37)ylalanine (retention time: 18.1 min), 70% of the transpeptidation product (retention time: 18.3 min) and 8% of the hydrolysis product [Leu 37 ]GLP-1(7-37) (retention time: 18.4 min).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Methods for the selective conjugation of peptides which comprises an enzymatic incorporation of a functional group at the C-terminal end of a peptide followed by reaction with a second compound comprising the moiety to be conjugated to the peptide, wherein said second compound comprises a functional group which selectively reacts with the incorporated functional group.
Description
- This application is a continuation of U.S. patent application Ser. No. 11/395,784, filed Mar. 31, 2006, which is a continuation of International Patent Application No. PCT/DK2004/000685, filed Oct. 8, 2004, which claims priority from Danish Patent Application No. PA 2003 01496, filed Oct. 10, 2003; and to U.S. Patent Application No. 60/510,892, filed Oct. 14, 2003.
- The present invention relates to a novel method for post-translational conjugation of peptides. Said conjugated peptides have altered characteristics and may thus be of use in therapeutic applications or they may ease the analysis or isolation and purification of said peptides.
- It is well-known to modify the properties and characteristics of peptides by conjugating groups to the peptide which duly changes the properties of the peptide. Such conjugation generally requires some functional group in the peptide to react with another functional group in a conjugating group. Typically, amino groups, such as the N-terminal amino group or the ε-amino group in lysines, have been used in combination with a suitable acylating reagent. It is often desired or even required to be able to control the conjugation reaction, i.e. to control where the conjugating compounds are attached and to control how many conjugating groups are attached. This is often referred to as specificity.
- It is an object of the present invention to provide a method by which peptides may be conjugated with a high degree of specificity. In general terms, the method exploits an enzyme capable of incorporating a compound comprising a suitable functional group into the C-terminal end of a peptide, where said functional group is subsequently used as a point where to conjugate.
- The use of carboxypeptidases to modify the C-terminal of peptides has been described earlier. WO 92/05271 discloses the use of carboxypeptidases and nucleophilic compounds to amidate the C-terminal carboxy group, and WO 98/38285 discloses variants of carboxypeptidase Y particular apt for this purpose.
- The grafting of PEG or PEG based chains have been amply describes in the literature. By way of example, U.S. Pat. No. 5,739,208 discloses the use of a PEG with a sulfone group which reacts with thioles present in the peptide.
- EP 605 963 discloses the grafting of aqueous polymers which form an oxime linkage with an aldehyde group on a protein. None of the natural amino acid comprises an aldehyde, so a hydroxyl group thus has to be oxidized as a first step in the conjugating process.
- EP 243 929 discloses the use of carboxypeptidase to incorporate polypeptides, reporter groups or cytotoxic agents into the C-terminal of proteins or polypeptides.
- The present inventors have surprisingly found that enzymes, e.g. carboxypeptidases may be used to incorporate into the C-terminal of peptides a first compound comprising one or more functional groups, which are not accessible in the peptide, to form a transacylated compound, and that this transacylated compound may subsequently be reacted with another compound comprising one or more functional groups which react with the functional group of the first compound but not with other functional groups accessible in the peptide. Such method provides a high degree of specificity in that the enzyme is chosen so that it only catalyses the incorporation at the C-terminal, and the two functional groups are selected so that they only react with each other, not with other functional groups accesible in the peptide. In this way, the conjugating group is only attached at one locus, and by selecting the functional groups, the number of conjugated groups can be controlled.
- Accordingly, in one embodiment, the present invention provides a method for conjugating peptides, said method comprising the steps of
-
- i) reacting in one or more steps a peptide with a first compound bearing one or more functional groups, which are not accessible in any of the amino acids constituting said peptide, in the presence of an enzyme capable of catalysing the incorporation of said first compound into the C-terminal of said peptide to form a transacylated peptide, and
- ii) reacting in one or more steps said transacylated peptide with a second compound comprising one or more functional groups, wherein said functional group(s) do not react with functional groups accessible in the amino acid residues constituting said peptide, and wherein said functional group(s) in said second compound is capable of reacting with said functional group(s) in said first compound so that a covalent bond between said transacylated peptide and said second compound is formed.
- It is also an objective of the present invention to provide peptides conjugated by the method of the present invention.
- It is a further objective of the present invention to provide peptides which are modified in a way to make them better suited for the method of the present invention.
- It is a still further objective of the present invention to provide reagents and enzymes suitable for use in the methods of the present invention.
- In a still further embodiment, the present invention provides the use of peptides conjugated by methods of the present invention in therapy.
- It is a still further objective of the present invention to provide compositions, e.g. pharmaceutical compositions comprising peptides conjugated by methods of the present invention.
- It is a still further objective of the present invention to provide therapeutic methods for the treatment of diseases comprising the administration of conjugated peptides prepared according to the methods of the present invention.
- It is a still further objective of the present invention to provide a use of conjugated peptides prepared according to the methods of the present invention in the manufacture of medicaments.
- It is a still further objective of the present invention to provide a method for improving the properties of a peptide by conjugation said peptide according to the methods of the present invention.
- In the present context, the term “transacylation” is intended to indicate a reaction in which a leaving group is exchanged for a nucleophile, wherein a nucleophile is understood to be an electron-rich reagent that tends to attack the nucleus of carbons. Transpeptidation is one example of a transacylation.
- In the present context, the term “not accessible” is intended to indicate that something is absent or de facto absent in the sense that it cannot be reached. When it is stated that functional groups are not accessible in a peptide to be conjugated it is intended to indicate that said functional group is absent from the peptide or, if present, in some way prevented from taking part in reactions. By way of example, said functional group could be buried deep in the structure of the peptide so that it is shielded from participating in the reaction. It is recognised that whether or not a functional group is accessible depends on the reaction conditions. It may be envisaged that in the presence of denaturing agents or at elevated temperatures the peptide may unfold to expose otherwise not accessible functional groups. It is to be understood that “not accessible” means “not accessible at the reaction condition chosen for the particular reaction of interest”.
- In the present context, the term “oxime bond” is intended to indicate a moiety of the formula —C═N—O—.
- In the present context, the term “hydrazone bond” is intended to indicate a moiety of the formula —C═N—N—.
- In the present context, the term “phenylhydrazone bond” is intended to indicate a moiety of the formula
- In the present context, the term “semicarbazone bond” is intended to indicate a moiety of the formula —C═N—N—C(O)—N—.
- The term “alkane” is intended to indicate a saturated, linear, branched and/or cyclic hydrocarbon. Unless specified with another number of carbon atoms, the term is intended to indicate hydrocarbons with from 1 to 30 (both included) carbon atoms, such as 1 to 20 (both included), such as from 1 to 10 (both included), e.g. from 1 to 5 (both included). The terms alkyl and alkylene refer to the corresponding radical and bi-radical, respectively.
- The term “alkene” is intended to indicate linear, branched and/or cyclic hydrocarbons comprising at least one carbon-carbon double bond. Unless specified with another number of carbon atoms, the term is intended to indicate hydrocarbons with from 2 to 30 (both included) carbon atoms, such as 2 to 20 (both included), such as from 2 to 10 (both included), e.g. from 2 to 5 (both included). The terms alkenyl and alkenylene refer to the corresponding radical and biradical, respectively.
- The term “alkyne” is intended to indicate linear, branched and/or cyclic hydrocarbons comprising at least one carbon-carbon triple bond, and it may optionally comprise one or more carbon-carbon double bonds. Unless specified with another number of carbon atoms, the term is intended to indicate hydrocarbons with from 2 to 30 (both included) carbon atoms, such as from 2 to 20 (both included), such as from 2 to 10 (both included), e.g. from 2 to 5 (both included). The terms alkynyl and alkynylene refer to the corresponding radical and bi-radical, respectively.
- The term “homocyclic aromatic compound” is intended to indicate aromatic hydrocarbons, such as benzene and naphthalene.
- The term “heterocyclic compound” is intended to indicate a cyclic compound comprising 5, 6 or 7 ring atoms from which 1, 2, 3 or 4 are hetero atoms selected from N, O and/or S. Examples include heterocyclic aromatic compounds, such as thiophene, furan, pyran, pyrrole, imidazole, pyrazole, isothiazole, isooxazole, pyridine, pyrazine, pyrimidine, pyridazine, as well as their partly or fully hydrogenated equivalents, such as piperidine, pirazolidine, pyrrolidine, pyroline, imidazolidine, imidazoline, piperazine and morpholine.
- The terms “hetero alkane”, “hetero alkene” and “hetero alkyne” is intended to indicate alkanes, alkenes and alkynes as defined above, in which one or more hetero atom or group have been inserted into the structure of said moieties. Examples of hetero groups and atoms include —O—, —S—, —S(O)—, —S(O)2—, —C(O)— —C(S)— and —N(R*)—, wherein R* represents hydrogen or C1-C6-alkyl. Examples of heteroalkanes include.
- The term “radical” or “biradical” is intended to indicate a compound from which one or two, respectively, hydrogen atoms have been removed. When specifically stated, a radical may also indicate the moiety formed by the formal removal of a larger group of atoms, e.g. hydroxyl, from a compound.
- The term “halogen” is intended to indicate members of the seventh main group of the periodic table, i.e. F, Cl, Br and I.
- The term “PEG” is intended to indicate polyethylene glycol of a molecular weight between 500 and 150,000 Da, including analogues thereof, wherein for instance the terminal OH-group has been replaced by a methoxy group (referred to as mPEG).
- In the present context, the words “peptide” and “protein” are used interchangeably and are intended to indicate the same. The term “peptide” is intended to indicate a compound with two or more amino acid residues linked by a peptide bond. The amino acids may be natural or unnatural. The term is also intended to include said compounds substituted with other peptides, saccharides, lipids, or other organic compound, as well as compounds wherein one or more amino acid residue have been chemically modified and peptides comprising a prosthetic group.
- In the present context, the term “aryl” is intended to indicate a carbocyclic aromatic ring radical or a fused aromatic ring system radical wherein at least one of the rings are aromatic. Typical aryl groups include phenyl, biphenylyl, naphthyl, and the like.
- The term “heteroaryl”, as used herein, alone or in combination, refers to an aromatic ring radical with for instance 5 to 7 member atoms, or to a fused aromatic ring system radical with for instance from 7 to 18 member atoms, wherein at least one ring is aromatic, containing one or more heteroatoms as ring atoms selected from nitrogen, oxygen, or sulfur heteroatoms, wherein N-oxides and sulfur monoxides and sulfur dioxides are permissible heteroaromatic substitutions. Examples include furanyl, thienyl, thiophenyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrazinyl, pyrimidinyl, quinolinyl, isoquinolinyl, benzofuranyl, benzothiophenyl, indolyl, and indazolyl, and the like.
- The term “conjugate” as a noun is intended to indicate a modified peptide, i.e. a peptide with a moiety bonded to it to modify the properties of said peptide. As a verb, the term is intended to indicate the process of bonding a moiety to a peptide to modify the properties of said peptide.
- As used herein, the term “prodrug” indicates biohydrolyzable amides and biohydrolyzable esters and also encompasses a) compounds in which the biohydrolyzable functionality in such a prodrug is encompassed in the compound according to the present invention, and b) compounds which may be oxidized or reduced biologically at a given functional group to yield drug substances according to the present invention. Examples of these functional groups include 1,4-dihydropyridine, N-alkylcarbonyl-1,4-dihydropyridine, 1,4-cyclohexadiene, tert-butyl, and the like.
- As used herein, the term “biohydrolyzable ester” is an ester of a drug substance (in casu, a compound according to the invention) which either a) does not interfere with the biological activity of the parent substance but confers on that substance advantageous properties in vivo such as duration of action, onset of action, and the like, or b) is biologically inactive but is readily converted in vivo by the subject to the biologically active principle. The advantage is, for example increased solubility or that the biohydrolyzable ester is orally absorbed from the gut and is transformed to a compound according to the present invention in plasma. Many examples of such are known in the art and include by way of example lower alkyl esters (e.g., C1-C4), lower acyloxyalkyl esters, lower alkoxyacyloxyalkyl esters, alkoxyacyloxy esters, alkyl acylamino alkyl esters, and choline esters.
- As used herein, the term “biohydrolyzable amide” is an amide of a drug substance (in casu, a compound according to the present invention) which either a) does not interfere with the biological activity of the parent substance but confers on that substance advantageous properties in vivo such as duration of action, onset of action, and the like, or b) is biologically inactive but is readily converted in vivo by the subject to the biologically active principle. The advantage is, for example increased solubility or that the biohydrolyzable amide is orally absorbed from the gut and is transformed to a compound according to the present invention in plasma. Many examples of such are known in the art and include by way of example lower alkyl amides, α-amino acid amides, alkoxyacyl amides, and alkylaminoalkylcarbonyl amides.
- In the present context, the term “pharmaceutically acceptable salt” is intended to indicate salts which are not harmful to the patient. Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable metal salts, ammonium and alkylated ammonium salts. Acid addition salts include salts of inorganic acids as well as organic acids. Representative examples of suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, nitric acids and the like. Representative examples of suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methanesulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids and the like. Further examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in J. Pharm. Sci. 1977, 66, 2, which is incorporated herein by reference. Examples of metal salts include lithium, sodium, potassium, magnesium salts and the like. Examples of ammonium and alkylated ammonium salts include ammonium, methylammonium, dimethylammonium, trimethylammonium, ethylammonium, hydroxyethylammonium, diethylammonium, butylammonium, tetramethylammonium salts and the like.
- A “therapeutically effective amount” of a compound as used herein means an amount sufficient to cure, alleviate or partially arrest the clinical manifestations of a given disease and its complications. An amount adequate to accomplish this is defined as “therapeutically effective amount”. Effective amounts for each purpose will depend on the severity of the disease or injury as well as the weight and general state of the subject. It will be understood that determining an appropriate dosage may be achieved using routine experimentation, by constructing a matrix of values and testing different points in the matrix, which is all within the ordinary skills of a trained physician or veterinary.
- The term “treatment” and “treating” as used herein means the management and care of a patient for the purpose of combating a condition, such as a disease or a disorder. The term is intended to include the full spectrum of treatments for a given condition from which the patient is suffering, such as administration of the active compound to alleviate the symptoms or complications, to delay the progression of the disease, disorder or condition, to alleviate or relief the symptoms and complications, and/or to cure or eliminate the disease, disorder or condition as well as to prevent the condition, wherein prevention is to be understood as the management and care of a patient for the purpose of combating the disease, condition, or disorder and includes the administration of the active compounds to prevent the onset of the symptoms or complications. The patient to be treated is preferably a mammal, in particular a human being, but it may also include animals, such as dogs, cats, cows, sheep and pigs.
- In principle, any enzyme capable of catalysing the incorporation of a compound into a peptide is useful in the methods of the present invention. By way of example, useful enzymes include carboxypeptidases, which constitute a group of peptide hydrolases belonging to the classification groups E.C. 3.4.16, 3.4.17 and 3.4.18. The in vivo reaction catalysed by said enzymes is the hydrolysis of the C-terminal amino acid residue. Various carboxypeptidases are known and they differ in what terminal amino acid residue they are capable of cleaving off. During the catalytic cycle an enzyme-substrate complex is formed which under normal in vivo conditions is subjected to a nucleophilic attack by a water molecule, which eventually leads to the hydrolysis of the peptide bond. In the methods of the present invention, however, a nucleophilic reagent is added, which can out compete water as a nucleophile. Moreover, the water activity may be reduced by running the reaction in solvents or in aqueous solvents. In the methods of the present invention, said nucleophile attacks the enzyme-substrate complex eventually forming a transacylated compound. On top of being a nuclophile, said reagent also has to comprise one or more functional groups, which are not accessible in the peptide to be conjugated.
- Other enzymes which could be applied in the methods of the present invention include trypsin.
- The reaction of the peptide and the nucleophile affords a transacylated peptide wherein the C-terminal amino acid residue has been exchanged with the nucleophilic compound, which comprises one or more functional groups which are not accessible in the peptide to be conjugated. The overall result of this reaction (or this series of reactions) is an incorporation of one or more functional groups into the peptide which are present at only one locus in the peptide. A subsequent reaction (or series of reactions) of this transacylated peptide with a compound comprising the moiety to be conjugated to the peptide and one or more functional groups, which only react with the functional groups added to the peptide in the transacylation reaction, effects a selective conjugation of the peptide to be conjugated.
- Compared to other conjugation methods which take advantage of functional groups already present in the peptide, e.g. N-terminal amino groups or ε-amino groups of lysines, the method of the present invention offers the advantage of improved selectivity. The incorporation of one or more functional groups not accessible in the peptide ensures that the conjugation takes place at only specified loci.
- As mentioned earlier, any enzyme capable of catalysing the incorporation of a compound into a peptide may be used in the methods of the present invention, and in particular carboxypeptidases are useful. Examples of particular useful carboxypeptidease are serine-type carboxypeptidases, such as lysosomalPro-X carboxypeptidase (also known as proline carboxypeptidase, angiotensinase C, lysosomal carboxypeptidase C and prolylcarboxypeptidase), serine-type D-Ala-D-Ala carboxypeptidase (also known as D-alanyl-D-alanine carboxypeptidase, DD-peptidase and DD-transpeptidase), carboxypeptidase C (also known as Serine-type carboxypeptidase I, cathepsin A, carboxypeptidase Y and lysosomal protective protein) and carboxypeptidase D (also known as carboxypeptidase KEX1 and carboxypeptidase S1); metallocarboxypeptidases, such as carboxypeptidase A, carboxypeptidase B (also known as protaminase), lysine(arginine) carboxypeptidase (also known as carboxypeptidase N), and Gly-X carboxypeptidase (also known as carboxypeptidase S); and cysteine-type carboxypeptidase (also known as lysosomal carboxypeptidase B, cathepsin B2, Cathepsin Iv and acid carboxypeptidase). It is also well-known that amino acid residues may be changed, added or deleted in the sequence of carboxypeptidases to modify the catalytic properties of the enzyme. Such modified carboxypeptidases are disclosed in, e.g. WO 98/38285, which is incorporated herein by reference. Particular mentioning is made of carboxypeptidase Y as a useful enzyme.
- Many nucleophilic compounds are known which could be incorporated into peptides according to the methods of the present invention, and α-amino acids is one such type of nucleophilic compounds. For the purpose of the present invention, it is, however, preferred to select the nucleophilic compound so that the transacylated compound formed is not itself a substrate for the enzyme applied. Stated differently, it is preferred to apply a nucleophilic compound which effectively blocks any further reaction of the enzyme. One example of such compounds is amides of α-amino acids as carboxy amidated peptides are not substrates for carboxypeptidases.
- It is recognised that whether or not a compound is a substrate for a given enzyme in principle depends on the conditions, e.g. the time frame, under which the reaction takes place. Given sufficient time, many compounds are, in fact, substrates for an enzyme although they are not under normal conditions regarded as such. When it is stated above that the transacylated compound itself should not be a substrate of the enzyme it is intended to indicate that the tranacylated compound itself is not a substrate for the enzyme to an extent where the following reactions in the method of the present invention are disturbed. If the transacylated compound is, in fact, a substrate for the enzyme, the enzyme may be removed or inactivated, e.g. by enzyme inhibitors, following the transacylation reaction.
- In one embodiment, the invention relates to a method of conjugating peptides, wherein a peptide P is reacted in one or more steps with a first compound, which is an α-amino acid amide represented by the formula
- in the presence of carboxypeptidase to form a transacylated peptide of the formula
- said transacylated peptide being further reacted in one or more steps with a second compound of the formula
-
Y-E-Z - to form a conjugated peptide of the formula
- wherein R represents a linker or a bond;
wherein P′ represents the peptide obtained when the C-terminal amino acid is removed from the peptide P;
X represents a radical comprising a functional group not accessible in the amino acid residues constituting the peptide P′;
Y represents a radical comprising one or more functional groups which groups react with functional groups present in X, and which functional groups do not react with functional groups accessible in the peptide P′;
E represents a linker or a bond;
A represents the moiety formed by the reaction between the functional groups comprised in X and Y; and
Z is the moiety to be conjugated to the peptide, wherein said moiety decreases the clearance of the compound of formula [a] in comparison with the clearance of P. - In a further embodiment, the invention relates to methods of conjugating peptides as disclosed above, which further comprises the step of formulating the resulting conjugated peptide in a pharmaceutical composition.
- Following the conjugation, the conjugated peptide may be isolated and purified by techniques well-known in the art. The conjugated peptide may also be converted into a pharmaceutically acceptable salt or prodrug, if relevant.
- The moiety, A, formed in the reaction between the functional groups of X and Y may in principle be of any kind depending on what properties of the final conjugated peptide is desired. In some situation it may be desirable to have a labile bond which can be cleaved at some later stage, e.g. by some enzymatic action or by photolysis. In other situations, it may be desirable to have a stable bond, so that a stable conjugated peptide is obtained. Particular mentioning is made of the type of moieties formed by reactions between amine derivatives and carbonyl groups, such as oxime, hydrazone, phenylhydrazone and semicarbazone moieties.
- In one embodiment the functional groups of X and Y are selected from amongst carbonyl groups, such as keto and aldehyde groups, and amino derivatives, such as
- hydrazine derivatives —NH—NH2,
hydrazine carboxylate derivatives —O—C(O)—NH—NH2,
semicarbazide derivatives —NH—C(O)—NH—NH2,
thiosemicarbazide derivatives —NH—C(S)—NH—NH2,
carbonic acid dihydrazide derivatives —NHC(O)—NH—NH—C(O)—NH—NH2,
carbazide derivatives —NH—NH—C(O)—NH—NH2,
thiocarbazide derivatives —NH—NH—C(S)—NH—NH2,
aryl hydrazine derivatives —NH—C(O)—C6H4—NH—NH2, and
hydrazide derivatives —C(O)—NH—NH2;
oxylamine derivatives, such as —O—NH2, —C(O)—O—NH2, —NH—C(O)—O—NH2 and —NH—C(S)—O—NH2. - It is to be understood, that if the functional group comprised in X is a carbonyl group, then the functional group comprised in Y is an amine derivative, and vice versa. Due to the presence of —NH2 groups in most peptides, a better selectivity is believed to be obtained if X comprises a keto- or an aldehyde-functionality.
- Another example of a suitable pair of X and Y is azide derivatives (—N3) and alkynes which react to form a triazole moiety.
- Another example of a suitable pair of X and Y is alkyne and nitril-oxide, which reacts to form a isooxazolidine moiety.
- In particular, the group to be transacylated,
- may be selected from amongst 2-amino-3-oxo-butyramide, 2-amino-6-(4-oxo-pentanoylamino)-hexanoic acid amide, 2-amino-3-(2-oxo-2-phenyl-ethylsulfanyl)-propionamide, 2-amino-5-oxo-hexanoic acid amide, 2-amino-3-oxo-propionamide, 2-amino-6-(4-acetylbenzoylamino)hexanoic acid amide, 2-amino-3-oxopropionic acid amide, (2S)-Amino-3-[4-(2-oxopropoxy)phenyl]propionamide, (2S)-Amino-3-[4-(2-oxobutoxy)phenyl]propionamide, (2S)-Amino-3-[4-(2-oxopentoxy)phenyl]propionamide, (2S)-Amino-3-[4-(4-oxopentoxy)phenyl]propionamide, (2S)-2-Amino-6-(4-oxo-4-phenylbutyrylamino)hexanoic acid amide, 4-Acetyl-N-((5S)-5-amino-5-carbamoylpentyl)benzamide, (2S)-2-Amino-6-(4-oxo-4-(4-chlorophenylbutyrylamino)hexanoic acid amide, 3-Acetyl-N-((5S)-5-amino-5-carbamoylpentyl)benzamide, 2-Acetyl-N-((5S)-5-amino-5-carbamoylpentyl)benzamide, (2S)-2-amino-3-(4-(prop-2-ynyloxy)phenyl)propionamide, (S)-2-aminopent-4-ynoicacid amide and S-phenylacylcysteine amide.
- Both the compound to be transacylated and the compound to be reacted with the transacylated peptide comprises a linker, R and E, respectively. These linkers, which are independent of each other, may be absent or selected from amongst alkane, alkene or alkyne diradicals and hetero alkane, hetero alkene and hetero alkyne diradicals, wherein one or more optionally substituted aromatic homocyclic biradical or biradical of a heterocyclic compound, e.g. phenylene or piperidine biradical may be inserted into the aforementioned biradicals. It is to be understood that said linkers may also comprise substitutions by groups selected from amongst hydroxyl, halogen, nitro, cyano, carboxyl, aryl, alkyl and heteroaryl.
- Both E and R represent bonds or linkers, and in the present context the term “linker” is intended to indicate a moiety functioning as a means to separate Y from Z and X from NH2—C(O)—C(NH2)—, respectively. One function of the linkers E and R may be to provide adequate flexibility in the linkage between the peptide and the conjugated moiety Z. Typical examples of E and R include bi-radicals of straight, branched and/or cyclic C1-10alkane, C2-10alkene, C2-10alkyne, C1-10heteroalkane, C2-10heteroalkene, C2-10heteroalkyne, wherein one or more homocyclic aromatic compound biradical or heterocyclic compound biradical may be inserted. Particular examples of E and R include
- A need for modifying peptides may arise for any number of reasons, and this is also reflected in the kind of compounds that may be conjugated to peptides according to the methods of the present invention. It may be desirable to conjugate peptides to alter the physicochemical properties of the peptide, such as e.g. to increase (or to decrease) solubility to modify the bioavailability of therapeutic peptides. In another embodiment, it may be desirable to modify the clearance rate in the body, e.g. by conjugating compounds to the peptide which binds to plasma proteins, such as e.g. albumin, or which increase the size of the peptide to prevent or delay discharge through the kidneys. In another embodiment, it may be desirable to conjugate a label to facilitate analysis of the peptide. Examples of such label include radioactive isotopes, fluorescent markers and enzyme substrates. In still another embodiment, a compound is conjugated to a peptide to facilitate isolation of the peptide. For example, a compound with a specific affinity to a particular column material may be conjugated to the peptide. It may also be desirable to modify the immunogenecity of a peptide, e.g. by conjugating a peptide so as to hide, mask or eclipse one or more immunogenic epitopes at the peptide.
- In particular, the methods of the present invention may be used to decrease the clearance in order to increase the plasma half-life of the modified peptide compared to the corresponding un-modified peptide. The term “plasma half-life” is used in its ordinary meaning, i.e. the time at which 50% of the biological activity of the peptide is present in the plasma prior to being cleared. Alternative terms include serum half-life, circulating half-life, circulatory half-life, serum clearance, plasma clearance, and clearance half-life.
- The term “increased” used in connection with plasma half-life is used to indicate that the half-life of the conjugated peptide is significantly increased relative to the half-life of the corresponding un-modified peptide. For instance, the half-life may be increased by at least 25%, at least 50%, at least 100%, at least 150%, at least 200% or even at least 500%.
- In one embodiment, the present invention relates to methods of conjugating peptides as disclosed above, which further comprises the step of measuring whether an increase in the plasma half-life has been effected.
- Particular examples of Z which gives rise to a decrease in clearance of compounds of formula [a] in comparison with the clearance of P include organic moieties, such as PEG or mPEG radicals and amino derivatives thereof; straight, branched and/or cyclic C1-22alkyl, C2-22alkenyl, C2-22alkynyl, C1-22heteroalkyl, C2-22heteroalkenyl, C2-22heteroalkynyl, wherein one or more homocyclic aromatic compound biradical or heterocyclic compound biradical may be inserted, and wherein said C1-C22 or C2-C22 radicals may optionally be substituted with one or more substituents selected from hydroxyl, halogen, carboxyl, heteroaryl and aryl, wherein said aryl or heteroaryl may optionally be further substituted by one or more substituents selected from hydroxyl, halogen, and carboxyl; steroid radicals; lipid radicals; polysaccharide radicals, e.g. dextrans; polyamide radicals e.g. polyamino acid radicals; PVP radicals; PVA radicals; poly(1-3-dioxalane); poly(1,3,6-trioxane); ethylene/maleic anhydride polymer; Cibacron dye stuffs, such as Cibacron Blue 3GA, and polyamide chains of specified length, as disclosed in WO 00/12587, which is incorporated herein by reference.
- Particular mentioning is made of C10-20alkyl, such as C15 and C17, and benzophenone derivatives of the formula
- The PEG conjugated to a peptide according to the present invention may be of any molecular weight. In particular the molecular weight may be between 500 and 100,000 Da, such as between 500 and 60,000 Da, such as between 1000 and 40,000 Da, such as between 5000 and 40,000 Da. In particular, PEG with molecular weights of 10000 Da, 20000 Da, 30000 Da or 40000 Da may be used in the present invention.
- In one embodiment, Z comprises one or more moieties that are known to bind to plasma proteins, such as e.g. albumin. The ability of a compound to bind to albumin may be determined as described in J. Med. Chem., 43, 2000, 1986-1992, which is incorporated herein by reference. In the present context, a compound is defined as binding to albumin if Ru/Da is above 0.05, such as above 0.10, such as above 0.12 or even above 0.15.
- In another embodiment of the invention the albumin binding moiety is a peptide, such as a peptide comprising less than 40 amino acid residues. A number of small peptides which are albumin binding moieties are disclosed in J. Biol. Chem. 277, 38 (2002) 35035-35043, which is incorporated herein by reference.
- Z may be branched so that Z comprises more than one of the above mentioned labels or radicals.
- Particular examples of compounds of the formula Y-E-Z include
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 10 kDa,
- wherein mPEG has a molecular weight of 10 kDa,
- wherein mPEG has a molecular weight of 10 kDa,
- wherein mPEG has a molecular weight of 10 kDa,
- wherein mPEG has a molecular weight of 10 kDa,
- wherein mPEG has a molecular weight of 10 kDa,
- wherein mPEG has a molecular weight of 10 kDa,
- wherein mPEG has a molecular weight of 10 kDa,
- wherein mPEG has a molecular weight of 10 kDa,
- wherein mPEG has a molecular weight of 10 kDa,
- wherein mPEG has a molecular weight of 10 kDa,
- wherein mPEG has a molecular weight of 10 kDa,
- wherein mPEG has a molecular weight of 10 kDa,
- wherein mPEG has a molecular weight of 10 kDa,
- wherein mPEG has a molecular weight of 10 kDa,
- wherein mPEG has a molecular weight of 10 kDa,
- wherein mPEG has a molecular weight of 10 kDa,
- wherein mPEG has a molecular weight of 10 kDa,
- wherein mPEG has a molecular weight of 10 kDa,
- wherein mPEG has a molecular weight of 10 kDa,
- wherein mPEG has a molecular weight of 10 kDa,
- wherein mPEG has a molecular weight of 10 kDa,
- wherein mPEG has a molecular weight of 10 kDa,
- wherein mPEG has a molecular weight of 10 kDa,
- wherein mPEG has a molecular weight of 10 kDa,
- wherein mPEG has a molecular weight of 10 kDa,
- wherein mPEG has a molecular weight of 10 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 30 kDa,
- wherein mPEG has a molecular weight of 30 kDa,
- wherein mPEG has a molecular weight of 30 kDa,
- wherein mPEG has a molecular weight of 30 kDa,
- wherein mPEG has a molecular weight of 30 kDa,
- wherein mPEG has a molecular weight of 30 kDa,
- wherein mPEG has a molecular weight of 30 kDa,
- wherein mPEG has a molecular weight of 30 kDa,
- wherein mPEG has a molecular weight of 30 kDa,
- wherein mPEG has a molecular weight of 30 kDa,
- wherein mPEG has a molecular weight of 20 kDa,
- wherein mPEG has a molecular weight of 20 kDa, and
- wherein mPEG has a molecular weight of 20 kDa.
- As explained above, the catalytic action of carboxypeptidases causes the C-terminal amino acid residue to be exchanged with, e.g. the compound of the formula
- If it is desired to maintain the entire sequence of the peptide to be conjugated it is thus necessary to elongate the sequence of the peptide with one amino acid residue. Means for doing so are well-known to persons skilled in the art, e.g. by recombinant techniques or by protein synthetic methods. Another reason for wanting to elongate the sequence of the peptide could be to make the peptide a substrate for the particular carboxypeptidase at hand. As explained earlier, the difference between carboxypeptidases mainly resides with the kind of amino acid residue they are able to cleave off. It may thus be necessary to add one or more amino acid residue to make a given peptide a substrate for a given carboxypeptidase. The added amino acid residues may either be natural or unnatural.
- It is recognised that some peptides, e.g. insulin and Factor VII, comprise more than one chain, which in turn means that they have more than one C-terminal. In some cases it might be possible to distinguish between the C-terminals by a proper selection of the carboxypeptidase used. In other cases it might be necessary to introduce a difference between the C-terminals, e.g. by adding or deleting one or more amino acid residues from one of the C-terminals to effect a conjugation at only a limited number of the C-terminals present. In still other cases it might be useful to conjugate the peptide at all C-terminals.
- Any peptide can be conjugated by the methods of the present invention, such as e.g. enzymes, peptide hormones, growth factors, antibodies, cytokines, receptors, lymphokines and vaccine antigenes, and particular mentioning is made of therapeutic peptides, such as insulin, glucagon like-peptide 1 (GLP-1), glucagon like-peptide 2 (GLP-2), growth hormone, cytokines, trefoil factor peptides (TFF), peptide melanocortin receptor modifiers and factor VII compounds.
- Particular applicable insulin is human insulin. In the present context the term “human insulin” refers to naturally produced insulin or recombinantly produced insulin. Recombinant human insulin may be produced in any suitable host cell, for example the host cells may be bacterial, fungal (including yeast), insect, animal or plant cells. Many insulin compounds have been disclosed in the literature, and they too are particular useful in the methods of the present invention. By “insulin compound” (and related expressions) is meant human insulin in which one or more amino acids have been deleted and/or replaced by other amino acids, including non-codeable amino acids, and/or human insulin comprising additional amino acids, i.e. more than 51 amino acids, and/or human insulin in which at least one organic substituent is bound to one or more of the amino acids.
- The following patent documents are mentioned as disclosures of insulin compounds particular applicable in the methods provided by the present invention.
- WO 97/31022 (Novo Nordisk), which is incorporated herein by reference, discloses insulin compounds with a protracted activity profile wherein the amino group of the N-terminal amino acid of the B-chain and/or the ε-amino group of LysB29 has a carboxylic acid containing lipophilic substituent. Particular mentioning is made of NεB29—(CO—(CH2)14—COOH) human insulin; NεB29—(CO—(CH2)16—COOH) human insulin; NεB29—(CO—(CH2)18—COOH) human insulin; NεB29—(CO—(CH2)2O—COOH); NεB29—(CO—(CH2)22—COOH) human insulin; NεB29—(CO—(CH2)14—COOH) AspB28-human insulin; NεB29—(CO—(CH2)16—COOH) AspB28-human insulin; NεB29—(CO—(CH2)18—COOH) AspB28-human insulin; NεB29—(CO—(CH2)20—COOH) AspB28-human insulin; NεB29—(CO—(CH2)22—COOH) AspB28-human insulin; NεB30—(CO—(CH2)14—COOH) ThrB29LysB30-human insulin; NεB30—(CO—(CH2)16—COOH) ThrB29LysB30-human insulin; NεB30-(CO—(CH2)18—COOH) ThrB29LysB30-human insulin; NB30—(CO—(CH2)20—COOH) ThrB29LysB30-human insulin; NεB30—(CO—(CH2)22—COOH) ThrB29LysB30-human insulin;
- NεB28-(CO—(CH2)14—COOH) LysB28ProB29-human insulin; NεB28 (CO—(CH2)16—COOH) LysB28ProB29-human insulin; NεB28—(CO—(CH2)18—COOH) LysB28ProB29-human insulin; NεB28—(CO—(CH2)20—COOH) LysB28ProB29-human insulin; NεB28—(CO—(CH2)22—COOH) LysB28ProB29-human insulin; NεB29—(CO—(CH2)14—COOH) desB30 human insulin; NεB29—(CO—(CH2)16—COOH) desB30 human insulin; NεB29—(CO—(CH2)18—COOH) desB30 human insulin; NεB29—(CO—(CH2)20—COOH) desB30 human insulin; and NεB29—(CO—(CH2)22COOH) desB30 human insulin.
- WO 96/29344 (Novo Nordisk), which is incorporated herein by reference, discloses insulin compounds with a protracted activity profile wherein either the amino group of the N-terminal amino acid of the B-chain has a lipophilic substituent comprising from 12 to 40 carbon atoms attached, or wherein the carboxylic acid group of the C-terminal amino acid of the B-chain has a lipophilic substituent comprising from 12 to 40 carbon atoms attached.
- WO 95/07931 (Novo Nordisk), which is incorporated herein by reference, discloses insulin compounds with a protracted activity profile, wherein the ε-amino group of LysB29 has a lipophilic substituent. Particular mentioning is made of NεB29-tridecanoyl des(B30) human insulin, NεB29-tetradecanoyl des(B30) human insulin, NεB29-decanoyl des(B30) human insulin, NεB29-dodecanoyl des(B30) human insulin, NεB29-tridecanoyl GlyA21 des(B30) human insulin, NεB29-tetradecanoyl GlyA21 des(B30) human insulin, NεB29-decanoyl GlyA21 des(B30) human insulin, NεB29-dodecanoyl GlyA21 des(B30) human insulin, NεB29-tridecanoyl GlyA21 GlnB3 des(B30) human insulin, NεB29-tetradecanoyl GlyA21 GlnB3 des(B30) human insulin, NεB29-decanoyl GlyA21 GlnB3 des(B30) human insulin, NεB29-dodecanoyl GlyA21 GlnB3 des(B30) human insulin, NεB29-tridecanoyl AlaA21 des(B30) human insulin, NεB29-tetradecanoyl AlaA21 des(B30) human insulin, NεB29-decanoyl AlaA21 des(B30) human insulin, NεB29-dodecanoyl AlaA21 des(B30) human insulin, NεB29-tridecanoyl AlaA21 GlnB3 des(B30) human insulin, NεB29-tetradecanoyl AlaA21 GlnB3 des(B30) human insulin, NεB29-decanoyl AlaA21 GlnB3 des(B30) human insulin, NεB29-dodecanoyl AlaA21 GlnB3 des(B30) human insulin, NεB29-tridecanoyl GlnB3 des(B30) human insulin, NεB29-tetradecanoyl GlnB3 des(B30) human insulin, NεB29-decanoyl GlnB3 des(B30) human insulin, NεB29-dodecanoyl GlnB3 des(B30) human insulin, NεB29-tridecanoyl GlyA21 human insulin, NεB29-tetradecanoyl GlyA21 human insulin, NεB29-decanoyl GlyA21 human insulin, NεB29-dodecanoyl GlyA21 human insulin, NεB29-tridecanoyl GlyA21 GlnB3 human insulin, NεB29-tetradecanoyl GlyA21 GlnB3 human insulin, NεB29-decanoyl GlyA21 GlnB3 human insulin, NεB29-dodecanoyl GlyA21 GlnB3 human insulin, NεB29-tridecanoyl AlaA21 human insulin, NεB29-tetradecanoyl AlaA21 human insulin, NεB29-decanoyl AlaA21 human insulin, NεB29-dodecanoyl AlaA21 human insulin, NεB29-tridecanoyl AlaA21 GlnB3 human insulin, NεB29-tetradecanoyl AlaA21 GlnB3 human insulin, N29-decanoyl AlaA21 GlnB3 human insulin, NεB29-dodecanoyl AlaA21 GlnB3 human insulin, NεB29-tridecanoyl GlnB3 human insulin, NεB29-tetradecanoyl GlnB3 human insulin, NεB29-decanoyl GlnB3 human insulin, NεB29-dodecanoyl GlnB3 human insulin, NεB29-tridecanoyl GluB30 human insulin, NεB29-tetradecanoyl GluB30 human insulin, NεB29-decanoyl GluB30 human insulin, NεB29-dodecanoyl GluB30 human insulin, NεB29-tridecanoyl GlyA21 GluB30 human insulin, NεB29-tetradecanoyl GlyA21 GluB30 human insulin, NεB29-decanoyl GlyA21 GluB30 human insulin, NεB29-dodecanoyl GlyA21 GluB30 human insulin, NεB29-tridecanoyl GlyA21 GlnB3 GluB30 human insulin, NεB29-tetradecanoyl GlyA21 GlnB3 GluB30 human insulin, NεB29-decanoyl GlyA21 GlnB3 GluB30 human insulin, NεB29-dodecanoyl GlyA21 GlnB3 GluB30 human insulin, NεB29-tridecanoyl AlaA21 GluB30 human insulin, NεB29-tetradecanoyl AlaA21 GluB30 human insulin, NεB29-decanoyl AlaA21 GluB30 human insulin, NεB29-dodecanoyl AlaA21 GluB30 human insulin, NεB29-tridecanoyl AlaA21 GlnB3 GluB30 human insulin, NεB22-tetradecanoyl AlaA21 GlnB3 GluB30 human insulin, NεB21-decanoyl Ala1 GlnB3 GluB30 human insulin, NεB2-dodecanoyl AlaA21 GlnB3 GluB30 human insulin, NεB29-tridecanoyl GlnB3 GluB30 human insulin, NεB29-tetradecanoyl GlnB3 GluB30 human insulin, NεB29-decanoyl GlnB3 GluB30 human insulin and NεB29-dodecanoyl GlnB3 GluB30 human insulin.
- WO 97/02043 (Novo Nordisk), which is incorporated herein by reference discloses hormonally inactive insulin compounds which are useful in insulin prophylaxis, and in particular such analogues of human insulin are selected from amongst desA1 human insulin; des(A1-A2) human insulin; des(A1-A3) human insulin; desA21 human insulin; des(B1-B5) human insulin; des(B1-B6) human insulin; des(B23-B30) human insulin; des(B24-B30) human insulin; des(B25-B30) human insulin; GlyA2 human insulin; AlaA2 human insulin; NleA2 human insulin; ThrA2 human insulin; ProA2 human insulin; D-allo IleA2 human insulin; NvaA3 human insulin; NleA3 human insulin; LeuA3 human insulin; ValA2,IleA3 human insulin; AbuA2,AbuA3 human insulin; GlyA2,GlyA3 human insulin; D-CysA6 human insulin; D-CysA6,D-CysA11 human insulin; SerA6,SerA11, des(A8-A10) human insulin; D-CysA7 human insulin; D-CysA11 human insulin; LeuA19 human insulin; GlyB6 human insulin; GluB12 human insulin; AsnB12 human insulin; PheB12 human insulin; D-AlaB12 human insulin; and AspB25 human insulin are applicable in the methods of the present invention.
- WO 92/15611 (Novo nordisk), which is incorporated herein by reference, discloses analogues of human insulin with a fast association rate constants in the insulin receptor binding process and characterised by comprising a tyrosine in position A13 and/or a phenylalanin, tryptophane or tyrosine in position B17. In particular, such analogues are selected from amongst TyrA13 human insulin, PheB17 human insulin, TrpB17 human insulin, TyrB17 human insulin, TyrA13,PheB17 human insulin, TyrA13, TrpB17 human insulin, TyrA13, TyrB17 human insulin, Phe13,PheB17 human insulin, PheA13,TrpB17 human insulin, PheA13,TyrB17 human insulin, TrpA13,PheB17 human insulin, TrpA13,TrpB17 human insulin and TrpA13,TyrB17 human insulin.
- WO 92/00322 (Novo Nordisk), which is incorporated herein by reference, discloses analogues of human insulin which are capable of being targeted to specific tissues, and which are characterized by having in the A13 position and/or in the B17 position in the insulin molecule a naturally occurring amino acid residue different from leucine and/or by having in the B18 position in the insulin molecule a naturally occurring amino acid residue different from valine. In particular, such analogues are selected from amongst AlaB17 human insulin, AlaB18 human insulin, AsnA13 human insulin, AsnA13,AlaB17human insulin, AsnA13,AspB17 human insulin, AsnB13,GluB17 human insulin, AsnB18 human insulin, AspA13 human insulin, AspA13,AlaB17 human insulin, AspA13,AspB17 human insulin, AspA13,GluB17 human insulin, AspB18 human insulin, GlnA13 human insulin, GlnA13,AlaB17 human insulin, GlnA13,AspB17 human insulin, GlnB18 human insulin, GluA13 human insulin, GluA13,AlaB17 human insulin, GluA13,AspB17 human insulin, GluA13, GluB17 human insulin, GluB18 human insulin, GlyA13 human insulin, GlyA13,AlaB17 human insulin, GlyA13,AsnB17 human insulin, GlyA13,AspB17 human insulin, GlyA13,GluB17 human insulin, GlyB18 human insulin, SerA13 human insulin, SerA13,GlnA17,GluB10,GlnB17-des(ThrB30) human insulin, SerA13,AlaB17 human insulin, SerA13,AsnB17 human insulin, SerA13,AspB17 human insulin, SerA13,GlnB17 human insulin, SerA13,GluB17 human insulin, SerA13,ThrB17 human insulin, SerB14,AspB17 human insulin, SerB18 human insulin, ThrA13 human insulin or ThrB18 human insulin.
- WO 90/01038 (Novo Nordisk), which is incorporated herein by reference, discloses analogues of human insulin with high biological activity and characterized by having PheB25 substituted by His or Tyr, by having substitutions in one or more of positions A4, A8, A17, A21, B9, B10, B12, B13, B21, B26, B27, B28 and B30, and by having the amino acid residue at position B30 optionally absent. In particular, such analogues are selected from amongst TyrB25 human insulin, TyrB25, AspB28 human insulin, HisB25 human insulin, HisB25, AspB21 human insulin, TyrB25 human insulin-B30-amide and HisB25 human insulin-B30-amide.
- WO 86/05496 (Nordisk Gentofte) discloses analogues of human insulin with a protracted action and characterized by having a blocked B30 carboxylic group, and by having one to four blocked carboxylic groups in the amino acid residues at positions A4, A17, A21, B13 and B21. In particular, such analogues are selected from amongst insulin-B30-octyl ester, insulin-B30-dodecyl amide, insulin-B30-hexadecyl amide, insulin-(B21,B30)-dimethyl ester, insulin-(B17,B30)-dimethyl ester, insulin-(A4,B30) diamide, insulin-A17amide-B30-octyl ester, insulin-(A4,B13)-diamide-B30-hexylamide, insulin-(A4,A17,B21,B30)-tetraamide, insulin-(A17,B30)-diamide, A4-Ala-insulin-B30-amide and B30-Leu-insulin-(A4,B30)-diamide.
- WO 86/05497 (Nordisk Gentofte), which is incorporated herein by reference, discloses insulin compounds in which one or more of the four amino acid residues in positions A4, A17, B13 and B21 comprises an uncharged side chain. Particular mentioning is made of human insulin A17-Gln, human insulin A4-Gln, porcine insulin B21-Gln, human insulin B13-Gln, human insulin (A17,B21)-Gln, human insulin A4-Ala, human insulin B21-Thr, human insulin B13-Val, human insulin-Thr-A17-Gln, human insulin B21-methyl ester and human insulin A17-methyl ester.
- WO 92/00321 (Novo Nordisk), which is incorporated herein by reference, discloses insulin compounds with prolonged activity wherein a positive charge in the N-terminal end of the B-chain has been introduced. Particular mentioning is made of ArgB5,SerA21,ThrB30-NH2 human insulin, ArgB5,ProB6,SerA21,ThrB30-NH2 human insulin, ArgB5,GlyA21,ThrB30-NH2 human insulin, ArgB5,ProB6,GlyA21,ThrB30-NH2 human insulin, ArgB2,SerA21,ThrB30-NH2 human insulin, ArgB2,ProB3,SerA21,ThrB30-NH2 human insulin, ArgB2,GlyA21, ThrB30-NH2 human insulin, ArgB2,ProB3,GlyA21,ThrB30-NH2 human insulin, ArgB2,ArgB3,SerA21,ThrB30-NH2 human insulin, ArgB2,ArgB3,SerA21 human insulin, ArgB4,ProB5,SerA21,ThrB30-NH2 human insulin, ArgB4,ArgB5,ProB6,GlyA2,ThrB30 human insulin, ArgB3,GlyA21,ThrB30-NH2 human insulin, ArgB3,SerA21,ThrB30-NH2 human insulin, ArgB4,GlyA21,ThrB30-NH2 human insulin, ArgB4,SerA21,ThrB30-NH2 human insulin and ArgB1,ProB2,GlyA21,ThrB30-NH2 human insulin.
- WO 90/07522 (Novo Nordisk), which is incorporated herein by reference, discloses insulin compounds exhibiting a low ability to associate in solution wherein there is a positively charged amino acid residue, i.e. Lys or Arg in the position B28. Particular mentioning is made of des[PheB25]-human insulin, des[TyrB26]-human insulin, des[ThrB27]-human insulin, des[ProB28]-human insulin, des[PheB25]-porcine insulin, des[ProB28]-porcine insulin, des[ProB28]-rabbit insulin, des[PheB25],des[ThrB30]-human insulin, des[TyrB26],des[ThrB30]-human insulin, [SerA21]-des[ProB28]-human insulin, [GlyA21]-des[ProB28]-human insulin, [GlyA21]-des[PheB25]-human insulin, [AspA21]-des[PheB25]-human insulin, [HisB25]-des[TyrB26],des[ThrB30]-human insulin, [AsnB25]-des[TyrB26],des[ThrB30]-human insulin, [AspA21]-des[PheB25],des[ThrB30]-human insulin, [AspB28]-des[PheB25]-human insulin, [AspB30]-des[PheB25]-human insulin, [LysB28-human insulin, [LysB28,ThrB29]-human insulin and [ArgB28]-des[LysB29]-human insulin.
- WO 90/11290 (Novo Nordisk), which is incorporated herein by reference discloses insulin compounds with a prolonged activity. Particular mentioning is made of [ArgA0]-human insulin-(B30-amide), [ArgA0,GlnB13]-human insulin-(B30-amide), [ArgA0,GlnA4,AspA21]-human insulin-(B30-amide), [ArgA0,SerA21]-human insulin-(B30-amide) and [ArgA0,ArgB27]-des[ThrB30]-human insulin.
- WO 90/10645 (Novo Nordisk), which is incorporated herein by reference discloses glycosylated insulins. Particular mentioning is made of Phe(B1) glucose human insulin, Phe(B1) mannose human insulin, Gly(A1) mannose human insulin, Lys(B29) mannose human insulin, Phe(B1) galactose human insulin, Gly(A1) galactose human insulin, Lys(B29) galactose human insulin, Phe(B1) maltose human insulin, Phe(B1) lactose human insulin, Gly(A1) glucose human insulin, Gly(A1) maltose human insulin, Gly(A1) lactose human insulin, Lys(B29) glucose human insulin, Lys(B29) maltose human insulin, Lys(B29) lactose human insulin, Gly(A1), Phe(B1) diglucose human insulin, Gly(A1), Lys(B29) diglucose human insulin, Phe(B1), Lys(B29) diglucose human insulin, Phe(B1) isomaltose human insulin, Gly(A1) isomaltose human insulin, Lys(B29) isomaltose human insulin, Phe(B1) maltotriose human insulin, Gly(A1) maltotriose human insulin, Lys(B29) maltotriose human insulin, Gly(A1), Phe(B1) dimaltose human insulin, Gly(A1), Lys(B29) dimaltose human insulin, Phe(B1), Lys(B29) dimaltose human insulin, Gly(A1), Phe(B1) dilactose human insulin, Gly(A1), Lys(B29) dilactose human insulin, Phe(B1), Lys(B29) dilactose human insulin, Gly(A1), Phe(B1) dimaltotriose human insulin, Gly(A1), Lys(B29) dimaltotriose human insulin, Phe(B1), Lys(B29) dimaltotriose human insulin, Phe(B1), Gly(A1) dimannose human insulin, Phe(B1), Lys(B29) dimannose human insulin, Gly(A1), Lys(B29) dimannose human insulin, Phe(B1), Gly(A1) digalactose human insulin, Phe(B1), Lys(B29) digalactose human insulin, Gly(A1), Lys(B29) digalactose human insulin, Phe(B1), Gly(A1) diisomaltose human insulin, Phe(B1), Lys(B29) diisomaltose human insulin, Gly(A1), Lys(B29) diisomaltose human insulin, Phe(B1) glucose [AspB10] human insulin and Gly(A1), Phe(B1) diglucose [AspB10] human insulin.
- WO 88/065999 (Novo Nordisk), which is incorporated herein by reference, discloses stabilized insulin compounds, wherein Ans21A has been substituted with other amino acid residues. Particular mentioning is made of GlyA21 human insulin, AlaA21 human insulin, SerA21 human insulin, ThrA21 human insulin and hSerA21 human insulin.
- EP 254516 (Novo Nordisk), which is incorporated herein by reference, discloses insulin compounds with a prolonged action, wherein basic amino acid residues have been substituted by neutral amino acid residues. Particular mentioning is made of GlyA21,LysB27,ThrB30-NH2 human insulin, SerA21, LysB27,ThrB30-NH2 human insulin, ThrA21,LysB27,ThrB30-NH2human insulin, AlaB21,LysB27,ThrB30-NH2human insulin, HisA21,LysB27,ThrB30-NH2human insulin, AspB21,LysB27,ThrB30-NH2human Insulin, GlyA21,ArgB21,ThrB30-NH2 human insulin, SerA21,ArgB27,ThrB30-NH2 human insulin, ThrA21,ArgB27,ThrB30-NH2 human insulin, AlaB21,ArgB27,ThrB30-NH2human insulin, HisA21,ArgB27,ThrB30-NH2 human insulin, AspB21,ArgB27,ThrB30-NH2 human insulin, GlnB13,GlyA21,ArgB27,ThrB30-NH2 human insulin, GlnB13,SerA21,ThrB30-NH2 human insulin, GlnB13,SerA21,ArgB27,ThrB30-NH2human insulin, GlnB13,ThrA21,ArgB27,ThrB30-NH2human insulin, GlnB13,AlaA21,ArgB27,ThrB30-NH2 human insulin, GlnB13,HisA21,ArgB27,ThrB30-NH2human insulin, GlnB13,AspA21,ArgB27,ThrB30-NH2 human insulin, GlnB13,GlyA21,LysB27,ThrB30-NH human insulin, GlnB13,SerA21,LysB27,ThrB30-NH2 human insulin, GlnB13-ThrA21,LysB27,ThrB30-NH2human insulin, GlnB13,AlaA21,LysB27, ThrB30-NH2 human insulin, GlyA21,ArgB27 human insulin, GlnB13,AspA21,LysB27,ThrB30-NH2 human insulin, AsnA21,LysB27 human insulin, SerA21,LysB27 human insulin, ThrA21,LysB27 human insulin, AlaA21,LysB27 human insulin, HisA21,LysB27 human insulin, AspA21,LysB27 human insulin, GlyA21,LysB27 human insulin, AsnA21,ArgB27 human insulin, SerA21,ArgB27 human insulin, ThrA21,ArgB27 human insulin, AlaA21,ArgB27 human insulin, HisA21, ArgB27 human insulin, AspA21,ArgB27 human insulin, GlyA21,ArgB27 human insulin, GlnA17,AsnA21,ArgB27 human insulin, GlnA17,SerA21,ArgB27 human insulin, GlnA17,ThrA21,ArgB27human insulin, GlnA17,AlaA21,ArgB27 human insulin, GlnA17,HisA21,ArgB27 human insulin, GlnA17,AlaA21,ArgB27 human insulin, GlnA17, GlyA21,ArgB27 human insulin, GlnA17,AsnA21,GlnB13 human insulin, GlnA17,SerA21,GlnB13 human insulin, GlnA17,ThrA21,GlnB13 human insulin, GlnA17,AlaA21,GlnB13 human insulin, GlnA17,HisA21,GlnB13 human insulin, GlnA17,AspA21,GlnB13 human insulin, GlnA17,GlyA21,GlnB13human insulin, ArgA27,AsnA21,GlnB13 human insulin, ArgA27,SerA21,GlnB13 human insulin, ArgA27,ThrA21,GlnB13 human insulin, ArgA27,AlaA21,GlnB13 human insulin, ArgA27,HisA21,GlnB13 human insulin, ArgA27,AspA21,GlnB13 human insulin, ArgA27,GlyA21,GlnB13 human insulin, GlnA17,AsnA21,LysB27 human insulin, GlnA17,SerA21,LysB27 human insulin, GlnA17,ThrA21,LysB27 human insulin, GlnA17,AlaA21,LysB27 human insulin, GlnA17,HisA21,LysB27 human insulin, GlnA17,AspA21,LysB27human insulin, GlnA17,GlyA21,LysB27 human insulin, GlnB13,AsnA21,LysB27human insulin, GlnB13 SerA21,LysB27human insulin, GlnB13,ThrA21,LysB27 human insulin, GlnB13,AlaA21,LysB27 human insulin, GlnB13,HisA2,LysB27 human insulin, GlnB13,AspA21,LysB27human insulin, and GlnB13,GlyA21,LysB27human insulin.
- EP 214826 (Novo Nordisk), which is incorporated herein by reference, discloses rapid onset insulin compounds.
- EP 194864 (Novo Nordisk), which is incorporated herein by reference, discloses insulin compounds with a prolonged action, wherein basic amino acid residues have been substituted by neutral amino acid residues. Particular mentioning is made of GlnA17,ArgB27,ThrB31-NH2 human insulin, GlnA17,GlnB13,ThrB30-NH2 human insulin, GlnA17,LysB27,ThrB30—NH2 human insulin, GlnA17,LysB27-NH2 human insulin, GlnA17, GlnA17,ThrB30-NH2 human insulin, GlnB13,ArgB27,ThrB30-NH2 human insulin, GlnB13,LysB27,ThrB30-NH2 human insulin, GlnB13,LysB30-NH2 human insulin, GlnB13,ThrB30-NH2 human insulin, ArgB27,ArgB30-NH2 human insulin, ArgB27,LysB30-NH2 human insulin, ArgB27,ThrB30-NH2 human insulin, LysB27,ArgB30-NH2 human insulin, LysB27,LysB30-NH2 human insulin, LysB27,ThrB30-NH2 human insulin, LysB29-NH2,des-(B30) human insulin, ThrB30-NH2 human insulin, LysB30-NH2 human insulin, LysB30(Lau)-NH2 human insulin, LysB30,ArgB31-NH2 human insulin, LysB30,LysB31-NH2 human insulin, ArgB30-NH2 human insulin, ArgB30,ArgB31-NH2 human insulin, and ArgB30,LysB31-NH2 human insulin.
- U.S. Pat. No. 3,528,960 (Eli Lilly), which is incorporated herein by reference, discloses N-carboxyaroyl insulin compounds in which one, two or three primary amino groups of the insulin molecule has a carboxyaroyl group.
- GB Patent No. 1.492.997 (Nat. Res. Dev. Corp.), which is incorporated herein by reference, discloses insulin compounds with a carbamyl substitution at NεB29 with an improved profile of hypoglycaemic effect.
- JP laid-open patent application No. 1-254699 (Kodama Co., Ltd.), which is incorporated herein by reference, discloses insulin compounds, wherein an alkanoyl group is bound to the amino group of PheB1 or to the ε-amino group of LysB29 or to both of these.
- JP laid-open patent application No. 57-067548 (Shionogi), which is incorporated herein by reference discloses insulin compounds, in which the B30 position have an amino acid having at least five carbon atoms which cannot necessarily be coded for by a triplet of nucleotides.
- WO 03/053339 (Eli Lilly), which is incorporated herein by reference, disclose insulin compounds, wherein the A-chain in the N-terminal has been extended with two amino acid residues, A-1 and A0, wherein the B-chain has been extended at the N-terminal with two amino acid residues, B-1 and B0, wherein the amino acid residues at positions B28, B29 and B39 may be substituted, and wherein the ε-amino group of Lys at position B28 or B29 is covalently bound to the α-carboxyl group of a positively charged amino acid to form a Lys-Nε-aminoacid derivative. Particular mentioning is made of said analogues, wherein A-1 and B-1 are both absent, and wherein A0 represent Arg and B0 represents Arg or is absent.
- Insulin compounds selected from the group consisting of
-
- i. An analogue wherein position B28 is Asp, Lys, Leu, Val, or Ala and position B29 is Lys or Pro; and
- ii. des(B28-B30), des(B27) or des(B30) human insulin.
are also applicable for the methods of the present invention, and in particular, the insulin compound wherein position B28 is Asp or Lys, and position B29 is Lys or Pro.
- des(B30) human insulin is also applicable in the methods of the present invention.
- Other applicable insulin compounds are selected from the group consisting of B29-Nε-myristoyl-des(B30) human insulin, B29-Nε-palmitoyl-des(B30) human insulin, B29-Nε-myristoyl human insulin, B29-Nε-palmitoyl human insulin, B28-Nε-myristoyl LysB28ProB29 human insulin, B28-Nε-palmitoyl LysB28ProB29 human insulin, B30-Nε-myristoyl-ThrB29LysB30 human insulin, B30-Nε-palmitoyl-ThrB29LysB30 human insulin, B29-Nε-(N-palmitoyl-γ-glutamyl)-des(B30) human insulin, B29-Nε-(N-lithocholyl-γ-glutamyl)-des(B30) human insulin, B29-Nε-(ω-carboxyheptadecanoyl)-des(B30) human insulin, B29-Nε-(o-carboxyheptadecanoyl) human insulin and B29-Nε-myristoyl-des(B30) human insulin.
- Examples of GLP-1 applicable in the methods of the present invention include human GLP-1 and GLP-1 compounds. Human GLP-1 is a 37 amino acid residue peptide originating from preproglucagon which is synthesised i.a. in the L-cells in the distal ileum, in the pancreas and in the brain. GLP-1 is an important gut hormone with regulatory function in glucose metabolism and gastrointestinal secretion and metabolism. Processing of preproglucagon to give GLP-1(7-36)-amide, GLP-1(7-37) and GLP-2 occurs mainly in the L-cells. The fragments GLP-1(7-36)-amide and GLP-1(7-37) are both glucose-dependent insulinotropic agents. In the past decades a number of structural analogues of GLP-1 were isolated from the venom of the Gila monster lizards (Heloderma suspectum and Heloderma horridum). Exendin-4 is a 39 amino acid residue peptide isolated from the venom of Heloderma horridum, and this peptide shares 52% homology with GLP-1. Exendin-4 is a potent GLP-1 receptor agonist which has been shown to stimulate insulin release and ensuring lowering of the blood glucose level when injected into dogs. The group of GLP-1(1-37) and exendin-4(1-39) and certain fragments, analogues and derivatives thereof (designated GLP-1 compounds herein) are potent insulinotropic agents, and they are all applicable in the method of the present invention. Insulinotropic fragments of GLP-1(1-37) are insulinotropic peptides for which the entire sequence can be found in the sequence of GLP-1(1-37) and where at least one terminal amino acid has been deleted. Examples of insulinotropic fragments of GLP-1(1-37) are GLP-1(7-37) wherein the amino acid residues in positions 1-6 of GLP-1(1-37) have been deleted, and GLP-1(7-36) where the amino acid residues in position 1-6 and 37 of GLP-1(1-37) have been deleted. Examples of insulinotropic fragments of exendin-4(1-39) are exendin-4(1-38) and exendin-4(1-31). The insulinotropic property of a compound may be determined by in vivo or in vitro assays well known in the art. For instance, the compound may be administered to an animal and monitoring the insulin concentration over time. Insulinotropic analogs of GLP-1(1-37) and exendin-4(1-39) refer to the respective molecules wherein one or more of the amino acids residues have been exchanged with other amino acid residues and/or from which one or more amino acid residues have been deleted and/or from which one or more amino acid residues have been added with the proviso that said analogue either is insulinotropic or is a prodrug of an insulinotropic compound. Examples of insulinotropic analogs of GLP-1(1-37) is e.g. Met8-GLP-1(7-37) wherein the alanine in position 8 has been replaced by methionine and the amino acid residues in position 1 to 6 have been deleted, and Arg34-GLP-1(7-37) wherein the valine in position 34 has been replaced with arginine and the amino acid residues in position 1 to 6 have been deleted. An example of an insulinotropic analog of exendin-4(1-39) is Ser2Asp3-exendin-4(1-39) wherein the amino acid residues in position 2 and 3 have been replaced with serine and aspartic acid, respectively (this particular analog also being known in the art as exendin-3). Insulinotropic derivatives of GLP-1(1-37), exendin-4(1-39) and analogs thereof are what the person skilled in the art considers to be derivatives of these peptides, i.e. having at least one substituent which is not present in the parent peptide molecule with the proviso that said derivative either is insulinotropic or is a prodrug of an insulinotropic compound. Examples of substituents are amides, carbohydrates, alkyl groups and lipophilic substituents. Examples of insulinotropic derivatives of GLP-1(1-37), exendin-4(1-39) and analogs thereof are GLP-1(7-36)-amide, Arg34, Lys26(Nε-(γ-Glu(N-hexadecanoyl)))-GLP-1(7-37) and Tyr31-exendin-4(1-31)-amide. Further examples of GLP-1(1-37), exendin-4(1-39), insulinotropic fragments thereof, insulinotropic analogs thereof and insulinotropic derivatives thereof are described in WO 98/08871, WO 99/43706, U.S. Pat. No. 5,424,286 and WO 00/09666, which are all enclosed herein by reference.
- GLP-2 and GLP-2 compounds may also be modified by the methods provided by the present invention. In the present context a GLP-2 compound binds to a GLP-2 receptor, preferably with an affinity constant (KD) or a potency (EC50) of below 1 μM, e.g. below 100 nM. The term “GLP-2 compound” is intended to indicate human GLP-2 in which one or more amino acid residue has been deleted and/or replaced by another amino acid residue, natural or unnatural, and/or human GLP-2 comprising additional amino acid residues, and/or human GLP-2 in which at least one organic substituent is bound to one or more of the amino acid residues. In particular, those peptides are considered, which amino acid sequence exhibit at any sequence of 33 consecutive amino acids more than 60% of the amino acid sequence of human GLP-2. Also those peptides are considered, which amino acid sequence exhibit at any sequence of 37 consecutive amino acids more than 60% of the amino acid sequence of human GLP-2 when up to four amino acids are deleted from the amino acid sequence. Also those peptides are considered, which amino acid sequence exhibit at any sequence of 31 consecutive amino acids more than 60% of the amino acid sequence of GLP-2, when up to two amino acids are added to their amino acid sequence. The term “GLP compounds” also includes natural allelic variations that may exist and occur from one individual to another. Also, degree and location of glycosylation or other post-translation modifications may vary depending on the chosen host cells and the nature of the host cellular environment.
- Candidate GLP-2 compounds, which may be used according to the present invention include the GLP-2 compounds described in WO 96/32414, WO 97/39031, WO 98/03547, WO 96/29342, WO 97/31943, WO 98/08872, which are all incorporated herein by reference.
- In particular, the following GLP-2 compounds are applicable in the methods of the present invention: A2G-GLP-2(1-33); K30R-GLP-2(1-33); S5K-GLP-2(1-33); S7K-GLP-2(1-33); D8K-GLP-2(1-33); E9K-GLP-2(1-33); M10K-GLP-2(1-33); N11K-GLP-2(1-33); T12K-GLP-2(1-33); 113K-GLP-2(1-33); L14K-GLP-2(1-33); D15K-GLP-2(1-33); N16K-GLP-2(1-33); L17K-GLP-2(1-33); A18K-GLP-2(1-33); D21K-GLP-2(1-33); N24K-GLP-2(1-33); Q28K-GLP-2(1-33); S5K/K30R-GLP-2(1-33); S7K/K30R-GLP-2(1-33); D8K/K30R-GLP-2(1-33); E9K/K30R-GLP-2(1-33); M10K/K30R-GLP-2(1-33); N11K/K30R-GLP-2(1-33); T12K/K30R-GLP-2(1-33); 113K/K30R-GLP-2(1-33); L14K/K30R-GLP-2(1-33); D15K/K30R-GLP-2(1-33); N16K/K30R-GLP-2(1-33); L17K/K30R-GLP-2(1-33); A18K/K30R-GLP-2(1-33); D21K/K30R-GLP-2(1-33); N24K/K30R-GLP-2(1-33); Q28K/K30R-GLP-2(1-33); K30R/D33K-GLP-2(1-33); D3E/K30R/D33E-GLP-2(1-33); D3E/S5K/K30R/D33E-GLP-2(1-33); D3E/S7K/K30R/D33E-GLP-2(1-33); D3E/D8K/K30R/D33E-GLP-2(1-33); D3E/E9K/K30R/D33E-GLP-2(1-33); D3E/M10K/K30R/D33E-GLP-2(1-33); D3E/N11K/K30R/D33E-GLP-2(1-33); D3E/T12K/K30R/D33E-GLP-2(1-33); D3E/I13K/K30R/D33E-GLP-2(1-33); D3E/L14K/K30R/D33E-GLP-2(1-33); D3E/D15K/K30R/D33E-GLP-2(1-33); D3E/N16K/K30R/D33E-GLP-2(1-33); D3E/L17K/K30R/D33E-GLP-2(1-33); D3E/A18K/K30R/D33E-GLP-2(1-33); D3E/D21K/K30R/D33E-GLP-2(1-33); D3E/N24K/K30R/D33E-GLP-2(1-33); and D3E/Q28K/K30R/D33E-GLP-2(1-33).
- In one embodiment of the invention the GLP-2 compound is selected from GLP-2(1-33), 34R-GLP-2(1-34), A2G-GLP-2(1-33), A2G/34R-GLP-2(1-34), K30R-GLP-2(1-33); S5K-GLP-2(1-33); S7K-GLP-2(1-33); D8K-GLP-2(1-33); E9K-GLP-2(1-33); M10K-GLP-2(1-33); N11K-GLP-2(1-33); T12K-GLP-2(1-33); 113K-GLP-2(1-33); L14K-GLP-2(1-33); D15K-GLP-2(1-33); N16K-GLP-2(1-33); L17K-GLP-2(1-33); A18K-GLP-2(1-33); D21K-GLP-2(1-33); N24K-GLP-2(1-33); Q28K-GLP-2(1-33); S5K/K30R-GLP-2(1-33); S7K/K30R-GLP-2(1-33); D8K/K30R-GLP-2(1-33); E9K/K30R-GLP-2(1-33); M10K/K30R-GLP-2(1-33); N11K/K30R-GLP-2(1-33); T12K/K30R-GLP-2(1-33); 113K/K30R-GLP-2(1-33); L14K/K30R-GLP-2(1-33); D15K/K30R-GLP-2(1-33); N16K/K30R-GLP-2(1-33); L17K/K30R-GLP-2(1-33); A18K/K30R-GLP-2(1-33); D21K/K30R-GLP-2(1-33); N24K/K30R-GLP-2(1-33); Q28K/K30R-GLP-2(1-33); K30R/D33K-GLP-2(1-33); D3E/K30R/D33E-GLP-2(1-33); D3E/S5K/K30R/D33E-GLP-2(1-33); D3E/S7K/K30R/D33E-GLP-2(1-33); D3E/D8K/K30R/D33E-GLP-2(1-33); D3E/E9K/K30R/D33E-GLP-2(1-33); D3E/M10K/K30R/D33E-GLP-2(1-33); D3E/N11K/K30R/D33E-GLP-2(1-33); D3E/T12K/K30R/D33E-GLP-2(1-33); D3E/113K/K30R/D33E-GLP-2(1-33); D3E/L14K/K30R/D33E-GLP-2(1-33); D3E/D15K/K30R/D33E-GLP-2(1-33); D3E/N16K/K30R/D33E-GLP-2(1-33); D3E/L17K/K30R/D33E-GLP-2(1-33); D3E/A18K/K30R/D33E-GLP-2(1-33); D3E/D21K/K30R/D33E-GLP-2(1-33); D3E/N24K/K30R/D33E-GLP-2(1-33); D3E/Q28K/K30R/D33E-GLP-2(1-33).
- GLP-2 derivatives with only one lipophilic substituent attached to the GLP-2 peptide are also applicable in the methods of the present invention, such as GLP-2 derivatives wherein the lipophilic substituent comprises from 4 to 40 carbon atoms, such as from 8 to 25 carbon atoms, e.g. from 12 to 20 carbon atoms.
- The lipophilic substituent may be attached to an amino acid residue in such a way that a carboxyl group of the lipophilic substituent forms an amide bond with an amino group of the amino acid residue.
- By way of example, the lipophilic substituent is attached to a Lys residue.
- The lipophilic substituent may be attached to an amino acid residue in such a way that an amino group of the lipophilic substituent forms an amide bond with a carboxyl group of the amino acid residue.
- The lipophilic substituent may also be attached to the GLP-2 peptide by means of a spacer, and said spacer may be selected from amongst β-alanine, gamma-aminobutyric acid (GABA), γ-glutamic acid, Lys, Asp, Glu, a dipeptide containing Asp, a dipeptide containing Glu, or a dipeptide containing Lys. In one embodiment of the invention the spacer is β-alanine.
- A carboxyl group of the parent GLP-2 peptide may also form an amide bond with an amino group of a spacer, and the carboxyl group of the amino acid or dipeptide spacer forms an amide bond with an amino group of the lipophilic substituent.
- An amino group of the parent GLP-2 peptide may also form an amide bond with a carboxylic group of a spacer, and an amino group of the spacer forms an amide bond with a carboxyl group of the lipophilic substituent.
- In one embodiment of the invention the lipophilic substituent is a straight-chain or branched alkyl group. In one embodiment of the invention the lipophilic substituent is the acyl group of a straight-chain or branched fatty acid.
- In one embodiment of the invention the lipophilic substituent is an acyl group of a straight-chain or branched alkane α,ω-dicarboxylic acid.
- In one embodiment of the invention the GLP-2 derivative has one lipophilic substituent. In one embodiment of the invention the GLP-2 derivative has two lipophilic substituents. In one embodiment of the invention the GLP-2 derivative has three lipophilic substituents. In one embodiment of the invention the GLP-2 derivative has four lipophilic substituents.
- The following list contains GLP-2 derivatives which are particular applicable in the methods of the present invention.
- S5K(3-(hexadecanoylamino)propionyl)-GLP-2(1-33);
S7K(3-(hexadecanoylamino)propionyl)-GLP-2(1-33);
D8K(3-(hexadecanoylamino)propionyl)-GLP-2(1-33);
E9K(3-(hexadecanoylamino)propionyl)-GLP-2(1-33);
M10K(3-(hexadecanoylamino)propionyl)-GLP-2(1-33);
N11K(3-(hexadecanoylamino)propionyl)-GLP-2(1-33);
T12K(3-(hexadecanoylamino)propionyl)-GLP-2(1-33);
I13K(3-(hexadecanoylamino)propionyl)-GLP-2(1-33);
L14K(3-(hexadecanoylamino)propionyl)-GLP-2(1-33);
D15K(3-(hexadecanoylamino)propionyl)-GLP-2(1-33);
N16K(3-(hexadecanoylamino)propionyl)-GLP-2(1-33);
L17K(3-(octanoylamino)propionyl)-GLP-2(1-33);
L17K(3-(nonanoylamino)propionyl)-GLP-2(1-33);
L17K(3-(decanoylamino)propionyl)-GLP-2(1-33);
L17K(3-(undecanoylamino)propionyl)-GLP-2(1-33);
L17K(3-(dodecanoylamino)propionyl)-GLP-2(1-33);
L17K(3-(tridecanoylamino)propionyl)-GLP-2(1-33);
L17K(3-(tetradecanoylamino)propionyl)-GLP-2(1-33);
L17K(3-(pentadecanoylamino)propionyl)-GLP-2(1-33);
L17K(3-(hexadecanoylamino)propionyl)-GLP-2(1-33);
L17K(3-(heptadecanoylamino)propionyl)-GLP-2(1-33);
L17K(3-(octadecanoylamino)propionyl)-GLP-2(1-33);
L17K(3-(nonadecanoylamino)propionyl)-GLP-2(1-33);
L17K(3-(eicosanoylamino)propionyl)-GLP-2(1-33);
L17K((S)-4-carboxy-4-(octanoylamino)butanoyl)-GLP-2(1-33);
L17K((S)-4-carboxy-4-(nonanoylamino)butanoyl)-GLP-2(1-33);
L17K((S)-4-carboxy-4-(decanoylamino)butanoyl)-GLP-2(1-33);
L17K((S)-4-carboxy-4-(undecanoylamino)butanoyl)-GLP-2(1-33);
L17K((S)-4-carboxy-4-(dodecanoylamino)butanoyl)-GLP-2(1-33);
L17K((S)-4-carboxy-4-(tridecanoylamino)butanoyl)-GLP-2(1-33);
L17K((S)-4-carboxy-4-(tetradecanoylamino)butanoyl)-GLP-2(1-33);
L17K((S)-4-carboxy-4-(pentadecanoylamino)butanoyl)-GLP-2(1-33);
L17K((S)-4-carboxy-4-(hexadecanoylamino)butanoyl)-GLP-2(1-33);
L17K((S)-4-carboxy-4-(heptadecanoylamino)butanoyl)-GLP-2(1-33);
L17K((S)-4-carboxy-4-(octadecanoylamino)butanoyl)-GLP-2(1-33);
L17K((S)-4-carboxy-4-(nonadecanoylamino)butanoyl)-GLP-2(1-33);
L17K((S)-4-carboxy-4-(eicosanoylamino)butanoyl)-GLP-2(1-33);
L17K(4-(octanoylamino)butanoyl)-GLP-2(1-33);
L17K(4-(nonanoylamino)butanoyl)-GLP-2(1-33);
L17K(4-(decanoylamino)butanoyl)-GLP-2(1-33);
L17K(4-(undecanoylamino)butanoyl)-GLP-2(1-33);
L17K(4-(dodecanoylamino)butanoyl)-GLP-2(1-33);
L17K(4-(tridecanoylamino)butanoyl)-GLP-2(1-33);
L17K(4-(tetradecanoylamino)butanoyl)-GLP-2(1-33);
L17K(4-(pentadecanoylamino)butanoyl)-GLP-2(1-33);
L17K(4-(hexadecanoylamino)butanoyl)-GLP-2(1-33);
L17K(4-(heptadecanoylamino)butanoyl)-GLP-2(1-33);
L17K(4-(octadecanoylamino)butanoyl)-GLP-2(1-33);
L17K(4-(nonadecanoylamino)butanoyl)-GLP-2(1-33);
L17K(4-(eicosanoylamino)butanoyl)-GLP-2(1-33);
A18K(3-(hexadecanoylamino)propionyl)-GLP-2(1-33);
D21K(3-(hexadecanoylamino)propionyl)-GLP-2(1-33);
N24K(3-(hexadecanoylamino)propionyl)-GLP-2(1-33);
Q28K(3-(hexadecanoylamino)propionyl)-GLP-2(1-33);
S5K(3-(hexadecanoylamino)propionyl)/K30R-GLP-2(1-33);
S7K(3-(hexadecanoylamino)propionyl)/K30R-GLP-2(1-33);
D8K(3-(hexadecanoylamino)propionyl)/K30R-GLP-2(1-33);
E9K(3-(hexadecanoylamino)propionyl)/K30R-GLP-2(1-33);
M10K(3-(hexadecanoylamino)propionyl)/K30R-GLP-2(1-33);
N11K(3-(hexadecanoylamino)propionyl)/K30R-GLP-2(1-33);
T12K(3-(hexadecanoylamino)propionyl)/K30R-GLP-2(1-33);
I13K(3-(hexadecanoylamino)propionyl)/K30R-GLP-2(1-33);
L14K(3-(hexadecanoylamino)propionyl)/K30R-GLP-2(1-33);
D15K(3-(hexadecanoylamino)propionyl)/K30R-GLP-2(1-33);
N 16K(3-(hexadecanoylamino)propionyl)/K30R-GLP-2(1-33);
L17K(3-(octanoylamino)propionyl)/K30R-GLP-2(1-33);
L17K(3-(nonanoylamino)propionyl)/K30R-GLP-2(1-33);
L17K(3-(decanoylamino)propionyl)/K30R-GLP-2(1-33);
L17K(3-(undecanoylamino)propionyl)/K30R-GLP-2(1-33);
L17K(3-(dodecanoylamino)propionyl)/K30R-GLP-2(1-33);
L17K(3-(tridecanoylamino)propionyl)/K30R-GLP-2(1-33);
L17K(3-(tetradecanoylamino)propionyl)/K30R-GLP-2(1-33);
L17K(3-(pentadecanoylamino)propionyl)/K30R-GLP-2(1-33);
L17K(3-(hexadecanoylamino)propionyl)/K30R-GLP-2(1-33);
L17K(3-(heptadecanoylamino)propionyl)/K30R-GLP-2(1-33);
L17K(3-(octadecanoylamino)propionyl)/K30R-GLP-2(1-33);
L17K(3-(nonadecanoylamino)propionyl)/K30R-GLP-2(1-33);
L17K(3-(eicosanoylamino)propionyl)/K30R-GLP-2(1-33);
L17K((S)-4-carboxy-4-(octanoylamino)butanoyl)/K30R-GLP-2(1-33);
L17K((S)-4-carboxy-4-(nonanoylamino)butanoyl)/K30R-GLP-2(1-33);
L17K((S)-4-carboxy-4-(decanoylamino)butanoyl)/K30R-GLP-2(1-33);
L17K((S)-4-carboxy-4-(undecanoylamino)butanoyl)/K30R-GLP-2(1-33);
L17K((S)-4-carboxy-4-(dodecanoylamino)butanoyl)/K30R-GLP-2(1-33);
L17K((S)-4-carboxy-4-(tridecanoylamino)butanoyl)/K30R-GLP-2(1-33);
L17K((S)-4-carboxy-4-(tetradecanoylamino)butanoyl)/K30R-GLP-2(1-33);
L17K((S)-4-carboxy-4-(pentadecanoylamino)butanoyl)/K30R-GLP-2(1-33);
L17K((S)-4-carboxy-4-(hexadecanoylamino)butanoyl)/K30R-GLP-2(1-33);
L17K((S)-4-carboxy-4-(heptadecanoylamino)butanoyl)/K30R-GLP-2(1-33);
L17K((S)-4-carboxy-4-(octadecanoylamino)butanoyl)/K30R-GLP-2(1-33);
L17K((S)-4-carboxy-4-(nonadecanoylamino)butanoyl)/K30R-GLP-2(1-33);
L17K((S)-4-carboxy-4-(eicosanoylamino)butanoyl)/K30R-GLP-2(1-33);
L17K(4-(octanoylamino)butanoyl)/K30R-GLP-2(1-33);
L 17K(4-(nonanoylamino)butanoyl)/K30R-GLP-2(1-33);
L17K(4-(decanoylamino)butanoyl)/K30R-GLP-2(1-33);
L17K(4-(undecanoylamino)butanoyl)/K30R-GLP-2(1-33);
L17K(4-(dodecanoylamino)butanoyl)/K30R-GLP-2(1-33);
L17K(4-(tridecanoylamino)butanoyl)/K30R-GLP-2(1-33);
L17K(4-(tetradecanoylamino)butanoyl)/K30R-GLP-2(1-33);
L17K(4-(pentadecanoylamino)butanoyl)/K30R-GLP-2(1-33);
L17K(4-(hexadecanoylamino)butanoyl)/K30R-GLP-2(1-33);
L17K(4-(heptadecanoylamino)butanoyl)/K30R-GLP-2(1-33);
L17K(4-(octadecanoylamino)butanoyl)/K30R-GLP-2(1-33);
L17K(4-(nonadecanoylamino)butanoyl)/K30R-GLP-2(1-33);
L17K(4-(eicosanoylamino)butanoyl)/K30R-GLP-2(1-33);
A18K(3-(hexadecanoylamino)propionyl)/K30R-GLP-2(1-33);
D21K(3-(hexadecanoylamino)propionyl)/K30R-GLP-2(1-33);
N24K(3-(hexadecanoylamino)propionyl)/K30R-GLP-2(1-33);
Q28K(3-(hexadecanoylamino)propionyl)/K30R-GLP-2(1-33);
D3E/S5K(3-(hexadecanoylamino)propionyl)/K30R/D33E-GLP-2(1-33);
D3E/S7K(3-(hexadecanoylamino)propionyl)/K30R/D33E-GLP-2(1-33);
D3E/D8K(3-(hexadecanoylamino)propionyl)/K30R/D33E-GLP-2(1-33);
D3E/E9K(3-(hexadecanoylamino)propionyl)/K30R/D33E-GLP-2(1-33);
D3E/M10K(3-(hexadecanoylamino)propionyl)/K30R/D33E-GLP-2(1-33);
D3E/N11K(3-(hexadecanoylamino)propionyl)/K30R/D33E-GLP-2(1-33);
D3E/T12K(3-(hexadecanoylamino)propionyl)/K30R/D33E-GLP-2(1-33);
D3E/I13K(3-(hexadecanoylamino)propionyl)/K30R/D33E-GLP-2(1-33);
D3E/L14K(3-(hexadecanoylamino)propionyl)/K30R/D33E-GLP-2(1-33);
D3E/D15K(3-(hexadecanoylamino)propionyl)/K30R/D33E-GLP-2(1-33);
D3E/N16K(3-(hexadecanoylamino)propionyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K(3-(octanoylamino)propionyl)/K30R/D33E-GLP-2(1-33);
D3E/L117K(3-(nonanoylamino)propionyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K(3-(decanoylamino)propionyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K(3-(undecanoylamino)propionyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K(3-(dodecanoylamino)propionyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K(3-(tridecanoylamino)propionyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K(3-(tetradecanoylamino)propionyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K(3-(pentadecanoylamino)propionyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K(3-(hexadecanoylamino)propionyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K(3-(heptadecanoylamino)propionyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K(3-(octadecanoylamino)propionyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K(3-(nonadecanoylamino)propionyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K(3-(eicosanoylamino)propionyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K((S)-4-carboxy-4-(octanoylamino)butanoyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K((S)-4-carboxy-4-(nonanoylamino)butanoyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K((S)-4-carboxy-4-(decanoylamino)butanoyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K((S)-4-carboxy-4-(undecanoylamino)butanoyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K((S)-4-carboxy-4-(dodecanoylamino)butanoyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K((S)-4-carboxy-4-(tridecanoylamino)butanoyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K((S)-4-carboxy-4-(tetradecanoylamino)butanoyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K((S)-4-carboxy-4-(pentadecanoylamino)butanoyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K((S)-4-carboxy-4-(hexadecanoylamino)butanoyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K((S)-4-carboxy-4-(heptadecanoylamino)butanoyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K((S)-4-carboxy-4-(octadecanoylamino)butanoyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K((S)-4-carboxy-4-(nonadecanoylamino)butanoyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K((S)-4-carboxy-4-(eicosanoylamino)butanoyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K(4-(octanoylamino)butanoyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K(4-(nonanoylamino)butanoyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K(4-(decanoylamino)butanoyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K(4-(undecanoylamino)butanoyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K(4-(dodecanoylamino)butanoyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K(4-(tridecanoylamino)butanoyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K(4-(tetradecanoylamino)butanoyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K(4-(pentadecanoylamino)butanoyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K(4-(hexadecanoylamino)butanoyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K(4-(heptadecanoylamino)butanoyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K(4-(octadecanoylamino)butanoyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K(4-(nonadecanoylamino)butanoyl)/K30R/D33E-GLP-2(1-33);
D3E/L17K(4-(eicosanoylamino)butanoyl)/K30R/D33E-GLP-2(1-33);
D3E/A18K(3-(hexadecanoylamino)propionyl)/K30R/D33E-GLP-2(1-33);
D3E/D21K(3-(hexadecanoylamino)propionyl)/K30R/D33E-GLP-2(1-33);
D3E/N24K(3-(hexadecanoylamino)propionyl)/K30R/D33E-GLP-2(1-33); and
D3E/Q28K(3-(hexadecanoylamino)propionyl)/K30R/D33E-GLP-2(1-33). - Factor VII compounds applicable in the methods of the present invention encompasses wild-type Factor VII (i.e., a polypeptide having the amino acid sequence disclosed in U.S. Pat. No. 4,784,950), as well as variants of Factor VII exhibiting substantially the same or improved biological activity relative to wild-type Factor VII, Factor VII-related polypeptides as well as Factor VII derivatives and Factor VII conjugates. The term “Factor VII compounds” is intended to encompass Factor VII polypeptides in their uncleaved (zymogen) form, as well as those that have been proteolytically processed to yield their respective bioactive forms, which may be designated Factor VIIa. Typically, Factor VII is cleaved between residues 152 and 153 to yield Factor VIIa. Such variants of Factor VII may exhibit different properties relative to human Factor VII, including stability, phospholipid binding, altered specific activity, and the like.
- As used herein, “Factor VII-related polypeptides” encompasses polypeptides, including variants, in which the Factor VIIa biological activity has been substantially modified or reduced relative to the activity of wild-type Factor VIIa. These polypeptides include, without limitation, Factor VII or Factor VIIa into which specific amino acid sequence alterations have been introduced that modify or disrupt the bioactivity of the polypeptide.
- The term “Factor VII derivative” as used herein, is intended to designate wild-type Factor VII, variants of Factor VII exhibiting substantially the same or improved biological activity relative to wild-type Factor VII and Factor VII-related polypeptides, in which one or more of the amino acids of the parent peptide have been chemically modified, e.g. by alkylation, PEGylation, acylation, ester formation or amide formation or the like. This includes but are not limited to PEGylated human Factor VIIa, cysteine-PEGylated human Factor VIIa and variants thereof.
- The term “PEGylated human Factor VIIa” means human Factor VIIa, having a PEG molecule conjugated to a human Factor VIIa polypeptide. It is to be understood, that the PEG molecule may be attached to any part of the Factor VIIa polypeptide including any amino acid residue or carbohydrate moiety of the Factor VIIa polypeptide. The term “cysteine-PEGylated human Factor VIIa” means Factor VIIa having a PEG molecule conjugated to a sulfhydryl group of a cysteine introduced in human Factor VIIa.
- The biological activity of Factor VIIa in blood clotting derives from its ability to (i) bind to tissue factor (TF) and (ii) catalyze the proteolytic cleavage of Factor IX or Factor X to produce activated Factor IX or X (Factor IXa or Xa, respectively). For purposes of the invention, Factor VIIa biological activity may be quantified by measuring the ability of a preparation to promote blood clotting using Factor VII-deficient plasma and thromboplastin, as described, e.g., in U.S. Pat. No. 5,997,864. In this assay, biological activity is expressed as the reduction in clotting time relative to a control sample and is converted to “Factor VII units” by comparison with a pooled human serum standard containing 1 unit/ml Factor VII activity. Alternatively, Factor VIIa biological activity may be quantified by (i) measuring the ability of Factor VIIa to produce of Factor Xa in a system comprising TF embedded in a lipid membrane and Factor X. (Persson et al., J. Biol. Chem. 272:19919-19924, 1997); (ii) measuring Factor X hydrolysis in an aqueous system; (iii) measuring its physical binding to TF using an instrument based on surface plasmon resonance (Persson, FEBS Letts. 413:359-363, 1997) and (iv) measuring hydrolysis of a synthetic substrate.
- Factor VII variants having substantially the same or improved biological activity relative to wild-type Factor VIIa encompass those that exhibit at least about 25%, preferably at least about 50%, more preferably at least about 75% and most preferably at least about 90% of the specific activity of Factor VIIa that has been produced in the same cell type, when tested in one or more of a clotting assay, proteolysis assay, or TF binding assay as described above. Factor VII variants having substantially reduced biological activity relative to wild-type Factor VIIa are those that exhibit less than about 25%, preferably less than about 10%, more preferably less than about 5% and most preferably less than about 1% of the specific activity of wild-type Factor VIIa that has been produced in the same cell type when tested in one or more of a clotting assay, proteolysis assay, or TF binding assay as described above. Factor VII variants having a substantially modified biological activity relative to wild-type Factor VII include, without limitation, Factor VII variants that exhibit TF-independent Factor X proteolytic activity and those that bind TF but do not cleave Factor X.
- Variants of Factor VII, whether exhibiting substantially the same or better bioactivity than wild-type Factor VII, or, alternatively, exhibiting substantially modified or reduced bioactivity relative to wild-type Factor VII, include, without limitation, polypeptides having an amino acid sequence that differs from the sequence of wild-type Factor VII by insertion, deletion, or substitution of one or more amino acids.
- The terms “variant” or “variants”, as used herein, is intended to designate Factor VII having the sequence of wild-type factor VII, wherein one or more amino acids of the parent protein have been substituted by another amino acid and/or wherein one or more amino acids of the parent protein have been deleted and/or wherein one or more amino acids have been inserted in protein and/or wherein one or more amino acids have been added to the parent protein. Such addition can take place either at the N-terminal end or at the C-terminal end of the parent protein or both. The “variant” or “variants” within this definition still have FVII activity in its activated form. In one embodiment a variant is 70% identical with the sequence of wild-type Factor VII. In one embodiment a variant is 80% identical with the sequence of wild-type factor VII. In another embodiment a variant is 90% identical with the sequence of wild-type factor VII. In a further embodiment a variant is 95% identical with the sequence of wild-type factor VII.
- Non-limiting examples of Factor VII variants having substantially the same biological activity as wild-type Factor VII include S52A-FVIIa, S60A-FVIIa (Lino et al., Arch. Biochem. Biophys. 352: 182-192, 1998); FVIIa variants exhibiting increased proteolytic stability as disclosed in U.S. Pat. No. 5,580,560; Factor VIIa that has been proteolytically cleaved between residues 290 and 291 or between residues 315 and 316 (Mollerup et al., Biotechnol. Bioeng. 48:501-505, 1995); oxidized forms of Factor VIIa (Kornfelt et al., Arch. Biochem. Biophys. 363:43-54, 1999); FVII variants as disclosed in PCT/DK02/00189; and FVII variants exhibiting increased proteolytic stability as disclosed in WO 02/38162 (Scripps Research Institute); FVII variants having a modified Gla-domain and exhibiting an enhanced membrane binding as disclosed in WO 99/20767 (University of Minnesota) and WO 00/66753 (University of Minnesota); and FVII variants as disclosed in WO 01/58935 (Maxygen ApS), WO 03/93465 (Maxygen ApS) and WO 04/029091 (Maxygen ApS) all of which are incorporated herein by reference.
- Particular mentioning is made of FVII variants having increased biological activity compared to wild-type FVIIa include FVII variants as disclosed in WO 01/83725, WO 02/22776, WO 02/077218, PCT/DK02/00635, WO 2004/029090, WO 2003/037932; WO 02/38162 (Scripps Research Institute); and FVIIa variants with enhanced activity as disclosed in JP 2001061479 (Chemo-Sero-Therapeutic Res Inst.), all of which are incorporated herein by reference, all of which are incorporated herein by reference.
- Examples of Factor VII variants having substantially reduced or modified biological activity relative to wild-type Factor VII include R152E-FVIIa (Wildgoose et al., Biochem 29:3413-3420, 1990), S344A-FVIIa (Kazama et al., J. Biol. Chem. 270:66-72, 1995), FFR-FVIIa (Holst et al., Eur. J. Vasc. Endovasc. Surg. 15:515-520, 1998), and Factor VIIa lacking the Gla domain, (Nicolaisen et al., FEBS Letts. 317:245-249, 1993), all of which are incorporated herein by reference.
- Examples of variants of factor VII, factor VII or factor VII-related polypeptides include wild-type Factor VII, L305V-FVII, L305V/M306D/D309S-FVII, L3051-FVII, L305T-FVII, F374P-FVII, V158T/M298Q-FVII, V158D/E296V/M298Q-FVII, K337A-FVII, M298Q-FVII, V158D/M298Q-FVII, L305V/K337A-FVII, V158D/E296V/M298Q/L305V-FVII, V158D/E296V/M298Q/K337A-FVII, V158D/E296V/M298Q/L305V/K337A-FVII, K157A-FVII, E296V-FVII, E296V/M298Q-FVII, V158D/E296V-FVII, V158D/M298K-FVII, and S336G-FVII, L305V/K337A-FVII, L305V/V158D-FVII, L305V/E296V-FVII, L305V/M298Q-FVII, L305V/V158T-FVII, L305V/K337A/V1158T-FVII, L305V/K337A/M298Q-FVII, L305V/K337A/E296V-FVII, L305V/K337V/V158D-FVII, L305V/V158D/M298Q-FVII, L305V/V158D/E296V-FVII, L305V/V158T/M298Q-FVII, L305V/V 158T/E296V-FVII, L305V/E296V/M298Q-FVII, L305V/V158D/E296V/M298Q-FVII, L305V/V158T/E296V/M298Q-FVII, L305V/V158T/K337A/M298Q-FVII, L305V/V158T/E296V/K337A-FVII, L305V/V158D/K337A/M298Q-FVII, L305V/V158D/E296V/K337A-FVII, L305V/V158D/E296V/M298Q/K337A-FVII, L305V/V 158T/E296V/M298Q/K337A-FVII, S314E/K316H-FVII, S314E/K316Q-FVII, S314E/L305V-FVII, S314E/K337A-FVII, S314E/V158D-FVII, S314E/E296V-FVII, S314E/M298Q-FVII, S314E/V158T-FVII, K316H/L305V-FVII, K316H/K337A-FVII, K316H/V158D-FVII, K316H/E296V-FVII, K316H/M298Q-FVII, K316H/V158T-FVII, K316Q/L305V-FVII, K316Q/K337A-FVII, K316Q/V158D-FVII, K316Q/E296V-FVII, K316Q/M298Q-FVII, K316Q/V158T-FVII, S314E/L305V/K337A-FVII, S314E/L305V/V158D-FVII, S314E/L305V/E296V-FVII, S314E/L305V/M298Q-FVII, S314E/L305V/V158T-FVII, S314E/L305V/K337A/V158T-FVII, S314E/L305V/K337A/M298Q-FVII, S314E/L305V/K337A/E296V-FVII, S314E/L305V/K337A/V158D-FVII, S314E/L305V/V158D/M298Q-FVII, S314E/L305V/V158D/E296V-FVII, S314E/L305V/V158T/M298Q-FVII, S314E/L305V/V158T/E296V-FVII, S314E/L305V/E296V/M298Q-FVII, S314E/L305V/V158D/E296V/M298Q-FVII, S314E/L305V/V158T/E296V/M298Q-FVII, S314E/L305V/V158T/K337A/M298Q-FVII, S314E/L305V/V158T/E296V/K337A-FVII, S314E/L305V/V158D/K337A/M298Q-FVII, S314E/L305V/V158D/E296V/K337A-FVII, S314E/L305V/V158D/E296V/M298Q/K337A-FVII, S314E/L305V/V158T/E296V/M298Q/K337A-FVII, K316H/L305V/K337A-FVII, K316H/L305V/V158D-FVII, K316H/L305V/E296V-FVII, K316H/L305V/M298Q-FVII, K316H/L305V/V158T-FVII, K316H/L305V/K337A/V158T-FVII, K316H/L305V/K337A/M298Q-FVII, K316H/L305V/K337A/E296V-FVII, K316H/L305V/K337A/V158D-FVII, K316H/L305V/V158D/M298Q-FVII, K316H/L305V/V158D/E296V-FVII, K316H/L305V/V158T/M298Q-FVII, K316H/L305V/V158T/E296V-FVII, K316H/L305V/E296V/M298Q-FVII, K316H/L305V/V158D/E296V/M298Q-FVII, K316H/L305V/V158T/E296V/M298Q-FVII, K316H/L305V/V158T/K337A/M298Q-FVII, K316H/L305V/V158T/E296V/K337A-FVII, K316H/L305V/V158D/K337A/M298Q-FVII, K316H/L305V/V158D/E296V/K337A-FVII, K316H/L305V/V158D/E296V/M298Q/K337A-FVII, K316H/L305V/V158T/E296V/M298Q/K337A-FVII, K316Q/L305V/K337A-FVII, K316Q/L305V/V158D-FVII, K316Q/L305V/E296V-FVII, K316Q/L305V/M298Q-FVII, K316Q/L305V/V158T-FVII, K316Q/L305V/K337A/V158T-FVII, K316Q/L305V/K337A/M298Q-FVII, K316Q/L305V/K337A/E296V-FVII, K316Q/L305V/K337A/V158D-FVII, K316Q/L305V/V158D/M298Q-FVII, K316Q/L305V/V158D/E296V-FVII, K316Q/L305V/V158T/M298Q-FVII, K316Q/L305V/V158T/E296V-FVII, K316Q/L305V/E296V/M298Q-FVII, K316Q/L305V/V158D/E296V/M298Q-FVII, K316Q/L305V/V158T/E296V/M298Q-FVII, K316Q/L305V/V158T/K337A/M298Q-FVII, K316Q/L305V/V158T/E296V/K337A-FVII, K316Q/L305V/V158D/K337A/M298Q-FVII, K316Q/L305V/V158D/E296V/K337A-FVII, K316Q/L305V/V158D/E296V/M298Q/K337A-FVII, K316Q/L305V/V158T/E296V/M298Q/K337A-FVII, F374Y/K337A-FVII, F374Y/V158D-FVII, F374Y/E296V-FVII, F374Y/M298Q-FVII, F374Y/V158T-FVII, F374Y/S314E-FVII, F374Y/L305V-FVII, F374Y/L305V/K337A-FVII, F374Y/L305V/V158D-FVII, F374Y/L305V/E296V-FVII, F374Y/L305V/M298Q-FVII, F374Y/L305V/V158T-FVII, F374Y/L305V/S314E-FVII, F374Y/K337A/S314E-FVII, F374Y/K337A/V158T-FVII, F374Y/K337A/M298Q-FVII, F374Y/K337A/E296V-FVII, F374Y/K337A/V158D-FVII, F374Y/V158D/S314E-FVII, F374Y/V158D/M298Q-FVII, F374Y/V158D/E296V-FVII, F374Y/V158T/S314E-FVII, F374Y/V158T/M298Q-FVII, F374Y/V158T/E296V-FVII, F374Y/E296V/S314E-FVII, F374Y/S314E/M298Q-FVII, F374Y/E296V/M298Q-FVII, F374Y/L305V/K337A/V158D-FVII, F374Y/L305V/K337A/E296V-FVII, F374Y/L305V/K337A/M298Q-FVII, F374Y/L305V/K337A/V158T-FVII, F374Y/L305V/K337A/S314E-FVII, F374Y/L305V/V158D/E296V-FVII, F374Y/L305V/V158D/M298Q-FVII, F374Y/L305V/V158D/S314E-FVII, F374Y/L305V/E296V/M298Q-FVII, F374Y/L305V/E296V/V158T-FVII, F374Y/L305V/E296V/S314E-FVII, F374Y/L305V/M298Q/V158T-FVII, F374Y/L305V/M298Q/S314E-FVII, F374Y/L305V/V158T/S314E-FVII, F374Y/K337A/S314E/V158T-FVII, F374Y/K337A/S314E/M298Q-FVII, F374Y/K337A/S314E/E296V-FVII, F374Y/K337A/S314E/V158D-FVII, F374Y/K337A/V158T/M298Q-FVII, F374Y/K337A/V158T/E296V-FVII, F374Y/K337A/M298Q/E296V-FVII, F374Y/K337A/M298Q/V158D-FVII, F374Y/K337A/E296V/V158D-FVII, F374Y/V158D/S314E/M298Q-FVII, F374Y/V158D/S314E/E296V-FVII, F374Y/V158D/M298Q/E296V-FVII, F374Y/V158T/S314E/E296V-FVII, F374Y/V158T/S314E/M298Q-FVII, F374Y/V158T/M298Q/E296V-FVII, F374Y/E296V/S314E/M298Q-FVII, F374Y/L305V/M298Q/K337A/S314E-FVII, F374Y/L305V/E296V/K337A/S314E-FVII, F374Y/E296V/M298Q/K337A/S314E-FVII, F374Y/L305V/E296V/M298Q/K337A-FVII, F374Y/L305V/E296V/M298Q/S314E-FVII, F374Y/V158D/E296V/M298Q/K337A-FVII, F374Y/V158D/E296V/M298Q/S314E-FVII, F374Y/L305V/V158D/K337A/S314E-FVII, F374Y/V158D/M298Q/K337A/S314E-FVII, F374Y/V158D/E296V/K337A/S314E-FVII, F374Y/L305V/V158D/E296V/M298Q-FVII, F374Y/L305V/V158D/M298Q/K337A-FVII, F374Y/L305V/V158D/E296V/K337A-FVII, F374Y/L305V/V158D/M298Q/S314E-FVII, F374Y/L305V/V158D/E296V/S314E-FVII, F374Y/V158T/E296V/M298Q/K337A-FVII, F374Y/V158T/E296V/M298Q/S314E-FVII, F374Y/L305V/V158T/K337A/S314E-FVII, F374Y/V158T/M298Q/K337A/S314E-FVII, F374Y/V158T/E296V/K337A/S314E-FVII, F374Y/L305V/V158T/E296V/M298Q-FVII, F374Y/L305V/V158T/M298Q/K337A-FVII, F374Y/L305V/V158T/E296V/K337A-FVII, F374Y/L305V/V158T/M298Q/S314E-FVII, F374Y/L305V/V158T/E296V/S314E-FVII, F374Y/E296V/M298Q/K337A/V158T/S314E-FVII, F374Y/V158D/E296V/M298Q/K337A/S314E-FVII, F374Y/L305V/V158D/E296V/M298Q/S314E-FVII, F374Y/L305V/E296V/M298Q/V158T/S314E-FVII, F374Y/L305V/E296V/M298Q/K337A/V158T-FVII, F374Y/L305V/E296V/K337A/V158T/S314E-FVII, F374Y/L305V/M298Q/K337A/V158T/S314E-FVII, F374Y/L305V/V158D/E296V/M298Q/K337A-FVII, F374Y/L305V/V158D/E296V/K337A/S314E-FVII, F374Y/L305V/V158D/M298Q/K337A/S314E-FVII, F374Y/L305V/E296V/M298Q/K337A/V158T/S314E-FVII, F374Y/L305V/V158D/E296V/M298Q/K337A/S314E-FVII, S52A-Factor VII, S60A-Factor VII; R152E-Factor VII, S344A-Factor VII, Factor VIIa lacking the Gla domain; and P11Q/K33E-FVII, T106N-FVII, K143N/N145T-FVII, V253N-FVII, R290N/A292T-FVII, G291N-FVII, R315N/V317T-FVII, K143N/N145T/R315N/V317T-FVII; and FVII having substitutions, additions or deletions in the amino acid sequence from 233Thr to 240Asn, FVII having substitutions, additions or deletions in the amino acid sequence from 304Arg to 329Cys.
- Growth hormone applicable in the methods of the present invention includes human growth hormone (hGH), which sequence and characteristics are set froth in, e.g. Hormone Drugs, Gueriguian, U.S.P. Covention, Rockvill, 1982 and growth hormone compounds. The term “growth hormone compound” is intended to indicate human growth hormone (hGH) in which one or more amino acid residues have been deleted and/or replaced by other amino acid residues, natural or unnatural, and/or hGH comprising addition amino acid residues, natural or unnatural, and/or hGH in which at least one organic substituent is bound to one or more organic substituent. Particular mentioning is made of the 191 native amino acid sequence (somatropin) and the 192 amino acid N-terminal methionine species (somatrem).
- Other examples of growth hormone compound applicable in the present invention include wherein amino acid No 172, 174, 176 and 178 as a group are replaced by one of the following groups of amino acids (R, S, F, R); (R, A, Y, R), (K, T, Y, K); (R, S, Y, R); (K, A, Y, R); (R, F, F, R); (K, Q, Y, R); (R, T, Y, H); (Q, R, Y, R); (K, K, Y, K); (R, S, F, S) or (K, S, N, R) as disclosed in WO 92/09690 (Genentech), which is incorporated herein by reference.
- Other examples of growth hormone compound applicable in the present invention include hGH with the following substitutions G120R, G120K, G120Y, G120F and G120E, as disclosed in U.S. Pat. No. 6,004,931 (Genentech), which is incorporated herein by reference.
- Other examples of growth hormone compound applicable in the present invention include hGH with the following set of substitutions R167N, D171S, E174S, F176Y and 1179T; R176E, D171S, E174S and F176Y; F10A, M14W, H18D and H21N; F10A, M14W, H18D, H21N, R167N, D171S, E174S, F176Y, 1179T; F10A, M14W, H18D, H21N, R167N, D171A, E174S, F176Y, 1179T; F10H, M14G, H18N and H21N; F10A, M14W, H18D, H21N, R167N, D171A, T175T and 1179T; and F101, M14Q, H18E, R167N, D171S and 1179T, as disclosed in U.S. Pat. No. 6,143,523 (Genentech), which is incorporated herein by reference.
- Other examples of growth hormone compound applicable in the present invention include hGH with the following set of substitutions H18A, Q22A, F25A, D26A, Q29A, E65A, K168A, E174A and G120K as disclosed in U.S. Pat. No. 6,136,536 (Genentech), which is incorporated herein by reference.
- Other examples of growth hormone compound applicable in the present invention include hGH with the following set of substitutions H18D, H21N, R167N, K168A, D171S, K172R, E174S, I179T and wherein G120 is further substituted with either R, K, W, Y, F or E, as disclosed in U.S. Pat. No. 6,057,292 (Genentech), which is incorporated herein by reference.
- Other examples of growth hormone compound applicable in the present invention include hGH with the following set of substitutions H18D, H21N, R167N, K168A, D171S, K172R, E174S and 1179T, as disclosed in U.S. Pat. No. 5,849,535 (Genentech), which is incorporated herein by reference.
- Other examples of growth hormone compound applicable in the present invention include hGH with the following set of substitutions H18D, H21D, R167N, K168A, D171S, K172R, E174S and 1179T; and H18A, Q22A, F25A, D26A, Q29A, E65A, K168A and E174A, as disclosed in WO 97/11178 (Genentech), which is incorporated herein by reference.
- Other examples of growth hormone compound applicable in the present invention include hGH with the following set of substitutions K168A and E174A; R178N and 1179M; K172A and F176A; and H54F, S56E, L581, E62S, D63N and Q66E as disclosed in WO 90/04788 (Genentech), which is incorporated herein by reference.
- Examples of cytokines which could be modified using the method of the present invention include erythropoietin (EPO), thrombopoietin, INF-α, IFN-β, IFN-γ, TNF-α, interleukin-1β (IL-1-β), IL-3, IL-4, IL-5, IL-10, IL-12, IL-15, IL-18, IL-19, IL-20, IL-21 IL-24, grannolyte colony-stimulating factor (G-CSF), GM-CSF, and chemokines such as machrophage inflammatory protein-1 (MIP-1) gamma interferon inducible protein and monokines induced by IFNγ (MIG).
- Particular examples of IL-19 applicable in the methods of the present invention include those disclosed WO 98/08870 (Human Genome Science), which is incorporated herein by reference. Particular mentioning is made of the peptide disclosed as SEQ ID NO:2 in WO 98/08870.
- Particular examples of applicable IL-20 include those disclosed in WO 99/27103 (Zymo-genetics), which is incorporated herein by reference. In the present context, IL-20 is intended to indicate IL-20 itself and fragments thereof as well as polypeptides being at least 90% identical to IL-20 or fragments thereof. Proteins particular applicable in the methods of the present invention includes those disclosed in WO 99/27103 as SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34 and SEQ ID NO:35.
- Examples of IL-21 applicable in the methods of the present invention include those disclosed in WO 00/53761 (Zymogenetics), which is incorporated herein by reference. particular mentioning is made of the peptide disclosed as SEQ ID NO:2 in WO 00/53761.
- TTF are applicable in the methods of the present invention. TTF peptides are a family of peptides found mainly in association with the gastrointestinal tract. Particular mentioning is made of breast cancer associated pS2 peptide (TFF-1), which is known from human, mouse, and rat, spasmolytical polypeptide (TFF-2), which is known from human, pig, rat, and mouse and intestinal trefoil factor (TFF-3), known from human, rat and mouse.
- Other peptides from the TFF family applicable in the methods of the present invention include those disclosed in WO 02/46226 (Novo Nordisk), which is included herein by reference. Particular mentioning is made of a TFF-2 peptide wherein a TFF2 peptide with an amino acid as disclosed in SEQ ID NO:1 of WO 02/46226 comprising disulphide bonds between Cys6-Cys104, Cys8-Cys35, Cys19-Cys34, Cys29-Cys46, Cys58-Cys84, Cys68-Cys83, and Cys78-Cys95 and wherein a moiety X independently selected from sugar residues and oligosaccharides is covalently attached to Asn15.
- Other peptides of the TFF family include TFF-1 and TFF-3 dimers as those disclosed in WO 96/06861 (Novo Nordisk), which is incorporated herein by reference.
- Several melanorcortin receptors are known, and particular mentioning of peptides applicable for the methods of the present invention is made of peptidic melanocortin-4 receptor agonists, which are known to have an appetite suppressive effect. Particular mentioning is made of peptides or proteins disclosed in the following patent documents, which are all incorporated herein by reference: U.S. Pat. No. 6,054,556 (Hruby), WO 00/05263 (William Harvey Research), WO 00/35952 (Melacure), WO 00/35952 (Melacure), WO 00/58361 (Procter & Gamble), WO 01/52880 (Merck), WO 02/26774 (Procter & Gamble), WO 03/06620 (Palatin), WO 98/27113 (Rudolf Magnus Institute) and WO 99/21571 (Trega).
- Other classes of peptides or proteins which are applicable in the methods of the present invention include enzymes. Many enzymes are used for various industrial purposes, and particular mentioning is made of hydrolases (proteases, lipases, cellulases, esterases), oxidoreductases (laccases, peroxidaxes, catalases, superoxide dismutases, lipoxygenases), transferases and isomerases.
- Other peptides or proteins applicable in the methods of the present invention include ACTH, corticotropin-releasing factor, angiotensin, calcitonin, insulin and fragments and analogues thereof, glucagon, IGF-1, IGF-2, enterogastrin, gastrin, tetragastrin, pentagastrin, urogastrin, epidermal growth factor, secretin, nerve growth factor, thyrotropin releasing hormone, somatostatin, growth hormone releasing hormone, somatomedin, parathyroid hormone, thrombopoietin, erythropoietin, hypothalamic releasing factors, prolactin, thyroid stimulating hormones, endorphins, enkephalins, vasopressin, oxytocin, opiods and analogues thereof, asparaginase, arginase, arginine deaminase, adenosine deaminase and ribonuclease.
- Peptides to be modified according to the methods of the present invention may either be isolated from natural sources (e.g. plants, animals or micro-organisms, such as yeast, bacteria, fungi or vira) or they may be synthesised. Peptides form natural sources also include peptides form transgenic sources, e.g. sources which have been genetically modified to express or to increase the expression of a peptide, wherein said peptide may be “natural” in the sense that it exists in nature or “unnatural” in the sense that it only exists due to human intervention. Peptides isolated form natural sources may also be subjected to synthetic modification prior to the conjugation of the present invention.
- In one embodiment, the invention relates to conjugated peptides obtainable according to the methods of the present invention. If the conjugated peptide obtained by the methods of the present invention is a therapeutic peptide, the invention also provides the use of such compounds in therapy, and pharmaceutical compositions comprising such compounds.
- In one embodiment, the invention provides conjugated peptides of the formula
- wherein P′, R, A, E and Z are as defined above, and wherein the group
- is bonded to the C-terminal of P′ via a peptide bond.
- Particular examples of such compounds include
- Lysε(4-((2-(1-(mPEGcarbonyl)piperidin-4-yl)ethoxy)imino)pentanoyl) 192)hGH(1-192) amide, in which mPEG has a molecular weight of 20 kDa;
- (Lysε(4-((3-(palmitoylamino)propoxy)imino)pentanoyl)192)hGH(1-192) amide;
- (Lysε(4-((3-((2S)-2,6-mPEGcarbonylamino)hexanoylamino)propoxy)imino)pentanoyl)34)GLP-2(1-34) amide, in which mPEG has a molecular weight of 20 kDa;
- (Lysε(4-(1-(2-(3-(mPEG)propanoylamino)hydrazino)ethyl)benzoyl)192)hGH(1-92) amide, in which mPEG has a molecular weight of 10 kDa;
- (S)-3-(4-((3-(3-Chlorophenyl)isoxazol-5-yl)methoxy)phenyl)-2-([Glu3, Leu10]GLP-2-ylleucinylamino)propionic amide;
- (S)-3-(4-((3-(3-Chlorophenyl)isoxazol-5-yl)methoxy)phenyl)-2-([Glu3]GLP-2ylleucinylamino)propionic amide;
- 3-(3-(3-((4-((S)-2-Carbamoyl-3-([Glu3,Leu10]GLP-2-ylleucinylamino)ethyl)phenoxyl)methyl)isoxazol-3-yl)benzylcarbamoyl)propionic acid;
- 11-(4-(4-((2S)-2-Carbamoyl-2-(([Glu3,Leu10]GLP-2ylleucinylamino)ethyl)pheoxymethyl)-1,2,3-triazolyl)undecanoic acid;
- 1′-(5-(4-((2S)-2-Carbamoyl-2-(([Glu3,Leu10]GLP-2ylleucinylamino)ethyl)pheoxymethyl)-1,2,3-triazolyl)undecanoic acid 1′-(4-(4-((S)-2-carbamoyl-2-([Glu3]GLP-2ylleucinylamino))phenoxymethyl)-1H-1,2,3-triazol-1-yl)undecanoic acid;
- 11-(5-(4-((S)-2-carbamoyl-2-([Glu3]GLP-2ylleucinylamino))phenoxymethyl)-1H-1,2,3-triazol-1-yl)undecanoic acid;
- 2-([Glu3]GLP-2ylleucinyl)-3-(4-((1-((N-(mPeg20kDayl)carbamoyl)decanyl)-1H-1,2,3-tetrazol-4-yl)methoxy)phenyl)propionamide; and
- 2-([Glu3]GLP-2ylleucinyl)-3-(4-((1-((N-(mPeg20kDayl)carbamoyl)decanyl)-1H-1,2,3-tetrazol-5-yl)methoxy)phenyl)propionamide.
- Insulin is used to treat or prevent diabetes, and in one embodiment, the present invention thus provides a method of treating type 1 or type 2 diabetes, the method comprising administering to a subject in need thereof a therapeutically effective amount of an insulin or insulin compound conjugate according to the present invention.
- In another embodiment, the invention provides the use of an insulin or insulin compound conjugate according to the present invention in the manufacture of a medicament used in the treatment of type 1 or type 2 diabetes.
- GLP-1 may be used in the treatment of hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, obesity, hypertension, syndrome X, dyslipidemia, β-cell apoptosis, β-cell deficiency, inflammatory bowel syndrome, dyspepsia, cognitive disorders, e.g. cognitive enhancing, neuroprotection, atheroschlerosis, coronary heart disease and other cardiovascular disorders. In one embodiment, the present invention thus provides a method of treating said diseases, the method comprising administering to a subject in need thereof a therapeutically effective amount of a GLP-1 or GLP-1 compound conjugate according to the present invention.
- In another embodiment, the invention provides the use of a GLP-1 or GLP-1 compound conjugate according to the present invention in the manufacture of a medicament used in the treatment of the above mentioned diseases.
- GLP-2 may be used in the treatment of intestinal failure leading to malabsorption of nutrients in the intestines, and in particular GLP-2 may be used in the treatment of small bowel syndrome, Inflammatory bowel syndrome, Crohns disease, colitis including collagen colitis, radiation colitis, post radiation atrophy, non-tropical (gluten intolerance) and tropical sprue, damaged tissue after vascular obstruction or trauma, tourist diarrhea, dehydration, bacteremia, sepsis, anorexia nervosa, damaged tissue after chemotherapy, premature infants, schleroderma, gastritis including atrophic gastritis, postantrectomy atrophic gastritis and helicobacter pylori gastritis, ulcers, enteritis, cul-de-sac, lymphatic obstruction, vascular disease and graft-versus-host, healing after surgical procedures, post radiation atrophy and chemotherapy, and osteoporosis. It is therefore an intension of the present invention to provide methods of treating the above diseases, the method comprising administering to a subject in need thereof a therapeutically effective amount of a GLP-2 or GLP-2 compound conjugate according to this invention.
- In another embodiment, the present invention provides the use of a GLP-2 or GLP-2 compound conjugate according to this invention in the manufacture of a medicament used in the treatment of the above mentioned diseases.
- Growth hormone has been implicated in the treatment of diseases benefiting from an increase in the plasma level of growth hormone. In one embodiment, the invention provides a method for the treatment of growth hormone deficiency (GHD); Turner Syndrome; Prader-Willi syndrome (PWS); Noonan syndrome; Down syndrome; chronic renal disease, juvenile rheumatoid arthritis; cystic fibrosis, HIV-infection in children receiving HAART treatment (HIV/HALS children); short children born short for gestational age (SGA); short stature in children born with very low birth weight (VLBW) but SGA; skeletal dysplasia; hypochondroplasia; achondroplasia; idiopathic short stature (ISS); GHD in adults; fractures in or of long bones, such as tibia, fibula, femur, humerus, radius, ulna, clavicula, matacarpea, matatarsea, and digit; fractures in or of spongious bones, such as the scull, base of hand, and base of food; patients after tendon or ligament surgery in e.g. hand, knee, or shoulder; patients having or going through distraction oteogenesis; patients after hip or discus replacement, meniscus repair, spinal fusions or prosthesis fixation, such as in the knee, hip, shoulder, elbow, wrist or jaw; patients into which osteosynthesis material, such as nails, screws and plates, have been fixed; patients with non-union or mal-union of fractures; patients after osteatomia, e.g. from tibia or 1st toe; patients after graft implantation; articular cartilage degeneration in knee caused by trauma or arthritis; osteoporosis in patients with Turner syndrome; osteoporosis in men; adult patients in chronic dialysis (APCD); malnutritional associated cardiovascular disease in APCD; reversal of cachexia in APCD; cancer in APCD; chronic abstractive pulmonal disease in APCD; HIV in APCD; elderly with APCD; chronic liver disease in APCD, fatigue syndrome in APCD; Crohn's disease; impaired liver function; males with HIV infections; short bowel syndrome; central obesity; HIV-associated lipodystrophy syndrome (HALS); male infertility; patients after major elective surgery, alcohol/drug detoxification or neurological trauma; aging; frail elderly; osteo-arthritis; traumatically damaged cartilage; erectile dysfunction; fibromyalgia; memory disorders; depression; traumatic brain injury; subarachnoid haemorrhage; very low birth weight; metabolic syndrome; glucocorticoid myopathy; or short stature due to glucucorticoid treatment inchildren, the method comprising administering to a patient in need thereof an effective amount of a growth hormone compound conjugate according to the present invention.
- In one aspect, the invention provides a method for the acceleration of the healing of muscle tissue, nervous tissue or wounds; the acceleration or improvement of blood flow to damaged tissue; or the decrease of infection rate in damaged tissue, the method comprising administration to a patient in need thereof an effective amount of a growth hormone compound onjugayte according to the present invention.
- In one aspect, the invention provides the use of growth hormone compound conjugates according to the present invention in the manufacture of medicaments for the treatment of the above mentioned diseases.
- Cytokines are implicated in the etiology of a host of diseases involving the immune system. In particular it is mentioned that IL-20 could be involved in psoriasis and its treatment, and I-21 is believed to be involved in cancer and could constitute a treatment to this disease. In one embodiment, the invention provides a method for the treatment of psoriasis comprising the administration of IL-20 conjugates according to the present invention. In another embodiment, the invention relates to the use of an IL-20 conjugate of the present invention in the manufacture of a medicament used in the treatment of psoriasis.
- In another embodiment, the present invention relates to a method of treating cancer, the method comprising administration of an IL-21 conjugate of the present invention to a subject in need thereof.
- In another embodiment, the invention relates to the use of an IL-21 conjugate according to the present invention in the manufacture of a medicament used in the treatment of cancer.
- TTF peptides may be used to increase the viscosity of muscus layers in subject, to reduce secretion of salvia, e.g. where the increase salvia secretion is caused by irradiation therapy, treatment with anticholinergics or Sjogren's syndrome, to treat allergic rhinitis, stress induced gastric ulcers secondary to trauma, shock, large operations, renal or liver diseases, treatment with NSAID, e.g. aspirin, steroids or alcohol. TTF peptides may also be used to treat Chrohn's disease, ulcerative colitis, keratoconjunctivitis, chronic bladder infections, intestinal cystitis, papillomas and bladder cancer. In one embodiment, the invention thus relates the a method of treating the above mention diseases or states, the method comprising administering to a subject patient in need thereof a therapeutically effective amount of a TTF conjugate according to the present invention.
- In another embodiment, the invention relates the use of a TTF conjugate of the present invention in the manufacture of a medicament for the treatment of the above mentioned diseases or states.
- Melanocortin receptor modifiers, and in particular melanorcortin 4 receptor agonists have been implicated the treatment and prevention of obesity and related diseases. In one embodiment, the present invention provides a method for preventing or delaying the progression of impaired glucose tolerance (IGT) to non-insulin requiring type 2 diabetes, for preventing or delaying the progression of non-insulin requiring type 2 diabetes to insulin requiring diabetes, for treating obesity and for regulating the appetite. Melanocortin 4 receptor agonists have also been implicated in the treatment of diseases selected from atherosclerosis, hypertension, diabetes, type 2 diabetes, impaired glucose tolerance (IGT), dyslipidemia, coronary heart disease, gallbladder disease, gall stone, osteoarthritis, cancer, sexual dysfunction and the risk of premature death. In one embodiment, the invention thus provides a method of treating the above diseases or states, the method comprising administering to a subject in need thereof a therapeutically effective amount of an melanocortin 4 receptor agonist conjugate of the present invention.
- In still another embodiment, the invention relates to the use of a melanocortin 4 receptor agonist conjugate of the present invention in the manufacture of a medicament for the treatment of the above mentioned diseases or states.
- Factor VII compounds have been implicated in the treatment of disease related to coagulation, and biological active Factor VII compounds in particular have been implicated in the treatment of hemophiliacs, hemophiliacs with inhibitors to Factor VIII and IX, patients with thrombocytopenia, patients with thrombocytopathies, such as Glanzmann's thrombastenia platelet release defect and strorage pool defects, patient with von Willebrand's disease, patients with liver disease and bleeding problems associated with traumas or surgery. Biologically inactive Factor VII compounds have been implicated in the treatment of patients being in hypercoagluable states, such as patients with sepsis, deep-vein thrombosis, patients in risk of myocardial infections or thrombotic stroke, pulmonary embolism, patients with acute coronary syndromes, patients undergoing coronary cardiac, prevention of cardiac events and restenosis for patient receiving angioplasty, patient with peripheral vascular diseases, and acute respiratory distress syndrome. In one embodiment, the invention thus provides a method for the treatment of the above mentioned diseases or states, the method comprising administering to a subject in need thereof a therapeutically effective amount of a Factor VII compound conjugate according to the present invention.
- In another embodiment, the invention provides the use of a Factor VII compound conjugate according to the present invention in the manufacture of a medicament used in the treatment of the above mentioned diseases or states.
- Many diseases are treated using more than one medicament in the treatment, either concomitantly administered or sequentially administered. It is therefore within the scope of the present invention to use the peptide conjugates of the present invention in therapeutic methods for the treatment of one of the above mentioned diseases in combination with one or more other therapeutically active compound normally used to in the treatment said disease. By analogy, it is also within the scope of the present invention to use the peptide conjugates of the present invention in combination with other therapeutically active compounds normally used in the treatment of one of the above mentioned diseases in the manufacture of a medicament for said disease.
- In another embodiment, the present invention provides the use of conjugated peptides of the present invention in diagnostics.
- α-amino acid amides are, as mentioned previously, particular well-suited as a nucleophile in the methods of the present invention. In one embodiment, the invention thus provides compounds according to formula (I)
- wherein A and E independently represent C1-6alkylene, C2-6alkenylene, C2-6alkynylene or arylene, all of which may optionally be substituted with one or more substituents selected from halogen, amino, cyano and nitro;
B and D represents —C(O)— or —NH— with the proviso that when B represents —C(O)— then D must represent —NH—, and when B represents —NH— then D must represent —C(O)—;
and G represents hydrogen or C1-6alkyl, C2-6alkenyl, C2-6alkynyl or aryl, all of which may optionally be substituted with one or more substituents selected from halogen, amino, cyano and nitro. - In one embodiment, A and E independently represent C1-6alkylene, such as methylene, ethylene, propylene, butylenes, pentylene or hexylene, or arylene, such as phenylene.
- In one embodiment, G represents hydrogen or methyl, ethyl, propyl or butyl.
- Particular examples of a compound of formula I include
- (2S)-2-Amino-6-(4-oxo-4-phenylbutyrylamino)hexanoic acid amide,
- 4-Acetyl-N-((5S)-5-amino-5-carbamoylpentyl)benzamide,
- (2S)-2-Amino-6-(4-oxo-4-(4-chlorophenylbutyrylamino)hexanoic acid amide,
- 3-Acetyl-N-((5S)-5-amino-5-carbamoylpentyl)benzamide, and
- 2-Acetyl-N-((5S)-5-amino-5-carbamoylpentyl)benzamide
- In another embodiment, the invention provides compounds according to formula II
- wherein J and L independently represent C1-6alkylene, C2-6alkenylene, C2-6alkynylene or arylene, all of which may optionally be substituted with one or more substituents selected from halogen, amino, cyano and nitro;
and M represents hydrogen or C1-6alkyl. - In one embodiment, J and L independently represent C1-6alkylene, such as methylene, ethylene, propylene, butylenes, pentylene or hexylene, or arylene, such as phenylene.
- In one embodiment, M represents hydrogen or methyl, ethyl, propyl or butyl.
- In one embodiment, the compounds of formula II are selected from amongst
- (2S)-Amino-3-[4-(2-oxopropoxy)phenyl]propionamide,
- (2S)-Amino-3-[4-(2-oxobutoxy)phenyl]propionamide,
- (2S)-Amino-3-[4-(2-oxopentoxy)phenyl]propionamide, and
- (2S)-Amino-3-[4-(4-oxopentoxy)phenyl]propionamide.
- In still another embodiment, the invention provides compounds according to formula III
- wherein Q represents represent C1-6alkylene, C2-6alkenylene, C2-6alkynylene or arylene, all of which may optionally be substituted with one or more substituents selected from halogen, amino, cyano and nitro;
and T represents hydrogen or C1-6alkyl. - In one embodiment, Q represents C1-6alkylene, such as methylene, ethylene, propylene, butylenes, pentylene or hexylene, or arylene, such as phenylene.
- In one embodiment, T represents hydrogen or methyl, ethyl, propyl or butyl.
- In still another embodiment, the invention provides compounds according to formula IV
- wherein J″ and L″ independently represent C1-6alkylene or arylene, all of which may optionally be substituted with one or more substituents selected from halogen amino, cyano and nitro.
- In one embodiment J and L independently represent methylene or ethylene.
- In one embodiment, the compounds of formula IV are selected from amongst
- (S)-2-amino-3-(4-(propargyloxy)phenyl)propionyl amide.
- Another object of the present invention is to provide a pharmaceutical composition comprising a compound of formula [a]which is present in a concentration from 10−12 mg/ml to 200 mg/ml, such as e.g. 10−10 mg/ml to 5 mg/ml and wherein said composition has a pH from 2.0 to 10.0. The composition may further comprise a buffer system, preservative(s), tonicity agent(s), chelating agent(s), stabilizers and surfactants. In one embodiment of the invention the pharmaceutical composition is an aqueous composition, i.e. composition comprising water. Such composition is typically a solution or a suspension. In a further embodiment of the invention the pharmaceutical composition is an aqueous solution. The term “aqueous composition” is defined as a composition comprising at least 50% w/w water. Likewise, the term “aqueous solution” is defined as a solution comprising at least 50% w/w water, and the term “aqueous suspension” is defined as a suspension comprising at least 50% w/w water.
- In another embodiment the pharmaceutical composition is a freeze-dried composition, whereto the physician or the patient adds solvents and/or diluents prior to use.
- In another embodiment the pharmaceutical composition is a dried composition (e.g. freeze-dried or spray-dried) ready for use without any prior dissolution.
- In a further aspect the invention relates to a pharmaceutical composition comprising an aqueous solution of a compound of formula [a], and a buffer, wherein said compound of formula [a] is present in a concentration from 0.1-100 mg/ml or above, and wherein said composition has a pH from about 2.0 to about 10.0.
- In another embodiment of the invention the pH of the composition is selected from the list consisting of 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, and 10.0.
- In a further embodiment of the invention the buffer is selected from the group consisting of sodium acetate, sodium carbonate, citrate, glycylglycine, histidine, glycine, lysine, arginine, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate, and tris(hydroxymethyl)-aminomethan, bicine, tricine, malic acid, succinate, maleic acid, fumaric acid, tartaric acid, aspartic acid or mixtures thereof. Each one of these specific buffers constitutes an alternative embodiment of the invention.
- In a further embodiment of the invention the composition further comprises a pharmaceutically acceptable preservative. In a further embodiment of the invention the preservative is selected from the group consisting of phenol, o-cresol, m-cresol, p-cresol, methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, 2-phenoxyethanol, butyl p-hydroxybenzoate, 2-phenylethanol, benzyl alcohol, chlorobutanol, and thiomerosal, bronopol, benzoic acid, imidurea, chlorohexidine, sodium dehydroacetate, chlorocresol, ethyl p-hydroxybenzoate, benzethonium chloride, chlorphenesine (3p-chlorphenoxypropane-1,2-diol) or mixtures thereof. In a further embodiment of the invention the preservative is present in a concentration from 0.1 mg/ml to 20 mg/ml. In a further embodiment of the invention the preservative is present in a concentration from 0.1 mg/ml to 5 mg/ml. In a further embodiment of the invention the preservative is present in a concentration from 5 mg/ml to 10 mg/ml. In a further embodiment of the invention the preservative is present in a concentration from 10 mg/ml to 20 mg/ml. Each one of these specific preservatives constitutes an alternative embodiment of the invention. The use of a preservative in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: The Science and Practice of Pharmacy, 20th edition, 2000.
- In a further embodiment of the invention the composition further comprises an isotonic agent. In a further embodiment of the invention the isotonic agent is selected from the group consisting of a salt (e.g. sodium chloride), a sugar or sugar alcohol, an amino acid (e.g. L-glycine, L-histidine, arginine, lysine, isoleucine, aspartic acid, tryptophan, threonine),
- an alditol (e.g. glycerol (glycerine), 1,2-propanediol (propyleneglycol), 1,3-propanediol, 1,3-butanediol) polyethyleneglycol (e.g. PEG400), or mixtures thereof. Any sugar such as mono-, di-, or polysaccharides, or water-soluble glucans, including for example fructose, glucose, mannose, sorbose, xylose, maltose, lactose, sucrose, trehalose, dextran, pullulan, dextrin, cyclodextrin, soluble starch, hydroxyethyl starch and carboxymethylcellulose-Na may be used. In one embodiment the sugar additive is sucrose. Sugar alcohol is defined as a C4-C8 hydrocarbon having at least one —OH group and includes, for example, mannitol, sorbitol, inositol, galactitol, dulcitol, xylitol, and arabitol. In one embodiment the sugar alcohol additive is mannitol. The sugars or sugar alcohols mentioned above may be used individually or in combination. There is no fixed limit to the amount used, as long as the sugar or sugar alcohol is soluble in the liquid preparation and does not adversely effect the stabilizing effects obtained using the methods of the invention. In one embodiment, the sugar or sugar alcohol concentration is between about 1 mg/ml and about 150 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 1 mg/ml to 50 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 1 mg/ml to 7 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 8 mg/ml to 24 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 25 mg/ml to 50 mg/ml. Each one of these specific isotonic agents constitutes an alternative embodiment of the invention. The use of an isotonic agent in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: The Science and Practice of Pharmacy, 20th edition, 2000.
- In a further embodiment of the invention the composition further comprises a chelating agent. In a further embodiment of the invention the chelating agent is selected from salts of ethylenediaminetetraacetic acid (EDTA), citric acid, and aspartic acid, and mixtures thereof. In a further embodiment of the invention the chelating agent is present in a concentration from 0.1 mg/ml to 5 mg/ml. In a further embodiment of the invention the chelating agent is present in a concentration from 0.1 mg/ml to 2 mg/ml. In a further embodiment of the invention the chelating agent is present in a concentration from 2 mg/ml to 5 mg/ml. Each one of these specific chelating agents constitutes an alternative embodiment of the invention. The use of a chelating agent in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: The Science and Practice of Pharmacy, 20th edition, 2000.
- In a further embodiment of the invention the composition further comprises a stabilizer. The use of a stabilizer in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: The Science and Practice of Pharmacy, 20th edition, 2000.
- More particularly, compositions of the invention are stabilized liquid pharmaceutical compositions whose therapeutically active components include a protein that possibly exhibits aggregate formation during storage in liquid pharmaceutical compositions. By “aggregate formation” is intended a physical interaction between the protein molecules that results in formation of oligomers, which may remain soluble, or large visible aggregates that precipitate from the solution. By “during storage” is intended a liquid pharmaceutical composition or composition once prepared, is not immediately administered to a subject. Rather, following preparation, it is packaged for storage, either in a liquid form, in a frozen state, or in a dried form for later reconstitution into a liquid form or other form suitable for administration to a subject. By “dried form” is intended the liquid pharmaceutical composition or composition is dried either by freeze drying (i.e., lyophilization; see, for example, Williams and Polli (1984) J. Parenteral Sci. Technol. 38:48-59), spray drying (see Masters (1991) in Spray-Drying Handbook (5th ed; Longman Scientific and Technical, Essez, U.K.), pp. 491-676; Broadhead et al. (1992) Drug Devel. Ind. Pharm. 18:1169-1206; and Mumenthaler et al. (1994) Pharm. Res. 11:12-20), or air drying (Carpenter and Crowe (1988) Cryobiology 25:459-470; and Roser (1991) Biopharm. 4:47-53). Aggregate formation by a protein during storage of a liquid pharmaceutical composition can adversely affect biological activity of that protein, resulting in loss of therapeutic efficacy of the pharmaceutical composition. Furthermore, aggregate formation may cause other problems such as blockage of tubing, membranes, or pumps when the protein-containing pharmaceutical composition is administered using an infusion system.
- The pharmaceutical compositions of the invention may further comprise an amount of an amino acid base sufficient to decrease aggregate formation by the protein during storage of the composition. By “amino acid base” is intended an amino acid or a combination of amino acids, where any given amino acid is present either in its free base form or in its salt form. Where a combination of amino acids is used, all of the amino acids may be present in their free base forms, all may be present in their salt forms, or some may be present in their free base forms while others are present in their salt forms. In one embodiment, amino acids to use in preparing the compositions of the invention are those carrying a charged side chain, such as arginine, lysine, aspartic acid, and glutamic acid. Any stereoisomer (i.e., L or D isomer, or mixtures thereof) of a particular amino acid (methionine, histidine, arginine, lysine, isoleucine, aspartic acid, tryptophan, threonine and mixtures thereof) or combinations of these stereoisomers or glycine or an organic base such as but not limited to imidazole, may be present in the pharmaceutical compositions of the invention so long as the particular amino acid or organic base is present either in its free base form or its salt form. In one embodiment the L-stereoisomer of an amino acid is used. In one embodiment the D-stereoisomer is used. Compositions of the invention may also be formulated with analogues of these amino acids. By “amino acid analogue” is intended a derivative of the naturally occurring amino acid that brings about the desired effect of decreasing aggregate formation by the protein during storage of the liquid pharmaceutical compositions of the invention. Suitable arginine analogues include, for example, aminoguanidine, ornithine and N-monoethyl L-arginine, suitable methionine analogues include ethionine and buthionine and suitable cysteine analogues include S-methyl-L cysteine. As with the other amino acids, the amino acid analogues are incorporated into the compositions in either their free base form or their salt form. In a further embodiment of the invention the amino acids or amino acid analogues are used in a concentration, which is sufficient to prevent or delay aggregation of the protein.
- In a further embodiment of the invention methionine (or other sulphuric amino acids or amino acid analogous) may be added to inhibit oxidation of methionine residues to methionine sulfoxide when the protein acting as the therapeutic agent is a protein comprising at least one methionine residue susceptible to such oxidation. By “inhibit” is intended minimal accumulation of methionine oxidized species over time. Inhibiting methionine oxidation results in greater retention of the protein in its proper molecular form. Any stereoisomer of methionine (L or D isomer) or any combinations thereof can be used. The amount to be added should be an amount sufficient to inhibit oxidation of the methionine residues such that the amount of methionine sulfoxide is acceptable to regulatory agencies. Typically, this means that the composition contains no more than about 10% to about 30% methionine sulfoxide. Generally, this can be obtained by adding methionine such that the ratio of methionine added to methionine residues ranges from about 1:1 to about 1000:1, such as 10:1 to about 100:1.
- In a further embodiment of the invention the composition further comprises a stabilizer selected from the group of high molecular weight polymers or low molecular compounds. In a further embodiment of the invention the stabilizer is selected from polyethylene glycol (e.g. PEG 3350), polyvinyl alcohol (PVA), polyvinylpyrrolidone, carboxy-/hydroxycellulose or derivates thereof (e.g. HPC, HPC-SL, HPC-L and HPMC), cyclodextrins, sulphur-containing substances as monothioglycerol, thioglycolic acid and 2-methylthioethanol, and different salts (e.g. sodium chloride). Each one of these specific stabilizers constitutes an alternative embodiment of the invention.
- The pharmaceutical compositions may also comprise additional stabilizing agents, which further enhance stability of a therapeutically active protein therein. Stabilizing agents of particular interest to the present invention include, but are not limited to, methionine and EDTA, which protect the protein against methionine oxidation, and a nonionic surfactant, which protects the protein against aggregation associated with freeze-thawing or mechanical shearing.
- In a further embodiment of the invention the composition further comprises a surfactant. In a further embodiment of the invention the surfactant is selected from a detergent, ethoxylated castor oil, polyglycolized glycerides, acetylated monoglycerides, sorbitan fatty acid esters, polyoxypropylene-polyoxyethylene block polymers (e.g. poloxamers such as Pluronice F68, poloxamer 188 and 407, Triton X-100), polyoxyethylene sorbitan fatty acid esters, polyoxyethylene and polyethylene derivatives such as alkylated and alkoxylated derivatives (tweens, e.g. Tween-20, Tween-40, Tween-80 and Brij-35), monoglycerides or ethoxylated derivatives thereof, diglycerides or polyoxyethylene derivatives thereof, alcohols, glycerol, lectins and phospholipids (e.g. phosphatidyl serine, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, diphosphatidyl glycerol and sphingomyelin), derivates of phospholipids (e.g. dipalmitoyl phosphatidic acid) and lysophospholipids (e.g. palmitoyl lysophosphatidyl-L-serine and 1-acyl-sn-glycero-3-phosphate esters of ethanolamine, choline, serine or threonine) and alkyl, alkoxyl (alkyl ester), alkoxy (alkyl ether)-derivatives of lysophosphatidyl and phosphatidylcholines, e.g. lauroyl and myristoyl derivatives of lysophosphatidylcholine, dipalmitoylphosphatidylcholine, and modifications of the polar head group, that is cholines, ethanolamines, phosphatidic acid, serines, threonines, glycerol, inositol, and the positively charged DODAC, DOTMA, DCP, BISHOP, lysophosphatidylserine and lysophosphatidylthreonine, and glycerophospholipids (e.g. cephalins), glyceroglycolipids (e.g. galactopyransoide), sphingoglycolipids (e.g. ceramides, gangliosides), dodecylphosphocholine, hen egg lysolecithin, fusidic acid derivatives—(e.g. sodium tauro-dihydrofusidate etc.), long-chain fatty acids and salts thereof C6-C12 (e.g. oleic acid and caprylic acid), acylcarnitines and derivatives, N-acylated derivatives of lysine, arginine or histidine, or side-chain acylated derivatives of lysine or arginine, N-acylated derivatives of dipeptides comprising any combination of lysine, arginine or histidine and a neutral or acidic amino acid, N-acylated derivative of a tripeptide comprising any combination of a neutral amino acid and two charged amino acids, DSS (docusate sodium, CAS registry no [577-11-7]), docusate calcium, CAS registry no [128-49-4]), docusate potassium, CAS registry no [7491-09-0]), SDS (sodium dodecyl sulphate or sodium lauryl sulphate), sodium caprylate, cholic acid or derivatives thereof, bile acids and salts thereof and glycine or taurine conjugates, ursodeoxycholic acid, sodium cholate, sodium deoxycholate, sodium taurocholate, sodium glycocholate, N-Hexadecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, anionic (alkyl-aryl-sulphonates) monovalent surfactants, zwitterionic surfactants (e.g. N-alkyl-N,N-dimethylammonio-1-propanesulfonates, 3-cholamido-1-propyldimethylammonio-1-propanesulfonate, cationic surfactants (quaternary ammonium bases) (e.g. cetyl-trimethylammonium bromide, cetylpyridinium chloride), non-ionic surfactants (e.g. Dodecyl β-D-glucopyranoside), poloxamines (e.g. Tetronic's), which are tetrafunctional block copolymers derived from sequential addition of propylene oxide and ethylene oxide to ethylenediamine, or the surfactant may be selected from the group of imidazoline derivatives, or mixtures thereof. Each one of these specific surfactants constitutes an alternative embodiment of the invention.
- The use of a surfactant in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: The Science and Practice of Pharmacy, 20th edition, 2000.
- It is possible that other ingredients may be present in the pharmaceutical composition of the present invention. Such additional ingredients may include wetting agents, emulsifiers, antioxidants, bulking agents, tonicity modifiers, chelating agents, metal ions, oleaginous vehicles, proteins (e.g., human serum albumin, gelatine or proteins) and a zwitterion (e.g., an amino acid such as betaine, taurine, arginine, glycine, lysine and histidine). Such additional ingredients, of course, should not adversely affect the overall stability of the pharmaceutical composition of the present invention.
- Pharmaceutical compositions containing a compound of formula [a]according to the present invention may be administered to a patient in need of such treatment at several sites, for example, at topical sites, for example, skin and mucosal sites, at sites which bypass absorption, for example, administration in an artery, in a vein, in the heart, and at sites which involve absorption, for example, administration in the skin, under the skin, in a muscle or in the abdomen.
- Administration of pharmaceutical compositions according to the invention may be through several routes of administration, for example, lingual, sublingual, buccal, in the mouth, oral, in the stomach and intestine, nasal, pulmonary, for example, through the bronchioles and alveoli or a combination thereof, epidermal, dermal, transdermal, vaginal, rectal, ocular, for examples through the conjunctiva, uretal, and parenteral to patients in need of such a treatment.
- Compositions of the present invention may be administered in several dosage forms, for example, as solutions, suspensions, emulsions, microemulsions, multiple emulsion, foams, salves, pastes, plasters, ointments, tablets, coated tablets, rinses, capsules, for example, hard gelatine capsules and soft gelatine capsules, suppositories, rectal capsules, drops, gels, sprays, powder, aerosols, inhalants, eye drops, ophthalmic ointments, ophthalmic rinses, vaginal pessaries, vaginal rings, vaginal ointments, injection solution, in situ transforming solutions, for example in situ gelling, in situ setting, in situ precipitating, in situ crystallization, infusion solution, and implants.
- Compositions of the invention may further be compounded in, or attached to, for example through covalent, hydrophobic and electrostatic interactions, a drug carrier, drug delivery system and advanced drug delivery system in order to further enhance stability of the compound of formula [a], increase bioavailability, increase solubility, decrease adverse effects, achieve chronotherapy well known to those skilled in the art, and increase patient compliance or any combination thereof. Examples of carriers, drug delivery systems and advanced drug delivery systems include, but are not limited to, polymers, for example cellulose and derivatives, polysaccharides, for example dextran and derivatives, starch and derivatives, poly(vinyl alcohol), acrylate and methacrylate polymers, polylactic and polyglycolic acid and block co-polymers thereof, polyethylene glycols, carrier proteins, for example albumin, gels, for example, thermogelling systems, for example block co-polymeric systems well known to those skilled in the art, micelles, liposomes, microspheres, nanoparticulates, liquid crystals and dispersions thereof, L2 phase and dispersions there of, well known to those skilled in the art of phase behaviour in lipid-water systems, polymeric micelles, multiple emulsions, self-emulsifying, self-microemulsifying, cyclodextrins and derivatives thereof, and dendrimers.
- Compositions of the present invention are useful in the composition of solids, semisolids, powder and solutions for pulmonary administration of compound of formula [a], using, for example a metered dose inhaler, dry powder inhaler and a nebulizer, all being devices well known to those skilled in the art.
- Compositions of the current invention are specifically useful in the composition of controlled, sustained, protracting, retarded, and slow release drug delivery systems. More specifically, but not limited to, compositions are useful in composition of parenteral controlled release and sustained release systems (both systems leading to a many-fold reduction in number of administrations), well known to those skilled in the art. Even more preferably, are controlled release and sustained release systems administered subcutaneous. Without limiting the scope of the invention, examples of useful controlled release system and compositions are hydrogels, oleaginous gels, liquid crystals, polymeric micelles, microspheres, nanoparticles,
- Methods to produce controlled release systems useful for compositions of the current invention include, but are not limited to, crystallization, condensation, co-crystallization, precipitation, co-precipitation, emulsification, dispersion, high pressure homogenisation, encapsulation, spray drying, microencapsulating, coacervation, phase separation, solvent evaporation to produce microspheres, extrusion and supercritical fluid processes. General reference is made to Handbook of Pharmaceutical Controlled Release (Wise, D. L., ed. Marcel Dekker, New York, 2000) and Drug and the Pharmaceutical Sciences vol. 99: Protein Composition and Delivery (MacNally, E. J., ed. Marcel Dekker, New York, 2000).
- Parenteral administration may be performed by subcutaneous, intramuscular, intraperitoneal or intravenous injection by means of a syringe, optionally a pen-like syringe. Alternatively, parenteral administration can be performed by means of an infusion pump. A further option is a composition which may be a solution or suspension for the administration of the Compound of formula [a] in the form of a nasal or pulmonal spray. As a still further option, the pharmaceutical compositions containing the compound of formula [a]of the invention can also be adapted to transdermal administration, e.g. by needle-free injection or from a patch, optionally an iontophoretic patch, or transmucosal, e.g. buccal, administration.
- All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference in their entirety and to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein (to the maximum extent permitted by law).
- All headings and sub-headings are used herein for convenience only and should not be construed as limiting the invention in any way.
- The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
- The citation and incorporation of patent documents herein is done for convenience only and does not reflect any view of the validity, patentability, and/or enforceability of such patent documents.
- This invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law.
- Following abbreviations are used for chemical groups:
- Following other abbreviations were used:
- DMSO: Dimethylsulfoxide
- CHCA: 4-Hydroxy-alpha-cyanocinnamic acid
- The RP-analyses was performed using an Alliance Waters 2695 system fitted with a Waters 2487 dualband detector. UV detections at 214 nm and 254 nm were collected using a Symmetry300 C18, 5 um, 3.9 mm×150 mm column, 42° C. The compounds are eluted with a linear gradient of 5-95% acetonitrile in water which is buffered with 0.05% trifluoroacetic acid over 15 minutes at a flow-rate of 1.0 min/min.
- The RP-analysis was performed using a Waters 2690 systems fitted with a Waters 996 diode array detector. UV detections were collected at 214, 254, 276, and 301 nm on a 218TP54 4.6 mm×250 mm 5μ C-18 silica column (The Seperations Group, Hesperia), which was eluted at 1 ml/min at 42° C. The column was equilibrated with 5% acetonitrile, which was buffered with 0.1% trifluoroacetic acid, in a 0.1% aqueous solution of trifluoroacetic acid in water. After injection, the sample was eluted by a gradient of 0% to 90% acetonitrile, which was buffered with 0.1% trifluoroacetic acid, in a 0.1% aqueous solution of trifluoroacetic acid in water during 50 min.
- Mass spectra for peptides were obtained on an Agilent 1100 Series in the range of 500-1800 Da or on Perkin Elmer PE API 100 in the range of 500-2000 Da. Typically the found signals for m/z correspond to a series of any of z=1, 2, 3, 4, 5, or 6. MALDI-TOF spectra were obtained on a Bruker Daltonix autoflex.
- The transacylating compound, e.g. the compound of the formula
- and the conjugating moiety, Y-E-Z, may either be acquired commercially or synthesized according to the following guidelines in general methods below.
- A compound of the general formula
- wherein R′ and R″ independently represents C1-15alkylene, C2-15alkenylene, C2-15alkynylene, C11-15heteroalkylene, C2-15heteroalkenylene, C2-15heteroalkynylene, wherein one or more homocyclic aromatic compound biradical or heterocyclic compound biradical may be inserted, may be prepared from a suitable amino acid methyl ester which is protected at the alpha-amino group by a suitable protecting group PG as described in the literature (e.g. T. W. Greene, P. G. M. Wuts, Protective groups in organic synthesis, 2nd ed., 1991 John Wiley & Sons, Inc. New York)
- by an acylation method, e.g. using an suitable acid, in which X may or may not be protected by a suitable protective group, as described in the literature (e.g. T. W. Greene, P. G. M. Wuts, Protective groups in organic synthesis, 2nd ed., 1991 John Wiley & Sons, Inc. New York)
- and a coupling reagent such as e.g. 1-hydroxybenzotriazole, 3,4-dihydro-3-hydroxybenzotriazin-4-one or 7-azabenzotriazole in combination with e.g. a carbodiimide such as e.g. diisopropylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in the presence or absence of a suitable base such as e.g. triethylamine or ethyldiisopropylamine to form the ester of type
- The ester may be transformed into the corresponding amide by reaction with e.g. ammonia in a suitable solvent or mixture of solvents such as e.g. water or N,N-dimethylformamide.
- The removal of all protective groups may be performed in one or several steps by methods as described in the literature (e.g. T. W. Greene, P. G. M. Wuts, Protective groups in organic synthesis, 2nd ed., 1991 John Wiley & Sons, Inc. New York)
- As defined in General Method (A)
- Amino acid methyl esters are generally commercially available, or they may be synthesized by well-known methods.
- A compound of the general formula
- wherein R′ and R″ are defined as above, may be prepared from a suitable amino acid methyl ester which is protected at the alpha-amino group by a suitable protecting group PG, as described in the literature (e.g. T. W. Greene, P. G. M. Wuts, Protective groups in organic synthesis, 2nd ed., 1991 John Wiley & Sons, Inc. New York)
- by an alkylation of the aromatic hydroxyl group using an suitable alcohol, in which X may or may not be protected by a suitable protective group, as described in the literature (e.g. T. W. Greene, P. G. M. Wuts, Protective groups in organic synthesis, 2nd ed., 1991 John Wiley & Sons, Inc. New York)
- under conditions which effect alkylation, as described in the literature, e.g. Mitsunobu conditions such as e.g. triphenylphosphine and ethyl azodicarboxylate to form the ester of type
- The ester may be transformed into the corresponding amide by reaction with e.g. ammonia in a suitable solvent or mixture of solvents such as e.g. water or N,N-dimethylformamide.
- The removal of all protective groups may be performed in one or several steps by methods as described in the literature (e.g. T. W. Greene, P. G. M. Wuts, Protective groups in organic synthesis, 2nd ed., 1991 John Wiley & Sons, Inc. New York)
- As defined in General Method (B)
- A compound of the general formula
- wherein R′ and R″ are defined as above, may be prepared from a suitable amino acid methyl ester which is protected at the alpha-amino group by a suitable protecting group PG, as and described in the literature, e.g. in T. W. Greene, P. G. M. Wuts, Protective groups in organic synthesis, 2nd ed., 1991 John Wiley & Sons, Inc. New York)
- by an alkylation of the aromatic hydroxyl group, using an suitable alkylation reagent
- in which the anion of LG′ is a suitable leaving group such as halogenide or sulfonate and X may or may not be protected by a suitable protective group as described in the literature, e.g. in T. W. Greene, P. G. M. Wuts, Protective groups in organic synthesis, 2nd ed., 1991 John Wiley & Sons, Inc. New York. The reaction may take place under basic conditions, applying bases such as e.g. potassium carbonate, diazabicylo[5,4,0]undec-5-ene, or tert-butyltetramethyluanidine at a suitable temperature, typically between −78° C. and 200° C.
- The ester may be transformed into the corresponding amide by reaction with e.g. ammonia in a suitable solvent or mixture of solvents such as e.g. water or N,N-dimethylformamide.
- The removal of all protective groups may be performed in one or several steps by methods as described in the literature, e.g. in T. W. Greene, P. G. M. Wuts, Protective groups in organic synthesis, 2nd ed., 1991 John Wiley & Sons, Inc. New York
- As defined in General Method (C)
- A compound of the general formula
- wherein R′ and R″ are defined as above, may be prepared from a suitable acid which is protected at the alpha-amino group by a suitable protecting group PG, as described in the literature, e.g. in T. W. Greene, P. G. M. Wuts, Protective groups in organic synthesis, 2nd ed., 1991 John Wiley & Sons, Inc. New York
- by reaction with a suitable primary or secondary amine, in which X may or may not be protected by a suitable protecting group, using acylation conditions known to a person skilled in the art e.g. a coupling reagent such as e.g. 1-hydroxybenzotriazole, 3,4-dihydro-3-hydroxybenzotriazin-4-one or 7-azabenzotriazole in combination with e.g. a carbodiimide such as e.g. diisopropylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in the presence or absence of a suitable base such as e.g. triethylamine or ethyldiisopropylamine to form an amide
- The removal of all protective groups may be performed in one or several steps as described in the literature, T. W. Greene, P. G. M. Wuts, Protective groups in organic synthesis, 2nd ed., 1991 John Wiley & Sons, Inc. New York
- As defined in general Method (D)
- General Method (E): Synthesis of Ketogroup-Containing Amino Acid Amides from Cysteine
- A conveniently N-protected cysteine derivative (for instance an ester, N-(2,4-dimethoxybenzyl)amide or N-bis(cyclopropyl)methyl amide) or conveniently N-protected cysteine amide is treated with a carbonyl-group-containing alkylating agent (R50CO(CH2)nLG″, LG″=leaving group for nucleophilic displacement selected from halogen, sulfonate (—O—SO2—R51), dialkylsulfonium, phenyliodonium, or hydroxy, wherein R51 represents C1-6alkyl, partially or completely fluorinated C1-6alkyl, or aryl, optionally substituted with alkyl, halogen, nitro, cyano, or acetamido, and R50 represents hydrogen, alkyl, aryl, or heteroaryl, said aryl or heteroaryl being optionally substituted once or several times with C1-6alkoxy, hydroxy, halogen, cyano, acyl, alkyl, or nitro, under suitable reaction conditions to yield an S-alkylated cysteine derivative. This derivative is converted into an amino acid amide by conversion of the acid derivative into an amide and deprotection of the alpha-amino group. Suitable N-protecting groups are for instance trityl, phthaloyl, or alkoxycarbonyl groups, such as tert-butyloxycarbonyl
- wherein n represents an integer from 1 to 10.
General Method (F): Synthesis of Ketogroup-Containing Amino Acid Amides from Aspartic or Glutamic Acid - Aspartic or glutamic acids can be selectively protected by treatment of an N-alkoxycarbonyl derivative with formaldehyde, to yield cyclic esters as shown below:
- These derivatives, in which R60 represents tert-butyl, benzyl, 2-chlorobenzyl, allyl, 2-(trimethylsilyl)ethyl, 2,2,2-trichloroethyl, or benzhydryl, can be converted to protected, ketone-containing amino acid derivatives by activation of the carboxylic acid (LvG representing halogen, aryloxy, or heteroaryloxy) and reaction with a carbon nucleophile R80-M1, in which R80 represents alkyl, aryl, or heteroaryl, said aryl or heteroaryl being optionally substituted once or several times with C1-6alkoxy, hydroxy, halogen, cyano, acyl, alkyl, or nitro, and in which M1 represents an alkali metal, Mg, Zn, Ti, Zr, Mn, Cu, Ce, or Ca, optionally in the presence of a suitable catalyst. Reaction of the product with ammonia and deprotection will yield the desired amino acid amide
- Similarly, reaction of N-alkoxycarbonyl pyroglutamic acid esters, in which R70 represents tert-butyl, benzyl, 2-chlorobenzyl, allyl, 2-(trimethylsilyl)ethyl, 2,2,2-trichloroethyl, or benzhydryl, and R80 represents lower alkyl, with nucleophilic carbon reagents can yield protected, keto-group-containing amino acid derivatives. Reaction of the product with ammonia and deprotection will yield the desired amino acid amide:
- Similarly, suitably N-protected glutamic acid diesters as those shown below, in which R90 represents lower alkyl, can be selectively acylated at carbon to yield, after hydrolysis and decarboxylation, protected derivatives of keto-group-containing amino acids, which can be converted into amino acid amides using standard procedures
- A compound of the general formula
- wherein R′″ represents C1-15alkylene, C2-15alkenylene, C2-15alkynylene, C1-15heteroalkylene, C2-15heteroalkenylene, C2-15heteroalkynylene, wherein one or more homocyclic aromatic compound biradical or heterocyclic compound biradical may be inserted, may be prepared from a suitable protected primary or secondary amine
- in which PG may be a suitable protection group, as described in the literature, e.g. in T. W. Greene, P. G. M. Wuts, Protective groups in organic synthesis, 2nd ed., 1991 John Wiley & Sons, Inc. New York, and wherein the anion of LG′″ is a leaving group, such as e.g. halogenide or sulfonate.
- This amine is reacted with a suitable protected hydroxylamine
- wherein PG′ is a protecting group, which is chosen in a way that PG can be removed from an amine without removal of PG′ from the hydroxylamine. Examples for that can be found in the literature, e.g. in T. W. Greene, P. G. M. Wuts, Protective groups in organic synthesis, 2nd ed., 1991 John Wiley & Sons, Inc. New York.
- The two components are reacted under basic conditions such as e.g. sodium hydride at a suitable temperature such as e.g. −78° C. to 200° C.
- The protecting group of the amine may be removed selectively with a method described in the literature
- The amine may be acylated with a suitable acid and a coupling reagent such as e.g. 1-hydroxybenzotriazole, 3,4-dihydro-3-hydroxybenzotriazin-4-one or 7-azabenzotriazole in combination with e.g. a carbodiimide such as e.g. diisopropylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in the presence or absence of a suitable base such as e.g. triethylamine or ethyldiisopropylamine to give an amide.
- Finally, the protecting group of the hydroxylamine may be removed by a method described in the literature, e.g. in T. W. Greene, P. G. M. Wuts, Protective groups in organic synthesis, 2nd ed., 1991 John Wiley & Sons, Inc. New York
- A compound of the general formula
- may be prepared from a suitable ester, in which RIV is C1-10alkyl in a suitable solvent such as ethanol by addition of hydrazine hydrate.
- At a suitable temperature such as e.g. 5-50° C. or room temperature, a solution of the peptide in question (final concentration 1-10 mM) and the nucleophile in question (final concentration 10 mM-2M) is dissolved or suspended in water containing low concentrations of EDTA.
- Organic solvents may be added to improve the solubility of the reactants. The mixture may be buffered to a suitable pH-value such as e.g. between pH 1 and pH 14, between e.g. between pH 3.5 and pH 9, between pH 6 and pH 8.5, with a suitable buffer such as e.g. phosphate buffer or HEPES, or the pH can be maintained by addition of base or acid. A suitable enzyme e.g. carboxypeptidase Y is added to the said mixture of peptide and nucleophile. The reaction may be stopped after a suitable time e.g. between 5 min and 10 days, by changing temperature or pH-value, by adding organic solvents, or by dialysis or gel filtration.
- The pH of choice is determined e.g. by the solubility of the peptide to be conjugated and the activity of the enzyme to be used. Solubility of peptides is to a large extent determined by the pKa of the peptide. Normally, the solubility of a given peptide is at its minimum when pH equals pKa of the peptide. It lies within the skills of a skilled person to choose a pH at which to run the reaction taking due care to the above considerations.
- An oxime moiety may be formed by dissolving the transacylated peptide in question, in which RV may be a substituted or unsubstituted aromatic ring, a substituted or an unsubstituted heteroaromatic ring, hydrogen, or C1-10alkyl, in water. Organic solvents may be added to increase solubility. The solution is buffered to a suitable pH-value such as e.g. between pH 0 and pH 14, between pH 3 and pH 6, or pH 5 and kept at a suitable temperature such as e.g. 0-60° C. The hydroxylamine in question is added, and oxime moiety is formed according to the reaction scheme below
- The pH of choice is determined e.g. by the solubility of the peptide to be. Solubility of peptides is to a large extent determined by the pKa of the peptide. Normally, the solubility of a given peptide is at its minimum when pH equals pKa of the peptide. It lies within the skills of a skilled person to choose a pH at which to run the reaction taking due care to the above consideration.
- An hydrazone moiety is formed by dissolving the transacylated peptide in question, in which RVI may be a substituted or unsubstituted aromatic ring, a substituted or an unsubstituted heteroaromatic ring, hydrogen, or C1-10alkyl, in water. The solution is buffered to a suitable pH-value such as e.g. between pH 2 and pH 14 or between pH 0 and pH 4 and kept at a suitable temperature such as e.g. 0-60° C. The hydrazide in question is added, whereby the hydrazone is formed
- An hydrazone is formed by dissolving the transacylated peptide in question, in which RVII may be a substituted or unsubstituted aromatic ring, a substituted or an unsubstituted heteroaromatic ring, hydrogen, or C1-10alkyl, in water. The solution is buffered to a suitable pH-value such as e.g. between pH 2 and pH 14 or between pH 0 and pH 4 and kept at a suitable temperature such as e.g. 0-60° C. The hydrazine in question is added, whereby the hydrazone is formed
- An isoxazole can be formed by reaction between a nitril-oxide and an alkyne. The nitril-oxide is formed by addition of a suitable oxidation-reagent such as e.g. bleach to an excess of a suitable oxime. A solution of an excess of the freshly formed nitrile-oxide may be added to the peptide in question.
- A triazole can be formed by reaction between an azide which is attached to the group Z and an alkyne, which is attached to the peptide in question, in the presence of Cu(I)-ions in a suitable solvent such as water or a mixture of water and an organic solvent such as e.g. acetonitrile. The triazole may be formed in two possible regioisomers.
- A triazole can be formed by reaction between an alkyne which is attached to the group Z and an azide, which is attached to the peptide in question, in the presence of Cu(I)-ions in a suitable solvent such as water or a mixture of water and an organic solvent such as e.g. acetonitrile. The triazole may be formed in two possible regioisomers.
- An amide can be regioselectively formed by reaction of an azide, which is covalently attached to a peptide with an ester, containing a triphenylphosphine-moiety as it is described in e.g. Tetrahedron Lett. 2003, 44, 4515-4518.
- An amide can be regioselectively formed by reaction of an azide, which is covalently attached to a peptide with a thioester, containing a diphenylphosphine-moiety as it is described in e.g. J. Org. Chem. 2002, 67, 4993-4996.
- An arylalkyne can be formed by reaction between an alkyne, which is covalently attached to a peptide and a haloaryl compound in the presence of a palladium catalyst, which is water-soluable, as described in e.g. Bioconjugate Chemistry, 2004, 15, 231-234. The haloaryl compound may be exchanged with the corresponding aryl trifluorosulfonate.
- An arylalkyne might be formed by reaction between a haloaryl-moiety, which is covalently attached to a peptide and an alkyne in the presence of a palladium catalyst, which is water-soluable, as described in e.g. Bioconjugate Chemistry, 2004, 15, 231-234. Instead of the haloaryl-moiety a trifluorosulfonyloxyaryl-moiety, which is attached to a peptide can be used as well.
- A compound of the general formula
- wherein R′ and R″ are as defined above may be prepared from a suitable amino acid, which is protected at the alpha-amino group, with an acid-labile protecting group PG1 such as e.g. BOC or trityl, and which is protected at the omega-amino group with a base-labile protecting group PG2 such as e.g. Fmoc. The acid may be attached to a Rink-amide resin using standard coupling conditions known to a person skilled in the art, such as e.g. use of a carbodiimide e.g. diisopropylcarbodiimide in the presence or absence of a reagent such as e.g. 1-hydroxybenzotriazole, 1-hydroxy-7-azabenzotriazole or 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazin and in the presence or absence of a base such as e.g. triethylamine or ethyldiisopropylamine. The protecting group at the omega-amine PG2, may be removed under basic conditions described for the particular protecting group in the literature such as e.g. T. W. Greene, P. G. M. Wuts, Protective groups in organic synthesis, 2nd ed., 1991 John Wiley & Sons, Inc. New York.
- An acid can be attached to the omega amino moiety using standard coupling conditions, such as e.g. use of a carbodiimide e.g. diisopropylcarbodiimide in the presence or absence of a reagent such as e.g. 1-hydroxybenzotriazole, 1-hydroxy-7-azabenzotriazole or 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazin and in the presence or absence of a base such as e.g. triethylamine or ethyldiisopropylamine. The intermediate may be cleaved from the solid support under acidic conditions such as e.g. trifluoroacetic acid or a 20-70% solution of trifluoroacetic acid in dichloromethane to give the desired aminamide.
- A compound of the general formula
- wherein R′ and R″ are defined as above, may be prepared from a suitable amino acid, which is protected with an acid labile protecting group PG1, such as e.g. Boc or trityl, which is reacted with an excess of ammonia in the presence of a coupling reagent, such as e.g. a carbodiimide e.g. diisopropylcarbodiimide in the presence or absence of a reagent such as e.g. 1-hydroxybenzotriazole, 1-hydroxy-7-azabenzotriazole or 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazin.
- The phenolic hydroxyl group may be alkylated with a suitable halogenide or sulfonate, in which Ra is any suitable substituted alkyl or aryl radical, in the presence of a suitable base such as e.g. potassium carbonate or tetramethylguanidine. The protecting group PG1 may be removed from the alpha amino acid under acidic conditions and described in the literature for the particular protecting group chosen e.g. in T. W. Greene, P. G. M. Wuts, Protective groups in organic synthesis, 2nd ed., 1991 John Wiley & Sons, Inc. New York, to give the desired amino amide.
- A reagent of the general formula
- in which
- is E, as defined above,
may be prepared from a suitable acid, which may be activated by reaction with a suitable reagent or a combination of reagents, such as e.g. 2-succinimido-1,1,3,3,-tetramethyluronium tetrafluoroborate (TSTU) in a suitable solvent such as e.g. N,N-dimethylformamide. The activated acid e.g. the obtained 2,5-dioxopyrrodin-1yl ester of said acid may be reacted with commercially available PEG-reagents, which are functionalized with a primary amine, optionally in the presence of a suitable base such as e.g. ethyldiisopropylamine or triethylamine. -
-
- 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (3.23 g, 16.8 mmol) was added to a solution of benzoylpropionic acid (3.00 g, 16.8 mmol) and 3,4-dihydro-3-hydroxybenzotriazin-4-one (2.75 g, 16.8 mmol) in a mixture of N,N-dimethylformamide (20 ml) and dichloromethane (20 ml). The reaction mixture was stirred for 20 min at room temperature. The hydrochloride salt of BOC-Lys-OMe (5.00 g, 16.8 mmol) and ethyldiisopropylamine (8.65 ml, 50.5 mmol) were added successively. The reaction mixture was stirred for 16 h. It was diluted with ethyl acetate (300 ml) and washed with a half-concentrated solution of sodium hydrogencarbonate (2×300 ml). The organic layer was dried over magnesium sulphate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (90 g), using ethyl acetate/heptane 2:1 as eluent, to give 2.41 g of (2S)-2-tert-(butoxycarbonylamino)-6-(4-oxo-4-phenylbutyrylamino)hexanoic acid methyl ester.
- 1H-NMR (CDCl3): δ 1.30-1.90 (m, 6H); 1.44 (s, 9H); 2.61 (t, 2H); 3.20 (q, 2H); 3.37 (t, 2H); 4.25 (m, 1H); 5.20 (br, 1H); 5.90 (br, 1H); 7.46 (m, 2H); 7.50 (m, 1H); 8.00 (d, 2H).
-
- A 25% solution of ammonia in water (25 ml) was added to (2S)-2-tert-(butoxycarbonylamino)-6-(4-oxo-4-phenylbutyrylamino)hexanoic acid methyl ester (0.70 g, 1.67 mmol). The reaction mixture was stirred for 2 days at room temperature. The solvent was removed in vacuo to give 0.56 g of [(1S)-1-carbamoyl-5-(4-oxo-4-phenylbutyrylamino)pentyl]carbamic acid tert-butyl ester.
- 1H-NMR (CDCl3): δ 0.90 (m, 6H); 2.75 (t, 2H); 3.20-3.50 (m, 4H); 4.15 (m, 1H); 7.35-7.60 (m, 3H); 8.00 (d, 2H).
- Trifluoroacetic acid (25 ml) was added to a solution of [(1S)-1-carbamoyl-5-(4-oxo-4-phenylbutyrylamino)pentyl]carbamic acid tert-butyl ester (0.56 g, 1.38 mmol) in dichloromethane (25 ml). The reaction mixture was stirred for 1 h at room temperature. The solvent was removed. The crude product was purified by HPLC on a RP-18 column, using a gradient of 20-45% acetonitrile in water, containing 0.1% of trifluoracetic acid as buffer to give 92 mg of the title compound with a purity of approx. 85%, which was used for the further experiments.
- 1H-NMR (CDCl3): δ 1.40 (m, 4H); 1.70 (m, 2H); 2.46 (t, 2H); 3.00 (q, 2H); 3.23 (t, 2H); 3.70 (m, 1H); 7.53 (m, 3H); 7.65 (t, 1H); 7.83 (br, 1H); 7.90 (t, 1H); 8.00 (d, 2H); 8.05 (br, 3H). MS: m/z=306 [M+1]+
-
- 1.65 g of the title compound was prepared as described for (2S)-2-amino-6-(4-oxo-4-phenylbutyrylamino)hexanoic acid amide, using 4-acetylbenzoic acid instead of benzoylpropionic acid.
- 1H-NMR (CDCl3): δ 1.40 (m, 2H); 1.60 (m, 2H); 1.80 (m, 2H); 2.62 (s, 3H); 3.30 (q, 2H); 3.75 (q, 1H); 7.55 (br, 1H); 7.85 (br, 1H); 7.97 (d, 2H); 8.05 (d, 2H); 8.10 (br, 3H); 8.65 (t, 1H).
-
- To a solution of the N-Boc cysteine methyl ester (2.05 ml, 9.93 mmol) in MeCN (20 ml) at 0° C. were added DIPEA (3.55 ml, 20.1 mmol), NaI (0.48 g, 3.20 mmol), and then a solution of phenacyl bromide (2.41 g, 12.1 mmol) in MeCN (4 ml). The mixture was stirred at room temperature for 19 h. Water (100 ml) and 1N aqueous HCl (30 ml) was added, and the product was extracted (3×AcOEt). The combined extracts were washed with brine, dried (MgSO4), and concentrated under reduced pressure to yield 4.37 g of an oil. Crystallization from AcOEt (approx 10 ml) and heptane (approx 40 ml) at −20° C. overnight yielded 3.49 g (99%) of the title methyl ester as a brown solid.
- 1H NMR (DMSO-d6): δ 1.37 (s, 9H), 2.74 (dd, J=9 Hz, 13 Hz, 1H), 2.89 (dd, J=5.5 Hz, 13 Hz, 1H), 3.62 (s, 3H), 4.03 (d, J=15 Hz, 1H), 4.14 (d, J=15 Hz, 1H), 4.22 (m, 1H), 7.33 (br d, J=8 Hz, 1H), 7.52 (m, 2H), 7.64 (m, 1H), 7.99 (m, 2H).
-
- To a solution of S-phenacyl-N-Boc-cystein methyl ester (1.77 g, 5.01 mmol) in MeCN (30 ml) was added aqueous ammonia (50 ml, 25%; 12.5 g NH3). After stirring at room temperature for 71 h no more starting material could be detected by TLC. The mixture was concentrated under reduced pressure, and the residue was resuspended in toluene and ethanol and concentrated again. stripping with PhMe+EtOH. Crystallization from cold methanol yielded 0.86 g (50%) of the title amide.
- 1H NMR (DMSO-d6): δ 1.37 (s, 9H), 2.66 (dd, J=9 Hz, 13 Hz, 1H), 2.83 (dd, J=5.5 Hz, 13 Hz, 1H), 4.07 (d, J=15 Hz, 1H), 4.10 (m, 1H), 4.12 (d, J=15 Hz, 1H), 6.88 (br d, J=8 Hz, 7.12 (br s, 1H), 7.35 (br s, 1H), 7.52 (t, J=8 Hz, 2H), 7.64 (m, 1H), 7.96 (m, 2H).
-
- S-Phenacyl-N-Boc cysteine amide (0.70 g, 2.07 mmol) was mixed with DCM (10 ml) and TFA (20 ml). After 30 min the mixture was concentrated, and the residue was mixed with toluene and MeCN and concentrated again. The residue was mixed with 1N HCl (1.5 ml), ethanol, MeCN, and toluene and concentrated again. The residue was suspended in boiling EtOH (approx 5 ml). Filtration and drying yielded 0.18 g (32%) of the title hydrochloride as a light brown solid. LCMS: only one product (HPLC, 210 nm), MH+=221 (product—water).
- 1H NMR (DMSO-d6): δ 2.93 (dd, J=7 Hz, 13 Hz, 1H), 3.06 (dd, J=6 Hz, 13 Hz, 1H), 3.97 (m, 1H), 4.33 (br s, 2H), 7.58 (m, 2H), 7.68 (m, 1H), 8.02 (m, 2H), 8.32 (br s, 3H).
-
- Rink-amide-resin (loading: 0.43 mmol/g, 6.66 g, 2.86 mmol) was swelled with dichloromethane (50 ml). The solvent was removed. A 20% solution of piperidine in N-methylpyrrolidinone was added (50 ml). The reactor was shaken for 20 min. The liquid was removed. The resin was washed with N-methylpyrrolidinone (3×50 ml) and dichloromethane (5×50 ml). A solution of BOC-Lys(FMOC)-OH (5.37 g, 11.5 mmol) in N-methylpyrrolidinone (50 ml) and a solution of 1-hydroxybenzotriazole (1.75 g, 11.5 mmol) in N-methylpyrrolidinone (20 ml) were added successively. Diisopropylcarbodiimide (1.79 ml, 11.5 mmol) and ethyldiisopropylamine (1.96 ml, 11.5 mmol) were added. The reactor was shaken at room temperature for 16 h. The liquid was removed. The resin was washed with N-methylpyrrolidinone (3×50 ml) and dichloromethane (3×50 ml). A solution of 4-acetylbenzoic acid (2.82 g, 11.5 mmol) in N-methylpyrrolidinone (50 ml) and a solution of 1-hydroxybenzotriazole (1.75 g, 11.5 mmol) in N-methylpyrrolidinone (20 ml) were added successively. Diisopropylcarbodiimide (1.79 ml, 11.5 mmol) and ethyldiisopropylamine (1.96 ml, 11.5 mmol) were added. The reactor was shaken at room temperature for 16 h. The resin was washed with N-methylpyrrolidinone (3×50 ml) and dichloromethane (3×50 ml). A solution of 50% of trifluoroacetic acid and 10% triisopropylsilane in dichloromethane (50 ml) was added to the resin. The reaction vessel was shaken for 1 h at room temperature. The liquid was collected. The solvent was removed in vacuo. The residue was redissolved in toluene (50 ml). The solvent was removed in vacuo.
- The crude products of 6 runs of the procedure described above were combined. They were purified by HPLC-chromatography on a C18-reversed phase column, using a gradient of 3-23% of acetonitrile in water in a 0.1% buffer of trifluoroacetic acid to afford 1.07 g of the trifluoroacetic acid salt of 4-acetyl-N-((5S)-5-amino-5-carbamoylpentyl)benzamide.
-
-
- Tosyl chloride (4.16 g, 21.8 mmol) was added to a solution of commercially available 4-(2-hydroxyethyl)piperidine-1-carbocylic ester tert-butyl ester (e.g. Aldrich 54, 724-7, 5.0 g, 21.8 mmol) and triethylamine (4.25 ml, 30.5 mmol) in dichloromethane (100 ml). The reaction mixture was stirred at room temperature for 16 h. It was diluted with ethyl acetate (300 ml) and washed with a 10% aqueous solution of sodium hydrogensulphate (200 ml). The aqueous phase was extracted with ethyl acetate (150 ml). The combined organic layers were washed with a saturated aqueous solution of sodium hydrogencarbonate (250 ml) and dried over magnesium sulphate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (80 g), using ethyl acetate/heptane first: 1:2 then 1:1 as eluent, to give 6.04 g of 4-[2-(toluene-4-sulfonyloxy)ethyl]piperidine-1-carboxylic acid tert-butyl ester.
- 1H-NMR (CDCl3): δ 1.05 (m, 2H); 1.45 (s, 9H); 1.55 (m, 5H); 2.50 (s, 3H); 2.65 (t, 2H); 4.05 (m, 4H); 7.35 (d, 2H); 7.80 (d, 2H).
-
- At 0° C., a 60% suspension of sodium hydride in mineral oil (0.69 g, 17.2 mmol) was added to a solution of N-hydroxyphthalimide (2.80 g, 17.2 mmol) in N,N-dimethylformamide (20 ml). The reaction mixture was stirred for 45 min at 0° C. A solution of 4-[2-(toluene-4-sulfonyloxy)ethyl]piperidine-1-carboxylic acid tert-butyl ester (5.99 g, 15.6 mmol) in N,N-dimethylformamide (15 ml) and tetrabutylammonium iodide (0.17 g, 0.47 mmol) were added successively. The reaction mixture was heated to 60° C. for 2 days and cooled to room temperature. Water (5 ml) was added carefully. The reaction mixture was diluted with ethyl acetate (250 ml) and washed with a 10% aqueous solution of sodium hydrogensulphate (200 ml). The aqueous phase was extracted with ethyl acetate (200 ml). The combined organic layers were washed with a saturated aqueous solution of sodium hydrogencarbonate (150 ml) and dried over magnesium sulphate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (80 g), using ethyl acetate/heptane 1:1 as eluent to give 4.36 g of 4-[2-(1,3-dioxo-1,3-dihydroisoindol-2-yloxy)ethyl]piperidine-1-carboxylic acid tert-butyl ester.
- 1H-NMR (CDCl3): δ 1.15 (m, 2H); 1.50 (s, 9H); 1.75 (m, 5H); 2.75 (m, 2H); 4.10 (m, 2H); 4.30 (t, 2H); 7.80 (m, 4H).
-
- Trifluoroacetic acid (20 ml) was added to a solution of 4-[2-(1,3-dioxo-1,3-dihydroisoindol-2-yloxy)ethyl]piperidine-1-carboxylic acid tert-butyl ester (4.26 g, 11.4 mmol) in dichloromethane (20 ml). The reaction mixture was stirred at room temperature for 50 min. The solvent was removed in vacuo. The residue was dissolved in dichloromethane (50 ml) and the solvent was removed in vacuo. The latter procedure was repeated twice to give 6.46 g of the crude trifluoroacetate salt of 2-(2-(piperidin-4-yl)ethoxy)isoindole-1,3-dione.
- MS: m/z=275 [M+1+]
- 1H-NMR (DMSO-d6): δ 1.30 (m, 2H); 1.65 (m, 2H); 1.90 (m, 3H); 2.90 (q, 2H); 3.30 (d, 2H); 4.20 (t, 2H); 7.90 (s, 4H); 8.30 (br, 1H); 8.65 (br, 1H).
-
- At 0° C., 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.04 g, 5.44 mmol) was added to a solution of palmic acid (1.40 g, 5.44 mmol) and 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazole (0.89 g, 5.44 mmol) in N,N-dimethylformamide (20 ml) and dichloromethane (20 ml). The reaction mixture was stirred at 0° C. for 20 min. A solution of the trifluoroacetate salt of 2-(2-(piperidin-4-yl)ethoxy)isoindole-1,3-dione (2.11 g, 5.44 mmol) in N,N-dimethylformamide (5 ml) and ethyldiisopropylamine (6.19 ml, 38.1 mmol) were added successively. The reaction mixture was stirred for 16 h, while it was warming up to room temperature. It was diluted with ethyl acetate (150 ml) and was washed with a 10% aqueous solution of sodium hydrogensulphate (150 ml). The aqueous phase was extracted with ethyl acetate. The combined organic layers were washed with a mixture of water (50 ml) and a saturated aqueous solution of sodium hydrogencarbonate (50 ml) and dried over magnesium sulphate. The crude product was purified by flash chromatography on silica (40 g), using ethyl acetate/heptane 1:1 as eluent to give 1.52 g of 2-[2-(1-(hexadecanoyl)piperidin-4-yl)ethoxy]isoindole-1,3-dione.
- MS: m/z=513 [M+1+]
- 1H-NMR (DMSO-d6): δ 0.90 (t, 3H); 1.10 (m, 2H); 1.25 (m, 26H); 1.45 (m, 2H); 1.65 (m, 1H); 1.80 (m, 2H); 2.30 (t, 2H); 2.95 (t, 1H); 3.85 (m, 3H); 4.20 (t, 2H); 4.40 (d, 1H); 7.90 (s, 4H).
- Hydrazine hydrate (0.14 ml, 2.96 mmol) was added to a solution of 2-[2-(1-(hexadecanoyl)piperidin-4-yl)ethoxy]isoindole-1,3-dione (1.52 g, 2.96 mmol) in ethanol (30 ml). The reaction mixture was heated to reflux for 75 min and cooled to room temperature. The formed precipitation was removed by filtration. The solvent of the filtrate was removed in vacuo. The crude product was purified by flash chromatography on silica (30 g), using a mixture of dichloromethane/methanol/25% aqueous ammonia (100:10:1) as eluent, to give 800 mg of 1-[4-(2-(aminooxy)ethyl)piperidin-1-yl]hexadecan-1-one.
- MS: m/z=383 [M+1+]
- 1H-NMR (CDCl3): δ 0.80 (t, 3H); 1.25 (m, 2H); 1.60 (m, 26H); 1.70 (m, 4H); 1.65 (m, 3H); 2.708t, 2H); 2.60 (t, 1H); 3.05 (t, 1H); 3.80 (m, 3H); 4.60 (d, 1H).
-
- At 0° C., 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (563 mg, 2.94 mmol) was added to a solution of commercially available (S)-2-(tert-butyoxycarbonylaminopent-4-ynoic acid (e.g. Acros, 626 mg, 2.94 mmol) and 1-hydroxybenzotriazole (397 mg, 2.94 mmol) in N,N-dimethylformamide (20 ml). The reaction mixture was stirred at 0° C. for 20 min. A 25% aqueous solution of ammonia (2.38 ml) was added. The reaction mixture was stirred for 16 h, while warming up to room temperature. It was diluted with ethyl acetate (150 ml) and washed with a 10% aqueous solution of sodium hydrogensulphate (150 ml). The aqueous phase was extracted with ethyl acetate (2×100 ml). The combined organic layers were washed with brine (250 ml) and dried over magnesium sulphate. The solvent was removed in vacuo. The residue was dissolved in ethyl acetate (100 ml) and washed with a mixture of brine (75 ml) and water (75 ml). The aqueous phase was extracted with ethyl acetate (2×50 ml). The combined organic layers were dried over magnesium sulphate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (50 g), using dichloromethane/methanol (10:1) as eluent, to give 138 mg of ((S)-1-carbamoylbut-3-ynyl)carbamic acid tert-butyl ester.
- 1H-NMR (CDCl3): δ 1.40 (s, 9H); 2.15 (t, 1H); 2.70 (m, 1H); 2.90 (m, 1H); 4.40 (m, 1H); 5.70 (d, 1H); 6.50 (br, 1H); 6.90 (br, 1H).
- Trifluoroacetic acid (3 ml) was added to a solution of ((S)-1-carbamoylbut-3-ynyl)carbamic acid tert-butyl ester (138 mg, 0.65 mmol) in dichloromethane (3 ml). The reaction mixture was stirred for 1.25 h at room temperature. The solvent was removed in vacuo. The residue was dissolved in dichloromethane (40 ml) and the solvent was removed in vacuo. The latter procedure was repeated twice to give crude trifluoroacetate salt of (S)-2-aminopent-4-ynoic acid amide, which was used for the following experiments.
- MS: m/z=113 [M+1+]
- 1H-NMR (DMSO-d6): δ 2.70 (m, 2H); 3.15 (t, 1H); 3.85 (m, 1H); 7.65 (s, 1H); 7.85 (s, 1H); 8.20 (br, 3H).
-
- A solution of [Leu37]GLP-1(7-37)ylalanine (0.348 mg, 100 nmol), trifluoroacetate salt of (S)-2-aminopent-4-ynoic acid amide (2.26 mg, 10000 nmol), and hydroxypropyl-beta-cyclodextrin (4 mg) in a buffer of 250 mM HEPES and 5 mM EDTA (0.085 ml), which had been adjusted to pH 7.5 prior its use, a 25% aqueous solution of ammonia and 1 N hydrochloric acid (together 0.011 ml) was prepared, having a pH of 7.96. A solution of CPY (1.0 U) in water (0.005 ml) was added. The reaction mixture was left at room temperature. After 40 min a mass corresponding to (S)-2-(([Leu37]GLP-1-(7-37)yl)amino)pent-4-ynoic amide could be found in the MALDI-TOF besides masses corresponding to [Leu37]GLP-1-(7-37)ylalanine, to [Leu37]GLP-1-(7-37) peptide, and to (S)-2-{(S)-2-(([Leu37]GLP-1-(7-37)yl)amino)pent-4-ynoylamino}pent-4-ynoyl amide.
- MALDI-TOF (CHCA): m/z=3508, 3485, 3604, 3413.
-
-
- Di-tert-butyl dicarbonate (15 g, 69 mmol) was added to a solution of the hydrochloride salt of tyrosine amide (15 g, 69 mmol) in dioxane (140 ml) and a 1 N aqueous solution of sodium hydroxide (140 ml). The reaction mixture was stirred for 16 h at room temperature. It was diluted with a 10% aqueous solution of sodium hydrogensulphate (200 ml) and extracted with ethyl acetate (3×200 ml). The combined organic layers were washed with a saturated aqueous solution of sodium hydrogencarbonate (100 ml) and dried over magnesium sulphate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (400 g), using a mixture of dichloromethane/methanol (10:1) to give 8.17 g of [(S)-1-carbamoyl-2-(4-hydroxyphenyl)ethyl]-carbamic acid tert-butyl ester.
- MS: m/z=303 (M+Na)+.
- 1H-NMR (DMSO-d6): δ 1.31 (s 9H); 2.80 (dd, 1H); 2.83 (dd, 1H); 4.00 (m, 1H); 6.62 (d, 2H); 6.70 (d, 1H); 6.97 (br, 1H); 7.03 (d, 2H); 7.31 (br, 1H); 9.14 (s, 1H).
-
- A mixture of [(S)-1-carbamoyl-2-(4-hydroxyphenyl)ethyl]-carbamic acid tert-butyl ester (1.0 g, 3.57 mmol), tetrabutylammonium iodide (65 mg, 0.17 mmol), potassium carbonate (3.94 g, 29 mmol), propargyl bromide (0.38 ml, 4.28 mmol) and N,N-dimethylformamide (15 ml) was heated to 60° C. for 16 h. It was cooled to room temperature, diluted with water (30 ml) and acidified with a 10% aqueous solution of sodium hydrogensulphate. The mixture was extracted with ethyl acetate (2×100 ml). The combined organic layers were washed with a saturated aqueous solution of sodium hydrogencarbonate (200 ml) and dried over magnesium sulphate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (100 g), using a mixture of dichloromethane/methanol (10:1) as eluent, to give 998 mg of [(S)-1-carbamoyl-2-(4-(prop-2-ynyloxy)phenyl)ethyl]carbamic acid tert-butyl ester.
- MS: m/z=341 (M+Na)+.
- 1H-NMR (DMSO-d6) δ 1.31 (s, 9H); 2.50 (s, 1H); 2.67 (dd, 1H); 2.91 (dd, 1H); 4.03 (m, 1H); 4.74 (s, 2H); 6.77 (d, 1H); 6.86 (d, 2H); 6.99 (s, 1H), 7.17 (d, 2H); 7.35 (s, 1H).
- Trifluoroacetic acid (10 ml) was added to a solution of [(S)-1-carbamoyl-2-(4-(prop-2-ynyloxy)phenyl)ethyl]carbamic acid tert-butyl ester (998 mg, 3.13 mmol) in dichloromethane (10 ml). The reaction mixture was stirred for 1.5 h at room temperature. The solvent was removed. The residue was dissolved in dichloromethane (30 ml). The solvent was removed. The latter procedure was repeated twice to give 1.53 g of the trifluoroacetate salt of (2S)-2-amino-3-(4-(prop-2-ynyloxy)phenyl)propionamide.
- HPLC (method 02-B4-4): Rf=5.62 min.
- MS: m/z=219(M+1)+.
- 1H-NMR (CDCl3) δ 2.51 (s, 1H); 3.02 (m, 2H); 3.90 (m, 1H); 4.78 (s, 2H); 6.95 (d, 2H); 7.20 (d, 2H); 7.56 (s, 1H); 7.87 (s, 1H); 8.10 (br, 3H).
-
- [Leu37]GLP-1(7-37)ylalanine
- [Leu37]GLP-1(7-37)ylalanine was prepared on an Applied Biosystems 433A Peptide Synthesizer by standard Fmoc-strategy starting with a commercially available Fmoc-Ala-Wang resin. Following amino acid derivatives were used:
-
coupling no. amino acid derivative 1 Fmoc-Leu-OH 2 Fmoc-Arg(Pmc)-OH 3 Fmoc-Gly-OH 4 Fmoc-Lys(Boc)-OH 5 Fmoc-Val-OH 6 Fmoc-Leu-OH 7 Fmoc-Trp(Boc)-OH 8 Fmoc-Ala-OH 9 Fmoc-Ile-OH 10 Fmoc-Phe-OH 11 Fmoc-Glu(OtBu)-OH 12 Fmoc-Lys(Boc)-OH 13 Fmoc-Ala-OH 14 Fmoc-Ala-OH 15 Fmoc-Gln(Trt)-OH 16 Fmoc-Gly-OH 17 Fmoc-Glu(OtBu)-OH 18 Fmoc-Leu-OH 19 Fmoc-Tyr(tBu)-OH 20 Fmoc-Ser(tBu)-OH 21 Fmoc-Ser(tBu)-OH 22 Fmoc-Val-OH 23 Fmoc-Asp(OtBu)-OH 24 Fmoc-Ser(tBu)-OH 25 Fmoc-Thr(tBu)-OH 26 Fmoc-Phe-OH 27 Fmoc-Thr(tBu)-OH 28 Fmoc-Gly-OH 29 Fmoc-Glu(OtBu)-OH 30 Fmoc-Ala-OH 31 Fmoc-His(Trt)-OH - A mixture of trifluoroacetic acid (10 ml), water (0.265 ml) and triisopropylsilane (0.265 ml) was added to the resin. It was shaken for 1.5 h. The liquid was collected. The resin was washed with trifluoroacetic acid (1 ml). The liquids were combined. The solution was concentrated under a stream of nitrogen. Ether (40 ml) was added. The precipitation was isolated by centrifugation. The crude product was purified on a reversed phase C1B-column on a HPLC, using a gradient of 37-65% acetonitrile in water in a buffer of 0.1% trifluoroacetic acid, as eluent.
- A mixture (0.100 ml final volume) of [Leu37]GLP-1(7-37)ylalanine (1 mM final concentration) and the trifluoroacetate salt of (2S)-2-amino-3-(4-(prop-2-ynyloxy)phenyl)propionamide (100 mM final concentration) and hydroxypropyl-beta-cyclodextrin (4 mg) in a buffer, consisting of 250 mM HEPES and 5 mM EDTA, was adjusted to pH 8, using a 1 N aqueous solution of sodium hydroxide. A solution of carboxypeptidase Y (CPY, 200 U/ml, 0.005 ml, 1 U) was added to obtain the desired final volume and concentrations. The mixture was left for 3 h at room temperature.
- MALDI-TOF (Matrix assisted laser desorption/ionization time of flight mass spectroscopy): m/z=3612 ((S)-2-([Leu37]GLP-1(7-37)ylamino)-3-(4-(prop-2-ynyl)phenyl)propionamide) along with 3412 ([Leu37]GLP-1 peptide).
- MS (electrospray): 1205 (M)3+.
-
- [Glu3,Leu10]GLP-2ylleuccinylalanine
- [Glu3,Leu10]GLP-2ylleuccinylalanine was prepared on an Applied Biosystems 433A Peptide Synthesizer by standard Fmoc-strategy starting with a commercially available Fmoc-Ala-Wang resin. Following amino acid derivatives were used:
-
coupling no. amino acid derivative 1 Fmoc-Leu-OH 2 Fmoc-Asp(OtBu)-OH 3 Fmoc-Thr(tBu)-OH 4 Fmoc-Ile-OH 5 Fmoc-Lys(Boc)-OH 6 Fmoc-Thr(tBu)-OH 7 Fmoc-Gln(Trt)-OH 8 Fmoc-Ile-OH 9 Fmoc-Leu-OH 10 Fmoc-Trp(Boc)-OH 11 Fmoc-Asn(Trt)-OH 12 Fmoc-Ile-OH 13 Fmoc-Phe-OH 14 Fmoc-Asp(OtBu)-OH 15 Fmoc-Arg(Pmc)-OH 16 Fmoc-Ala-OH 17 Fmoc-Ala-OH 18 Fmoc-Leu-OH 19 Fmoc-Asn(Trt)-OH 20 Fmoc-Asp(OtBu)-OH 21 Fmoc-Leu-OH 22 Fmoc-Ile-OH 23 Fmoc-Thr(tBu)-OH 24 Fmoc-Asn(Trt)-OH 25 Fmoc-Leu-OH 26 Fmoc-Glu(OtBu)-OH 27 Fmoc-Asp(OtBu)-OH 28 Fmoc-Ser(tBu)-OH 29 Fmoc-Phe-OH 30 Fmoc-Ser(tBu)-OH 31 Fmoc-Gly-OH 32 Fmoc-Glu(OtBu)-OH 33 Fmoc-Ala-OH 34 Fmoc-His(Trt)-OH - A mixture of trifluoroacetic acid (10 ml), water (0.265 ml) and triisopropylsilane (0.265 ml) was added to the resin. It was shaken for 1.5 h. The liquid was collected. The resin was washed with trifluoroacetic acid (1 ml). The liquids were combined. The solution was concentrated under a stream of nitrogen. Ether (40 ml) was added. The precipitation was isolated by centrifugation. The crude product was purified on a reversed phase C1B-column on a HPLC, using a gradient of 37-65% acetonitrile in water in a buffer of 0.1% trifluoroacetic acid, as eluent.
- HPLC: 8.81 min (method 02-B4-4).
- MALDI-TOF: m/z=3946
- MS: m/z=1317. 988, 790.
- CPY-Reaction of (2S)-2-Amino-3-(4-(prop-2-ynyloxy)phenyl)propionamide with (([Glu3,Leu10]GLP-2yl)leucinyl)alanine
- A mixture (1.5 ml final volume) of (([Glu3,Leu10]GLP-2yl)leucinyl)alanine (1 mM final concentration) and the trifluoroacetate salt of (2S)-2-amino-3-(4-(prop-2-ynyloxy)phenyl)propionamide (6 mg, 150 mM final concentration) and hydroxypropyl-beta-cyclodextrin (61 mg) in a buffer, consisting of 250 mM HEPES and 5 mM EDTA, was adjusted to pH 8, using a 1 N aqueous solution of sodium hydroxide. A solution of carboxypeptidase Y (CPY, 800 U/ml, 0.019 ml, 15 U) was added to obtain the desired final volume and concentrations. The mixture was left for 3.5 h at room temperature. The mixture was diluted with water to a volume of 10 ml. The product was isolated by HPLC-purification, using a C1B-column and a gradient of 39-67% acetonitrile in water, which was acidified with 0.1% trifluoroacetic acid, to give (2S)-2-([Glu3,Leu10]GLP-2ylleucinylamino)-3-(4-(prop-2-ynyloxy)phenyl)propionamide. Using an absorption coefficient of 1500000 at 214 nm, a yield of 2.5 mg was determined.
- MALDI-TOF: 4073.
- HPLC (system 02-b4-4): 9.14 min.
- MS (electrospray): m/z=815, 1120, 1359.
-
- Step 1:
-
- A solution of hydroxylamine hydrochloride (3.68 g, 53 mmol) in water (5 ml) was added to a solution of 3-chlorobenzaldehyde (5.00 ml, 44 mmol) in ethanol (20 ml). A solution of sodium hydroxide (2.64 g, 66 mmol) in water (5 ml) was added. The reaction mixture was stirred at room temperature for 48 h. The reaction mixture was given onto water/ice (150 ml). The formed precipitation was isolated by filtration and dissolved in dichloromethane (200 ml). This solution was dried over magnesium sulphate. The solvent was removed to give 3.88 g of 3-chlorobenzaldehyde oxime, which was used without further purification.
- Step 2:
- A 10% solution of sodium hypochlorite (0.008 ml) was added to a suspension of 3-chlorobenzaldehyde oxime (4.2 mg, 0.027 mmol) in water (0.5 ml). The solution was left for 10 min at room temperature. A solution of (2S)-2-([Glu3,Leu10]GLP-2ylleucinylamino)-3-(4-(prop-2ynyloxy)phenyl)propionamide (1.1 mg, 0.00027 mmol) and triethylamine (0.003 ml) in water (0.5 ml) was added. The reaction mixture was left at room temperature for 16 h. The crude product was purified on a reversed phase C18-HPLC, using a gradient of 43-75% acetonitrile in water in a 0.1% buffer of TFA.
- HPLC (method 02-b4-4): 9.56 min.
- MS (EI): m/z=1410 (M3+), 1054 (M4+) and 844 (M5+)
-
- Step 1:
-
- 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (6.82 g, 35.5 mmol) was added to a solution of BOC-protected tyrosine (10.0 g, 35.5 mmol) and 1-hydroxybenzotriazole (5.44 g, 35.5 mmol) in a mixture of N,N-dimethylformamide (10 ml) and dichloromethane (10 ml). The reaction mixture was stirred for 20 min. A 25% aqueous solution of ammonia in water was added. The reaction mixture was stirred at room temperature for 16 h. It was diluted with ethyl acetate (100 ml) and washed with water (3×100 ml) and subsequently with a saturated aqueous solution of sodium hydrogencarbonate (100 ml). It was dried over magnesium sulphate. The solvent was removed in vacuo to give 4.24 g of [(S)-1-carbamoyl-2-(4-hydroxyphenyl)ethyl]-carbamic acid tert-butyl ester.
- 1H-NMR (DMSO-d6): δ 1.31 (s 9H); 2.80 (dd, 1H); 2.83 (dd, 1H); 4.00 (m, 1H); 6.62 (d, 2H); 6.70 (d, 1H); 6.97 (br, 1H); 7.03 (d, 2H); 7.31 (br, 1H); 9.14 (s, 1H).
- Step 2:
-
- To a mixture of [(S)-1-carbamoyl-2-(4-hydroxyphenyl)ethyl]-carbamic acid tert-butyl ester (3.00 g, 10.7 mmol) and potassium carbonate (7.40 g, 53.5 mmol) in N,N-dimethylformamide (50 ml) were added subsequently chloroacetone (1.02 ml, 12.8 mmol) and tetrabutylammonium iodide (197 mg, 0.54 mmol). The reaction mixture was heated to 90° C. for 16 h and cooled to room temperature. It was diluted with water (100 ml) and acidified with a 10% solution of sodium hydrogensulphate to pH 2. Ethyl acetate (300 ml) was added. The phases were separated. The organic layer was washed with water (3×150 ml) and dried over magnesium sulphate. The solvent was removed in vacuo to give 2.65 g of {(S)-1-carbamoyl-2-[4-(2-oxopropoxy)phenyl]ethyl}carbamic acid tert-butyl ester.
- MS: m/z=359 (M+Na+)
- 1H-NMR (DMSO-d6) δ 1.30 (s, 9H); 2.10 (s, 3H); 2.70 (dd, 1H); 2.90 (dd, 1H); 3.95 (br, 1H); 4.00 (m, 1H); 4.75 (s, 2H); 6.80 (d, 2H); 7.00 (br, 1H); 7.20 (d, 2H); 7.35 (br, 1H).
- Step 3:
- Trifluoroacetic acid (50 ml) was added to a solution of {(S)-1-carbamoyl-2-[4-(2-oxopropoxy)phenyl]ethyl}carbamic acid tert-butyl ester (2.65 g, 7.88 mmol) in dichloromethane (50 ml). The reaction mixture was stirred for 1 h at room temperature. The solvent was removed in vacuo. The residue was dissolved in dichloromethane (50 ml) and the solvent was removed in vacuo. The latter procedure was repeated once. The crude product was purified by C-18 reversed phase chromatography on a HPLC, using a gradient of 13-33% acetonitrile in water in a buffer of trifluoroacetic acid (0.1%) to give 460 mg of (S)-2-amino-3-[4-(2-oxopropoxy)phenyl]propionamide.
- MS: m/z=237 (M+)
- 1H-NMR (DMSO-d6, TFA-salt) δ 2.20 (s, 3H); 2.80-3.10 (m, 2H); 3.90 (m, 1H); 4.80 (s, 2H); 6.90 (d, 2H); 7.20 (d, 2H); 7.55 (br, 1H); 7.90 (br, 1H); 8.10+ (br, 3H).
-
- A solution of (([Glu3,Leu10]GLP-2yl)leucinyl)alanine (0.50 mg, 127 pmol) in water (0.040 ml) and an 1 N aqueous solution of sodium hydroxide (0.003 ml) was added to a solution of the trifluoroacetate salt of (S)-2-amino-3-[4-(2-oxopropoxy)phenyl]propionamide (13.3 mg, 0.038 mmol) in an aqueous buffer containing 250 mM HEPES and 5 mM EDTA, which had been adjusted to pH 8 with sodium hydroxide. The solution was adjusted to pH 8 with a 1 N aqueous solution of sodium hydroxide. The solution was diluted to a final volume of 0.127 ml with an aqueous buffer containing 250 mM HEPES and 5 mM EDTA, which had been adjusted to pH 8 with sodium hydroxide. A solution of CPY in water (0.005 ml, 1 U) was added. The reaction mixture was left at room temperature for 16 h. The MS analysis showed the formation of the product with the desired mass.
- MALDI-TOF: m/z=4090.321
- MS: m/z=1365, 1024
- HPLC (Method 03-b6-1): 30.69 min.
-
- Step 1:
- (([Glu3]GLP-2yl)leucinyl)alanine
- (([Glu3]GLP-2yl)leucinyl)alanine was prepared as described for (([Glu3,Leu10]GLP-2yl)leucinyl)alanine from commercially available Fmoc-Ala-Wang resin. Following amino acid derivatives were used:
-
coupling no. amino acid derivative 1 Fmoc-Leu-OH 2 Fmoc-Asp(OtBu)-OH 3 Fmoc-Thr(tBu)-OH 4 Fmoc-Ile-OH 5 Fmoc-Lys(Boc)-OH 6 Fmoc-Thr(tBu)-OH 7 Fmoc-Gln(Trt)-OH 8 Fmoc-Ile-OH 9 Fmoc-Leu-OH 10 Fmoc-Trp(Boc)-OH 11 Fmoc-Asn(Trt)-OH 12 Fmoc-Ile-OH 13 Fmoc-Phe-OH 14 Fmoc-Asp(OtBu)-OH 15 Fmoc-Arg(Pmc)-OH 16 Fmoc-Ala-OH 17 Fmoc-Ala-OH 18 Fmoc-Leu-OH 19 Fmoc-Asn(Trt)-OH 20 Fmoc-Asp(OtBu)-OH 21 Fmoc-Leu-OH 22 Fmoc-Ile-OH 23 Fmoc-Thr(tBu)-OH 24 Fmoc-Asn(Trt)-OH 25 Fmoc-Met-OH 26 Fmoc-Glu(OtBu)-OH 27 Fmoc-Asp(OtBu)-OH 28 Fmoc-Ser(tBu)-OH 29 Fmoc-Phe-OH 30 Fmoc-Ser(tBu)-OH 31 Fmoc-Gly-OH 32 Fmoc-Glu(OtBu)-OH 33 Fmoc-Ala-OH 34 Fmoc-His(Trt)-OH - HPLC: 8.60 min (method 02-B4-4).
- MALDI-TOF: m/z=3964.17.
- Step 2:
- CPY-Reaction of (2S)-2-Amino-3-(4-(prop-2-ynyloxy)phenyl)propionamide with (([Glu3]GLP-2yl)leucinyl)alanine:
- (([Glu3]GLP-2yl)leucinyl)alanine was prepared by standard solid phase peptide synthesis on an ABI-433A Peptide Synthesizer using a FMOC-strategy, known to a person skilled in the art. A mixture (7 ml final volume) of (([Glu3]GLP-2yl)leucinyl)alanine (1 mM final concentration) and the trifluoroacetate salt of (2S)-2-amino-3-(4-(prop-2-ynyloxy)phenyl)propionamide (28 mg, 150 mM final concentration) and hydroxypropyl-beta-cyclodextrin (284 mg) in a buffer, consisting of 250 mM HEPES and 5 mM EDTA, was adjusted to pH 8, using a 1 N aqueous solution of sodium hydroxide. A solution of carboxypeptidase Y (CPY, 800 U/ml, 0.088 ml, 70 U) was added to obtain the desired final volume and concentrations. The mixture was left for 100 min at room temperature. The mixture was diluted with water to a volume of 10 ml. The product was isolated by HPLC-purification, using a C18-column and a gradient of 36-75% acetonitrile in water, which was acidified with 0.1% trifluoroacetic acid, to give (2S)-2-([Glu3]GLP-2ylleucinylamino)-3-(4-(prop-2-ynyloxy)phenyl)propionamide. Using an absorption coefficient of 1500000 at 214 nm, a yield of 9.9 mg was determined.
- MALDI-TOF: 4096 (M+)
- HPLC (system 02-b4-4): 8.97 min
- MS (electrospray): m/z=1366 (M3+), 1024 (M4+), and 819 (M5+).
-
- A 10% solution of sodium hypochlorite (0.062 ml) was added to a suspension of 3-chlorobenzaldehyde oxime (32 mg, 0.205 mmol) in water (4.2 ml). The mixture was left for 10 min at room temperature and added to a solution of (2S)-2-([Glu3]GLP-2ylleucinylamino)-3-(4-(prop-2-ynyloxy)phenyl)propionamide (8.4 mg, 0.0021 mmol) and triethylamine (0.025 ml) in water (4.7 ml). The reaction mixture was left at room temperature for 16 h. The crude product was purified on a reversed phase C18-HPLC, using a gradient of 40-80% acetonitrile in water in a 0.1% buffer of TFA. Using an absorption coefficient of 1500000 at 214 nm, a yield of 0.132 mg was determined.
- MALDI-TOF: 4244 (M+)and 4228 (M-O+)
- HPLC (method 02-b4-4): 9.41 min.
- MS (EI): m/z=1417 (M3+) and 1062 (M4+).
-
-
- At 0° C., ethyl chloroformate (1.93 ml, 20 mmol) was added to a solution of 3-(tert-butoxycarbonylaminomethyl)benzoic acid (5.0 g, 20 mmol) and triethylamine (3.33 ml, 24 mmol) in tetrahydrofuran (30 ml). The reaction mixture was stirred for 40 min at 0° C., and the formed precipitation was filtered off. The filtrate was cooled to 0° C. A 2.0 M solution of lithium borohydride in THF (25 ml, 50 mmol) was added. The reaction mixture was stirred for 16 h, while warming up to room temperature. Water was added carefully, until no gas was formed. A 10% solution of sodium hydrogensulphate (10 ml) was added. A saturated solution of sodium hydrogen carbonate (200 ml) was added. The mixture was extracted with ethyl acetate (200 and 100 ml). The combined organic layers were dried over magnesium sulphate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (80 g), using ethyl acetate/heptane 1:1 as eluent, to give 3.73 g of (3-hydroxymethylbenzyl)carbamic acid tert butylester.
- MS: m/z=260 (M+23+)
- 1H-NMR (CDCl3): δ 1.48 (s, 9H); 4.30 (br, 2H); 4.70 (s, 2H); 4.85 (br, 1H); 7.15-7.35 (m, 5H).
-
- Trifluoroacetic acid (5 ml) was added to a solution of (3-hydroxymethylbenzyl)carbamic acid tert butylester (1.70 g, 7.17 mmol) in dichloromethane (5 ml). The reaction mixture was stirred for 40 min. The solvent was removed in vacuo. The residue was dissolved in dichloromethane (40 ml). The solvent was removed in vacuo. The latter procedure was repeated twice. The residue was dissolved in water (50 ml) and an 1 N aqueous solution of sodium hydroxide (100 ml). It was washed with tert-butyl methyl ether (3×100 ml). It was saturated with sodium chloride and extracted with dichloromethane (3×75 ml). The combined dichloromethane-phases were dried over magnesium sulphate. The solvent was removed in vacuo to give 328 mg of crude (3-(aminomethyl)phenyl)methanol, which was used for the further steps without purification.
- 1H-NMR (DMSO-d6): δ 3.30 (br, 2H); 3.70 (s, 2H); 4.45 (s, 2H); 5.15 (br, 1H); 7.10-7.30 (m, 4H).
-
- At 0° C., 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (451 mg, 2.35 mmol) was added to a solution of mono-tert-butyl succinate (410 mg, 2.35 mmol) and 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazin (384 mg, 2.35 mmol) in a mixture of N,N-dimethylformamide (5 ml) and dichloromethane (5 ml). The reaction mixture was stirred for 25 min at 0° C. A solution of crude (3-(aminomethyl)phenyl)methanol (340 mg, 2.48 mmol) in N,N-dimethylformamide (5 ml) and ethyldiisopropylamine (0.40 ml, 2.48 mmol) were added successively. The reaction mixture was stirred for 16 h, while it was slowly warming up to room temperature. It was diluted with ethyl acetate (150 ml) and washed with a 10% aqueous solution of sodium hydrogensulphate (100 ml). The aqueous phase was extracted with ethyl acetate (50 ml). The combined organic layers were washed with a saturated aqueous solution of sodium hydrogencarbonate (150 ml) and dried over magnesium sulphate. The solvent was removed in vacuo. The crude product was purified by flash chromatography on silica (60 g), using a mixture of ethyl acetate and heptane (2:1) as eluent to give 372 mg of N-(3-(hydroxymethyl)benzyl)succinamic acid tert-butyl ester.
- MS: m/z=316 (M+23+)
- 1H-NMR (CDCl3): δ 1.45 (s, 9H); 2.45 (t, 2H); 2.60 (t, 2H); 4.45 (d, 2H); 4.70 (s, 2H); 6.15 (br, 1H); 7.15-7.35 (m, 5H).
-
- At −78° C., oxalyl chloride (0.142 ml, 1.63 mmol) was added dropwise to a solution of dimethyl sulphoxide (0.232 ml. 3.26 mmol) in dichloromethane (5 ml). The reaction mixture was stirred for 10 min at −78° C. A solution of N-(3-(hydroxymethyl)benzyl)succinamic acid tert-butyl ester (372 mg, 1.55 mmol) in dichloromethane (5 ml) was added. The reaction mixture was stirred at −78° C. for 10 min. Triethylamine (1.08 ml, 7.77 mmol) was added. The reaction mixture was stirred at −78° C. for 5 min and then warmed to room temperature. It was stirred at room temperature for 40 min and diluted with ethyl acetate (100 ml). It was washed with a 10% aqueous solution of sodium hydrogensulphate (100 ml). The aqueous phase was extracted with ethyl acetate (2×50 ml). The combined organic layers were washed with a saturated aqueous solution of sodium hydrogencarbonate (150 ml) and dried over magnesium sulphate. The solvent was removed to give 312 mg of crude N-(3-formylbenzyl)succinamic acid tert-butyl ester, which was used for the next step without further purification.
- MS: m/z=314 (M+23+)
- 1H-NMR (CDCl3): δ 1.35 (s, 9H); 2.45 (t, 2H); 2.55 (t, 2H); 4.45 (d, 2H); 6.20 (br, 1H); 7.44 (t, 1H); 7.50 (d, 1H); 7.75 (m, 2H); 9.95 (s, 1H).
-
- A 3.2 M aqueous solution of sodium hydroxide (0.5 ml, 1.60 mmol) was added to a solution of N-(3-formylbenzyl)succinamic acid tert-butyl ester (312 mg, 1.07 mmol) and hydroxylamine hydrochloride (89 mg, 1.29 mmol) in ethanol (2.5 ml) and water (0.5 ml). The reaction mixture was stirred at room temperature for 3 days. A 10% aqueous solution of sodium hydrogensulphate (20 ml) and water (50 ml) were added. The mixture was extracted with ethyl acetate (3×50 ml). The combined organic layers were dried over magnesium sulphate. The solvent was removed in vacuo to give 249 mg of crude N-[3-((hydroxyimino)methyl)benzyl]succinamic acid tert-butyl ester, which was used without further purification in the next step.
- MS: m/z=329 (M+23+), 307 (M+1+)
- 1H-NMR (DMSO-d6): δ 1.35 (s, 9H); 2.40 (m, 4H); 4.30 (d, 2H); 7.25 (d, 1H); 7.35 (t, 1H); 7.50 (m, 2H); 8.10 (s, 1H); 8.40 (t, 1H); 11.20 (s, 1H).
-
- Trifluoroacetic acid (7 ml) was added to a solution of crude N-[3-((hydroxyimino)methyl)benzyl]succinamic acid tert-butyl ester (249 mg, 0.81 mmol) in dichloromethane (7 ml). The reaction mixture was stirred for 55 min at room temperature. The solvent was removed in vacuo. The residue was redissolved in dichloromethane (50 ml). The solvent was removed in vacuo. The latter procedure was repeated twice to give 294 mg of crude N-[3-(hydroxyiminomethyl)benzyl]succinamic acid, which was used in the next step without further purification.
- MS: m/z=273 (M+23+), 251 (M+1+)
- 1H-NMR (DMSO-d6): δ 2.45 (A2B2, 4H); 4.30 (d, 2H); 7.20-7.50 (m, 4H); 8.10 (s, 1H); 8.40 (t, 1H); 11.20 (br, 1H).
- A 10% aqueous solution of sodium hypochlorite (0.0015 ml, 2600 pmol) was added to a solution of crude N-[3-(hydroxyiminomethyl)benzyl]succinamic acid (1.29 mg, 5150 pmol) in a mixture of water (0.11 ml) and a saturated aqueous solution of sodium hydrogencarbonate (0.01 ml). The reaction mixture was left for 10 min at room temperature. A solution of (2S)-2-([Glu3,Leu10]GLP-2-ylleucinylamino)-3-(4-(prop-2ynyloxy)phenyl)propionamide (0.210 mg, 51 pmol) and triethylamine (0.0006 ml) in water (0.11 ml) was added. The reaction mixture was shaken at room temperature. After 1 h, the MALDI-TOF showed small amounts of m/z=4323, corresponding to the mass of 3-(3-(3-((4-((S)-2-carbamoyl-3-([Glu3,Leu10]GLP-2ylleucinylamino)ethyl)phenoxyl)methyl)isoxazol-3-yl)benzylcarbamoyl)propionic acid, along with majour amounts of m/z=4076, corresponding to the mass of (2S)-2-([Glu3,Leu10]GLP-2ylleucinylamino)-3-(4-(prop-2ynyloxy)phenyl)propionamide. After 2 h, the LC-MS electrospray showed masses of m/z=1442, 1082, and 866, corresponding to (M3+), (M4+) and (M5+) respectively of 3-(3-(3-((4-((S)-2-carbamoyl-3-([Glu3,Leu10]GLP-2ylleucinylamino)ethyl)phenoxyl)methyl)isoxazol-3-yl)benzylcarbamoyl)propionic acid along with masses of m/z=1359, 1020, and 816, corresponding to (M3+), (M4+) and (M5+) respectively of (2S)-2-([Glu3,Leu10]GLP-2ylleucinylamino)-3-(4-(prop-2ynyloxy)phenyl)propionamide. After 8 h, the LC-MS electrospray showed small amounts of masses of m/z=1442 and 1082, corresponding to (M3+) and (M4+) respectively of 3-(3-(3-((4-((S)-2-carbamoyl-3-([Glu3,Leu10]GLP-2ylleucinylamino)ethyl)phenoxyl)methyl)isoxazol-3-yl)benzylcarbamoyl)propionic acid along with major amounts of masses of m/z=1360 and 1020, corresponding to (M3+) and (M4+) respectively of (2S)-2-([Glu3,Leu10]GLP-2ylleucinylamino)-3-(4-(prop-2ynyloxy)phenyl)propionamide.
-
-
- Sodium azide (4.66 g, 72 mmol) and tetrabutylammonium iodide (66 mg, 0.18 mmol) were successively added to a solution of methyl 11-bromoundecanoate (commercially available at Aldrich, 5.00 g, 17.9 mmol) in N,N-dimethylformamide (50 ml). The reaction mixture was heated to 60° C. for 16 h and cooled to room temperature. It was diluted with water (200 ml) and extracted with ethyl acetate (200 ml). The aqueous phase was washed with water (2×200 ml). The organic phase was dried over sodium sulphate. The solvent was removed in vacuo to give 4.28 g of methyl 11-azidoundecanoate.
- MS: m/z=264 (M+23+), 214 (M−N2 +)
-
- Crunched sodium hydroxide (709 mg, 17.7 mmol) was added to a solution of methyl 11-azidoundecanoate (4.03 g, 17.7 mmol) in methanol (75 ml). The reaction mixture was stirred for 16 h at room temperature. Water (50 ml) was added. The mixture was acidified to pH 2 by addition of a 10% aqueous solution of sodium hydrogensulphate and was extracted with ethyl acetate (3×50 ml). The combined organic layers were dried over sodium sulphate. The solvent was removed in vacuo. The residue was dissolved in methanol (50 ml). Crunched sodium hydroxide (1.42 g, 35.4 mmol) was added. The reaction mixture was stirred at room temperature for 16 h. Water (50 ml) was added. The mixture was acidified to pH 2 by addition of a 10% aqueous solution of sodium hydrogensulphate and was extracted with ethyl acetate (3×50 ml). The combined organic layers were dried over sodium sulphate. The solvent was removed in vacuo to give 3.13 g of 11-azidoundecanoic acid.
- MS: m/z=250 (M+23+), 200 (M−N2 +).
- 1H-NMR (CDCl3): δ 1.30 (m, 12H); 1.65 (m, 4H); 2.40 (t, 2H); 3.20 (t, 2H); 9.00-10.80 (br, 1H).
- A solution of 11-azidoundecanoic acid (0.116 mg, 510 nmol) in acetonitrile (0.055 ml) was added to a solution of (2S)-2-([Glu3,Leu10]GLP-2ylleucinylamino)-3-(4-(prop-2ynyloxy)phenyl)propionamide (0.210 mg, 51 nmol) and 2,6-lutidine (0.0012 ml, 10200 nmol) in water (0.105 ml). A solution of copper(1) iodide (0.001 mg, 5 nmol) in acetonitrile (0.050 ml) was added. The reaction mixture was kept at room temperature. After 4 h, a solution of copper(1) iodide (0.098 mg, 500 nmol) in acetonitrile was added. The reaction mixture was kept at room temperature for 16 h. A 2.5% solution of ammonia in water (0.200 ml) was added. The reaction mixture was kept at room temperature and room atmosphere for 4 h. The masses found by MS and MALDI-TOF were in correspondence with the expectations for the mass found for 11-(4-(4-((2S)-2-Carbamoyl-2-(([Glu3,Leu10]GLP-2ylleucinylamino)ethyl)pheoxymethyl)-1,2,3-triazolyl)undecanoic acid and 11-(5-(4-((2S)-2-Carbamoyl-2-(([Glu3, Leu10]GLP-2ylleucinylamino)ethyl)pheoxymethyl)-1,2,3-triazolyl)undecanoic acid.
- HPLC: 9.43 min (method 02-B4-4).
- MS: m/z=1435, 1077.
- MALDI-TOF: 4303.
-
- 2,6-Lutidine was added to a mixture of (2S)-2-([Glu3]GLP-2ylleucinylamino)-3-(4-(prop-2-ynyloxy)phenyl)propionamide (1.0 mg, 244 pmol) in water (0.5 ml) to give a clear solution. A solution of 11-azidoundecanoic acid (0.554 mg, 0.0025 mmol) in acetonitrile (0.25 ml) and a solution of copper(I) iodide (0.467 mg, 0.0025 mmol) in acetonitrile (0.25 ml) were added successively. The reaction mixture was left for 16 h at room temperature. It was fractionated on a reversed phase C18 column on a HPLC, using a gradient of 35-75% acetonitrile in water in a buffer of 0.1% trifluoroacetic acid to give approx. 0.3 mg of 11-(4-(4-((S)-2-carbamoyl-2-([Glu3]GLP-2ylleucinylamino))phenoxymethyl)-1,2,3-triazolyl)undecanoic acid or 11-(5-(4-((S)-2-carbamoyl-2-([Glu3]GLP-2ylleucinylamino))phenoxymethyl)-1H-1,2,3-triazol-1-yl)undecanoic acid or a mixture thereof.
- HPLC: 9.27 min (method 02-B4-4).
- MS: m/z=1441.8, 1081.3, 865.2, 721.2, 618.9.
- MALDI-TOF: m/z=4317
-
-
- N,N,N′,N′-Tetramethyl-O-(N-succinimidyl)uranium tetrafluoroborate (1.32 g, 4.40 mmol) was added to a solution of 11-azidoundecanoic acid (1.00 g, 4.40 mmol) and triethylamine (0.61 ml, 4.40 mmol) in N,N-dimethylformamide (10 ml). The reaction mixture was stirred for 2 h at room temperature. It was diluted with ethyl acetate (50 ml) and washed with water (3×50 ml). The organic phase was dried over sodium sulphate. The solvent was removed in vacuo to give 1.40 g of crude 11-azidoundecanoic acid 2,5-dioxopyrroldin-1-yl ester, which was used in the next steps without further purification.
- MS: m/z=347 [M+Na+]
- 1H-NMR (CDCl3): δ 1.35 (m, 12H); 1.60 (quintett, 2H); 1.75 (quintett, 2H); 2.60 (t, 2H); 1.85 (m, 4H); 3.25 (t, 2H).
- 11-AzidoundecanoylaminomPEG20kDa
- A solution of 11-azidoundecanoic acid 2,5-dioxopyrroldin-1-yl ester (227 mg, 0.7 mmol) was added to a solution of commercially available mPEG20000DA-amine (Nektar 2M2U0P01, 5.00 g, 0.25 mmol) and triethylamine (0.174 ml, 1.25 mmol) in dichloromethane (50 ml). The reaction mixture was stirred at room temperature for 16 h. Ether (800 ml) was added. The formed precipitation was isolated by filtration and washed with ether (2×100 ml). It was dried in vacuo to give 4.58 g of 11-azidoundecanoylaminomPEG20kDa.
- A solution of ascorbic acid (1.72 mg, 9766 nmol) and 2,6-lutidine (0.0024 ml) in water (0.10 ml) was added to a solution of copper(II) sulphate pentahydrate (0.49 mg, 1954 nmol) in water (0.1 ml). This solution was kept for 5 min at room temperature. A part of the resulting mixture (0.025 ml) was added to a solution of (S)-2-([Glu3]GLP-2ylleucinyl)-3-(4-propargyloxyphenyl)propionamide (0.1 mg, 24 nmol), 2,6-lutidine (0.0012 ml) and 11-azidoundecanoylaminomPEG20kDa (0.049 mg, 240 nmol) in water (0.075 ml). The reaction mixture was kept at room temperature. After 24 h, a SDS-gel electrophoreses applying a 10% Bis-Tirs Gel of NuPAGE (Invitrogen) and a SilverXpress® silver staining method, showed the formation of high-molecular peptide, in accordance with the expectations for 2-([Glu3]GLP-2ylleucinyl)-3-(4-((1-((N-(mPeg20kDayl)carbamoyl)decanyl)-1H-1,2,3-tetrazol-4-yl)methoxy)phenyl)propionamide and 2-([Glu3]GLP-2ylleucinyl)-3-(4-((1-((N-(mPeg20kDayl)carbamoyl)decanyl)-1H-1,2,3-tetrazol-5-yl)methoxy)phenyl)propionamide.
-
- [Leu37]GLP-1(7-37)ylalanine was prepared as in example 9
- CPY-catalyzed transpeptidation of 4-acetyl-N-((5S)-5-amino-5-carbamoylpentyl)benzamide with [Leu37]GLP-1(7-37)ylalanine:
- To a mixture of 4-acetyl-N-((5S)-5-amino-5-carbamoylpentyl)benzamide (final concentration 100 mM) and hydroxypropyl-β-cyclodextrin (4% w/v final concentration) in solution in HEPES buffer 250 mM pH8 containing 5 mM EDTA was added [Leu37]GLP-1(7-37)ylalanine (1 mM final concentration) in solution in HEPES buffer 250 mM pH8 containing 5 mM EDTA. The pH was adjusted to 8.1 by addition of diisopropylethylamine. The reaction was started by addition of the enzyme in solution in water (10 U/ml final concentration). The reaction is monitored by HPLC.
- 1.5 ml/min
5 to 45% B over 20 min
detection at 214 nm - After 6 h30 at 30° C., the reaction mixture content was about 22% of the remaining starting compound [Leu37]GLP-1(7-37)ylalanine (retention time: 18.1 min), 70% of the transpeptidation product (retention time: 18.3 min) and 8% of the hydrolysis product [Leu37]GLP-1(7-37) (retention time: 18.4 min).
- MALDI-TOF: m/z=3684 (S)-5-[Leu37]GLP-1(7-37)ylamino)-5-carbamoylpentyl) 4-acetyl benzamide), 3482 ([Leu37]GLP-1(7-37)ylalanine), 3411 ([Leu37]GLP-1(7-37)) and 1162 and 1742 ([Leu37]GLP-1(7-37)ylalanine).
- MS (electrospray): m/z=1844 and 1229 ((S)-5-[Leu37]GLP-1(7-37)ylamino)-5-carbamoylpentyl) 4-acetyl benzamide), 1139 ad 1702 ([Leu37]GLP-1(7-37)) and 1162 and 1742 ([Leu37]GLP-1(7-37)ylalanine).
-
- To a solution of N—((S)-5-([Leu37]GLP-1(7-37)ylamino)-5-carbamoylpentyl)-4-acetyl benzamide in acetate buffer 50 mM pH4 (final concentration 0.3 mM) was added 1-[4-(2-(aminooxy)ethyl)piperidin-1-yl]hexadecan-1-one (final concentration 3 mM) in solution in acetonitrile (final acetonitrile concentration: 18% v/v). The reaction was run at 30° C. and followed by HPLC.
- 10% B for 5 min, then 10 to 91% B over 27 min
1 ml/min - Retention time of N—((S)-5-([Leu37]GLP-1(7-37)ylamino)-5-carbamoylpentyl)-4-acetyl benzamide: 18.4 min, retention times of products: 26.5 and 27.1 min.
- More than 90% yield was obtained after 4 h reaction time.
- MS (electrospray): m/z=1351.4 (calc: 1350.9)
- MALDI-TOF: m/z=4048 (calc: 4049.8).
- All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference in their entirety and to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein (to the maximum extent permitted by law).
- All headings and sub-headings are used herein for convenience only and should not be construed as limiting the invention in any way.
- The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
- The citation and incorporation of patent documents herein is done for convenience only and does not reflect any view of the validity, patentability, and/or enforceability of such patent documents.
- This invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law.
Claims (32)
1. A method for preparing a conjugated peptide, said method comprising the steps of
i) reacting in one or more steps a peptide with a first compound bearing one or more functional groups, which are not accessible in any of the amino acids residues constituting said peptide, in the presence of an enzyme capable of catalysing the incorporation of said first compound into the C-terminal of said peptide to form a transacylated peptide, and
ii) reacting in one or more steps said transacylated peptide with a second compound comprising one or more functional groups, wherein said functional group(s) do not react with functional groups accessible in the amino acid residues constituting said peptide, and wherein said functional group(s) in said second compound is capable of reacting with said functional group(s) in said first compound so that one or more covalent bond between said transacylated peptide and said second compound is formed.
2. A method according to claim 1 , wherein a peptide P is reacted in one or more steps with a first compound, which is an α-amino acid amide represented by the formula
said transacylated peptide being further reacted in one or more steps with a second compound of the formula
Y-E-Z
Y-E-Z
to form a conjugated peptide of the formula
wherein R represents a linker or a bond;
P′ represents a peptide formed by removing the C-terminal amino acid from the peptide P;
X represents a radical comprising one or more functional group not accessible in the amino acid residues constituting the peptide P′;
Y represents a radical comprising one or more functional group which functional group(s) do not react with functional groups accessible in the amino acid residues constituting the peptide P′, and which functional group(s) react with said functional group(s) present in X;
E represents a linker or a bond;
wherein A represents the moiety formed by the reaction between the functional groups comprised in X and Y; and
Z comprises the moiety to be conjugated to the peptide, wherein said moiety decrease the clearance of compounds of formula [a] in comparison with the clearance of P.
3. The method according to claim 2 , wherein A represents oxime, hydrazone, phenylhydrazone, semicarbazone or triazole moieties.
4. The method according to claim 2 , wherein the functional group present in X is selected from the group consisting of: keto-, aldehyde-, —NH—NH2, —O—C(O)—NH—NH2, —NH—C(O)—NH—NH2, —NH—C(S)—NH—NH2, —NHC(O)—NH—NH—C(O)—NH—NH2, —NH—NH—C(O)—NH—NH2, —NH—NH—C(S)—NH—NH2, —NH—C(O)—C6H4—NH—NH2, —C(O)—NH—NH2, —O—NH2, —C(O)—O—NH2, —NH—C(O)—O—NH2, —NH—C(S)—O—NH2, alkyne, nitril-oxide and azide.
5. The method according to claim 2 , wherein the functional group present in Y is selected from the group consisting of: keto-, aldehyde-, —NH—NH2, —O—C(O)—NH—NH2, —NH—C(O)—NH—NH2, —NH—C(S)—NH—NH2, —NHC(O)—NH—NH—C(O)—NH—NH2, —NH—NH—C(O)—NH—NH2, —NH—NH—C(S)—NH—NH2, —NH—C(O)—C6H4—NH—NH2, —C(O)—NH—NH2, —O—NH2, —C(O)—O—NH2, —NH—C(O)—O—NH2, —NH—C(S)—O—NH2, alkyne, nitril-oxide and azide.
6. The method according to claim 2 , wherein X is selected from the group consisting of keto- and aldehyde-derivatives, and Y is selected from the group consisting of —NH—NH2, —O—C(O)—NH—NH2, —NH—C(O)—NH—NH2, —NH—C(S)—NH—NH2, —NHC(O)—NH—NH—C(O)—NH—NH2, —NH—NH—C(O)—NH—NH2, —NH—NH—C(S)—NH—NH2, —NH—C(O)—C6H4—NH—NH2, —C(O)—NH—NH2, —O—NH2, —C(O)—O—NH2, —NH—C(O)—O—NH2, and —NH—C(S)—O—NH2.
7. The method according to claim 2 , wherein X represents alkyne, and Y represents azide or nitril-oxide.
8. The method according to claim 2 , wherein X represents azide or nitril-oxide, and Y represents azide.
9. The method according to claim 2 , wherein R and E each independently represents a bi-radical of straight, branched and/or cyclic C1-10alkane, C2-10alkene, C2-10alkyne, C1-10heteroalkane, C2-10heteroalkene, or C2-10heteroalkyne, wherein one or more homocyclic aromatic compound bi-radical or heterocyclic compound biradical may be inserted.
10. The method according to claim 2 , wherein said α-amino acid amide represents a compound selected from the group consisting of: 2-amino-3-oxo-butyramide, 2-amino-6-(4-oxo-pentanoylamino)-hexanoic acid amide, 2-amino-3-(2-oxo-2-phenyl-ethylsulfanyl)-propionamide, 2-amino-5-oxo-hexanoic acid amide, 2-amino-3-oxo-propionamide, 2-amino-6-(4-acetylbenzoylamino)hexanoic acid amide, 2-amino-3-oxopropionic acid amide, (2S)-Amino-3-[4-(2-oxopropoxy)phenyl]propionamide, (2S)-Amino-3-[4-(2-oxobutoxy)phenyl]propionamide, (2S)-Amino-3-[4-(2-oxopentoxy)phenyl]propionamide, (2S)-Amino-3-[4-(4-oxopentoxy)phenyl]propionamide, (2S)-2-Amino-6-(4-oxo-4-phenylbutyrylamino)hexanoic acid amide, 4-Acetyl-N-((5S)-5-amino-5-carbamoylpentyl)benzamide, (2S)-2-Amino-6-(4-oxo-4-(4-chlorophenylbutyrylamino)hexanoic acid amide, 3-Acetyl-N-((5S)-5-amino-5-carbamoylpentyl)benzamide, 2-Acetyl-N-((5S)-5-amino-5-carbamoylpentyl)benzamide, (2S)-2-amino-3-(4-(prop-2-ynyloxy)phenyl)propionamide, and (S)-2-aminopent-4-ynoicacid amide and S-phenylacylcysteine amide.
11. A method according to claim 2 , wherein Z comprises one or more polyethylene glycol or methoxy polyethylene glycol radicals and amino derivatives thereof; straight, branched and/or cyclic C1-22alkyl, C2-22alkenyl, C2-22alkynyl, C1-22heteroalkyl, C2-22heteroalkenyl, C2-22heteroalkynyl, wherein one or more homocyclic aromatic compound biradical or heterocyclic compound biradical may be inserted, and wherein said C1-C22 or C2-C22 radicals may optionally be substituted with one or more substituents selected from hydroxyl, halogen, carboxyl and aryl, wherein said aryl may optionally be further substituted by one or more substituents selected from hydroxyl, halogen, and carboxyl; steroid radicals; lipid radicals; polysaccharide radicals; dextran radicals; polyamide radicals; polyamino acid radicals; PVP radicals; PVA radicals; poly(1-3-dioxalane) radicals; poly(1,3,6-trioxane) radicals; ethylene/maleic anhydride polymer radicals; Cibacron dye stuff radicals; and Cibacron Blue 3GA radical.
12. A method according to claim 11 , wherein Z comprises one or more polyethylene glycol or methoxy polyethylene glycol radical with a molecular weight of about 10, 20, 30 or 40 kDa.
13. A method according to claim 11 , wherein Z comprises one or more C10-20alkyl, optionally substituted with a carboxy group.
14. A method according to claim 11 , wherein Z represents a undecanoic acid radical.
16. The method according to claim 11 , wherein Z comprises one or more moieties that bind to albumin.
17. The method according to claim 1 , wherein the enzyme is Carboxypeptidase Y.
18. The method according to claim 2 , wherein P represents a peptide selected from the group consisting of: insulin, GLP-1, GLP-2, growth hormone, cytokines, TFF, melanocortin receptor modifiers and Factor VII.
19. The method according to claim 2 , which further comprises the step of formulating said conjugated peptide in a pharmaceutical composition.
21. A peptide according to claim 20 selected from the group consisting of:
Lysε(4-((2-(1-(mPEGcarbonyl)piperidin-4yl)ethoxy)imino)pentanoyl) 192)hGH(1-192) amide, in which mPEG has a molecular weight of 20 kDa;
(Lysε(4-((3-(palmitoylamino)propoxy)imino)pentanoyl)192)hGH(1-192) amide;
(Lysε(4-((3-((2S)-2,6-mPEGcarbonylamino)hexanoylamino)propoxy)imino)pentanoyl)34)GLP-2(1-34) amide, in which mPEG has a molecular weight of 20 kDa;
(Lysε(4-(1-(2-(3-(mPEG)propanoylamino)hydrazino)ethyl)benzoyl)192)hGH(1-92) amide, in which mPEG has a molecular weight of 10 kDa;
(S)-3-(4-((3-(3-Chlorophenyl)isoxazol-5-yl)methoxy)phenyl)-2-([Glu3,Leu10]GLP-2ylleucinylamino)propionic amide;
(S)-3-(4-((3-(3-Chlorophenyl)isoxazol-5-yl)methoxy)phenyl)-2-([Glu3]GLP-2ylleucinylamino)propionic amide;
3-(3-(3-((4-((S)-2-Carbamoyl-3-([Glu3,Leu10]GLP-2ylleucinylamino)ethyl)phenoxyl)methyl)isoxazol-3-yl)benzylcarbamoyl)propionic acid;
11-(4-(4-((2S)-2-Carbamoyl-2-(([Glu3,Leu10]GLP-2ylleucinylamino)ethyl)pheoxymethyl)-1,2,3-triazolyl)undecanoic acid;
11-(5-(4-((2S)-2-Carbamoyl-2-(([Glu3,Leu10]GLP-2ylleucinylamino)ethyl)pheoxymethyl)-1,2,3-triazolyl)undecanoic acid 1-(4-(4-((S)-2-carbamoyl-2-([Glu3]GLP-2ylleucinylamino))phenoxymethyl)-1H-1,2,3-triazol-1-yl)undecanoic acid;
11-(5-(4-((S)-2-carbamoyl-2-([Glu3]GLP-2ylleucinylamino))phenoxymethyl)-1H-1,2,3-triazol-1-yl)undecanoic acid;
2-([Glu3]GLP-2ylleucinyl)-3-(4-((1-((N-(mPeg20kDayl)carbamoyl)decanyl)-1H-1,2,3-tetrazol-4-yl)methoxy)phenyl)propionamide; and
2-([Glu3]GLP-2ylleucinyl)-3-(4-((1-((N-(mPeg20kDayl)carbamoyl)decanyl)-1H-1,2,3-tetrazol-5-yl)methoxy)phenyl)propionamide.
22. A pharmaceutical composition comprising one or more peptides according to claim 21 .
23. A compound according for formula I
wherein A and E independently represent C1-6alkylene, C2-6alkenylene, C2-6alkynylene or arylene, all of which may optionally be substituted with one or more substituents selected from halogen, amino, cyano and nitro;
B and D represents —C(O)— or —NH— with the proviso that when B represents —C(O)— then D must represent —NH—, and when B represents —NH— then D must represent —C(O)—;
and F represents hydrogen or C1-6alkylene, C2-6alkenylene, C2-6alkynylene or arylene, all of which may optionally be substituted with one or more substituents selected from halogen, amino, cyano and nitro.
24. A compound according to claim 23 selected from the group consisting of:
(2S)-2-Amino-6-(4-oxo-4-phenylbutyrylamino)hexanoic acid amide,
4-Acetyl-N-((5S)-5-amino-5-carbamoylpentyl)benzamide,
(2S)-2-Amino-6-(4-oxo-4-(4-chlorophenylbutyrylamino)hexanoic acid amide,
3-Acetyl-N-((5S)-5-amino-5-carbamoylpentyl)benzamide, and
2-Acetyl-N-((5S)-5-amino-5-carbamoylpentyl)benzamide.
26. A compound according to formula 25 selected from the group consisting of:
(2S)-Amino-3-[4-(2-oxopropoxy)phenyl]propionamide,
(2S)-Amino-3-[4-(2-oxobutoxy)phenyl]propionamide,
(2S)-Amino-3-[4-(2-oxopentoxy)phenyl]propionamide, and
(2S)-Amino-3-[4-(4-oxopentoxy)phenyl]propionamide.
29. The compound according to claim 28 , which is (S)-2-amino-3-(4-(propargyloxy)phenyl)propionyl amide.
30. A conjugated peptide obtainable by a method according to claim 2 .
31. A method for conjugating a first peptide, wherein said peptide comprises an alkyne group, the method comprising reacting said first peptide with a second compound, wherein said second compound comprises a nitri-oxide to form a conjugated peptide, wherein said first peptide is bonded to said second compound via a isoxazoline moiety.
32. A method for conjugating a first peptide, wherein said peptide comprises an nitril-oxide group, the method comprising reacting said first peptide with a second compound, wherein said second compound comprises an alkyne to form a conjugated peptide, wherein said first peptide is bonded to said second compound via a isoxazoline moiety.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/406,267 US20090253166A1 (en) | 2003-10-10 | 2009-03-18 | Conjugation of Peptides |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200301496 | 2003-10-10 | ||
DKPA200301496 | 2003-10-10 | ||
US51089203P | 2003-10-14 | 2003-10-14 | |
PCT/DK2004/000685 WO2005035553A2 (en) | 2003-10-10 | 2004-10-08 | Conjugation of peptides |
US11/395,784 US7524813B2 (en) | 2003-10-10 | 2006-03-31 | Selectively conjugated peptides and methods of making the same |
US12/406,267 US20090253166A1 (en) | 2003-10-10 | 2009-03-18 | Conjugation of Peptides |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/395,784 Continuation US7524813B2 (en) | 2003-10-10 | 2006-03-31 | Selectively conjugated peptides and methods of making the same |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090253166A1 true US20090253166A1 (en) | 2009-10-08 |
Family
ID=46045529
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/395,784 Expired - Fee Related US7524813B2 (en) | 2003-10-10 | 2006-03-31 | Selectively conjugated peptides and methods of making the same |
US12/406,267 Abandoned US20090253166A1 (en) | 2003-10-10 | 2009-03-18 | Conjugation of Peptides |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/395,784 Expired - Fee Related US7524813B2 (en) | 2003-10-10 | 2006-03-31 | Selectively conjugated peptides and methods of making the same |
Country Status (1)
Country | Link |
---|---|
US (2) | US7524813B2 (en) |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080187955A1 (en) * | 2001-10-10 | 2008-08-07 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US20080300173A1 (en) * | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
US20100015684A1 (en) * | 2001-10-10 | 2010-01-21 | Neose Technologies, Inc. | Factor vii: remodeling and glycoconjugation of factor vii |
US20100261872A1 (en) * | 2001-10-10 | 2010-10-14 | Neose Technologies, Inc. | Factor VIII: remodeling and glycoconjugation of factor VIII |
US7932364B2 (en) | 2003-05-09 | 2011-04-26 | Novo Nordisk A/S | Compositions and methods for the preparation of human growth hormone glycosylation mutants |
US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
US8247381B2 (en) | 2003-03-14 | 2012-08-21 | Biogenerix Ag | Branched water-soluble polymers and their conjugates |
US8268967B2 (en) | 2004-09-10 | 2012-09-18 | Novo Nordisk A/S | Glycopegylated interferon α |
US8361961B2 (en) | 2004-01-08 | 2013-01-29 | Biogenerix Ag | O-linked glycosylation of peptides |
US8404809B2 (en) | 2005-05-25 | 2013-03-26 | Novo Nordisk A/S | Glycopegylated factor IX |
US8632770B2 (en) | 2003-12-03 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated factor IX |
US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US8716239B2 (en) | 2001-10-10 | 2014-05-06 | Novo Nordisk A/S | Granulocyte colony stimulating factor: remodeling and glycoconjugation G-CSF |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
US8841439B2 (en) | 2005-11-03 | 2014-09-23 | Novo Nordisk A/S | Nucleotide sugar purification using membranes |
US8853161B2 (en) | 2003-04-09 | 2014-10-07 | Novo Nordisk A/S | Glycopegylation methods and proteins/peptides produced by the methods |
US8911967B2 (en) | 2005-08-19 | 2014-12-16 | Novo Nordisk A/S | One pot desialylation and glycopegylation of therapeutic peptides |
US8916360B2 (en) | 2003-11-24 | 2014-12-23 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
US9029331B2 (en) | 2005-01-10 | 2015-05-12 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
US9050304B2 (en) | 2007-04-03 | 2015-06-09 | Ratiopharm Gmbh | Methods of treatment using glycopegylated G-CSF |
US9150848B2 (en) | 2008-02-27 | 2015-10-06 | Novo Nordisk A/S | Conjugated factor VIII molecules |
US9187546B2 (en) | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
US9187532B2 (en) | 2006-07-21 | 2015-11-17 | Novo Nordisk A/S | Glycosylation of peptides via O-linked glycosylation sequences |
US9200049B2 (en) | 2004-10-29 | 2015-12-01 | Novo Nordisk A/S | Remodeling and glycopegylation of fibroblast growth factor (FGF) |
US9493499B2 (en) | 2007-06-12 | 2016-11-15 | Novo Nordisk A/S | Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography |
WO2017127567A1 (en) * | 2016-01-19 | 2017-07-27 | Genebiologics, Llc | Production of arginine-rich proteins and use as a fertilizer and germination enhancer |
US10875826B2 (en) | 2006-09-07 | 2020-12-29 | Emisphere Technologies, Inc. | Process for the manufacture of SNAC (salcaprozate sodium) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
US20070105770A1 (en) * | 2004-01-21 | 2007-05-10 | Novo Nordisk A/S | Transglutaminase mediated conjugation of peptides |
WO2006020372A2 (en) * | 2004-07-23 | 2006-02-23 | Neose Technologies, Inc. | Enzymatic modification of glycopeptides |
US20090176967A1 (en) * | 2004-08-02 | 2009-07-09 | Novo Nordisk Healthcare A/G | Conjugation of FVII |
US20110003744A1 (en) * | 2005-05-25 | 2011-01-06 | Novo Nordisk A/S | Glycopegylated Erythropoietin Formulations |
KR100700869B1 (en) * | 2005-06-03 | 2007-03-29 | 재단법인 목암생명공학연구소 | The stabilized parathyroid hormone composition comprising parathyroid hormone buffer and stabilizing agent |
KR20080038391A (en) * | 2005-08-30 | 2008-05-06 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Liquid formulations of pegylated growth hormone |
US8940871B2 (en) | 2006-03-20 | 2015-01-27 | The Regents Of The University Of California | Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting |
AU2007271150A1 (en) * | 2006-07-07 | 2008-01-10 | Novo Nordisk Health Care Ag | New protein conjugates and methods for their preparation |
CN101600448B (en) * | 2006-10-04 | 2015-11-25 | 诺和诺德公司 | The sugar of the PEGization that glycerol connects and glycopeptide |
WO2008151258A2 (en) * | 2007-06-04 | 2008-12-11 | Neose Technologies, Inc. | O-linked glycosylation using n-acetylglucosaminyl transferases |
CA2695384A1 (en) | 2007-07-31 | 2009-02-05 | Burnham Institute For Medical Research | Bi-dentate compounds as kinase inhibitors |
US8431529B2 (en) * | 2007-07-31 | 2013-04-30 | Sanford-Burnham Medical Research Institute | Bi-dentate compounds as kinase inhibitors |
JP6126773B2 (en) | 2007-09-04 | 2017-05-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | High affinity anti-prostatic stem cell antigen (PSCA) antibody for cancer targeting and detection |
EP2740490A1 (en) * | 2007-10-03 | 2014-06-11 | Cornell University | Treatment of proliferative disorders using antibodies to PSMA |
US8980210B2 (en) * | 2008-01-28 | 2015-03-17 | Battelle Memorial Institute | Capture and release of acid-gasses with acid-gas binding organic compounds |
US20110046348A1 (en) * | 2008-05-14 | 2011-02-24 | Marian Kruszynski | Methods of preparing peptide derivatives |
EP2157432A1 (en) * | 2008-08-15 | 2010-02-24 | Qiagen GmbH | Method for analysing a complex sample by mass spectrometry |
CN102149726A (en) * | 2008-09-09 | 2011-08-10 | 诺沃—诺迪斯克保健股份有限公司 | Growth hormone conjugate with increased stability |
ES2712732T3 (en) * | 2009-02-17 | 2019-05-14 | Cornell Res Foundation Inc | Methods and kits for the diagnosis of cancer and the prediction of therapeutic value |
EP2506876B1 (en) | 2009-12-02 | 2016-10-12 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
US20130045215A1 (en) | 2010-04-28 | 2013-02-21 | University Of Southern California | Growth hormone receptor deficiency causes a major reduction in pro-aging signaling, cancer and diabetes in humans |
WO2012118780A2 (en) * | 2011-02-28 | 2012-09-07 | Polytechnic Institute Of New York University | Preparation of peptide mixtures by protease catalysis designed to provide useful biological and physical properties |
EP4137158A1 (en) | 2015-08-07 | 2023-02-22 | Imaginab, Inc. | Antigen binding constructs to target molecules |
WO2018147960A1 (en) | 2017-02-08 | 2018-08-16 | Imaginab, Inc. | Extension sequences for diabodies |
JP2022545917A (en) * | 2019-08-27 | 2022-11-01 | トニックス ファーマ リミテッド | Modified TFF2 polypeptide |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US5739208A (en) * | 1993-11-12 | 1998-04-14 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
US20070105770A1 (en) * | 2004-01-21 | 2007-05-10 | Novo Nordisk A/S | Transglutaminase mediated conjugation of peptides |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8610551D0 (en) | 1986-04-30 | 1986-06-04 | Hoffmann La Roche | Polypeptide & protein derivatives |
ES2113354T3 (en) | 1990-05-04 | 1998-05-01 | American Cyanamid Co | STABILIZATION OF SOMATOTROPINS AND OTHER PROTEINS BY MODIFICATION OF CYSTEINE WASTE. |
DK220890D0 (en) | 1990-09-14 | 1990-09-14 | Ole Buchardt | PROCEDURE FOR THE PREPARATION OF C-TERMINALLY AMIDATED PEPTIDES |
US5985627A (en) | 1997-02-28 | 1999-11-16 | Carlsberg Laboratory | Modified carboxypeptidase |
JP2005525302A (en) | 2001-11-20 | 2005-08-25 | ファルマシア・コーポレーション | Chemically modified human growth hormone conjugates |
-
2006
- 2006-03-31 US US11/395,784 patent/US7524813B2/en not_active Expired - Fee Related
-
2009
- 2009-03-18 US US12/406,267 patent/US20090253166A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US5739208A (en) * | 1993-11-12 | 1998-04-14 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
US20070105770A1 (en) * | 2004-01-21 | 2007-05-10 | Novo Nordisk A/S | Transglutaminase mediated conjugation of peptides |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8716240B2 (en) | 2001-10-10 | 2014-05-06 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US20100015684A1 (en) * | 2001-10-10 | 2010-01-21 | Neose Technologies, Inc. | Factor vii: remodeling and glycoconjugation of factor vii |
US20100261872A1 (en) * | 2001-10-10 | 2010-10-14 | Neose Technologies, Inc. | Factor VIII: remodeling and glycoconjugation of factor VIII |
US20080187955A1 (en) * | 2001-10-10 | 2008-08-07 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US8008252B2 (en) | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
US8076292B2 (en) | 2001-10-10 | 2011-12-13 | Novo Nordisk A/S | Factor VIII: remodeling and glycoconjugation of factor VIII |
US8716239B2 (en) | 2001-10-10 | 2014-05-06 | Novo Nordisk A/S | Granulocyte colony stimulating factor: remodeling and glycoconjugation G-CSF |
US8247381B2 (en) | 2003-03-14 | 2012-08-21 | Biogenerix Ag | Branched water-soluble polymers and their conjugates |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
US8853161B2 (en) | 2003-04-09 | 2014-10-07 | Novo Nordisk A/S | Glycopegylation methods and proteins/peptides produced by the methods |
US7932364B2 (en) | 2003-05-09 | 2011-04-26 | Novo Nordisk A/S | Compositions and methods for the preparation of human growth hormone glycosylation mutants |
US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US8916360B2 (en) | 2003-11-24 | 2014-12-23 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US8632770B2 (en) | 2003-12-03 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated factor IX |
US8361961B2 (en) | 2004-01-08 | 2013-01-29 | Biogenerix Ag | O-linked glycosylation of peptides |
US8791066B2 (en) | 2004-07-13 | 2014-07-29 | Novo Nordisk A/S | Branched PEG remodeling and glycosylation of glucagon-like peptide-1 [GLP-1] |
US20080300173A1 (en) * | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
US8268967B2 (en) | 2004-09-10 | 2012-09-18 | Novo Nordisk A/S | Glycopegylated interferon α |
US9200049B2 (en) | 2004-10-29 | 2015-12-01 | Novo Nordisk A/S | Remodeling and glycopegylation of fibroblast growth factor (FGF) |
US10874714B2 (en) | 2004-10-29 | 2020-12-29 | 89Bio Ltd. | Method of treating fibroblast growth factor 21 (FGF-21) deficiency |
US9029331B2 (en) | 2005-01-10 | 2015-05-12 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
US9187546B2 (en) | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
US8404809B2 (en) | 2005-05-25 | 2013-03-26 | Novo Nordisk A/S | Glycopegylated factor IX |
US8911967B2 (en) | 2005-08-19 | 2014-12-16 | Novo Nordisk A/S | One pot desialylation and glycopegylation of therapeutic peptides |
US8841439B2 (en) | 2005-11-03 | 2014-09-23 | Novo Nordisk A/S | Nucleotide sugar purification using membranes |
US9187532B2 (en) | 2006-07-21 | 2015-11-17 | Novo Nordisk A/S | Glycosylation of peptides via O-linked glycosylation sequences |
US10875826B2 (en) | 2006-09-07 | 2020-12-29 | Emisphere Technologies, Inc. | Process for the manufacture of SNAC (salcaprozate sodium) |
US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
US9050304B2 (en) | 2007-04-03 | 2015-06-09 | Ratiopharm Gmbh | Methods of treatment using glycopegylated G-CSF |
US9493499B2 (en) | 2007-06-12 | 2016-11-15 | Novo Nordisk A/S | Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography |
US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
US9150848B2 (en) | 2008-02-27 | 2015-10-06 | Novo Nordisk A/S | Conjugated factor VIII molecules |
WO2017127567A1 (en) * | 2016-01-19 | 2017-07-27 | Genebiologics, Llc | Production of arginine-rich proteins and use as a fertilizer and germination enhancer |
Also Published As
Publication number | Publication date |
---|---|
US7524813B2 (en) | 2009-04-28 |
US20070111926A1 (en) | 2007-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7524813B2 (en) | Selectively conjugated peptides and methods of making the same | |
EP1708755B1 (en) | Transglutaminase mediated conjugation of peptides | |
US20090264366A1 (en) | Transglutaminase Mediated Conjugation of Peptides | |
WO2005035553A2 (en) | Conjugation of peptides | |
US8586532B2 (en) | Method for selectively modifying a protein via transglutaminase catalyzed reaction | |
US10946074B2 (en) | GLP-1 derivatives and uses thereof | |
AU2006215566A1 (en) | Insulinotropic agents conjugated with structurally well defined branched polymers | |
US20080182783A1 (en) | Growth Hormone Conjugates | |
JP2010536923A5 (en) | ||
KR100997835B1 (en) | Exendin 4 polypeptide fragment | |
US20090105134A1 (en) | C-Terminally Pegylated Growth Hormones | |
US20080305986A1 (en) | Multimers of Peptides | |
KR20070017494A (en) | Transglutaminase mediated conjugation of peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION |